2024/03/31 更新

写真a

サカグチ マサキヨ
阪口 政清
SAKAGUCHI Masakiyo
所属
医歯薬学域 教授
職名
教授
外部リンク

学位

  • 博士(医学) ( 岡山大学 )

研究キーワード

  • 細胞生物学

  • Cell Biology

  • REIC/Dkk-3

  • S100タンパク質

  • がん

研究分野

  • ライフサイエンス / 細胞生物学

学歴

  • 岡山大学   Graduate School, Division of Medicine  

    - 2001年

      詳細を見る

  • 岡山大学    

    - 2001年

      詳細を見る

    国名: 日本国

    researchmap

経歴

  • 岡山大学 学術研究院 医歯薬学域   細胞生物学分野   教授

    2021年4月 - 現在

      詳細を見る

  • 岡山大学大学院医歯薬学総合研究科   細胞生物学分野   教授

    2018年7月 - 2020年3月

      詳細を見る

  • - 岡山大学医歯薬学総合研究科 教授

    2018年

      詳細を見る

  • - Professor,Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,Okayama University

    2018年

      詳細を見る

  • Associate Professor,Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,Okayama University

    2008年 - 2018年

      詳細を見る

  • 岡山大学医歯薬学総合研究科 准教授

    2008年 - 2018年

      詳細を見る

  • Assistant Professor,Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,Okayama University

    2007年 - 2008年

      詳細を見る

  • 岡山大学医歯薬学総合研究科 助教

    2007年 - 2008年

      詳細を見る

  • 岡山大学医歯薬学総合研究科 助手

    2005年 - 2007年

      詳細を見る

  • Research Associate,Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,Okayama University

    2005年 - 2007年

      詳細を見る

  • 岡山大学医歯薬学総合研究科 助手

    2004年 - 2005年

      詳細を見る

  • Research Associate,Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,Okayama University

    2004年 - 2005年

      詳細を見る

▼全件表示

所属学協会

▼全件表示

委員歴

  • 日本組織培養学会第95回大会   大会長  

    2023年8月 - 2023年9月   

      詳細を見る

  • 日本組織培養学会   理事  

    2021年4月 - 現在   

      詳細を見る

  • 日本癌学会   評議員  

    2020年1月 - 現在   

      詳細を見る

  • 日本組織培養学会第90回大会   プログラム 運営委員  

    2017年7月   

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本組織培養学会   大会運営補助  

    2004年   

      詳細を見る

    団体区分:学協会

    日本組織培養学会

    researchmap

 

論文

  • Lysyl oxidase-like 4 promotes the invasiveness of triple-negative breast cancer cells by orchestrating the invasive machinery formed by annexin A2 and S100A11 on the cell surface

    Tetta Takahashi, Nahoko Tomonobu, Rie Kinoshita, Ken-ichi Yamamoto, Hitoshi Murata, Ni Luh Gede Yoni Komalasari, Youyi Chen, Fan Jiang, Yuma Gohara, Toshiki Ochi, I Made Winarsa Ruma, I Wayan Sumardika, Jin Zhou, Tomoko Honjo, Yoshihiko Sakaguchi, Akira Yamauchi, Futoshi Kuribayashi, Eisaku Kondo, Yusuke Inoue, Junichiro Futami, Shinichi Toyooka, Yoshito Zamami, Masakiyo Sakaguchi

    Frontiers in Oncology   14   2024年3月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Frontiers Media SA  

    Background

    Our earlier research revealed that the secreted lysyl oxidase-like 4 (LOXL4) that is highly elevated in triple-negative breast cancer (TNBC) acts as a catalyst to lock annexin A2 on the cell membrane surface, which accelerates invasive outgrowth of the cancer through the binding of integrin-β1 on the cell surface. However, whether this machinery is subject to the LOXL4-mediated intrusive regulation remains uncertain.

    Methods

    Cell invasion was assessed using a transwell-based assay, protein–protein interactions by an immunoprecipitation–Western blotting technique and immunocytochemistry, and plasmin activity in the cell membrane by gelatin zymography.

    Results

    We revealed that cell surface annexin A2 acts as a receptor of plasminogen via interaction with S100A10, a key cell surface annexin A2-binding factor, and S100A11. We found that the cell surface annexin A2/S100A11 complex leads to mature active plasmin from bound plasminogen, which actively stimulates gelatin digestion, followed by increased invasion.

    Conclusion

    We have refined our understanding of the role of LOXL4 in TNBC cell invasion: namely, LOXL4 mediates the upregulation of annexin A2 at the cell surface, the upregulated annexin 2 binds S100A11 and S100A10, and the resulting annexin A2/S100A11 complex acts as a receptor of plasminogen, readily converting it into active-form plasmin and thereby enhancing invasion.

    DOI: 10.3389/fonc.2024.1371342

    researchmap

  • PRRX1-TOP2A interaction is a malignancy-promoting factor in human malignant peripheral nerve sheath tumours. 国際誌

    Shota Takihira, Daisuke Yamada, Tatsunori Osone, Tomoka Takao, Masakiyo Sakaguchi, Michiyuki Hakozaki, Takuto Itano, Eiji Nakata, Tomohiro Fujiwara, Toshiyuki Kunisada, Toshifumi Ozaki, Takeshi Takarada

    British journal of cancer   2024年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Paired related-homeobox 1 (PRRX1) is a transcription factor in the regulation of developmental morphogenetic processes. There is growing evidence that PRRX1 is highly expressed in certain cancers and is critically involved in human survival prognosis. However, the molecular mechanism of PRRX1 in cancer malignancy remains to be elucidated. METHODS: PRRX1 expression in human Malignant peripheral nerve sheath tumours (MPNSTs) samples was detected immunohistochemically to evaluate survival prognosis. MPNST models with PRRX1 gene knockdown or overexpression were constructed in vitro and the phenotype of MPNST cells was evaluated. Bioinformatics analysis combined with co-immunoprecipitation, mass spectrometry, RNA-seq and structural prediction were used to identify proteins interacting with PRRX1. RESULTS: High expression of PRRX1 was associated with a poor prognosis for MPNST. PRRX1 knockdown suppressed the tumorigenic potential. PRRX1 overexpressed in MPNSTs directly interacts with topoisomerase 2 A (TOP2A) to cooperatively promote epithelial-mesenchymal transition and increase expression of tumour malignancy-related gene sets including mTORC1, KRAS and SRC signalling pathways. Etoposide, a TOP2A inhibitor used in the treatment of MPNST, may exhibit one of its anticancer effects by inhibiting the PRRX1-TOP2A interaction. CONCLUSION: Targeting the PRRX1-TOP2A interaction in malignant tumours with high PRRX1 expression might provide a novel tumour-selective therapeutic strategy.

    DOI: 10.1038/s41416-024-02632-8

    PubMed

    researchmap

  • Correction to: Periostin secreted by cancer‑associated fibroblasts promotes cancer progression and drug resistance in non‑small cell lung cancer. 国際誌

    Fumiaki Takatsu, Ken Suzawa, Shuta Tomida, Yin Min Thu, Masakiyo Sakaguchi, Tomohiro Toji, Masayoshi Ohki, Shimpei Tsudaka, Keiichi Date, Naoki Matsuda, Kazuma Iwata, Yidan Zhu, Kentaro Nakata, Kazuhiko Shien, Hiromasa Yamamoto, Akiko Nakayama, Mikio Okazaki, Seiichiro Sugimoto, Shinichi Toyooka

    Journal of molecular medicine (Berlin, Germany)   2023年12月

     詳細を見る

  • Periostin secreted by cancer-associated fibroblasts promotes cancer progression and drug resistance in non-small cell lung cancer. 査読 国際誌

    Fumiaki Takatsu, Ken Suzawa, Shuta Tomida, Yin Min Thu, Masakiyo Sakaguchi, Tomohiro Toji, Masayoshi Ohki, Shimpei Tsudaka, Keiichi Date, Naoki Matsuda, Kazuma Iwata, Yidan Zhu, Kentaro Nakata, Kazuhiko Shien, Hiromasa Yamamoto, Akiko Nakayama, Mikio Okazaki, Seiichiro Sugimoto, Shinichi Toyooka

    Journal of molecular medicine (Berlin, Germany)   2023年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Cancer-associated fibroblasts (CAFs) are important components in the tumor microenvironment, and we sought to identify effective therapeutic targets in CAFs for non-small cell lung cancer (NSCLC). In this study, we established fibroblast cell lines from the cancerous and non-cancerous parts of surgical lung specimens from patients with NSCLC and evaluated the differences in behaviors towards NSCLC cells. RNA sequencing analysis was performed to investigate the differentially expressed genes between normal fibroblasts (NFs) and CAFs, and we identified that the expression of periostin (POSTN), which is known to be overexpressed in various solid tumors and promote cancer progression, was significantly higher in CAFs than in NFs. POSTN increased cell proliferation via NSCLC cells' ERK pathway activation and induced epithelial-mesenchymal transition (EMT), which improved migration in vitro. In addition, POSTN knockdown in CAFs suppressed these effects, and in vivo experiments demonstrated that the POSTN knockdown improved the sensitivity of EGFR-mutant NSCLC cells for osimertinib treatment. Collectively, our results showed that CAF-derived POSTN is involved in tumor growth, migration, EMT induction, and drug resistance in NSCLC. Targeting CAF-secreted POSTN could be a potential therapeutic strategy for NSCLC. KEY MESSAGES: • POSTN is significantly upregulated in CAFs compared to normal fibroblasts in NCSLC. • POSTN increases cell proliferation via activation of the NSCLC cells' ERK pathway. • POSTN induces EMT in NSCLC cells and improves the migration ability. • POSTN knockdown improves the sensitivity for osimertinib in EGFR-mutant NSCLC cells.

    DOI: 10.1007/s00109-023-02384-7

    PubMed

    researchmap

  • Phosphorylated SARM1 is involved in the pathological process of rotenone-induced neurodegeneration. 査読 国際誌

    Hitoshi Murata, May Tha Zin Phoo, Toshiki Ochi, Nahoko Tomonobu, Ken-Ichi Yamamoto, Rie Kinoshita, Ikuko Miyazaki, Masahiro Nishibori, Masato Asanuma, Masakiyo Sakaguchi

    Journal of biochemistry   2023年9月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Sterile alpha and Toll/interleukin receptor motif-containing protein 1 (SARM1) is a NAD+ hydrolase that plays a key role in axonal degeneration and neuronal cell death. We reported that c-Jun N-terminal kinase (JNK) activates SARM1 through phosphorylation at Ser-548. The importance of SARM1 phosphorylation in the pathological process of Parkinson's disease (PD) has not been determined. We thus conducted the present study by using rotenone (an inducer of PD-like pathology) and neurons derived from induced pluripotent stem cells (iPSCs) from healthy donors and a patient with familial PD PARK2 (FPD2). The results showed that compared to the healthy neurons, FPD2 neurons were more vulnerable to rotenone-induced stress and had higher levels of SARM1 phosphorylation. Similar cellular events were obtained when we used PARK2-knockdown neurons derived from healthy donor iPSCs. These events in both types of PD-model neurons were suppressed in neurons treated with JNK inhibitors, Ca2+-signal inhibitors, or by a SARM1-knockdown procedure. The degenerative events were enhanced in neurons overexpressing wild-type SARM1 and conversely suppressed in neurons overexpressing the SARM1-S548A mutant. We also detected elevated SARM1 phosphorylation in the midbrain of PD-model mice. The results indicate that phosphorylated SARM1 plays an important role in the pathological process of rotenone-induced neurodegeneration.

    DOI: 10.1093/jb/mvad068

    PubMed

    researchmap

  • STAT1/3 signaling suppresses axon degeneration and neuronal cell death through regulation of NAD+-biosynthetic and consuming enzymes. 査読 国際誌

    Hitoshi Murata, Yu Yasui, Kazuma Oiso, Toshiki Ochi, Nahoko Tomonobu, Ken-Ichi Yamamoto, Rie Kinoshita, Masakiyo Sakaguchi

    Cellular signalling   108   110717 - 110717   2023年5月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Nicotinamide adenine dinucleotide (NAD)+-biosynthetic and consuming enzymes are involved in various intracellular events through the regulation of NAD+ metabolism. Recently, it has become clear that alterations in the expression of NAD+-biosynthetic and consuming enzymes contribute to the axonal stability of neurons. We explored soluble bioactive factor(s) that alter the expression of NAD+-metabolizing enzymes and found that cytokine interferon (IFN)-γ increased the expression of nicotinamide nucleotide adenylyltransferase 2 (NMNAT2), an NAD+-biosynthetic enzyme. IFN-γ activated signal transducers and activators of transcription 1 and 3 (STAT1/3) followed by c-Jun N-terminal kinase (JNK) suppression. As a result, STAT1/3 increased the expression of NMNAT2 at both mRNA and protein levels in a dose- and time-dependent manner and, at the same time, suppressed activation of sterile alpha and Toll/interleukin receptor motif-containing 1 (SARM1), an NAD+-consuming enzyme, and increased intracellular NAD+ levels. We examined the protective effect of STAT1/3 signaling against vincristine-mediated cell injury as a model of chemotherapy-induced peripheral neuropathy (CIPN), in which axonal degeneration is involved in disease progression. We found that IFN-γ-mediated STAT1/3 activation inhibited vincristine-induced downregulation of NMNAT2 and upregulation of SARM1 phosphorylation, resulting in modest suppression of subsequent neurite degradation and cell death. These results indicate that STAT1/3 signaling induces NMNAT2 expression while simultaneously suppressing SARM1 phosphorylation, and that both these actions contribute to suppression of axonal degeneration and cell death.

    DOI: 10.1016/j.cellsig.2023.110717

    PubMed

    researchmap

  • SPRED2: A Novel Regulator of Epithelial-Mesenchymal Transition and Stemness in Hepatocellular Carcinoma Cells. 査読 国際誌

    Tong Gao, Xu Yang, Masayoshi Fujisawa, Toshiaki Ohara, Tianyi Wang, Nahoko Tomonobu, Masakiyo Sakaguchi, Teizo Yoshimura, Akihiro Matsukawa

    International journal of molecular sciences   24 ( 5 )   2023年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The downregulation of SPRED2, a negative regulator of the ERK1/2 pathway, was previously detected in human cancers; however, the biological consequence remains unknown. Here, we investigated the effects of SPRED2 loss on hepatocellular carcinoma (HCC) cell function. Human HCC cell lines, expressing various levels of SPRED2 and SPRED2 knockdown, increased ERK1/2 activation. SPRED2-knockout (KO)-HepG2 cells displayed an elongated spindle shape with increased cell migration/invasion and cadherin switching, with features of epithelial-mesenchymal transition (EMT). SPRED2-KO cells demonstrated a higher ability to form spheres and colonies, expressed higher levels of stemness markers and were more resistant to cisplatin. Interestingly, SPRED2-KO cells also expressed higher levels of the stem cell surface markers CD44 and CD90. When CD44+CD90+ and CD44-CD90- populations from WT cells were analyzed, a lower level of SPRED2 and higher levels of stem cell markers were detected in CD44+CD90+ cells. Further, endogenous SPRED2 expression decreased when WT cells were cultured in 3D, but was restored in 2D culture. Finally, the levels of SPRED2 in clinical HCC tissues were significantly lower than those in adjacent non-HCC tissues and were negatively associated with progression-free survival. Thus, the downregulation of SPRED2 in HCC promotes EMT and stemness through the activation of the ERK1/2 pathway, and leads to more malignant phenotypes.

    DOI: 10.3390/ijms24054996

    PubMed

    researchmap

  • Novel extracellular role of REIC/Dkk-3 protein in PD-L1 regulation in cancer cells. 査読 国際共著 国際誌

    Yuma Gohara, Nahoko Tomonobu, Rie Kinoshita, Junichiro Futami, Léna Audebert, Youyi Chen, Ni Luh Gede Yoni Komalasari, Fan Jiang, Chikako Yoshizawa, Hitoshi Murata, Ken-Ichi Yamamoto, Masami Watanabe, Hiromi Kumon, Masakiyo Sakaguchi

    Journal of molecular medicine (Berlin, Germany)   101 ( 4 )   431 - 447   2023年3月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The adenovirus-REIC/Dkk-3 expression vector (Ad-REIC) has been the focus of numerous clinical studies due to its potential for the quenching of cancers. The cancer-suppressing mechanisms of the REIC/DKK-3 gene depend on multiple pathways that exert both direct and indirect effects on cancers. The direct effect is triggered by REIC/Dkk-3-mediated ER stress that causes cancer-selective apoptosis, and the indirect effect can be classified in two ways: (i) induction, by Ad-REIC-mis-infected cancer-associated fibroblasts, of the production of IL-7, an important activator of T cells and NK cells, and (ii) promotion, by the secretory REIC/Dkk-3 protein, of dendritic cell polarization from monocytes. These unique features allow Ad-REIC to exert effective and selective cancer-preventative effects in the manner of an anticancer vaccine. However, the question of how the REIC/Dkk-3 protein leverages anticancer immunity has remained to be answered. We herein report a novel function of the extracellular REIC/Dkk-3-namely, regulation of an immune checkpoint via modulation of PD-L1 on the cancer-cell surface. First, we identified novel interactions of REIC/Dkk-3 with the membrane proteins C5aR, CXCR2, CXCR6, and CMTM6. These proteins all functioned to stabilize PD-L1 on the cell surface. Due to the dominant expression of CMTM6 among the proteins in cancer cells, we next focused on CMTM6 and observed that REIC/Dkk-3 competed with CMTM6 for PD-L1, thereby liberating PD-L1 from its complexation with CMTM6. The released PD-L1 immediately underwent endocytosis-mediated degradation. These results will enhance our understanding of not only the physiological nature of the extracellular REIC/Dkk-3 protein but also the Ad-REIC-mediated anticancer effects. KEY MESSAGES: • REIC/Dkk-3 protein effectively suppresses breast cancer progression through an acceleration of PD-L1 degradation. • PD-L1 stability on the cancer cell membrane is kept high by binding with mainly CMTM6. • Competitive binding of REIC/Dkk-3 protein with CMTM6 liberates PD-L1, leading to PD-L1 degradation.

    DOI: 10.1007/s00109-023-02292-w

    PubMed

    researchmap

  • LOXL1 and LOXL4 are novel target genes of the Zn2+-bound form of ZEB1 and play a crucial role in the acceleration of invasive events in triple-negative breast cancer cells 査読 国際共著 国際誌

    Daisuke Hirabayashi, Ken-ichi Yamamoto, Akihiro Maruyama, Nahoko Tomonobu, Rie Kinoshita, Youyi Chen, Ni Luh Gede Yoni Komalasari, Hitoshi Murata, Yuma Gohara, Fan Jiang, Jin Zhou, I Made Winarsa Ruma, I Wayan Sumardika, Akira Yamauchi, Futoshi Kuribayashi, Shinichi Toyooka, Yusuke Inoue, Masakiyo Sakaguchi

    Frontiers in Oncology   13   1142886 - 1142886   2023年2月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Frontiers Media SA  

    Background

    EMT has been proposed to be a crucial early event in cancer metastasis. EMT is rigidly regulated by the action of several EMT-core transcription factors, particularly ZEB1. We previously revealed an unusual role of ZEB1 in the S100A8/A9-mediated metastasis in breast cancer cells that expressed ZEB1 at a significant level and showed that the ZEB1 was activated on the MCAM-downstream pathway upon S100A8/A9 binding. ZEB1 is well known to require Zn2+ for its activation based on the presence of several Zn-finger motifs in the transcription factor. However, how Zn2+-binding works on the pleiotropic role of ZEB1 through cancer progression has not been fully elucidated.

    Methods

    We established the engineered cells, MDA-MB-231 MutZEB1 (MDA-MutZEB1), that stably express MutZEB1 (ΔZn). The cells were then evaluated in vitro for their invasion activities. Finally, an RNA-Seq analysis was performed to compare the gene alteration profiles of the established cells comprehensively.

    Results

    MDA-MutZEB1 showed a significant loss of the EMT, ultimately stalling the invasion. Inclusive analysis of the transcription changes after the expression of MutZEB1 (ΔZn) in MDA-MB-231 cells revealed the significant downregulation of LOX family genes, which are known to play a critical role in cancer metastasis. We found that LOXL1 and LOXL4 remarkably enhanced cancer invasiveness among the LOX family genes with altered expression.

    Conclusions

    These findings indicate that ZEB1 potentiates Zn2+-mediated transcription of plural EMT-relevant factors, including LOXL1 and LOXL4, whose upregulation plays a critical role in the invasive dissemination of breast cancer cells.

    DOI: 10.3389/fonc.2023.1142886

    PubMed

    researchmap

  • PPARα activation partially drives NAFLD development in liver-specific Hnf4a-null mice 査読 国際誌

    Carlos Ichiro Kasano-Camones, Masayuki Takizawa, Noriyasu Ohshima, Chinatsu Saito, Wakana Iwasaki, Yuko Nakagawa, Yoshio Fujitani, Ryo Yoshida, Yoshifumi Saito, Takashi Izumi, Shin-Ichi Terawaki, Masakiyo Sakaguchi, Frank J Gonzalez, Yusuke Inoue

    The Journal of Biochemistry   173 ( 5 )   393 - 411   2023年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Oxford University Press (OUP)  

    Abstract

    HNF4α regulates various genes to maintain liver function. There have been reports linking HNF4α expression to the development of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). In this study, liver-specific Hnf4a-deficient mice (Hnf4aΔHep mice) developed hepatosteatosis and liver fibrosis, and they were found to have difficulty utilizing glucose. In Hnf4aΔHep mice, the expression of fatty acid oxidation-related genes, which are PPARα target genes, was increased in contrast to the decreased expression of PPARα, suggesting that Hnf4aΔHep mice take up more lipids in the liver instead of glucose. Furthermore, Hnf4aΔHep/Ppara-/- mice, which are simultaneously deficient in HNF4α and PPARα, showed improved hepatosteatosis and fibrosis. Increased C18:1 and C18:1/C18:0 ratio was observed in the livers of Hnf4aΔHep mice and the transactivation of PPARα target gene was induced by C18:1. When the C18:1/C18:0 ratio was close to that of Hnf4aΔHep mouse liver, a significant increase in transactivation was observed. In addition, the expression of Pgc1a, a coactivator of PPARs, was increased, suggesting that elevated C18:1 and Pgc1a expression could contribute to PPARα activation in Hnf4aΔHep mice. These insights may contribute to the development of new diagnostic and therapeutic approaches for NAFLD by focusing on the HNF4α and PPARα signaling cascade.

    DOI: 10.1093/jb/mvad005

    PubMed

    researchmap

  • Lysyl oxidase-like 4 exerts an atypical role in breast cancer progression that is dependent on the enzymatic activity that targets the cell-surface annexin A2. 査読 国際共著 国際誌

    Ni Luh Gede Yoni Komalasari, Nahoko Tomonobu, Rie Kinoshita, Youyi Chen, Yoshihiko Sakaguchi, Yuma Gohara, Fan Jiang, Ken-Ich Yamamoto, Hitoshi Murata, I Made Winarsa Ruma, I Wayan Sumardika, Jin Zhou, Akira Yamauchi, Futoshi Kuribayashi, Yusuke Inoue, Shinichi Toyooka, Masakiyo Sakaguchi

    Frontiers in oncology   13   1142907 - 1142907   2023年

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: LOX family members are reported to play pivotal roles in cancer. Unlike their enzymatic activities in collagen cross-linking, their precise cancer functions are unclear. We revealed that LOXL4 is highly upregulated in breast cancer cells, and we thus sought to define an unidentified role of LOXL4 in breast cancer. METHODS: We established the MDA-MB-231 sublines MDA-MB-231-LOXL4 mutCA and -LOXL4 KO, which stably overexpress mutant LOXL4 that loses its catalytic activity and genetically ablates the intrinsic LOXL4 gene, respectively. In vitro and in vivo evaluations of these cells' activities of cancer outgrowth were conducted by cell-based assays in cultures and an orthotopic xenograft model, respectively. The new target (s) of LOXL4 were explored by the MS/MS analytic approach. RESULTS: Our in vitro results revealed that both the overexpression of mutCA and the KO of LOXL4 in cells resulted in a marked reduction of cell growth and invasion. Interestingly, the lowered cellular activities observed in the engineered cells were also reflected in the mouse model. We identified a novel binding partner of LOXL4, i.e., annexin A2. LOXL4 catalyzes cell surface annexin A2 to achieve a cross-linked multimerization of annexin A2, which in turn prevents the internalization of integrin β-1, resulting in the locking of integrin β-1 on the cell surface. These events enhance the promotion of cancer cell outgrowth. CONCLUSIONS: LOXL4 has a new role in breast cancer progression that occurs via an interaction with annexin A2 and integrin β-1 on the cell surface.

    DOI: 10.3389/fonc.2023.1142907

    PubMed

    researchmap

  • Toll-like receptor 4 promotes bladder cancer progression upon S100A8/A9 binding, which requires TIRAP-mediated TPL2 activation. 査読 国際誌

    Acosta Gonzalez Herik Rodrigo, Nahoko Tomonobu, Haruka Yoneda, Rie Kinoshita, Yosuke Mitsui, Takuya Sadahira, Shin-Ichi Terawaki, Yuma Gohara, Ni Luh Gede Yoni Komalasari, Fan Jiang, Hitoshi Murata, Ken-Ichi Yamamoto, Junichiro Futami, Akira Yamauchi, Futoshi Kuribayashi, Yusuke Inoue, Eisaku Kondo, Shinichi Toyooka, Masahiro Nishibori, Masami Watanabe, Yasutomo Nasu, Masakiyo Sakaguchi

    Biochemical and biophysical research communications   634   83 - 91   2022年12月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Bladder cancer is an often widely disseminated and deadly cancer. To block the malignant outgrowth of bladder cancer, we must elucidate the molecular-level characteristics of not only bladder cancer cells but also their surrounding milieu. As part of this effort, we have long been studying extracellular S100A8/A9, which is elevated by the inflammation associated with certain cancers. Extracellularly enriched S100A8/A9 can hasten a shift to metastatic transition in multiple types of cancer cells. Intriguingly, high-level S100A8/A9 has been detected in the urine of bladder-cancer patients, and the level increases with the stage of malignancy. Nonetheless, S100A8/A9 has been investigated mainly as a potential biomarker of bladder cancers, and there have been no investigations of its role in bladder-cancer growth and metastasis. We herein report that extracellular S100A8/A9 induces upregulation of growth, migration and invasion in bladder cancer cells through its binding with cell-surface Toll-like receptor 4 (TLR4). Our molecular analysis revealed the TLR4 downstream signal that accelerates such cancer cell events. Tumor progression locus 2 (TPL2) was a key factor facilitating the aggressiveness of cancer cells. Upon binding of S100A8/A9 with TLR4, TPL2 activation was enhanced by an action with a TLR4 adaptor molecule, TIR domain-containing adaptor protein (TIRAP), which in turn led to activation of the mitogen-activated protein kinase (MAPK) cascade of TPL2. Finally, we showed that sustained inhibition of TLR4 in cancer cells effectively dampened cancer survival in vivo. Collectively, our results indicate that the S100A8/A9-TLR4-TPL2 axis influences the growth, survival, and invasive motility of bladder cancer cells.

    DOI: 10.1016/j.bbrc.2022.09.116

    PubMed

    researchmap

  • Inhibiting S100A8/A9 attenuates airway obstruction in a mouse model of heterotopic tracheal transplantation. 査読 国際誌

    Dai Shimizu, Mikio Okazaki, Seiichiro Sugimoto, Rie Kinoshita, Kentaro Nakata, Shin Tanaka, Kohei Hashimoto, Kentaroh Miyoshi, Masaomi Yamane, Akihiro Matsukawa, Masakiyo Sakaguchi, Shinichi Toyooka

    Biochemical and biophysical research communications   629   86 - 94   2022年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Although bronchiolitis obliterans syndrome (BOS) is a major cause of death after lung transplantation, an effective drug therapy for BOS has not yet developed. Here, we assessed the effectiveness of a neutralizing anti-S100 calcium binding protein (S100) A8/A9 antibody against BOS. A murine model of heterotopic tracheal transplantation was used. Mice were intraperitoneally administered control IgG or the S100A8/A9 antibody on day 0 and twice per week until they were sacrificed. Tissue sections were used to evaluate the obstruction ratio, epithelium-preservation ratio, α-smooth muscle actin (SMA)-positive myofibroblast infiltration, and luminal cell death. Quantitative reverse transcriptase-polymerase chain reaction analysis was performed to analyze the mRNA-expression levels of collagen, inflammatory cytokines, and chemokines on days 7, 14, and 21. The anti-S100A8/A9 antibody significantly improved the obstruction ratio and epithelium-preservation ratio, with less α-SMA-positive myofibroblast infiltration compared to the control group. Antibody treatment reduced the type-III collagen: type-I collagen gene-expression ratio. The antibody also significantly suppressed the number of dead cells in the graft lumen. The expression levels of tumor growth factor β1 and C-C motif chemokine 2 on day 21, but not those of interleukin-1β, interleukin-6, and tumor necrosis factor α, were significantly suppressed by S100A8/A9 antibody treatment. These findings suggest that S100A8/A9 may be a potential therapeutic target for BOS after lung transplantation.

    DOI: 10.1016/j.bbrc.2022.08.087

    PubMed

    researchmap

  • Functional Blockage of S100A8/A9 Ameliorates Ischemia-Reperfusion Injury in the Lung. 査読 国際誌

    Kentaro Nakata, Mikio Okazaki, Tomohisa Sakaue, Rie Kinoshita, Yuhei Komoda, Dai Shimizu, Haruchika Yamamoto, Shin Tanaka, Ken Suzawa, Kazuhiko Shien, Kentaroh Miyoshi, Hiromasa Yamamoto, Toshiaki Ohara, Seiichiro Sugimoto, Masaomi Yamane, Akihiro Matsukawa, Masakiyo Sakaguchi, Shinichi Toyooka

    Bioengineering (Basel, Switzerland)   9 ( 11 )   2022年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    (1) Background: Lung ischemia-reperfusion (IR) injury increases the mortality and morbidity of patients undergoing lung transplantation. The objective of this study was to identify the key initiator of lung IR injury and to evaluate pharmacological therapeutic approaches using a functional inhibitor against the identified molecule. (2) Methods: Using a mouse hilar clamp model, the combination of RNA sequencing and histological investigations revealed that neutrophil-derived S100A8/A9 plays a central role in inflammatory reactions during lung IR injury. Mice were assigned to sham and IR groups with or without the injection of anti-S100A8/A9 neutralizing monoclonal antibody (mAb). (3) Results: Anti-S100A8/A9 mAb treatment significantly attenuated plasma S100A8/A9 levels compared with control IgG. As evaluated by oxygenation capacity and neutrophil infiltration, the antibody treatment dramatically ameliorated the IR injury. The gene expression levels of cytokines and chemokines induced by IR injury were significantly reduced by the neutralizing antibody. Furthermore, the antibody treatment significantly reduced TUNEL-positive cells, indicating the presence of apoptotic cells. (4) Conclusions: We identified S100A8/A9 as a novel therapeutic target against lung IR injury.

    DOI: 10.3390/bioengineering9110673

    PubMed

    researchmap

  • Inhibition of pancreatic cancer-cell growth and metastasis in vivo by a pyrazole compound characterized as a cell-migration inhibitor by an in vitro chemotaxis assay. 査読 国際誌

    Shuichiro Okamoto, Kei Miyano, Tominari Choshi, Norihiko Sugisawa, Takashi Nishiyama, Rika Kotouge, Masahiro Yamamura, Masakiyo Sakaguchi, Rie Kinoshita, Nahoko Tomonobu, Naoki Katase, Kyo Sasaki, Sohji Nishina, Keisuke Hino, Koji Kurose, Mikio Oka, Hisako Kubota, Tomio Ueno, Toshihiro Hirai, Hideyo Fujiwara, Chikage Kawai, Masumi Itadani, Aya Morihara, Kouji Matsushima, Shiro Kanegasaki, Robert M Hoffman, Akira Yamauchi, Futoshi Kuribayashi

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie   155   113733 - 113733   2022年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Pancreatic cancer is recalcitrant to treatment as it is highly metastatic and rapidly progressive. While observing the behavior of human pancreatic BxPC-3 cells using an optical assay device called TAXIScan, we found that several synthetic pyrazole and pyrimidine derivatives inhibited cell migration. One such compound, 14-100, inhibited metastasis of fluorescence-labeled BxPC-3 cells, which were transplanted into the pancreas of nude mice as a subcutaneously grown cancer fragment. Surprisingly, despite its low cytotoxicity, the compound also showed an inhibitory effect on cancer cell proliferation in vivo, suggesting that the compound alters cancer cell characteristics needed to grow in situ. Single-cell RNA-sequencing revealed changes in gene expression associated with metastasis, angiogenesis, inflammation, and epithelial-mesenchymal transition. These data suggest that the compound 14-100 could be a good drug candidate against pancreatic cancer.

    DOI: 10.1016/j.biopha.2022.113733

    PubMed

    researchmap

  • Exosomal Wnt7a from a low metastatic subclone promotes lung metastasis of a highly metastatic subclone in the murine 4t1 breast cancer. 査読 国際誌

    Chunning Li, Teizo Yoshimura, Miao Tian, Yuze Wang, Takamasa Kondo, Ken-Ichi Yamamoto, Masayoshi Fujisawa, Toshiaki Ohara, Masakiyo Sakaguchi, Akihiro Matsukawa

    Breast cancer research : BCR   24 ( 1 )   60 - 60   2022年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Patients with triple-negative breast cancer (TNBC) often have poorer prognosis than those with other subtypes because of its aggressive behaviors. Cancer cells are heterogeneous, and only a few highly metastatic subclones metastasize. Although the majority of subclones may not metastasize, they could contribute by releasing factors that increase the capacity of highly metastatic cells and/or provide a favorable tumor microenvironment (TME). Here, we analyzed the interclonal communication in TNBC which leads to efficient cancer progression, particularly lung metastasis, using the polyclonal murine 4T1 BC model. METHODS: We isolated two 4T1 subclones, LM.4T1 and HM.4T1 cells with a low and a high metastatic potential, respectively, and examined the effects of LM.4T1 cells on the behaviors of HM.4T1 cells using the cell scratch assay, sphere-forming assay, sphere invasion assay, RT-qPCR, and western blotting in vitro. We also examined the contribution of LM.4T1 cells to the lung metastasis of HM.4T1 cells and TME in vivo. To identify a critical factor which may be responsible for the effects by LM.4T1 cells, we analyzed the data obtained from the GEO database. RESULTS: Co-injection of LM.4T1 cells significantly augmented lung metastases by HM.4T1 cells. LM.4T1-derived exosomes promoted the migration and invasion of HM.4T1 cells in vitro, and blocking the secretion of exosome abrogated their effects on HM.4T1 cells. Analyses of data obtained from the GEO database suggested that Wnt7a might be a critical factor responsible for the enhancing effects. In fact, a higher level of Wnt7a was detected in LM.4T1 cells, especially in exosomes, than in HM.4T1 cells, and deletion of Wnt7a in LM.4T1 cells significantly decreased the lung metastasis of HM.4T1 cells. Further, treatment with Wnt7a increased the spheroid formation by HM.4T1 cells via activation of the PI3K/Akt/mTOR signaling pathway. Finally, infiltration of αSMA-positive fibroblasts and angiogenesis was more prominent in tumors of LM.4T1 cells and deletion of Wnt7a in LM.4T1 cells markedly reduced angiogenesis. CONCLUSIONS: We demonstrated, for the first time, that a low metastatic subclone can enhance lung metastasis of highly metastatic subclone via exosomal Wnt7a and propose Wnt7a as a molecular target to treat TNBC patients.

    DOI: 10.1186/s13058-022-01557-5

    PubMed

    researchmap

  • Histidine-Rich Glycoprotein Suppresses the S100A8/A9-Mediated Organotropic Metastasis of Melanoma Cells. 査読 国際共著 国際誌

    Nahoko Tomonobu, Rie Kinoshita, Hidenori Wake, Yusuke Inoue, I Made Winarsa Ruma, Ken Suzawa, Yuma Gohara, Ni Luh Gede Yoni Komalasari, Fan Jiang, Hitoshi Murata, Ken-Ichi Yamamoto, I Wayan Sumardika, Youyi Chen, Junichiro Futami, Akira Yamauchi, Futoshi Kuribayashi, Eisaku Kondo, Shinichi Toyooka, Masahiro Nishibori, Masakiyo Sakaguchi

    International journal of molecular sciences   23 ( 18 )   10300 - 10300   2022年9月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:MDPI AG  

    The dissection of the complex multistep process of metastasis exposes vulnerabilities that could be exploited to prevent metastasis. To search for possible factors that favor metastatic outgrowth, we have been focusing on secretory S100A8/A9. A heterodimer complex of the S100A8 and S100A9 proteins, S100A8/A9 functions as a strong chemoattractant, growth factor, and immune suppressor, both promoting the cancer milieu at the cancer-onset site and cultivating remote, premetastatic cancer sites. We previously reported that melanoma cells show lung-tropic metastasis owing to the abundant expression of S100A8/A9 in the lung. In the present study, we addressed the question of why melanoma cells are not metastasized into the brain at significant levels in mice despite the marked induction of S100A8/A9 in the brain. We discovered the presence of plasma histidine-rich glycoprotein (HRG), a brain-metastasis suppression factor against S100A8/A9. Using S100A8/A9 as an affinity ligand, we searched for and purified the binding plasma proteins of S100A8/A9 and identified HRG as the major protein on mass spectrometric analysis. HRG prevents the binding of S100A8/A9 to the B16-BL6 melanoma cell surface via the formation of the S100A8/A9 complex. HRG also inhibited the S100A8/A9-induced migration and invasion of A375 melanoma cells. When we knocked down HRG in mice bearing skin melanoma, metastasis to both the brain and lungs was significantly enhanced. The clinical examination of plasma S100A8/A9 and HRG levels showed that lung cancer patients with brain metastasis had higher S100A8/A9 and lower HRG levels than nonmetastatic patients. These results suggest that the plasma protein HRG strongly protects the brain and lungs from the threat of melanoma metastasis.

    DOI: 10.3390/ijms231810300

    PubMed

    researchmap

  • Dkk3/REIC Deficiency Impairs Spermiation, Sperm Fibrous Sheath Integrity and the Sperm Motility of Mice. 査読 国際誌

    Ruizhi Xue, Wenfeng Lin, Hirofumi Fujita, Jingkai Sun, Rie Kinoshita, Kazuhiko Ochiai, Junichiro Futami, Masami Watanabe, Hideyo Ohuchi, Masakiyo Sakaguchi, Zhengyan Tang, Peng Huang, Yasutomo Nasu, Hiromi Kumon

    Genes   13 ( 2 )   2022年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The role of Dickkopf-3 (Dkk3)/REIC (The Reduced Expression in Immortalized Cells), a Wnt-signaling inhibitor, in male reproductive physiology remains unknown thus far. To explore the functional details of Dkk3/REIC in the male reproductive process, we studied the Dkk3/REIC knock-out (KO) mouse model. By examining testicular sections and investigating the sperm characteristics (count, vitality and motility) and ultrastructure, we compared the reproductive features between Dkk3/REIC-KO and wild-type (WT) male mice. To further explore the underlying molecular mechanism, we performed RNA sequencing (RNA-seq) analysis of testicular tissues. Our results showed that spermiation failure existed in seminiferous tubules of Dkk3/REIC-KO mice, and sperm from Dkk3/REIC-KO mice exhibited inferior motility (44.09 ± 8.12% vs. 23.26 ± 10.02%, p < 0.01). The Ultrastructure examination revealed defects in the sperm fibrous sheath of KO mice. Although the average count of Dkk3/REIC-KO epididymal sperm was less than that of the wild-types (9.30 ± 0.69 vs. 8.27 ± 0.87, ×106), neither the gap (p > 0.05) nor the difference in the sperm vitality rate (72.83 ± 1.55% vs. 72.50 ± 0.71%, p > 0.05) were statistically significant. The RNA-seq and GO (Gene Oncology) enrichment results indicated that the differential genes were significantly enriched in the GO terms of cytoskeleton function, cAMP signaling and calcium ion binding. Collectively, our research demonstrates that Dkk3/REIC is involved in the process of spermiation, fibrous sheath integrity maintenance and sperm motility of mice.

    DOI: 10.3390/genes13020285

    PubMed

    researchmap

  • Multifaceted Analysis of IL-23A- and/or EBI3-Including Cytokines Produced by Psoriatic Keratinocytes. 査読 国際誌

    Kota Tachibana, Nina Tang, Hitoshi Urakami, Ai Kajita, Mina Kobashi, Hayato Nomura, Minori Sasakura, Satoru Sugihara, Fan Jiang, Nahoko Tomonobu, Masakiyo Sakaguchi, Mamoru Ouchida, Shin Morizane

    International journal of molecular sciences   22 ( 23 )   2021年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Interleukin (IL) 23 (p19/p40) plays a critical role in the pathogenesis of psoriasis and is upregulated in psoriasis skin lesions. In clinical practice, anti-IL-23Ap19 antibodies are highly effective against psoriasis. IL-39 (p19/ Epstein-Barr virus-induced (EBI) 3), a newly discovered cytokine in 2015, shares the p19 subunit with IL-23. Anti-IL-23Ap19 antibodies may bind to IL-39; also, the cytokine may contribute to the pathogenesis of psoriasis. To investigate IL23Ap19- and/or EBI3-including cytokines in psoriatic keratinocytes, we analyzed IL-23Ap19 and EBI3 expressions in psoriasis skin lesions, using immunohistochemistry and normal human epidermal keratinocytes (NHEKs) stimulated with inflammatory cytokines, using quantitative real-time polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), and liquid chromatography-electrospray tandem mass spectrometry (LC-Ms/Ms). Immunohistochemical analysis showed that IL-23Ap19 and EBI3 expressions were upregulated in the psoriasis skin lesions. In vitro, these expressions were synergistically induced by the triple combination of tumor necrosis factor (TNF)-α, IL-17A, and interferon (IFN)-γ, and suppressed by dexamethasone, vitamin D3, and acitretin. In ELISA and LC-Ms/Ms analyses, keratinocyte-derived IL-23Ap19 and EBI3, but not heterodimeric forms, were detected with humanized anti-IL-23Ap19 monoclonal antibodies, tildrakizumab, and anti-EBI3 antibodies, respectively. Psoriatic keratinocytes may express IL-23Ap19 and EBI3 proteins in a monomer or homopolymer, such as homodimer or homotrimer.

    DOI: 10.3390/ijms222312659

    PubMed

    researchmap

  • Oncogenic potential of human pluripotent stem cell-derived lung organoids with HER2 overexpression. 査読 国際誌

    Akihiro Miura, Daisuke Yamada, Masahiro Nakamura, Shuta Tomida, Dai Shimizu, Yan Jiang, Tomoka Takao, Hiromasa Yamamoto, Ken Suzawa, Kazuhiko Shien, Masaomi Yamane, Masakiyo Sakaguchi, Shinichi Toyooka, Takeshi Takarada

    International journal of cancer   149 ( 8 )   1593 - 1604   2021年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Lung adenocarcinoma (LUAD) is the most common types among lung cancers generally arising from terminal airway and understanding of multistep carcinogenesis is crucial to develop novel therapeutic strategy for LUAD. Here we used human induced pluripotent stem cells (hiPSCs) to establish iHER2-hiPSCs in which doxycycline induced the expression of the oncoprotein human epidermal growth factor receptor 2 (HER2)/ERBB2. Lung progenitors that differentiated from iHER2-hiPSCs, which expressed NKX2-1/TTF-1 known as a lung lineage maker, were cocultured with human fetal fibroblast and formed human lung organoids (HLOs) comprising alveolar type 2-like cells. HLOs that overexpressed HER2 transformed to tumor-like structures similar to atypical adenomatous hyperplasia, which is known for lung precancerous lesion and upregulated the activities of oncogenic signaling cascades such as RAS/RAF/MAPK and PI3K/AKT/mTOR. The degree of morphological irregularity and proliferation capacity were significantly higher in HLOs from iHER2-hiPSCs. Moreover, the transcriptome profile of the HLOs shifted from a normal lung tissue-like state to one characteristic of clinical LUAD with HER2 amplification. Our results suggest that hiPSC-derived HLOs may serve as a model to recapitulate the early tumorigenesis of LUAD and would provide new insights into the molecular basis of tumor initiation and progression.

    DOI: 10.1002/ijc.33713

    PubMed

    researchmap

  • マウス異所性気管移植モデルを用いたS100A8/A9抗体の慢性移植肺機能不全に対する効果の検討

    清水 大, 岡崎 幹生, 木下 理恵, 中田 憲太郎, 三好 健太郎, 大谷 真二, 杉本 誠一郎, 山根 正修, 阪口 政清, 豊岡 伸一

    移植   56 ( 総会臨時 )   369 - 369   2021年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本移植学会  

    researchmap

  • Inhibitory effects of RAGE-aptamer on development of monocrotaline-induced pulmonary arterial hypertension in rats. 査読 国際誌

    Kazufumi Nakamura, Satoshi Akagi, Kentaro Ejiri, Masashi Yoshida, Toru Miyoshi, Masakiyo Sakaguchi, Naofumi Amioka, Luh Oliva Saraswati Suastika, Megumi Kondo, Rie Nakayama, Yoichi Takaya, Yuichiro Higashimoto, Kei Fukami, Hiromi Matsubara, Hiroshi Ito

    Journal of cardiology   78 ( 1 )   12 - 16   2021年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The receptor for advanced glycation end products (RAGE), a transmembrane receptor belonging to the immunoglobulin superfamily, is overexpressed in pulmonary artery smooth muscle cells (PASMCs) in patients with pulmonary arterial hypertension (PAH) and is implicated in the etiology of PAH. Recently, we reported that RAGE-aptamer, a short and single-stranded DNA directed against RAGE, inhibited an inappropriate increase in cultured PASMCs in PAH. The aim of this study was to determine the efficacy of RAGE-aptamer in monocrotaline-induced PAH in rats. METHODS AND RESULTS: Rats were assigned to either an untreated control group, a group that received continuous subcutaneous administration of RAGE-aptamer immediately after monocrotaline injection, or a group that received control-aptamer immediately after monocrotaline injection. All rats survived 21 days after injection of monocrotaline and control-aptamer or RAGE-aptamer. Injection of monocrotaline with continuous subcutaneous delivery of control-aptamer resulted in higher right ventricular systolic pressure compared with controls. This increase was attenuated by continuous subcutaneous delivery of RAGE-aptamer. The proportion of small pulmonary arteries with full muscularization was greater in the monocrotaline and control-aptamer group than in the control group. Continuous subcutaneous delivery of RAGE-aptamer significantly reduced the percentage of small pulmonary arteries with full muscularization. CONCLUSIONS: Continuous subcutaneous delivery of RAGE-aptamer suppresses development of monocrotaline-induced PAH in rats. Inhibition of RAGE ameliorates muscularization of small pulmonary arteries. Treatment with RAGE-aptamer might be a new therapeutic option for PAH.

    DOI: 10.1016/j.jjcc.2020.12.009

    PubMed

    researchmap

  • PLOD2-driven IL-6/STAT3 signaling promotes the invasion and metastasis of oral squamous cell carcinoma via activation of integrin β1. 査読 国際誌

    Ken Saito, Ayaka Mitsui, I Wayan Sumardika, Yusuke Yokoyama, Masakiyo Sakaguchi, Eisaku Kondo

    International journal of oncology   58 ( 6 )   2021年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We previously reported that high expression of procollagen‑lysine 2‑oxoglutarate 5‑dioxygenase 2 (PLOD2) leads to stabilization and plasma membrane translocation of integrin β1 to promote the invasion and metastasis of oral squamous cell carcinoma (SCC). The present study aimed to further understand the relationship between PLOD2‑integrin β1 signaling and the tumor microenvironment. This study provided further advanced insights indicating that elevated interleukin (IL)‑6 in the tumor microenvironment acts as a key molecule that triggers PLOD2‑integrin β1 axis‑derived acceleration of tumor invasion and metastasis. It was found using the dual‑luciferase reporter assay system that signal transducer and activator of transcription 3 (STAT3) activation by IL‑6 was essential for increasing the expression levels of PLOD2 through direct activation of the PLOD2 promoter in oral SCC, whereas IL‑6 stimulation did not contribute to integrin β1 expression or the subsequent maturation process towards a functional form on the plasma membrane. Furthermore, the expression of IL‑6 in oral SCC tissues was mainly observed in the tumor stroma. Finally, with double immunofluorescence staining, it was found that IL‑6 expression occurred in CD163‑positive M2 macrophages distributed around the tumor nest. These results combined with our previous results indicate that as IL‑6 significantly increases STAT3‑mediated PLOD2 promoter activity, IL‑6 released by M2‑type tumor‑associated macrophages is a crucial factor that promotes PLOD2‑integrin β1 axis‑enhanced invasion and metastasis of oral SCC cells.

    DOI: 10.3892/ijo.2021.5209

    PubMed

    researchmap

  • Presence of Microplastics in Four Types of Shellfish Purchased at Fish Markets in Okayama City, Japan. 査読 国際誌

    Kenichi Yamamoto, Toshiyuki Oshiki, Hiroko Kagawa, Masayoshi Namba, Masakiyo Sakaguchi

    Acta medica Okayama   75 ( 3 )   381 - 384   2021年6月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The worldwide microplastic pollution in our environment is a matter of great concern. Harmful effects of plastics have been reported in various types of organisms including murine animals. We examined the presence of microplastics in four types of shellfish purchased from fish markets in Okayama, Japan and served to the public: short-neck clam (Ruditapes philippinarum, asari in Japanese), hard-shell clam (Meretrix lusoria, hamaguri), brackishwater clam (Cyrenidae, shijimi), and oyster (Crassostrea gigas, kaki). Our analyses demonstrated that approx. 3 pieces of microplastics were present per single shellfish, based on the division of the total number of pieces of microplastic obtained from all 4 types of shellfish by the total number of shellfish examined. Since health problems in humans due to microplastics have not yet been confirmed, further examinations of the effects of ingested microplastics are needed.

    DOI: 10.18926/AMO/62234

    PubMed

    researchmap

  • 肺腺癌におけるSpred2の発現と増殖、浸潤との関連の検討

    太田 陽子, 藤澤 真義, 吉村 禎造, スマルディカ・イワヤン, 枝園 和彦, 阪口 政清, 豊岡 伸一, 松川 昭博

    日本病理学会会誌   110 ( 1 )   291 - 291   2021年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本病理学会  

    researchmap

  • 異なる亜集団の腫瘍細胞から放出されたエクソソームWnt7aによリ4T1細胞の転移は促進される(4T1 cells promote tumor metastasis by exosomal Wnt7a released from distinct subpopulations)

    李 春寧, 大原 利章, 藤澤 真義, 阪口 政清, 山本 健一, 田 ミャオ, 王 宇沢, 吉村 禎造, 松川 昭博

    日本病理学会会誌   110 ( 1 )   231 - 231   2021年3月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本病理学会  

    researchmap

  • Histidine-Rich Glycoprotein Stimulates Human Neutrophil Phagocytosis and Prolongs Survival through CLEC1A. 査読 国際誌

    Yohei Takahashi, Hidenori Wake, Masakiyo Sakaguchi, Yukinori Yoshii, Kiyoshi Teshigawara, Dengli Wang, Masahiro Nishibori

    Journal of immunology (Baltimore, Md. : 1950)   206 ( 4 )   737 - 750   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Histidine-rich glycoprotein (HRG) is a multifunctional plasma protein and maintains the homeostasis of blood cells and vascular endothelial cells. In the current study, we demonstrate that HRG and recombinant HRG concentration dependently induced the phagocytic activity of isolated human neutrophils against fluorescence-labeled Escherichia coli and Staphylococcus aureus through the stimulation of CLEC1A receptors, maintaining their spherical round shape. The phagocytosis-inducing effects of HRG were inhibited by a specific anti-HRG Ab and enhanced by opsonization of bacteria with diluted serum. HRG and C5a prolonged the survival time of isolated human neutrophils, in association with a reduction in the spontaneous production of extracellular ROS. In contrast, HRG maintained the responsiveness of neutrophils to TNF-α, zymosan, and E. coli with regard to reactive oxygen species production. The blocking Ab for CLEC1A and recombinant CLEC1A-Fc fusion protein significantly inhibited the HRG-induced neutrophil rounding, phagocytic activity, and prolongation of survival time, suggesting the involvement of the CLEC1A receptor in the action of HRG on human neutrophils. These results as a whole indicated that HRG facilitated the clearance of E. coli and S. aureus by maintaining the neutrophil morphology and phagocytosis, contributing to the antiseptic effects of HRG in vivo.

    DOI: 10.4049/jimmunol.2000817

    PubMed

    researchmap

  • The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis. 査読 国際誌

    Kota Araki, Rie Kinoshita, Nahoko Tomonobu, Yuma Gohara, Shuta Tomida, Yuta Takahashi, Satoru Senoo, Akihiko Taniguchi, Junko Itano, Ken-Ichi Yamamoto, Hitoshi Murata, Ken Suzawa, Kazuhiko Shien, Hiromasa Yamamoto, Mikio Okazaki, Seiichiro Sugimoto, Kouichi Ichimura, Masahiro Nishibori, Nobuaki Miyahara, Shinichi Toyooka, Masakiyo Sakaguchi

    Journal of molecular medicine (Berlin, Germany)   99 ( 1 )   131 - 145   2021年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    In patients with interstitial pneumonia, pulmonary fibrosis is an irreversible condition that can cause respiratory failure. Novel treatments for pulmonary fibrosis are necessary. Inflammation is thought to activate lung fibroblasts, resulting in pulmonary fibrosis. Of the known inflammatory molecules, we have focused on S100A8/A9 from the onset of inflammation to the subsequent progression of inflammation. Our findings confirmed the high expression of S100A8/A9 in specimens from patients with pulmonary fibrosis. An active role of S100A8/A9 was demonstrated not only in the proliferation of fibroblasts but also in the fibroblasts' differentiation to myofibroblasts (the active form of fibroblasts). S100A8/A9 also forced fibroblasts to upregulate the production of collagen. These effects were induced via the receptor of S100A8/A9, i.e., the receptor for advanced glycation end products (RAGE), on fibroblasts. The anti-S100A8/A9 neutralizing antibody inhibited the effects of S100A8/A9 on fibroblasts and suppressed the progression of fibrosis in bleomycin (BLM)-induced pulmonary fibrosis mouse model. Our findings strongly suggest a crucial role of S100A8/A9 in pulmonary fibrosis and the usefulness of S100A8/A9-targeting therapy for fibrosis interstitial pneumonia. HIGHLIGHTS: S100A8/A9 level is highly upregulated in the IPF patients' lungs as well as the blood. S100A8/A9 promotes not only the growth of fibroblasts but also differentiation to myofibroblasts. The cell surface RAGE acts as a crucial receptor to the extracellular S100A8/A9 in fibroblasts. The anti-S100A8/A9 antibody effectively suppresses the progression of IPF in a mouse model. In idiopathic pulmonary fibrosis (IPF), S100A8/A9, a heterodimer composed of S100A8 and S100A9 proteins, plays a crucial role in the onset of inflammation and the subsequent formation of a feed-forward inflammatory loop that promotes fibrosis. (1) The local, pronounced increase in S100A8/A9 in the injured inflammatory lung region-which is provided mainly by the activated neutrophils and macrophages-exerts strong inflammatory signals accompanied by dozens of inflammatory soluble factors including cytokines, chemokines, and growth factors that further act to produce and secrete S100A8/A9, eventually making a sustainable inflammatory circuit that supplies an indefinite presence of S100A8/A9 in the extracellular space with a mal-increased level. (2) The elevated S100A8/A9 compels fibroblasts to activate through receptor for advanced glycation end products (RAGE), one of the major S100A8/A9 receptors, resulting in the activation of NFκB, leading to fibroblast mal-events (e.g., elevated cell proliferation and transdifferentiation to myofibroblasts) that actively produce not only inflammatory cytokines but also collagen matrices. (3) Finally, the S100A8/A9-derived activation of lung fibroblasts under a chronic inflammation state leads to fibrosis events and constantly worsens fibrosis in the lung. Taken together, these findings suggest that the extracellular S100A8/A9 heterodimer protein is a novel mainstay soluble factor for IPF that exerts many functions as described above (1-3). Against this background, we herein applied the developed S100A8/A9 neutralizing antibody to prevent IPF. The IPF imitating lung fibrosis in an IPF mouse model was effectively blocked by treatment with the antibody, leading to enhanced survival. The developed S100A8/A9 antibody, as an innovative novel biologic, may help shed light on the difficulties encountered with IPF therapy in clinical settings.

    DOI: 10.1007/s00109-020-02001-x

    PubMed

    researchmap

  • RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion. 査読 国際誌

    Fang He, Yoshinori Matsumoto, Yosuke Asano, Yuriko Yamamura, Takayuki Katsuyama, Jose La Rose, Nahoko Tomonobu, Ni Luh Gede Yoni Komalasari, Masakiyo Sakaguchi, Robert Rottapel, Jun Wada

    Frontiers in oncology   11   665273 - 665273   2021年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Activity of transcription factors is normally regulated through interaction with other transcription factors, chromatin remodeling proteins and transcriptional co-activators. In distinction to these well-established transcriptional controls of gene expression, we have uncovered a unique activation model of transcription factors between tyrosine kinase ABL and RUNX2, an osteoblastic master transcription factor, for cancer invasion. We show that ABL directly binds to, phosphorylates, and activates RUNX2 through its SH2 domain in a kinase activity-dependent manner and that the complex formation of these proteins is required for expression of its target gene MMP13. Additionally, we show that the RUNX2 transcriptional activity is dependent on the number of its tyrosine residues that are phosphorylated by ABL. In addition to regulation of RUNX2 activity, we show that ABL transcriptionally enhances RUNX2 expression through activation of the bone morphogenetic protein (BMP)-SMAD pathway. Lastly, we show that ABL expression in highly metastatic breast cancer MDA-MB231 cells is associated with their invasive capacity and that ABL-mediated invasion is abolished by depletion of endogenous RUNX2 or MMP13. Our genetic and biochemical evidence obtained in this study contributes to a mechanistic insight linking ABL-mediated phosphorylation and activation of RUNX2 to induction of MMP13, which underlies a fundamental invasive capacity in cancer and is different from the previously described model of transcriptional activation.

    DOI: 10.3389/fonc.2021.665273

    PubMed

    researchmap

  • Analysis of a plasmid encoding botulinum neurotoxin type G gene in Clostridium argentinense. 査読 国際誌

    Yoshihiko Sakaguchi, Jumpei Uchiyama, Akira Také, Kazuyoshi Gotoh, Masakiyo Sakaguchi, Tomonori Suzuki, Yumiko Yamamoto, Koji Hosomi, Tomoko Kohda, Masafumi Mukamoto, Shunji Kozaki, Shunji Hayashi, Keiji Oguma

    Anaerobe   66   102281 - 102281   2020年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Clostridium argentinense produces botulinum neurotoxin type G (BoNT/G). We sequenced and analyzed the plasmid harboring the bont/G gene, designated pCAG, in C. argentinense strain 2740. The pCAG consisted of 140,070 bp containing the bont/G gene cluster. Although this gene cluster showed high similarities in its DNA sequence and ORF arrangement to those of other bont gene clusters, the other regions of the plasmid did not. A phylogenetic study suggested that pCAG had a unique evolutionary history compared with other clostridial bont-harboring plasmids. This suggests that pCAG is possibly a novel type of plasmid expressing the bont/G gene in C. argentinense.

    DOI: 10.1016/j.anaerobe.2020.102281

    PubMed

    researchmap

  • Enhancement of intestinal epithelial barrier function by Weissella confusa F213 and Lactobacillus rhamnosus FBB81 probiotic candidates in an in vitro model of hydrogen peroxide-induced inflammatory bowel disease. 査読 国際誌

    Ni Nengah Dwi Fatmawati, Kazuyoshi Gotoh, I Putu Bayu Mayura, Komang Ayu Nocianitri, Gede Ngurah Rsi Suwardana, Ni Luh Gede Yoni Komalasari, Yan Ramona, Masakiyo Sakaguchi, Osamu Matsushita, I Nengah Sujaya

    BMC research notes   13 ( 1 )   489 - 489   2020年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: Weissella confusa F213 (WCF213) and Lactobacillus rhamnosus FBB81 (LrFBB81) are two probiotic candidates isolated from humans in our previous study. Their functional activity on the mucosal barrier has not yet been adequately investigated. Therefore, the objective of this study was to investigate the effect of these strains on maintaining mucosal integrity in vitro. Caco-2 cell monolayers were pretreated with WCF213 and LrFBB81 before being exposed to hydrogen peroxide. The integrity of mucosal cells was evaluated by measuring the transepithelial resistance (TER), flux of FITC-labelled dextran, and ZO-1 protein distribution with the help of an immunofluorescence method. RESULTS: WCF213 was found to significantly maintain the TER better than the control hydrogen peroxide-treated cells (p < 0.001), followed by the strain combination, and LrFBB81 alone (p < 0.05). The permeability of mucosa was also successfully maintained by the WCF213 strain. This was illustrated by the significant reduction in the flux of FITC-labelled dextran (p < 0.05), which was larger than that exhibited by the other groups. The ZO-1 distribution of strain-treated cells showed less disruption than hydrogen peroxide-treated cells, consistent with the TER and FITC experimental results. These findings indicate that WCF213 and LrFBB81 plays important roles in the maintenance of mucosal integrity in a strain-dependent manner.

    DOI: 10.1186/s13104-020-05338-1

    PubMed

    researchmap

  • Synergistic regulation of hepatic Fsp27b expression by HNF4α and CREBH. 査読 国際誌

    Carlos Ichiro Kasano-Camones, Masayuki Takizawa, Wakana Iwasaki, Shota Sasaki, Mume Hamada, Aoi Morimoto, Masakiyo Sakaguchi, Frank J Gonzalez, Yusuke Inoue

    Biochemical and biophysical research communications   530 ( 2 )   432 - 439   2020年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The CIDE (cell death-inducing DFF45-like effector) family composed of CIDEA, CIDEB, CIDEC/FSP27 (fat-specific protein 27), has a critical role in growth of lipid droplets. Of these, CIDEB and CIDEC2/FSP27B are abundant in the liver, and the steatotic livers, respectively. Hepatocyte nuclear factor 4α (HNF4α) has an important role in lipid homeostasis because liver-specific HNF4α-null mice (Hnf4aΔHep mice) exhibit hepatosteatosis. We investigated whether HNF4α directly regulates expression of CIDE family genes. Expression of Cideb and Fsp27b was largely decreased in Hnf4aΔHep mice, while expression of Cidea was increased. Similar results were observed only in CIDEC2, the human orthologue of the Fsp27b, in human hepatoma cell lines in which HNF4α expression was knocked down. Conversely, overexpression of HNF4α strongly induced CIDEC2 expression in hepatoma cell lines. Furthermore, HNF4α transactivated Fsp27b by direct binding to an HNF4α response element in the Fsp27b promoter. In addition, Fsp27b is known to be transactivated by CREBH that is regulated by HNF4α, and expression of CREBH was induced by HNF4α in human hepatoma cells. Co-transfection of HNF4α and CREBH resulted in synergistic transactivation and induction of Fsp27b compared to that of HNF4α or CREBH alone. These results suggest that HNF4α, in conjunction with CREBH, plays an important role in regulation of Fsp27b expression.

    DOI: 10.1016/j.bbrc.2020.05.070

    PubMed

    researchmap

  • Cytotoxic Effects of Alcohol Extracts from a Plastic Wrap (Polyvinylidene Chloride) on Human Cultured Liver Cells and Mouse Primary Cultured Liver Cells. 査読

    Ken-Ichi Yamamoto, Hiroko Kagawa, Sakae Arimoto, Xian Wen Tan, Kento Yasui, Toshiyuki Oshiki, Masakiyo Sakaguchi

    Acta medica Okayama   74 ( 4 )   327 - 334   2020年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    An increasing accumulation of microplastics and further degraded nanoplastics in our environment is suspected to have harmful effects on humans and animals. To clarify this problem, we tested the cytotoxicity of two types of plastic wrap on human cultured liver cells and mouse primary cultured liver cells. Alcohol extracts from plastic wrap, i.e., polyvinylidene chloride (PVDC), showed cytotoxic effects on the cells. Alcohol extracts of polyethylene (PE) wrap were not toxic. The commercially available PVDC wrap consists of vinylidene chloride, epoxidized soybean oil, epoxidized linseed oil as a stiffener and stabilizer; we sought to identify which component(s) are toxic. The epoxidized soybean oil and epoxidized linseed oil exerted strong cytotoxicity, but the plastic raw material itself, vinylidene chloride, did not. Our findings indicate that plastic wraps should be used with caution in order to prevent health risks.

    DOI: 10.18926/AMO/60371

    PubMed

    researchmap

  • Neuroplastinβ-mediated upregulation of solute carrier family 22 member 18 antisense (SLC22A18AS) plays a crucial role in the epithelial-mesenchymal transition, leading to lung cancer cells' enhanced motility. 査読 国際誌

    Karolina Bajkowska, I Wayan Sumardika, Nahoko Tomonobu, Youyi Chen, Ken-Ichi Yamamoto, Rie Kinoshita, Hitoshi Murata, Ni Luh Gede Yoni Komalasari, Fan Jiang, Akira Yamauchi, I Made Winarsa Ruma, Carlos Ichiro Kasano-Camones, Yusuke Inoue, Masakiyo Sakaguchi

    Biochemistry and biophysics reports   22   100768 - 100768   2020年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    Our recent study revealed an important role of the neuroplastin (NPTN)β downstream signal in lung cancer dissemination in the lung. The molecular mechanism of the signal pathway downstream of NPTNβ is a serial activation of the key molecules we identified: tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) adaptor, nuclear factor (NF)IA/NFIB heterodimer transcription factor, and SAM pointed-domain containing ETS transcription factor (SPDEF). The question of how dissemination is controlled by SPDEF under the activated NPTNβ has not been answered. Here, we show that the NPTNβ-SPDEF-mediated induction of solute carrier family 22 member 18 antisense (SLC22A18AS) is definitely required for the epithelial-mesenchymal transition (EMT) through the NPTNβ pathway in lung cancer cells. In vitro, the induced EMT is linked to the acquisition of active cellular motility but not growth, and this is correlated with highly disseminative tumor progression in vivo. The publicly available data also show the poor survival of SLC22A18AS-overexpressing lung cancer patients. Taken together, these data highlight a crucial role of SLC22A18AS in lung cancer dissemination, which provides novel input of this molecule to the signal cascade of NPTNβ. Our findings contribute to a better understanding of NPTNβ-mediated lung cancer metastasis.

    DOI: 10.1016/j.bbrep.2020.100768

    PubMed

    researchmap

  • Histidine-Rich Glycoprotein Inhibits High-Mobility Group Box-1-Mediated Pathways in Vascular Endothelial Cells through CLEC-1A. 査読 国際誌

    Shangze Gao, Hidenori Wake, Masakiyo Sakaguchi, Dengli Wang, Youhei Takahashi, Kiyoshi Teshigawara, Hui Zhong, Shuji Mori, Keyue Liu, Hideo Takahashi, Masahiro Nishibori

    iScience   23 ( 6 )   101180 - 101180   2020年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    High-mobility group box-1 (HMGB1) protein has been postulated to play a pathogenic role in severe sepsis. Histidine-rich glycoprotein (HRG), a 75 kDa plasma protein, was demonstrated to improve the survival rate of septic mice through the regulation of neutrophils and endothelium barrier function. As the relationship of HRG and HMGB1 remains poorly understood, we investigated the effects of HRG on HMGB1-mediated pathway in endothelial cells, focusing on the involvement of specific receptors for HRG. HRG potently inhibited the HMGB1 mobilization and effectively suppressed rHMGB1-induced inflammatory responses and expression of all three HMGB1 receptors in endothelial cells. Moreover, we first clarified that these protective effects of HRG on endothelial cells were mediated through C-type lectin domain family 1 member A (CLEC-1A) receptor. Thus, current study elucidates protective effects of HRG on vascular endothelial cells through inhibition of HMGB1-mediated pathways may contribute to the therapeutic effects of HRG on severe sepsis.

    DOI: 10.1016/j.isci.2020.101180

    PubMed

    researchmap

  • MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions. 査読 国際誌

    Hiroki Sato, Adam J Schoenfeld, Evan Siau, Yue Christine Lu, Huichun Tai, Ken Suzawa, Daisuke Kubota, Allan J W Lui, Besnik Qeriqi, Marissa Mattar, Michael Offin, Masakiyo Sakaguchi, Shinichi Toyooka, Alexander Drilon, Neal X Rosen, Mark G Kris, David Solit, Elisa De Stanchina, Monika A Davare, Gregory J Riely, Marc Ladanyi, Romel Somwar

    Clinical cancer research : an official journal of the American Association for Cancer Research   26 ( 12 )   2932 - 2945   2020年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: ROS1 tyrosine kinase inhibitors (TKI) provide significant benefit in lung adenocarcinoma patients with ROS1 fusions. However, as observed with all targeted therapies, resistance arises. Detecting mechanisms of acquired resistance (AR) is crucial to finding novel therapies and improve patient outcomes. EXPERIMENTAL DESIGN: ROS1 fusions were expressed in HBEC and NIH-3T3 cells either by cDNA overexpression (CD74/ROS1, SLC34A2/ROS1) or CRISPR-Cas9-mediated genomic engineering (EZR/ROS1). We reviewed targeted large-panel sequencing data (using the MSK-IMPACT assay) patients treated with ROS1 TKIs, and genetic alterations hypothesized to confer AR were modeled in these cell lines. RESULTS: Eight of the 75 patients with a ROS1 fusion had a concurrent MAPK pathway alteration and this correlated with shorter overall survival. In addition, the induction of ROS1 fusions stimulated activation of MEK/ERK signaling with minimal effects on AKT signaling, suggesting the importance of the MAPK pathway in driving ROS1 fusion-positive cancers. Of 8 patients, 2 patients harbored novel in-frame deletions in MEK1 (MEK1delE41_L54) and MEKK1 (MEKK1delH907_C916) that were acquired after ROS1 TKIs, and 2 patients harbored NF1 loss-of-function mutations. Expression of MEK1del or MEKK1del, and knockdown of NF1 in ROS1 fusion-positive cells activated MEK/ERK signaling and conferred resistance to ROS1 TKIs. Combined targeting of ROS1 and MEK inhibited growth of cells expressing both ROS1 fusion and MEK1del. CONCLUSIONS: We demonstrate that downstream activation of the MAPK pathway can mediate of innate acquired resistance to ROS1 TKIs and that patients harboring ROS1 fusion and concurrent downstream MAPK pathway alterations have worse survival. Our findings suggest a treatment strategy to target both aberrations.

    DOI: 10.1158/1078-0432.CCR-19-3321

    PubMed

    researchmap

  • Xylitol acts as an anticancer monosaccharide to induce selective cancer death via regulation of the glutathione level. 査読 国際誌

    Nahoko Tomonobu, Ni Luh Gede Yoni Komalasari, I Wayan Sumardika, Fan Jiang, Youyi Chen, Ken-Ichi Yamamoto, Rie Kinoshita, Hitoshi Murata, Yusuke Inoue, Masakiyo Sakaguchi

    Chemico-biological interactions   324   109085 - 109085   2020年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Herbal medicines and their bioactive compounds are increasingly being recognized as useful drugs for cancer treatments. The parasitic fungus Cordyceps militaris is an attractive anticancer herbal since it shows very powerful anticancer activity due to its phytocompound cordycepin. We previously discovered and reported that a high amount of xylitol is present in Cordyceps militaris extract, and that xylitol unexpectedly showed anticancer activity in a cancer-selective manner. We thus hypothesized that xylitol could become a useful supplement to help prevent various cancers, if we can clarify the specific machinery by which xylitol induces cancer cell death. It is also unclear whether xylitol acts on cancer suppression in vivo as well as in vitro. Here we show for the first time that induction of the glutathione-degrading enzyme CHAC1 is the main cause of xylitol-induced apoptotic cell death in cancer cells. The induction of CHAC1 is required for the endoplasmic reticulum (ER) stress that is triggered by xylitol in cancer cells, and is linked to a second induction of oxidative stress in the treated cells, and eventually leads to apoptotic cell death. Our in vivo approach also demonstrated that an intravenous injection of xylitol had a tumor-suppressing effect in mice, to which the xylitol-triggered ER stress also greatly contributed. We also observed that xylitol efficiently sensitized cancer cells to chemotherapeutic drugs. Based on our findings, a chemotherapeutic strategy combined with xylitol might improve the outcomes of patients facing cancer.

    DOI: 10.1016/j.cbi.2020.109085

    PubMed

    researchmap

  • exMCAM-Fc, an S100A8/A9-mediated-metastasis blocker, efficiently reduced the number of circulating tumor cells that appeared in the blood flow. 査読 国際誌

    Nahoko Tomonobu, Rie Kinoshita, Masakiyo Sakaguchi

    Molecular biology reports   47 ( 6 )   4879 - 4883   2020年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Metastasis is the major cause of treatment failure in cancer patients and of cancer-associated death so that therapeutic regulation of metastasis is very important subject for the cancer treatment. We have been reported that S100A8/A9, a heterodimer complex of S100A8 and S100A9, and its receptors play a crucial role in the lung tropic cancer metastasis, i.e., S100A8/A9 is actively secreted from the lung when cancer mass exists even at remote area from the lung and then functions to attract the distant cancer cells to the lung since cancer cells own the S100A8/A9 receptor(s) on their cell surface. Interestingly, one of the newly developed decoys, exMCAM-Fc, a Fc fusion protein with the extracellular region of melanoma cell adhesion molecule (MCAM), one of the S100A8/A9 receptors, that could prevent the interaction of S100A8/A9 with MCAM, efficiently suppressed the lung tropic cancer metastasis through exerting the several inhibitory effects on the S100A8/A9-mediated cancer cell events including enhanced mobility, invasion and attachment to the endothelial cells. However, it still remains to clarify if the decoy will reduce the number of circulating tumor cells (CTCs) that are defined as substantial cells in the context of organ tropic cancer metastasis. Here, we first show that exMCAM-Fc effectively reduces the number of CTCs in the blood flow of the melanoma bearing mice. The novel finding reinforces the suppressive role of exMCAM-Fc on the cancer metastasis. We therefore expect that exMCAM-Fc may greatly contribute to reduce treatment failure by the efficient blocking of the life threatening cancer metastasis.

    DOI: 10.1007/s11033-020-05495-3

    PubMed

    researchmap

  • Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation. 査読 国際誌

    Shunsaku Miyauchi, Kazuhiko Shien, Tatsuaki Takeda, Kota Araki, Kentaro Nakata, Akihiro Miura, Yuta Takahashi, Eisuke Kurihara, Yusuke Ogoshi, Kei Namba, Ken Suzawa, Hiromasa Yamamoto, Mikio Okazaki, Junichi Soh, Shuta Tomida, Masaomi Yamane, Masakiyo Sakaguchi, Shinichi Toyooka

    Anticancer research   40 ( 5 )   2667 - 2673   2020年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND/AIM: The therapeutic strategy for patients with non-small-cell lung cancer (NSCLC) harboring the BRAF non-V600E mutation has not been established. LY3009120, a newly discovered pan-RAF inhibitor, has shown strong antitumor effects in cancers with various BRAF genotypes. This study investigated the antitumor effects of LY3009120 in NSCLC cells harboring the BRAF non-V600E mutation. MATERIALS AND METHODS: We examined the antitumor effects of LY3009120 by MTS assay and flow cytometry. We analyzed the expression status of proteins by western blot. The mouse xenograft models were used for the in vivo experiments. RESULTS: LY3009120 suppressed BRAF-related downstream pathway molecules and induced cleavage of poly ADP-ribose polymerase in all examined NSCLC cell lines. LY3009120 also inhibited in vivo tumor growth in NSCLC cells harboring the BRAF non-V600E mutation. CONCLUSION: LY3009120 is a potent therapeutic agent for patients with BRAF non-V600E mutant NSCLC.

    DOI: 10.21873/anticanres.14237

    PubMed

    researchmap

  • S100 Soil Sensor Receptors and Molecular Targeting Therapy Against Them in Cancer Metastasis. 査読 国際誌

    Nahoko Tomonobu, Rie Kinoshita, Masakiyo Sakaguchi

    Translational oncology   13 ( 4 )   100753 - 100753   2020年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The molecular mechanisms underlying the 'seed and soil' theory are unknown. S100A8/A9 (a heterodimer complex of S100A8 and S100A9 proteins that exhibits a 'soil signal') is a ligand for Toll-like receptor 4, causing distant melanoma cells to approach the lung as a 'seeding' site. Unknown soil sensors for S100A8/A9 may exist, e.g., extracellular matrix metalloproteinase inducer, neuroplastin, activated leukocyte cell adhesion molecule, and melanoma cell adhesion molecule. We call these receptor proteins 'novel S100 soil sensor receptors (novel SSSRs).' Here we review and summarize a crucial role of the S100A8/A9-novel SSSRs' axis in cancer metastasis. The binding of S100A8/A9 to individual SSSRs is important in cancer metastasis via upregulations of the epithelial-mesenchymal transition, cellular motility, and cancer cell invasiveness, plus the formation of an inflammatory immune suppressive environment in metastatic organ(s). These metastatic cellular events are caused by the SSSR-featured signal transductions we identified that provide cancer cells a driving force for metastasis. To deprive cancer cells of these metastatic forces, we developed novel biologics that prevent the interaction of S100A8/A9 with SSSRs, followed by the efficient suppression of S100A8/A9-mediated lung-tropic metastasis in vivo.

    DOI: 10.1016/j.tranon.2020.100753

    PubMed

    researchmap

  • PLOD2 Is Essential to Functional Activation of Integrin β1 for Invasion/Metastasis in Head and Neck Squamous Cell Carcinomas. 査読 国際誌

    Yushi Ueki, Ken Saito, Hidekazu Iioka, Izumi Sakamoto, Yasuhiro Kanda, Masakiyo Sakaguchi, Arata Horii, Eisaku Kondo

    iScience   23 ( 2 )   100850 - 100850   2020年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Identifying the specific functional regulator of integrin family molecules in cancer cells is critical because they are directly involved in tumor invasion and metastasis. Here we report high expression of PLOD2 in oropharyngeal squamous cell carcinomas (SCCs) and its critical role as a stabilizer of integrin β1, enabling integrin β1 to initiate tumor invasion/metastasis. Integrin β1 stabilized by PLOD2-mediated hydroxylation was recruited to the plasma membrane, its functional site, and accelerated tumor cell motility, leading to tumor metastasis in vivo, whereas loss of PLOD2 expression abrogated it. In accordance with molecular analysis, examination of oropharyngeal SCC tissues from patients corroborated PLOD2 expression associated with integrin β1 at the invasive front of tumor nests. PLOD2 is thus implicated as the key regulator of integrin β1 that prominently regulates tumor invasion and metastasis, and it provides important clues engendering novel therapeutics for these intractable cancers.

    DOI: 10.1016/j.isci.2020.100850

    PubMed

    researchmap

  • Caco-2 cells monolayer as an in-vitro model for probiotic strain translocation

    Ni Nengah Dwi Fatmawati, Kazuyoshi Goto, I. Putu Bayu Mayura, Komang Ayu Nocianitri, Yan Ramona, Masakiyo Sakaguchi, Osamu Matsushita, I. Nengah Sujaya

    Bali Medical Journal   9 ( 1 )   137 - 142   2020年

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Background: Caco-2 cells monolayer is one of in vitro models to evaluate the translocation capacity of Lactobacillus spp probiotic strains. The translocation is influenced by mucosa permeability of enterocytes as shown by increasing transepithelial resistance (TER) and formation of tight junction proteins. The pore size of the supported permeable membrane used in in vitro assay was one of the crucial factors in performing bacterial translocation assay. Almost no study has been conducted using Caco-2 cells monolayer grown on 8-μm pore size polycarbonate membrane for evaluating probiotics translocation. Therefore this study aimed to determine whether the Caco-2 cells monolayer model was suitable as an in vitro translocation model. Methods: Caco-2 cells monolayer was seeded onto 8-μm collagen-coated polycarbonate membrane insert Transwell®. Differentiation of Caco-2 cells was detected by measuring the TER, while the ZO-1 protein (the tight junction proteins) was detected by immunofluorescence. H2 O2 was used as a tight junction disruptive agent. Data were analyzed using SPSS version 23 software to compare the mean of TER measurement between untreated and H2 O2-treated Caco-2 cells monolayer. Results: The result showed that the TER of Caco-2 cells monolayer was gradually increasing until day 14, reaching more than 800 ohm.cm2. Furthermore, the ZO-1 protein was successfully detected, indicated the tight junction formation. TER value of H2 O2-treated cells showed significantly lower than that of untreated cells (P<0.05), indicating a disturbance of cells monolayer integrity. Lactobacillus rhamnosus FBB81 was used for validating the translocation. There was no translocation observed; however, translocation was observed in H2 O2-treated cells. Conclusion: Altogether suggests that Caco-2 cells grown on 8 μm-pore size permeable filters could be considered as a suitable in vitro model for probiotics strains translocation.

    DOI: 10.15562/bmj.v9i1.1633

    Scopus

    researchmap

  • PODXL1 promotes metastasis of the pancreatic ductal adenocarcinoma by activating the C5aR/C5a axis from the tumor microenvironment. 査読 国際誌

    Ken Saito, Hidekazu Iioka, Satoshi Maruyama, I Wayan Sumardika, Masakiyo Sakaguchi, Eisaku Kondo

    Neoplasia (New York, N.Y.)   21 ( 12 )   1121 - 1132   2019年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Pancreatic invasive ductal adenocarcinoma (PDAC) is a representative intractable malignancy under the current cancer therapies, and is considered a scirrhous carcinoma because it develops dense stroma. Both PODXL1, a member of CD34 family molecules, and C5aR, a critical cell motility inducer, have gained recent attention, as their expression was reported to correlate with poor prognosis for patients with diverse origins including PDAC; however, previous studies reported independently on their respective biological significance. Here we demonstrate that PODXL1 is essential for metastasis of PDAC cells through its specific interaction with C5aR. In vitro assay demonstrated that PODXL1 bound to C5aR, which stabilized C5aR protein and recruited it to cancer cell plasma membranes to receive C5a, an inflammatory chemoattractant factor. PODXL1 knockout in PDAC cells abrogated their metastatic property in vivo, emulating the liver metastatic mouse model treated with anti-C5a neutralizing antibody. In molecular studies, PODXL1 triggered EMT on PDAC cells in response to stimulation by C5a, corroborating PODXL1 involvement in PDAC cellular invasive properties via specific interaction with the C5aR/C5a axis. Confirming the molecular assays, histological examination showed coexpression of PODXL1 and C5aR at the invasive front of primary cancer nests as well as in liver metastatic foci of PDAC both in the mouse metastasis model and patient tissues. Hence, the novel direct interaction between PODXL1 and the C5aR/C5a axis may provide a better integrated understanding of PDAC biological characteristics including its tumor microenvironment factors.

    DOI: 10.1016/j.neo.2019.09.003

    PubMed

    researchmap

  • Crumbs3 promotes metastasis of colon cancer by regulating focal adhesion components 査読

    Iioka Hidekazu, Saito Ken, Sakaguchi Masakiyo, Morii Eiichi, Kondo Eisaku

    CANCER SCIENCE   145 ( 10 )   2740 - 2753   2019年11月

  • Crumbs3 is a critical factor that regulates invasion and metastasis of colon adenocarcinoma via the specific interaction with FGFR1. 査読 国際誌

    Hidekazu Iioka, Ken Saito, Masakiyo Sakaguchi, Taro Tachibana, Keiichi Homma, Eisaku Kondo

    International journal of cancer   145 ( 10 )   2740 - 2753   2019年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Epithelial cell polarity regulator Crumbs3 (Crb3), a mammalian homolog within the Drosophila Crb gene family, was initially identified as an essential embryonic development factor. It is recently implicated in tumor suppression, though its specific functions are controversial. We here demonstrate that Crb3 strongly promotes tumor invasion and metastasis of human colon adenocarcinoma cells. Crb3 centrality to tumor migration was supported by strong expression at invasive front and metastatic foci of colonic adenocarcinoma of the patient tissues. Accordingly, two different Crb3-knockout (KO) lines, Crb3-KO (Crb3 -/-) DLD-1 and Crb3-KO WiDr from human colonic adenocarcinomas, were generated by the CRISPR-Cas9 system. Crb3-KO DLD-1 cells exhibited loss of cellular mobility in vitro and dramatic suppression of liver metastases in vivo in contrast to the wild type of DLD-1. Unlike DLD-1, Crb3-KO WiDr mobility and metastasis were unaffected, which were similar to wild-type WiDr. Proteome analysis of Crb3-coimmunopreciptated proteins identified different respective fibroblast growth factor receptor (FGFR) isotypes specifically bound to Crb3 isoform a through their intracellular domain. In DLD-1, Crb3 showed membranous localization of FGFR1 leading to its functional activation, whereas Crb3 bound to cytoplasmic FGFR4 in WiDr without FGFR1 expression, leading to cellular growth. Correlative expression between Crb3 and FGFR1 was consistently detected in primary and metastatic colorectal cancer patient tissues. Taking these together, Crb3 critically accelerates cell migration, namely invasion and metastasis of human colon cancers, through specific interaction to FGFR1 on colon cancer cells.

    DOI: 10.1002/ijc.32336

    PubMed

    researchmap

  • S100A11は筋浸潤性膀胱癌細胞と線維芽細胞のクロストークに関与し腫瘍進行に寄与する(S100A11 contributes to tumor progression with cross talking between muscle invasive bladder cancer cells and fibroblasts)

    光井 洋介, 定平 卓也, 渡部 昌実, 丸山 雄樹, 荒木 元朗, 渡邉 豊彦, 阪口 政清, 那須 保友

    西日本泌尿器科   81 ( 増刊 )   138 - 138   2019年10月

     詳細を見る

    記述言語:英語   出版者・発行元:西日本泌尿器科学会  

    researchmap

  • Upregulation of Mobility in Pancreatic Cancer Cells by Secreted S100A11 Through Activation of Surrounding Fibroblasts. 査読 国際誌

    Yosuke Mitsui, Nahoko Tomonobu, Masami Watanabe, Rie Kinoshita, I Wayan Sumardika, Chen Youyi, Hitoshi Murata, Ken-Ichi Yamamoto, Takuya Sadahira, Acosta Gonzalez Herik Rodrigo, Hitoshi Takamatsu, Kota Araki, Akira Yamauchi, Masahiro Yamamura, Hideyo Fujiwara, Yusuke Inoue, Junichiro Futami, Ken Saito, Hidekazu Iioka, Eisaku Kondo, Masahiro Nishibori, Shinichi Toyooka, Yasuhiko Yamamoto, Yasutomo Nasu, Masakiyo Sakaguchi

    Oncology research   27 ( 8 )   945 - 956   2019年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    S100A11, a member of the S100 family of proteins, is actively secreted from pancreatic ductal adenocarcinoma (PDAC) cells. However, the role of the extracellular S100A11 in PDAC progression remains unclear. In the present study, we investigated the extracellular role of S100A11 in crosstalking between PDAC cells and surrounding fibroblasts in PDAC progression. An abundant S100A11 secreted from pancreatic cancer cells stimulated neighboring fibroblasts through receptor for advanced glycation end products (RAGE) upon S100A11 binding and was followed by not only an enhanced cancer cell motility in vitro but also an increased number of the PDAC-derived circulating tumor cells (CTCs) in vivo. Mechanistic investigation of RAGE downstream in fibroblasts revealed a novel contribution of a mitogen-activated protein kinase kinase kinase (MAPKKK), tumor progression locus 2 (TPL2), which is required for positive regulation of PDAC cell motility through induction of cyclooxygenase 2 (COX2) and its catalyzed production of prostaglandin E2 (PGE2), a strong chemoattractive fatty acid. The extracellularly released PGE2 from fibroblasts was required for the rise in cellular migration as well as infiltration of their adjacent PDAC cells in a coculture setting. Taken together, our data reveal a novel role of the secretory S100A11 in PDAC disseminative progression through activation of surrounding fibroblasts triggered by the S100A11-RAGE-TPL2-COX2 pathway. The findings of this study will contribute to the establishment of a novel therapeutic antidote to PDACs that are difficult to treat by regulating cancer-associated fibroblasts (CAFs) through targeting the identified pathway.

    DOI: 10.3727/096504019X15555408784978

    PubMed

    researchmap

  • Newly developed anti-S100A8/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis. 査読 国際誌

    Rie Kinoshita, Hiroki Sato, Akira Yamauchi, Yuta Takahashi, Yusuke Inoue, I Wayan Sumardika, Youyi Chen, Nahoko Tomonobu, Kota Araki, Kazuhiko Shien, Shuta Tomida, Hidejiro Torigoe, Kei Namba, Eisuke Kurihara, Yusuke Ogoshi, Hitoshi Murata, Ken-Ichi Yamamoto, Junichiro Futami, Endy Widya Putranto, I Made Winarsa Ruma, Hiromasa Yamamoto, Junichi Soh, Toshihiko Hibino, Masahiro Nishibori, Eisaku Kondo, Shinichi Toyooka, Masakiyo Sakaguchi

    International journal of cancer   145 ( 2 )   569 - 575   2019年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The metastatic dissemination of cancer cells to remote areas of the body is the most problematic aspect in cancer patients. Among cancers, melanomas are notoriously difficult to treat due to their significantly high metastatic potential even during early stages. Hence, the establishment of advanced therapeutic approaches to regulate metastasis is required to overcome the melanoma disease. An accumulating mass of evidence has indicated a critical role of extracellular S100A8/A9 in melanoma distant metastasis. Lung S100A8/A9 is induced by melanoma cells from distant organs and it attracts these cells to its enriched lung environment since melanoma cells possess several receptors that sense the S100A8/A9 ligand. We hence aimed to develop a neutralizing antibody against S100A8/A9 that would efficiently block melanoma lung metastasis. Our protocol provided us with one prominent antibody, Ab45 that efficiently suppressed not only S100A8/A9-mediated melanoma mobility but also lung tropic melanoma metastasis in a mouse model. This prompted us to make chimeric Ab45, a chimera antibody consisting of mouse Ab45-Fab and human IgG2-Fc. Chimeric Ab45 also showed significant inhibition of the lung metastasis of melanoma. From these results, we have high hopes that the newly produced antibody will become a potential biological tool to block melanoma metastasis in future clinical settings.

    DOI: 10.1002/ijc.31982

    PubMed

    researchmap

  • Newly developed anti-S100A8/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis. 査読 国際誌

    Rie Kinoshita, Hiroki Sato, Akira Yamauchi, Yuta Takahashi, Yusuke Inoue, I Wayan Sumardika, Youyi Chen, Nahoko Tomonobu, Kota Araki, Kazuhiko Shien, Shuta Tomida, Hidejiro Torigoe, Kei Namba, Eisuke Kurihara, Yusuke Ogoshi, Hitoshi Murata, Ken-Ichi Yamamoto, Junichiro Futami, Endy Widya Putranto, I Made Winarsa Ruma, Hiromasa Yamamoto, Junichi Soh, Toshihiko Hibino, Masahiro Nishibori, Eisaku Kondo, Shinichi Toyooka, Masakiyo Sakaguchi

    International journal of cancer   145 ( 2 )   569 - 575   2019年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The metastatic dissemination of cancer cells to remote areas of the body is the most problematic aspect in cancer patients. Among cancers, melanomas are notoriously difficult to treat due to their significantly high metastatic potential even during early stages. Hence, the establishment of advanced therapeutic approaches to regulate metastasis is required to overcome the melanoma disease. An accumulating mass of evidence has indicated a critical role of extracellular S100A8/A9 in melanoma distant metastasis. Lung S100A8/A9 is induced by melanoma cells from distant organs and it attracts these cells to its enriched lung environment since melanoma cells possess several receptors that sense the S100A8/A9 ligand. We hence aimed to develop a neutralizing antibody against S100A8/A9 that would efficiently block melanoma lung metastasis. Our protocol provided us with one prominent antibody, Ab45 that efficiently suppressed not only S100A8/A9-mediated melanoma mobility but also lung tropic melanoma metastasis in a mouse model. This prompted us to make chimeric Ab45, a chimera antibody consisting of mouse Ab45-Fab and human IgG2-Fc. Chimeric Ab45 also showed significant inhibition of the lung metastasis of melanoma. From these results, we have high hopes that the newly produced antibody will become a potential biological tool to block melanoma metastasis in future clinical settings.

    DOI: 10.1002/ijc.31982

    PubMed

    researchmap

  • Critical role of the MCAM-ETV4 axis triggered by extracellular S100A8/A9 in breast cancer aggressiveness. 査読 国際誌

    Youyi Chen, I Wayan Sumardika, Nahoko Tomonobu, Rie Kinoshita, Yusuke Inoue, Hidekazu Iioka, Yosuke Mitsui, Ken Saito, I Made Winarsa Ruma, Hiroki Sato, Akira Yamauchi, Hitoshi Murata, Ken-Ichi Yamamoto, Shuta Tomida, Kazuhiko Shien, Hiromasa Yamamoto, Junichi Soh, Junichiro Futami, Miyoko Kubo, Endy Widya Putranto, Takashi Murakami, Ming Liu, Toshihiko Hibino, Masahiro Nishibori, Eisaku Kondo, Shinichi Toyooka, Masakiyo Sakaguchi

    Neoplasia (New York, N.Y.)   21 ( 7 )   627 - 640   2019年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Metastatic breast cancer is the leading cause of cancer-associated death in women. The progression of this fatal disease is associated with inflammatory responses that promote cancer cell growth and dissemination, eventually leading to a reduction of overall survival. However, the mechanism(s) of the inflammation-boosted cancer progression remains unclear. In this study, we found for the first time that an extracellular cytokine, S100A8/A9, accelerates breast cancer growth and metastasis upon binding to a cell surface receptor, melanoma cell adhesion molecule (MCAM). Our molecular analyses revealed an important role of ETS translocation variant 4 (ETV4), which is significantly activated in the region downstream of MCAM upon S100A8/A9 stimulation, in breast cancer progression in vitro as well as in vivo. The MCAM-mediated activation of ETV4 induced a mobile phenotype called epithelial-mesenchymal transition (EMT) in cells, since we found that ETV4 transcriptionally upregulates ZEB1, a strong EMT inducer, at a very high level. In contrast, downregulation of either MCAM or ETV4 repressed EMT, resulting in greatly weakened tumor growth and lung metastasis. Overall, our results revealed that ETV4 is a novel transcription factor regulated by the S100A8/A9-MCAM axis, which leads to EMT through ZEB1 and thereby to metastasis in breast cancer cells. Thus, therapeutic strategies based on our findings might improve patient outcomes.

    DOI: 10.1016/j.neo.2019.04.006

    PubMed

    researchmap

  • Convenient methodology for extraction and subsequent selective propagation of mouse melanocytes in culture from adult mouse skin tissue. 査読 国際誌

    Nahoko Tomonobu, Rie Kinoshita, I Wayan Sumardika, Youyi Chen, Yusuke Inoue, Akira Yamauchi, Ken-Ichi Yamamoto, Hitoshi Murata, Masakiyo Sakaguchi

    Biochemistry and biophysics reports   18   100619 - 100619   2019年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Mouse melanoma B16-BL6 cells are useful cells for cancer metastatic studies. To understand the metastatic principle at molecular levels, it is necessary to carry out experiments in which cancer cells and their normal counterparts are compared. However, unlike normal human melanocytes, preparation of normal mouse melanocytes is quite difficult due to the lack of marketing and insufficient information on an established protocol for primary culture of mouse melanocytes. In this study, we aimed to establish a convenient method for primary culture of mouse melanocytes on the basis of the protocol for human melanocytes. The main obstacles to preparing pure mouse melanocytes are how to digest mouse skin tissue and how to reduce the contamination of keratinocytes and fibroblasts. The obstacles were overcome by collagenase digestion for skin specimens, short time trypsinization for separating melanocytes and keratinocytes, and use of 12-O-Tetradecanoylphorbol 13-acetate (TPA) and cholera toxin in the culture medium. These supplements act to prevent the proliferation of keratinocytes and fibroblasts, respectively. The convenient procedure enabled us to prepare a pure culture of normal mouse melanocytes. Using enriched normal mouse melanocytes and cancerous B16-BL6 cells, we compared the expression levels of melanoma cell adhesion molecule (MCAM), an important membrane protein for melanoma metastasis, in the cells. The results showed markedly higher expression of MCAM in B16-BL6 cells than in normal mouse melanocytes.

    DOI: 10.1016/j.bbrep.2019.100619

    PubMed

    researchmap

  • Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion. 査読 国際誌

    Youyi Chen, I Wayan Sumardika, Nahoko Tomonobu, I Made Winarsa Ruma, Rie Kinoshita, Eisaku Kondo, Yusuke Inoue, Hiroki Sato, Akira Yamauchi, Hitoshi Murata, Ken-Ichi Yamamoto, Shuta Tomida, Kazuhiko Shien, Hiromasa Yamamoto, Junichi Soh, Ming Liu, Junichiro Futami, Kaori Sasai, Hiroshi Katayama, Miyoko Kubo, Endy Widya Putranto, Toshihiko Hibino, Bei Sun, Masahiro Nishibori, Shinichi Toyooka, Masakiyo Sakaguchi

    Cancer letters   452   178 - 190   2019年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Since metastasis accounts for the majority of cancer-associated deaths, studies on the mechanisms of metastasis are needed to establish innovative strategies for cancer treatment. We previously reported that melanoma cell adhesion molecule (MCAM) functions as a critical receptor for S100A8/A9, and binding of S100A8/A9 to MCAM results in the migration of melanoma cells to lung tissue. However, the critical role of MCAM in the original melanoma skin lesion is still not clear. In this study, we aimed to determine the importance of the S100A8/A9-MCAM axis in melanoma dissemination in a skin lesion as a critical early step for metastasis. Mechanistic studies revealed the downstream signaling of MCAM that signaled the induction of metastasis. S100A8/A9-MCAM binding activates mitogen-activated protein kinase kinase kinase 8 (MAP3K8), also termed TPL2, leading to strong activation of the transcription factor ETV4 and subsequent induction of matrix metalloproteinase-25 (MMP25), and finally to induction of melanoma lung tropic metastasis. Collectively, our results demonstrate a crucial role of the S100A8/A9-MCAM signaling axis in metastatic onset of melanoma cells and indicate that strategies targeting the identified pathway may be useful for the establishment of innovative anti-cancer therapies.

    DOI: 10.1016/j.canlet.2019.03.023

    PubMed

    researchmap

  • Extracellular S100A11 Plays a Critical Role in Spread of the Fibroblast Population in Pancreatic Cancers. 査読 国際誌

    Hitoshi Takamatsu, Ken-Ichi Yamamoto, Nahoko Tomonobu, Hitoshi Murata, Yusuke Inoue, Akira Yamauchi, I Wayan Sumardika, Youyi Chen, Rie Kinoshita, Masahiro Yamamura, Hideyo Fujiwara, Yosuke Mitsui, Kota Araki, Junichiro Futami, Ken Saito, Hidekazu Iioka, I Made Winarsa Ruma, Endy Widya Putranto, Masahiro Nishibori, Eisaku Kondo, Yasuhiko Yamamoto, Shinichi Toyooka, Masakiyo Sakaguchi

    Oncology research   27 ( 6 )   713 - 727   2019年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The fertile stroma in pancreatic ductal adenocarcinomas (PDACs) has been suspected to greatly contribute to PDAC progression. Since the main cell constituents of the stroma are fibroblasts, there is crosstalking(s) between PDAC cells and surrounding fibroblasts in the stroma, which induces a fibroblast proliferation burst. We have reported that several malignant cancer cells including PDAC cells secrete a pronounced level of S100A11, which in turn stimulates proliferation of cancer cells via the receptor for advanced glycation end products (RAGE) in an autocrine manner. Owing to the RAGE+ expression in fibroblasts, the extracellular abundant S100A11 will affect adjacent fibroblasts. In this study, we investigated the significance of the paracrine axis of S100A11-RAGE in fibroblasts for their proliferation activity. In in vitro settings, extracellular S100A11 induced upregulation of fibroblast proliferation. Our mechanistic studies revealed that the induction is through RAGE-MyD88-mTOR-p70 S6 kinase upon S100A11 stimulation. The paracrine effect on fibroblasts is linked mainly to triggering growth but not cellular motility. Thus, the identified pathway might become a potential therapeutic target to suppress PDAC progression through preventing PDAC-associated fibroblast proliferation.

    DOI: 10.3727/096504018X15433161908259

    PubMed

    researchmap

  • exSSSRs (extracellular S100 soil sensor receptors)-Fc fusion proteins work as prominent decoys to S100A8/A9-induced lung tropic cancer metastasis. 査読 国際誌

    Rie Kinoshita, Hiroki Sato, Akira Yamauchi, Yuta Takahashi, Yusuke Inoue, I Wayan Sumardika, Youyi Chen, Nahoko Tomonobu, Kota Araki, Kazuhiko Shien, Shuta Tomida, Hidejiro Torigoe, Kei Namba, Eisuke Kurihara, Yusuke Ogoshi, Hitoshi Murata, Ken-Ichi Yamamoto, Junichiro Futami, Endy Widya Putranto, I Made Winarsa Ruma, Hiromasa Yamamoto, Junichi Soh, Toshihiko Hibino, Masahiro Nishibori, Eisaku Kondo, Shinichi Toyooka, Masakiyo Sakaguchi

    International journal of cancer   144 ( 12 )   3138 - 3145   2019年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Within the "seed and soil" theory of organ tropic cancer metastasis is a growing compilation of evidence that S100A8/A9 functions as a soil signal that attracts cancer cells to certain organs, which prove beneficial to their growth. S100A8/A9-sensing receptors including Toll-like receptor 4 (TLR4), advanced glycation end products (RAGE), and also important receptors we recently succeeded in identifying (EMMPRIN, NPTNβ, MCAM, and ALCAM) have the potential to become promising therapeutic targets. In our study, we prepared extracellular regions of these novel molecules and fused them to human IgG2-Fc to extend half-life expectancy, and we evaluated the anti-metastatic effects of the purified decoy proteins on metastatic cancer cells. The purified proteins markedly suppressed S100A8/A9-mediated lung tropic cancer metastasis. We hence expect that our novel biologics may become a prominent medicine to prevent cancer metastasis in clinical settings through cutting the linkage between "seed and soil".

    DOI: 10.1002/ijc.31945

    PubMed

    researchmap

  • Neuroplastin-β mediates S100A8/A9-induced lung cancer disseminative progression. 査読 国際誌

    Sumardika IW, Chen Y, Tomonobu N, Kinoshita R, Ruma IMW, Sato H, Kondo E, Inoue Y, Yamauchi A, Murata H, Yamamoto KI, Tomida S, Shien K, Yamamoto H, Soh J, Futami J, Putranto EW, Hibino T, Nishibori M, Toyooka S, Sakaguchi M

    Mol Carcinog.   58 ( 6 )   980 - 995   2019年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/mc.22987

    PubMed

    researchmap

  • Histidine-rich glycoprotein augments natural killer cell function by modulating PD-1 expression via CLEC-1B. 査読 国際誌

    Nishimura Y, Wake H, Teshigawara K, Wang D, Sakaguchi M, Otsuka F, Nishibori M

    Pharmacol Res Perspect.   7 ( 3 )   e00481   2019年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/prp2.481.

    PubMed

    researchmap

  • Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations. 査読 国際誌

    Yusuke Ogoshi, Kazuhiko Shien, Takahiro Yoshioka, Hidejiro Torigoe, Hiroki Sato, Masakiyo Sakaguchi, Shuta Tomida, Kei Namba, Eisuke Kurihara, Yuta Takahashi, Ken Suzawa, Hiromasa Yamamoto, Junichi Soh, Shinichi Toyooka

    Oncology letters   17 ( 3 )   2729 - 2736   2019年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Human epidermal growth factor receptor 2 (HER2) is a member of the ErbB family of receptor tyrosine kinases. Numerous studies have reported the amplification and overexpression of HER2 in several types of cancer, including non-small cell lung cancer (NSCLC). However, the benefits of HER2-targeted therapy have not been fully established. In the present study, the anti-tumor effect of neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), against NSCLC cells harboring HER2 alterations was investigated. The sensitivity of normal bronchial epithelial cells (BEAS-2B) ectopically overexpressing wild-type or mutant HER2 to neratinib was assessed. Furthermore, the anti-tumor activity of neratinib in several NSCLC cell lines harboring HER2 alterations was determined in vitro and in vivo, and the association between their genetic alterations and sensitivity to neratinib treatment was investigated. BEAS-2B cells ectopically overexpressing wild-type HER2 or mutants (A775insYVMA, G776VC, G776LC, P780insGSP, V659E, G660D and S310F) exhibited constitutive autophosphorylation of HER2, as determined by western blotting. While these BEAS-2B cells were sensitive to neratinib, they were insensitive to erlotinib, a first-generation epidermal growth factor receptor-TKI. Neratinib also exerted anti-proliferative effects on HER2-altered (H2170, Calu-3 and H1781) NSCLC cell lines. Neratinib was also demonstrated to exert strong tumor growth inhibitory activity in mouse xenograft models using HER2-altered lung cancer cells. The results of the present study strongly suggest that neratinib has potential as a promising therapeutic option for the treatment of HER2-altered NSCLC.

    DOI: 10.3892/ol.2019.9908

    PubMed

    researchmap

  • Hepatocyte nuclear factor 4α regulates megalin expression in proximal tubular cells. 査読 国際誌

    Sasaki S, Hara A, Sakaguchi M, Nangaku M, Inoue Y

    Biochem Biophys Rep.   17   87 - 92   2019年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.bbrep.2018.11.010

    PubMed

    researchmap

  • c-Jun N-terminal kinase (JNK)-mediated phosphorylation of SARM1 regulates NAD+ cleavage activity to inhibit mitochondrial respiration. 査読 国際誌

    Hitoshi Murata, Cho Cho Khine, Akane Nishikawa, Ken-Ichi Yamamoto, Rie Kinoshita, Masakiyo Sakaguchi

    The Journal of biological chemistry   293 ( 49 )   18933 - 18943   2018年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Mitochondrial dysfunction is a key pathological feature of many different types of neurodegenerative disease. Sterile alpha and Toll/interleukin receptor motif-containing protein 1 (SARM1) has been attracting much attention as an important molecule for inducing axonal degeneration and neuronal cell death by causing loss of NAD (NADH). However, it has remained unclear what exactly regulates the SARM1 activity. Here, we report that NAD+ cleavage activity of SARM1 is regulated by its own phosphorylation at serine 548. The phosphorylation of SARM1 was mediated by c-jun N-terminal kinase (JNK) under oxidative stress conditions, resulting in inhibition of mitochondrial respiration concomitant with enhanced activity of NAD+ cleavage. Nonphosphorylatable mutation of Ser-548 or treatment with a JNK inhibitor decreased SARM1 activity. Furthermore, neuronal cells derived from a familial Parkinson's disease (PD) patient showed a congenitally increased level of SARM1 phosphorylation compared with that in neuronal cells from a healthy person and were highly sensitive to oxidative stress. These results indicate that JNK-mediated phosphorylation of SARM1 at Ser-548 is a regulator of SARM1 leading to inhibition of mitochondrial respiration. These findings suggest that an abnormal regulation of SARM1 phosphorylation is involved in the pathogenesis of Parkinson's disease and possibly other neurodegenerative diseases.

    DOI: 10.1074/jbc.RA118.004578

    PubMed

    researchmap

  • JNK-mediated phosphorylation of SARM1 regulates NAD(+) cleavage activity to inhibit mitochondrial respiration. 査読

    Murata H, Khine CC, Nishikawa A, Yamamoto KI, Kinoshita R, Sakaguchi M

    J Biol Chem   2018年10月

  • Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer. 査読 国際誌

    Hiroki Sato, Hiromasa Yamamoto, Masakiyo Sakaguchi, Kazuhiko Shien, Shuta Tomida, Tadahiko Shien, Hirokuni Ikeda, Minami Hatono, Hidejiro Torigoe, Kei Namba, Takahiro Yoshioka, Eisuke Kurihara, Yusuke Ogoshi, Yuta Takahashi, Junichi Soh, Shinichi Toyooka

    Cancer science   109 ( 10 )   3183 - 3196   2018年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Compensatory activation of the signal transduction pathways is one of the major obstacles for the targeted therapy of non-small cell lung cancer (NSCLC). Herein, we present the therapeutic strategy of combined targeted therapy against the MEK and phosphoinositide-3 kinase (PI3K) pathways for acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in NSCLC. We investigated the efficacy of combined trametinib plus taselisib therapy using experimentally established EGFR-TKI-resistant NSCLC cell lines. The results showed that the feedback loop between MEK/ERK and PI3K/AKT pathways had developed in several resistant cell lines, which caused the resistance to single-agent treatment with either inhibitor alone. Meanwhile, the combined therapy successfully regulated the compensatory activation of the key intracellular signals and synergistically inhibited the cell growth of those cells in vitro and in vivo. The resistance mechanisms for which the dual kinase inhibitor therapy proved effective included (MET) mesenchymal-epithelial transition factor amplification, induction of epithelial-to-mesenchymal transition (EMT) and EGFR T790M mutation. In further analysis, the combination therapy induced the phosphorylation of p38 MAPK signaling, leading to the activation of apoptosis cascade. Additionally, long-term treatment with the combination therapy induced the conversion from EMT to mesenchymal-to-epithelial transition in the resistant cell line harboring EMT features, restoring the sensitivity to EGFR-TKI. In conclusion, our results indicate that the combined therapy using MEK and PI3K inhibitors is a potent therapeutic strategy for NSCLC with the acquired resistance to EGFR-TKIs.

    DOI: 10.1111/cas.13763

    PubMed

    researchmap

  • Induction of hepatic metabolic functions by a novel variant of hepatocyte nuclear factor 4γ. 査読

    Sasaki S, Urabe M, Maeda T, Suzuki J, Irie R, Suzuki M, Tomaru Y, Sakaguchi M, Gonzalez FJ, Inoue Y

    Molecular and cellular biology   38 ( 24 )   e00213 - e00218   2018年9月

  • EGFR変異陽性肺癌におけるLRIG1の抗腫瘍効果(Tumor-suppressive effect of LRIG1 in non-small cell lung cancer harboring mutant EGFR)

    鳥越 英次郎, 山本 寛斉, 阪口 政清, 難波 圭, 佐藤 博紀, 枝園 和彦, 諏澤 憲, 宗 淳一, 冨田 秀太, 佃 和憲, 三好 新一郎, 豊岡 伸一

    日本癌学会総会記事   77回   940 - 940   2018年9月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • Embigin Promotes Prostate Cancer Progression by S100A4-Dependent and-Independent Mechanisms. 査読 国際誌

    I Made Winarsa Ruma, Rie Kinoshita, Nahoko Tomonobu, Yusuke Inoue, Eisaku Kondo, Akira Yamauchi, Hiroki Sato, I Wayan Sumardika, Youyi Chen, Ken-Ichi Yamamoto, Hitoshi Murata, Shinichi Toyooka, Masahiro Nishibori, Masakiyo Sakaguchi

    Cancers   10 ( 7 )   2018年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Embigin, a transmembrane glycoprotein belonging to the immunoglobulin superfamily, is involved in prostate and mammary gland development. As embigin's roles in cancer remain elusive, we studied its biological functions and interaction with extracellular S100A4 in prostate cancer progression. We found by a pull-down assay that embigin is a novel receptor for S100A4, which is one of the vital cancer microenvironment milleu. Binding of extracellular S100A4 to embigin mediates prostate cancer progression by inhibition of AMPK activity, activation of NF-κB, MMP9 and mTORC1 signaling, and inhibition of autophagy, which increase prostate cancer cell motility. We also found that embigin promotes prostate cancer growth, spheroid- and colony-forming ability, and survival upon chemotherapy independently of S100A4. An in vivo growth mouse model confirmed the importance of embigin and its cytoplasmic tail in mediating prostate tumor growth. Moreover, embigin and p21WAF1 can be used to predict survival of prostate cancer patients. Our results demonstrated for the first time that the S100A4-embigin/AMPK/mTORC1/p21WAF1 and NF-κB/MMP9 axis is a vital oncogenic molecular cascade for prostate cancer progression. We proposed that embigin and p21WAF1 could be used as prognostic biomarkers and a strategy to inhibit S100A4-embigin binding could be a therapeutic approach for prostate cancer patients.

    DOI: 10.3390/cancers10070239

    PubMed

    researchmap

  • 膵がん進展に導く膵がん細胞 間質線維芽細胞クロストークを介在する分泌性S100A11 受容体RAGE連携の役割

    光井 洋介, 山本 健一, Sumardika I Wayan, 木下 理恵, 村田 等, 二見 淳一郎, 高松 仁, 山本 靖彦, 西堀 正洋, 豊岡 伸一, 渡部 昌実, 那須 保友, 阪口 政清

    日本がん免疫学会総会プログラム・抄録集   22回   156 - 156   2018年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本がん免疫学会  

    researchmap

  • 分泌性S100A11-受容体RAGEシグナルに着眼した膵がん間質増大のメカニズムの解明

    山本 健一, 高松 仁, 光井 洋介, 木下 理恵, 村田 等, 二見 淳一郎, 山本 靖彦, 西堀 正洋, 豊岡 伸一, 阪口 政清

    日本がん免疫学会総会プログラム・抄録集   22回   117 - 117   2018年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本がん免疫学会  

    researchmap

  • Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR. 査読 国際誌

    Hidejiro Torigoe, Hiromasa Yamamoto, Masakiyo Sakaguchi, Chen Youyi, Kei Namba, Hiroki Sato, Kazuhiko Shien, Junichi Soh, Ken Suzawa, Shuta Tomida, Kazunori Tsukuda, Shinichiro Miyoshi, Shinichi Toyooka

    Carcinogenesis   39 ( 5 )   719 - 727   2018年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Epidermal growth factor receptor (EGFR) is a member of the ErbB (HER) family that is known to play important roles in the pathogenesis of various human cancers. Mutations of the EGFR gene are commonly found as oncogenic driver mutations and have been targeted for treatment of non-small cell lung cancer (NSCLC). Leucine-rich repeat and immunoglobulin-like domain protein-1 (LRIG1) is a cell-surface protein that is known as a negative regulator of the ErbB (HER) family. In this study, we first confirmed that the expression levels of LRIG1 were much lower in NSCLC than in non-malignant cells or tissues. Next, we focused on the effect of LRIG1 in NSCLC. For this purpose, we established clones stably overexpressing LRIG1, using EGFR-mutant (HCC827, HCC4011 and NCI-H1975) and wild-type (A549) cells. Transfection of LRIG1 was associated with a decrease in the expression and phosphorylation levels of EGFR in the HCC827, HCC4011 and NCI-H1975 cells. It was also associated with strong suppression of the cell proliferative, invasive, migratory and tumorigenic potential of the HCC827 cells. On the other hand, no such effects were observed in the A549 cells. In addition, LRIG1 also downregulated the expression and phosphorylation levels of other tyrosine kinase receptors, such as HER2, HER3, MET and IGF-1R, and prevented the epithelial-to-mesenchymal transition induced by TGF-β in the HCC827 cells. These findings suggest that LRIG1 exerts important tumor-suppressive effects in EGFR-mutant NSCLC and has the potential to become a novel therapeutic target for EGFR-mutant NSCLC.

    DOI: 10.1093/carcin/bgy044

    Web of Science

    PubMed

    researchmap

  • Tumor necrosis factor-α downregulates the REIC/Dkk-3 tumor suppressor gene in normal human skin keratinocytes. 査読

    Kataoka K, Maehara N, Ayabe Y, Murata H, Huh NH, Sakaguchi M

    Molecular medicine reports   17 ( 5 )   6661 - 6666   2018年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3892/mmr.2018.8676

    Web of Science

    Scopus

    PubMed

    researchmap

  • Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations 査読

    Hidejiro Torigoe, Kazuhiko Shien, Tatsuaki Takeda, Takahiro Yoshioka, Kei Namba, Hiroki Sato, Ken Suzawa, Hiromasa Yamamoto, Junichi Soh, Masakiyo Sakaguchi, Shuta Tomida, Kazunori Tsukuda, Shinichiro Miyoshi, Shinichi Toyooka

    Cancer Science   109 ( 5 )   1493 - 1502   2018年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Blackwell Publishing Ltd  

    Human epidermal growth factor receptor 2 (HER2) plays an important role in the pathogenesis of various cancers. HER2 alterations have been suggested to be a therapeutic target in non-small-cell lung cancer (NSCLC), just as in breast and gastric cancers. We previously reported that the pan-HER inhibitor afatinib could be a useful therapeutic agent as HER2-targeted therapy for patients with NSCLC harboring HER2 alterations. However, acquired resistance to afatinib was observed in the clinical setting, similar to the case for other HER inhibitors. Thus, elucidation of the mechanisms underlying the development of acquired drug resistance and exploring means to overcome acquired drug resistance are important issues in the treatment of NSCLC. In this study, we experimentally established afatinib-resistant cell lines from NSCLC cell lines harboring HER2 alterations, and investigated the mechanisms underlying the acquisition of drug resistance. The established cell lines showed several unique afatinib-resistance mechanisms, including MET amplification, loss of HER2 amplification and gene expression, epithelial-to-mesenchymal transition (EMT) and acquisition of cancer stem cell (CSC)-like features. The afatinib-resistant cell lines showing MET amplification were sensitive to the combination of afatinib plus crizotinib (a MET inhibitor), both in vitro and in vivo. The resistant cell lines which showed EMT or had acquired CSC-like features remained sensitive to docetaxel, like the parental cells. These findings may provide clues to countering the resistance to afatinib in NSCLC patients with HER2 alterations.

    DOI: 10.1111/cas.13571

    Web of Science

    Scopus

    PubMed

    researchmap

  • ß-1,3-galactosyl-O-glycosyl-glycoprotein ß-1,6-N-acetylglucosaminyltransferase 3 Increases MCAM Stability, Which Enhances S100A8/A9-Mediated Cancer Motility. 査読 国際誌

    Sumardika IW, Youyi C, Kondo E, Inoue Y, Ruma IMW, Murata H, Kinoshita R, Yamamoto KI, Tomida S, Shien K, Satoh H, Yamauchi A, Futami J, Putranto EW, Hibino T, Toyooka S, Nishibori M, Sakaguchi M

    Oncology research   26 ( 3 )   431 - 444   2018年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3727/096504017X15031557924123

    Web of Science

    PubMed

    researchmap

  • 肺腺がんにおけるSpred2の役割の解明

    太田 陽子, 藤澤 真義, 吉村 禎造, スマルディカ・イワヤン, 枝園 和彦, 阪口 政清, 豊岡 伸一, 松川 昭博

    日本病理学会会誌   107 ( 1 )   414 - 414   2018年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本病理学会  

    researchmap

  • Effects of Histidine-rich glycoprotein on erythrocyte aggregation and hemolysis: Implications for a role under septic conditions 査読

    Hui Zhong, Hidenori Wake, Keyue Liu, Yuan Gao, Kiyoshi Teshigawara, Masakiyo Sakaguchi, Shuji Mori, Masahiro Nishibori

    Journal of Pharmacological Sciences   136 ( 3 )   97 - 106   2018年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Japanese Pharmacological Society  

    The apoptotic process of erythrocytes is known as eryptosis, and is characterized by phosphatidylserine (PS) expression on the outer membrane. PS-positive erythrocytes are increased in sepsis, and PS is believed to facilitate coagulation of erythrocytes and activate macrophages. However, the relationship between eryptosis and abnormal coagulation in sepsis is still not fully understood. Histidine-rich glycoprotein (HRG) inhibits immunothrombus formation by regulating neutrophils and vascular endothelial cells. In the present study, we subjected isolated erythrocytes to Zn2+ stimulation, which activated their aggregation and PS expression. We then determined the Zn2+ contents in septic lung and kidney tissues, and found that they were elevated, suggesting that eryptosis was enhanced in these tissues. Erythrocyte adhesion to endothelial cells was also significantly increased after Zn2+ stimulation, and this effect was inhibited by HRG. Finally, we examined HRG treatment in septic model mice, and found that HRG decreased hemolysis, possibly due to its ability to bind heme. Our study demonstrated a novel Zn2+-initiated aggregation/thrombus formation pathway. We also showed the regulatory role of HRG in this pathway, together with the ability of HRG to inhibit hemolysis under septic conditions. HRG supplementation might be a novel therapeutic strategy for inflammatory disorders, especially sepsis.

    DOI: 10.1016/j.jphs.2017.11.003

    Web of Science

    Scopus

    PubMed

    researchmap

  • Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma 査読

    Hiroki Sato, Masakiyo Sakaguchi, Hiromasa Yamamoto, Shuta Tomida, Keisuke Aoe, Kazuhiko Shien, Takahiro Yoshioka, Kei Namba, Hidejiro Torigoe, Junichi Soh, Kazunori Tsukuda, Hiroyuki Tao, Kazunori Okabe, Shinichiro Miyoshi, Harvey I. Pass, Shinichi Toyooka

    Oncogenesis   7 ( 1 )   11   2018年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Nature Publishing Group  

    Malignant pleural mesothelioma (MPM) is an aggressive tumor with an unfavorable prognosis. The standard therapeutic approaches are limited to surgery, chemotherapy, and radiotherapy. Because the consequent clinical outcome is often unsatisfactory, a different approach in MPM treatment is required. S100A11, a Ca2+-binding small protein with two EF-hands, is frequently upregulated in various human cancers. Interestingly, it has been found that intracellular and extracellular S100A11 have different functions in cell viability. In this study, we focused on the impact of extracellular S100A11 in MPM and explored the therapeutic potential of an S100A11-targeting strategy. We examined the secretion level of S100A11 in various kinds of cell lines by enzyme-linked immunosorbent assay. Among them, six out of seven MPM cell lines actively secreted S100A11, whereas normal mesothelial cell lines did not secrete it. To investigate the role of secreted S100A11 in MPM, we inhibited its function by neutralizing S100A11 with an anti-S100A11 antibody. Interestingly, the antibody significantly inhibited the proliferation of S100A11-secreting MPM cells in vitro and in vivo. Microarray analysis revealed that several pathways including genes involved in cell proliferation were negatively enriched in the antibody-treated cell lines. In addition, we examined the secretion level of S100A11 in various types of pleural effusions. We found that the secretion of S100A11 was significantly higher in MPM pleural effusions, compared to others, suggesting the possibility for the use of S100A11 as a biomarker. In conclusion, our results indicate that extracellular S100A11 plays important roles in MPM and may be a therapeutic target in S100A11-secreting MPM.

    DOI: 10.1038/s41389-017-0017-3

    Web of Science

    Scopus

    PubMed

    researchmap

  • Crumbs3 promotes metastasis of colon cancer by regulating focal adhesion components 査読

    Iioka Hidekazu, Saito Ken, Sakaguchi Masakiyo, Morii Eiichi, Kondo Eisaku

    CANCER SCIENCE   109   1039   2018年1月

  • Development of novel biologics for cancer metastasis via prevention of extracellular S100A8/A9 function 査読

    Kinoshita Rie, Yamauchi Akira, Shien Kazuhiko, Tomida Shuta, Toyooka Shinichi, Kondo Eisaku, Sakaguchi Masakiyo

    CANCER SCIENCE   109   1017   2018年1月

  • Crucial role of RAGE in inappropriate increase of smooth muscle cells from patients with pulmonary arterial hypertension. 査読 国際誌

    Kazufumi Nakamura, Masakiyo Sakaguchi, Hiromi Matsubara, Satoshi Akagi, Toshihiro Sarashina, Kentaro Ejiri, Kaoru Akazawa, Megumi Kondo, Koji Nakagawa, Masashi Yoshida, Toru Miyoshi, Takeshi Ogo, Takahiro Oto, Shinichi Toyooka, Yuichiro Higashimoto, Kei Fukami, Hiroshi Ito

    PloS one   13 ( 9 )   e0203046   2018年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Pulmonary vascular remodeling of pulmonary arterial hypertension (PAH) is characterized by an inappropriate increase of vascular cells. The receptor for advanced glycation end products (RAGE) is a type I single-pass transmembrane protein belonging to the immunoglobulin superfamily and is involved in a broad range of hyperproliferative diseases. RAGE is also implicated in the etiology of PAH and is overexpressed in pulmonary artery smooth muscle cells (PASMCs) in patients with PAH. We examined the role of RAGE in the inappropriate increase of PASMCs in patients with PAH. METHODS AND RESULTS: PASMCs were obtained from 12 patients with PAH including 9 patients with idiopathic PAH (IPAH) and 3 patients with heritable PAH (HPAH) (2 patients with BMPR2 mutation and one patient with SMAD9 mutation) who underwent lung transplantation. Western blot analysis and immunofluorescence staining revealed that RAGE and S100A8 and A9, ligands of RAGE, were overexpressed in IPAH and HPAH-PASMCs in the absence of any external growth stimulus. PDGF-BB (10 ng/mL) up-regulated the expression of RAGE in IPAH and HPAH-PASMCs. PAH-PASMCs are hyperplastic in the absence of any external growth stimulus as assessed by 3H-thymidine incorporation. This result indicates overgrowth characterized by continued growth under a condition of no growth stimulation in PAH-PASMCs. PDGF-BB stimulation caused a higher growth rate of PAH-PASMCs than that of non-PAH-PASMCs. AS-1, an inhibitor of TIR domain-mediated RAGE signaling, significantly inhibited overgrowth characterized by continued growth under a condition of no growth stimulation in IPAH and HPAH-PASMCs (P<0.0001). Furthermore, AS-1 significantly inhibited PDGF-stimulated proliferation of IPAH and HPAH-PASMCs (P<0.0001). CONCLUSIONS: RAGE plays a crucial role in the inappropriate increase of PAH-PASMCs. Inhibition of RAGE signaling may be a new therapeutic strategy for PAH.

    DOI: 10.1371/journal.pone.0203046

    PubMed

    researchmap

  • Stromal mesenchymal stem cells facilitate pancreatic cancer progression by regulating specific secretory molecules through mutual cellular interaction. 査読 国際誌

    Ken Saito, Masakiyo Sakaguchi, Satoshi Maruyama, Hidekazu Iioka, Endy Widya Putranto, I Wayan Sumardika, Nahoko Tomonobu, Takashi Kawasaki, Keiichi Homma, Eisaku Kondo

    Journal of Cancer   9 ( 16 )   2916 - 2929   2018年

     詳細を見る

    記述言語:英語  

    Pancreatic ductal adenocarcinoma (PDAC) is currently one of the most intractable malignancies with a typical scirrhous pattern in histology. Due to its abundant tumor stroma and scant vascularization, chemotherapeutic agents are considered inefficiently permeable to cancer nests, making it highly difficult to cure the patients with PDAC. However, PDAC is also considered to owe its intractability to other critical factors such as cellular interaction between tumor cells and tumor microenvironment as well as architectural barriers, which increases in therapeutic resistance. Here, we report a specific cellular interaction between PDAC cells and mesenchymal stem cells (MSCs) intermingled in PDAC stroma, which facilitates cancer invasion. Secretory phenotype profiling revealed that production of Amphiregulin (AREG) and MMP-3 were specifically upregulated under the coexistence of BxPC3 cells with human MSCs (approximately four to ten folds in AREG, and twenty to sixty-folds in MMP-3 compared to that of BxPC3 cells alone), whereas MMP-9 expression was decreased (less than one-tenth comparing with that of BxPC3 cells alone). Blockage of AREG production by its specific siRNA removed MSC-mediated driving force of BxPC3 invasiveness. Immunohistochemical analysis of tissue samples obtained both from PDAC patients and PDAC imitating mouse xenografted models revealed that significant coexpression of AREG and its receptor EGFR were detected on the cancer cells at invasive front. These results strongly suggested that cellular interaction between cancer cells and MSCs in the PDAC stroma might be critical to cancer progression, especially in the process of local invasion and the early stage development of metastasis.

    DOI: 10.7150/jca.24415

    Web of Science

    PubMed

    researchmap

  • Signal Diversity of Receptor for Advanced Glycation End Products 査読

    Masakiyo Sakaguchi, Rie Kinoshita, Endy Widya Putranto, I. Made Winarsa Ruma, I. Wayan Sumardika, Chen Youyi, Naoko Tomonobu, Ken-ichi Yamamoto, Hitoshi Murata

    ACTA MEDICA OKAYAMA   71 ( 6 )   459 - 465   2017年12月

     詳細を見る

    記述言語:英語   出版者・発行元:OKAYAMA UNIV MED SCHOOL  

    The receptor for advanced glycation end products (RAGE) is involved in inflammatory pathogenesis. It functions as a receptor to multiple ligands such as AGEs, HMGB1 and S100 proteins, activating multiple intracellular signaling pathways with each ligand binding. The molecular events by which ligand-activated RAGE controls diverse signaling are not well understood, but some progress was made recently. Accumulating evidence revealed that RAGE has multiple binding partners within the cytoplasm and on the plasma membrane. It was first pointed out in 2008 that RAGE's cytoplasmic tail is able to recruit Diaphanous-1 (Dia-1), resulting in the acquisition of increased cellular motility through Rac1/Cdc42 activation. We also observed that within the cytosol, RAGE's cytoplasmic tail behaves similarly to a Toll-like receptor (TLR4)-TIR domain, interacting with TIRAP and MyD88 adaptor molecules that in turn activate multiple downstream signals. Subsequent studies demonstrated the presence of an alternative adaptor molecule, DAP10, on the plasma membrane. The coupling of RAGE with DAP10 is critical for enhancing the RAGE-mediated survival signal. Interestingly, RAGE interaction on the membrane was not restricted to DAP10 alone. The chemotactic G-protein-coupled receptors (GPCRs) formyl peptide receptors1 and 2 (FPR1 and FPR2) also interacted with RAGE on the plasma membrane. Binding interaction between leukotriene B4 receptor 1 (BLT1) and RAGE was also demonstrated. All of the interactions affected the RAGE signal polarity. These findings indicate that functional interactions between RAGE and various molecules within the cytoplasmic area or on the membrane area coordinately regulate multiple ligand-mediated RAGE responses, leading to typical cellular phenotypes in several pathological settings. Here we review RAGE's signaling diversity, to contribute to the understanding of the elaborate functions of RAGE in physiological and pathological contexts.

    DOI: 10.18926/AMO/55582

    Web of Science

    PubMed

    researchmap

  • Exogenous DKK-3/REIC inhibits Wnt/β-catenin signaling and cell proliferation in human kidney cancer KPK1. 査読

    Xu J, Sadahira T, Kinoshita R, Li SA, Huang P, Wada K, Araki M, Ochiai K, Noguchi H, Sakaguchi M, Nasu Y, Watanabe M

    Oncology letters   14 ( 5 )   5638 - 5642   2017年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3892/ol.2017.6833

    Web of Science

    PubMed

    researchmap

  • Promising therapeutic efficacy of a novel reduced expression in immortalized cells/dickkopf-3 expressing adenoviral vector for hepatocellular carcinoma 査読

    Hiroaki Sawahara, Hidenori Shiraha, Daisuke Uchida, Hironari Kato, Ryo Kato, Atsushi Oyama, Teruya Nagahara, Masaya Iwamuro, Shigeru Horiguchi, Koichiro Tsutsumi, Mari Mandai, Tetsushige Mimura, Nozomu Wada, Yasuto Takeuchi, Kenji Kuwaki, Hideki Onishi, Shinichiro Nakamura, Masami Watanabe, Masakiyo Sakaguchi, Akinobu Takaki, Kazuhiro Nouso, Takahito Yagi, Yasutomo Nasu, Hiromi Kumon, Hiroyuki Okada

    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY   32 ( 10 )   1769 - 1777   2017年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY  

    Background and Aim: Reduced expression in immortalized cells (REIC)/dickkopf-3 (Dkk-3) is a tumor suppressor gene that is downregulated in various cancers. In our previous study of prostate cancer, the REIC/Dkk-3-expressing adenoviral vector (Ad-REIC) was found to induce cancer-selective apoptosis. This study recently developed a novel super gene expression (SGE) system and used this system to re-construct an Ad-REIC vector, termed the Ad-SGE-REIC, to achieve more effective therapeutic outcomes. In this study, the therapeutic effects of Ad-SGE-REIC on hepatocellular carcinoma (HCC) was assessed.
    Methods: Human HCC cell lines (HLE, Huh7, HepG2, HLF, SK-Hep1, and PLC), human HCC tissues, and mouse HCC cell line (Hepa1-6) were used in this study. REIC/Dkk-3 expression was assessed by immunoblotting and immunohistochemistry. The relative cell viability and the apoptotic effect were examined in vitro, and the anti-tumor effects of Ad-SGE-REIC treatment were analyzed in the mouse xenograft model. This study additionally assessed anti-tumor immunological effects on the immunocompetent mice.
    Results: REIC/Dkk-3 expression was decreased in HCC cell lines and HCC tissues. Ad-SGE-REIC reduced cell viability and induced apoptosis in HCC cell lines (HLE and Huh7), inhibited tumor growth in the mouse xenograft model, and demonstrated in vivo anti-cancer immunostimulatory effects on the HCC cell line (Hepa1-6).
    Conclusions: Ad-SGE-REIC treatment not only enhanced cell killing effects in vitro but also elicited significant therapeutic effects, with tumor growth suppression, in vivo. REIC/Dkk-3 gene therapy using Ad-SGE-REIC potentially represents an innovative new therapeutic tool for HCC.

    DOI: 10.1111/jgh.13757

    Web of Science

    PubMed

    researchmap

  • Identification of a novel component leading to anti-tumor activity besides the major ingredient cordycepin in Cordyceps militaris extract 査読

    Takeharu Wada, I. Wayan Sumardika, Shingo Saito, I. Made Winarsa Ruma, Eisaku Kondo, Masami Shibukawa, Masakiyo Sakaguchi

    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES   1061   209 - 219   2017年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCIENCE BV  

    In accordance with our previous study that was carried out to identify novel anti-tumor ingredients, chromatographic separation in combination with an anti-tumor activity assay was used for analysis of Cordyceps militaris extract in this study. Various modes of chromatography including reversed-phase, cation-exchange and anion exchange were used to separate components of Cordyceps militaris, which showed various chemical properties. Anti-tumor activity of each fraction was assessed by a Hoechst staining-based apoptosis assay using malignant melanoma MeWo cells. By these repeated approaches through chromatographic segregation and cell biological assay, we finally succeeded in identifying the target substance from a certain fraction that included neutral hydrophilic components using a pre-column and post-column chlorine adduct ionization LC APCI MS method. The target substance was a mono-carbohydrate, xylitol, that induced apoptotic cell death in MeWo cells but not in normal human OUMS-24 fibroblasts. This is the first study showing that Cordyceps militaris extract contains a large amount of xylitol. Thus, our results will contribute greatly to uncovering the mysterious multifunctional herbal drug Cordyceps militaris as an anti-tumor agent.

    DOI: 10.1016/j.jchromb.2017.07.022

    Web of Science

    PubMed

    researchmap

  • Robust cancer-specific gene expression by a novel cassette with hTERT and CMV promoter elements 査読

    Masakiyo Sakaguchi, Takuya Sadahira, Hideo Ueki, Rie Kinoshita, Hitoshi Murata, Ken-Ichi Yamamoto, Junichiro Futami, Yasutomo Nasu, Kazuhiko Ochiai, Hiromi Kumon, Nam-Ho Huh, Masami Watanabe

    ONCOLOGY REPORTS   38 ( 2 )   1108 - 1114   2017年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPANDIDOS PUBL LTD  

    We developed and validated a novel hTERT/CMV promoter element-driven gene expression cassette that can robustly enhance cancer-specific gene expression. The following gene expressional elements were located in tandem within the plasmid construct: [hTERT core promoter, cytomegalovirus (CMV) minimized promoter, RU5' sequence, an inserted gene, BGH polyA, hTERT enhancer]; this is hereafter referred to as the hT/Cm-R-hT construct. Using various human cancer cell lines and normal cells, the cancer-specific transcription of the green fluorescent protein (GFP) gene was examined by western blotting and fluorescence microscopy. Cancer-specific gene expression was robustly achieved in the hT/Cm-R-hT plasmid in comparison to the other control hT/Cm-driven construct. Notably, the expression level of GFP observed in the hT/Cm-RhT-driven construct was superior to that of the control plasmid with the conventional CMV promoter in HEK293 cells, which are known to possess higher hTERT activity than normal cells. We next examined the availability of hT/Cm-R-hT in detecting the target GFP expressing cancer cells from human peripheral blood mononuclear cells (PBMCs). The hT/Cm-R-hT plasmid successfully induced cancer-specific gene expression; the robust expression of GFP was observed in target HeLa cancer cells, whereas GFP was not visibly expressed in normal PBMCs. The plasmid allowed for the selective visualization of viable HeLa cancer cells in mixed cell cultures containing up to 10000-fold more PBMCs. These findings indicate that the hT/Cm-R-hT expressional system is a valuable tool for detecting viable cancer cells mixed with normal cells. The current system can therefore be applied to the in vitro detection of cancer cells that are disseminated in the blood and other types of body fluid in vivo. Since the current system can also be applied to other types of vectors, including virus vectors, this approach using the hTERT promoter-based construct is expected to become a valuable tool for enhancing cancer specific gene expression.

    DOI: 10.3892/or.2017.5710

    Web of Science

    PubMed

    researchmap

  • Expression of tumor suppressor REIC/Dkk-3 by a newly improved adenovirus vector with insertion of a hTERT promoter at the 3'-side of the transgene 査読

    Endy Widya Putranto, Rie Kinoshita, Masami Watanabe, Takuya Sadahira, Hitoshi Murata, Ken-Ichi Yamamoto, Junichiro Futami, Ken Kataoka, Yusuke Inoue, I. Made Winarsa Ruma, I. Wayan Sumardika, Chen Youyi, Miyoko Kubo, Yoshihiko Sakaguchi, Kenji Saito, Yasutomo Nasu, Hiromi Kumon, Nam-Ho Huh, Masakiyo Sakaguchi

    ONCOLOGY LETTERS   14 ( 1 )   1041 - 1048   2017年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPANDIDOS PUBL LTD  

    Reduced expression in immortalized cells (REIC)/Dickkopf-3 (Dkk-3) overexpression, induced using an adenovirus (Ad)-REIC, has been revealed to have a dramatic therapeutic effect on multiple types of cancer. To achieve an improved therapeutic effect from Ad-REIC on cancer, our group previously developed an enhanced gene expression system, the C-TSC cassette [cytomegalovirus (CMV)-RU5' located upstream (C); another promoter unit composed of triple tandem promoters, human telomerase reverse transcriptase (hTERT), simian virus 40 and CMV, located downstream of the cDNA (TSC); plus a polyadenylation (polyA) signal]. When applied to the conventional Ad-REIC, this novel system induced the development of an enhanced product, Ad-C-TSC-REIC, which exhibited a noticeable anticancer effect. However, there were difficulties in terms of Ad-C-TSC-REIC productivity in HEK293 cells, which are a widely used donor cell line for viral production. Productivity of Ad-C-TSC-REIC was significantly reduced compared with the conventional Ad-REIC, as the Ad-C-TSC-REIC had a significantly higher ability to induce apoptotic cell death of not only various types of cancer cell, but also HEK293 cells. The present study aimed to overcome this problem by modifying the C-TSC structure, resulting in an improved candidate: A C-T cassette (C: CMV-RU5' located upstream; T: another promoter unit composed of a single hTERT promoter, located downstream of the cDNA plus a polyA signal), which demonstrated gene expression comparable to that of the C-TSC system. The improved adenovirus REIC/Dkk-3 product with the C-T cassette, named Ad-C-T-REIC, exhibited a higher expression level of REIC/Dkk3, similar to that of Ad-C-TSC-REIC. Notably, the vector mitigated the cell death of donor HEK293 cells, resulting in a higher rate of production of its adenovirus. These results indicated that Ad-C-T-REIC has the potential to be a useful tool for application in cancer gene therapy.

    DOI: 10.3892/ol.2017.6201

    Web of Science

    PubMed

    researchmap

  • An HNF4α-microRNA-194/192 signaling axis maintains hepatic cell function. 査読

    Morimoto A, Kannari M, Tsuchida Y, Sasaki S, Saito C, Matsuta T, Maeda T, Akiyama M, Nakamura T, Sakaguchi M, Nameki N, Gonzalez FJ, Inoue Y

    The Journal of biological chemistry   292 ( 25 )   10574 - 10585   2017年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1074/jbc.M117.785592

    Web of Science

    PubMed

    researchmap

  • Distant Bystander Effect of REIC/DKK3 Gene Therapy Through Immune System Stimulation in Thoracic Malignancies 査読

    Ken Suzawa, Kazuhiko Shien, Huang Peng, Masakiyo Sakaguchi, Masami Watanabe, Shinsuke Hashida, Yuho Maki, Hiromasa Yamamoto, Shuta Tomida, Junichi Soh, Hiroaki Asano, Kazunori Tsukuda, Yasutomo Nasu, Hiromi Kumon, Shinichiro Miyoshi, Shinichi Toyooka

    ANTICANCER RESEARCH   37 ( 1 )   301 - 307   2017年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:INT INST ANTICANCER RESEARCH  

    Background: Reduced expression in immortalized cell (REIC)/Dickkoph-3 (DKK3) is a tumor-suppressor gene, and its overexpression by adenovirus vector (Ad-REIC) exhibits a remarkable therapeutic effect on various human cancer types through a mechanism triggered by endoplasmic reticulum stress. Materials and Methods: We examined the direct anti-tumor effect of Ad-REIC gene therapy on lung cancer and malignant mesothelioma cell lines in vitro, and the distant bystander effect using immunocompetent mouse allograft models with bilateral flank tumors. Results: Ad-REIC treatment showed antitumor effect in many lung cancer and malignant mesothelioma cell lines in vitro. In an in vivo model, Ad-REIC treatment inhibited the growth not only of directly treated tumors but also of distant untreated tumors. By immunohistochemical analysis, infiltration of T-cells and natural killer (NK) cells and expression of the major histocompatibility complex (MHC) class I molecules were observed in bilateral tumors. Conclusion: Ad-REIC treatment not only had a direct antitumor effect but also an indirect bystander effect through stimulation of the immune system.

    DOI: 10.21873/anticanres.11321

    Web of Science

    PubMed

    researchmap

  • S100-SPECT uncovers cellular and molecular events of pre-metastatic niche formation and following organ-specific cancer metastasis 査読

    Masakiyo Sakaguchi

    THERANOSTICS   7 ( 10 )   2649 - 2651   2017年

     詳細を見る

    記述言語:英語   出版者・発行元:IVYSPRING INT PUBL  

    Great progress has been made in in vivo imaging for cancer metastasis. Eisenblaetter et al. developed an innovative S100A8/A9-specific single photon emission computed tomography (SPECT) probe for imaging and succeeded in detecting the metastatic organ favored by the cancer before the cancer arrival. By utilizing this advanced method, researchers have also found that cancer-derived monocytes are the main source of the abundant production of S100A8/A9 in the pre-metastatic area. The CCL2-CCR2 axis is associated with S100A8/A9 production. Clinical establishment of this technique is expected to enable accurate prediction and monitoring of cancer metastasis during therapy.

    DOI: 10.7150/thno.19866

    Web of Science

    PubMed

    researchmap

  • 平成28年度岡山医学会賞 総合研究奨励賞(結城賞)

    阪口 政清

    岡山医学会雑誌   129 ( 2 )   81 - 83   2017年

     詳細を見る

    記述言語:日本語   出版者・発行元:岡山医学会  

    DOI: 10.4044/joma.129.81

    CiNii Article

    CiNii Books

    researchmap

  • Crucial Role of RAGE in Inappropriate Increase of Smooth Muscle Cells From Patients With Pulmonary Arterial Hypertension 査読

    Kazufumi Nakamura, Satoshi Akagi, Toshihiro Sarashina, Masakiyo Sakaguchi, Hiromi Matsubara, Hiroshi Ito

    CIRCULATION   134   2016年11月

     詳細を見る

    記述言語:英語   出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS  

    Web of Science

    researchmap

  • PINK1 Regulation of Mitochondrial Homeostasis and Cell Survival. 査読

    Hitoshi Murata, Ken-ichi Yamamoto, Rie Kinoshita, Ken Kataoka, Nam-ho Huh, Masakiyo Sakaguchi

    IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL   52   S8 - S8   2016年6月

     詳細を見る

    記述言語:英語   出版者・発行元:SPRINGER  

    Web of Science

    researchmap

  • Development of a Novel REIC/DKK-3-Encoding Adenoviral Agent: Its Robust and Promising Therapeutic Effects in Pancreatic Cancer 査読

    Daisuke Uchida, Hidenori Shiraha, Hironari Kato, Sawahara Hiroaki, Masakiyo Sakaguchi, Masami Watanabe, Yasutomo Nasu, Hiromi Kumon, Hiroyuki Okada

    GASTROENTEROLOGY   150 ( 4 )   S294 - S294   2016年4月

     詳細を見る

    記述言語:英語   出版者・発行元:W B SAUNDERS CO-ELSEVIER INC  

    0

    DOI: 10.1016/S0016-5085(16)31025-3

    Web of Science

    researchmap

  • Receptor for advanced glycation endproducts modulates leukotriene B-4 receptor 1 signaling 査読

    Takako Ichiki, Tomoaki Koga, Toshiaki Okuno, Kazuko Saeki, Yasuhiko Yamamoto, Masakiyo Sakaguchi, Takehiko Yokomizo

    FASEB JOURNAL   30   2016年4月

     詳細を見る

    記述言語:英語   出版者・発行元:FEDERATION AMER SOC EXP BIOL  

    DOI: 10.1089/dna.2016.3552

    Web of Science

    researchmap

  • Promising Therapeutic Efficacy of a Novel REIC/Dkk-3 Expressing Adenoviral Vector for Hepatocellular Carcinoma 査読

    Sawahara Hiroaki, Hidenori Shiraha, Daisuke Uchida, Masakiyo Sakaguchi, Masami Watanabe, Yasutomo Nasu, Hiromi Kumon, Hiroyuki Okada

    GASTROENTEROLOGY   150 ( 4 )   S1153 - S1153   2016年4月

     詳細を見る

    記述言語:英語   出版者・発行元:W B SAUNDERS CO-ELSEVIER INC  

    DOI: 10.1016/S0016-5085(16)33891-4

    Web of Science

    researchmap

  • Receptor for advanced glycation endproducts modulates leukotriene B-4 receptor 1 signaling 査読

    Takako Ichiki, Tomoaki Koga, Toshiaki Okuno, Kazuko Saeki, Yasuhiko Yamamoto, Masakiyo Sakaguchi, Takehiko Yokomizo

    FASEB JOURNAL   30   2016年4月

     詳細を見る

    記述言語:英語   出版者・発行元:FEDERATION AMER SOC EXP BIOL  

    DOI: 10.1089/dna.2016.3552

    Web of Science

    researchmap

  • Hepatocyte Nuclear Factor 4 alpha Controls Iron Metabolism and Regulates Transferrin Receptor 2 in Mouse Liver 査読

    Shunsuke Matsuo, Masayuki Ogawa, Martina U. Muckenthaler, Yumiko Mizui, Shota Sasaki, Takafumi Fujimura, Masayuki Takizawa, Nagayuki Ariga, Hiroaki Ozaki, Masakiyo Sakaguchi, Frank J. Gonzalez, Yusuke Inoue

    JOURNAL OF BIOLOGICAL CHEMISTRY   290 ( 52 )   30855 - 30865   2015年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC  

    Iron is an essential element in biological systems, but excess iron promotes the formation of reactive oxygen species, resulting in cellular toxicity. Several iron-related genes are highly expressed in the liver, a tissue in which hepatocyte nuclear factor 4 alpha (HNF4 alpha) plays a critical role in controlling gene expression. Therefore, the role of hepatic HNF4 alpha in iron homeostasis was examined using liver-specific HNF4 alpha-null mice (Hnf4a(Delta H) mice). Hnf4a(Delta H) mice exhibit hypoferremia and a significant change in hepatic gene expression. Notably, the expression of transferrin receptor 2 (Tfr2) mRNA was markedly decreased in Hnf4a(Delta H) mice. Promoter analysis of the Tfr2 gene showed that the basal promoter was located at a GC-rich region upstream of the transcription start site, a region that can be transactivated in an HNF4 alpha-independent manner. HNF4 alpha-dependent expression of Tfr2 was mediated by a proximal promoter containing two HNF4 alpha-binding sites located between the transcription start site and the translation start site. Both the GC-rich region of the basal promoter and the HNF4 alpha-binding sites were required for maximal transactivation. Moreover, siRNA knockdown of HNF4 alpha suppressed TFR2 expression in human HCC cells. These results suggest that Tfr2 is a novel target gene for HNF4 alpha, and hepatic HNF4 alpha plays a critical role in iron homeostasis.

    DOI: 10.1074/jbc.M115.694414

    Web of Science

    researchmap

  • NRF2 Regulates PINK1 Expression under Oxidative Stress Conditions 査読

    Hitoshi Murata, Hitoshi Takamatsu, Sulai Lie, Ken Kataoka, Nam-ho Huh, Masakiyo Sakaguchi

    PLoS One   10 ( 11 )   e0142438   2015年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PUBLIC LIBRARY SCIENCE  

    Mutations of the PTEN-induced putative kinase 1 (PINK1) gene are a cause of autosomal recessive forms of Parkinson's disease. Recent studies have revealed that PINK1 is an essential factor for controlling mitochondrial quality, and that it protects cells from oxidative stresses. Although there has been considerable progress in the elucidation of various aspects of PINK1 protein regulation such as activation, stability and degradation, the transcriptional regulation of PINK1 mRNA under stress conditions remains unclear. In this study, we found that nuclear factor (erythroid-derived 2)-like 2 (NRF2), an antioxidant transcription factor, regulates PINK1 expression under oxidative stress conditions. Damaged mitochondria arising from stress conditions induced NRF2-dependent transcription of the PINK1 gene through production of reactive oxygen species (ROS). Either an ROS scavenger or forced expression of KEAP1, a potent inhibitory partner to NRF2, restricted PINK1 expression induced by activated NRF2. Transcriptionally up-regulated PINK1 diminished oxidative stress-associated cell death. The results indicate that PINK1 expression is positively regulated by NRF2 and that the NRF2-PINK1 signaling axis is deeply involved in cell survival.

    DOI: 10.1371/journal.pone.0142438

    Web of Science

    PubMed

    researchmap

  • T790M変異を含むEGFR遺伝子変異を有する非小細胞肺癌細胞株に対するTAE226の抗腫瘍効果

    山本 寛斉, 阪口 政清, 宗 淳一, 佃 和憲, 木浦 勝行, 猶本 良夫, 三好 新一郎, 豊岡 伸一

    日本癌学会総会記事   74回   P - 2193   2015年10月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • REIC/Dkk-3遺伝子治療の胸部悪性腫瘍に対する免疫刺激を介する抗腫瘍効果

    諏澤 憲, 枝園 和彦, 阪口 政清, 渡部 昌実, 橋田 真輔, 宗 淳一, 山本 寛斉, 牧 祐歩, 佃 和憲, 那須 保友, 公文 裕巳, 三好 新一郎, 豊岡 伸一

    日本癌学会総会記事   74回   J - 1224   2015年10月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • TAE226, a Bis-Anilino Pyrimidine Compound, Shows Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells including T790M Mutant 査読

    Hiromasa Yamamoto, Hiroki Otani, Munenori Takaoka, Masakiyo Sakaguchi, Junichi Soh, Masaru Jida, Tsuyoshi Ueno, Takafumi Kubo, Hiroaki Asano, Kazunori Tsukuda, Katsuyuki Kiura, Shinji Hatakeyama, Eiji Kawahara, Yoshio Naomoto, Shinichiro Miyoshi, Shinichi Toyooka

    JOURNAL OF THORACIC ONCOLOGY   10 ( 9 )   S311 - S312   2015年9月

     詳細を見る

    記述言語:英語   出版者・発行元:ELSEVIER SCIENCE INC  

    DOI: 10.1371/journal.pone.0129838

    Web of Science

    researchmap

  • Distant Bystander Effect of REIC/Dkk-3 Gene Therapy through Immune System Stimulation in a Murine Model of Thoracic Malignancies 査読

    Ken Suzawa, Kazuhiko Shien, Peng Huang, Masakiyo Sakaguchi, Masami Watanabe, Shinsuke Hashida, Junichi Soh, Hiromasa Yamamoto, Yuho Maki, Hiroaki Asano, Kazunori Tsukuda, Yasutomo Nasu, Hiromi Kumon, Shinichiro Miyoshi, Shinichi Toyooka

    JOURNAL OF THORACIC ONCOLOGY   10 ( 9 )   S599 - S599   2015年9月

     詳細を見る

    記述言語:英語   出版者・発行元:ELSEVIER SCIENCE INC  

    Web of Science

    researchmap

  • Anti-tumor effect of afatinib, an irreversible EGFR/HER2 dual inhibitor, in lung cancers harboring HER2 oncogene 査読

    Ken Suzawa, Shinichi Toyooka, Masakiyo Sakaguchi, Tomoaki Ohtsuka, Mototsugu Watanabe, Shinsuke Hashida, Yuho Maki, Hiromasa Yamamoto, Junichi Soh, Hiroaki Asano, Kazunori Tsukuda, Shinichiro Miyoshi

    CANCER RESEARCH   75   2015年8月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2015-2588

    Web of Science

    researchmap

  • Identification of a novel binding protein playing a critical role in HER2 activation in lung cancer cells 査読

    Tomoaki Ohtsuka, Masakiyo Sakaguchi, Katsuyoshi Takata, Shinsuke Hashida, Mototsugu Watanabe, Ken Suzawa, Yuho Maki, Hiromasa Yamamoto, Junichi Soh, Hiroaki Asano, Kazunori Tsukuda, Shinichiro Miyoshi, Shinichi Toyooka

    CANCER RESEARCH   75   2015年8月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2015-48

    Web of Science

    researchmap

  • Novel germline G660D mutation in HER2 gene detected by whole-exome sequencing can predispose a patient to developing familial lung adenocarcinoma 査読

    Hiromasa Yamamoto, Koichiro Higasa, Masakiyo Sakaguchi, Kazuhiko Shien, Junichi Soh, Koichi Ichimura, Masashi Furukawa, Shinsuke Hashida, Kazunori Tsukuda, Nagio Takigawa, Keitaro Matsuo, Katsuyuki Kiura, Sinichiro Miyoshi, Fumihiko Matsuda, Shinichi Toyooka

    CANCER RESEARCH   74 ( 19 )   2014年10月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2014-LB-291

    Web of Science

    researchmap

  • 家族性・孤発性肺腺癌におけるHER2膜貫通領域の新規遺伝子変異(Novel functional mutations in the transmembrane domain of HER2 gene in familial and sporadic lung adenocarcinomas)

    山本 寛斉, 日笠 幸一郎, 阪口 政清, 枝園 和彦, 宗 淳一, 市村 浩一, 佃 和憲, 瀧川 奈義夫, 松尾 恵太郎, 木浦 勝行, 三好 新一郎, 松田 文彦, 豊岡 伸一

    日本癌学会総会記事   73回   E - 2012   2014年9月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • がんマーカー、サイトケラチン19(CK19)機能の新展開 HER2活性化におけるCK19の役割(Critical role of Cytokeratin-19 in an oncogenic activation of HER2)

    大塚 智昭, 阪口 政清, 渡邉 元嗣, 諏澤 憲, 橋田 真輔, 牧 佑歩, 山本 寛斉, 宗 淳一, 浅野 博昭, 佃 和憲, 三好 新一郎, 豊岡 伸一

    日本癌学会総会記事   73回   E - 2071   2014年9月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • 新規HER2膜貫通部領域遺伝子変異の機能解析(Novel HER2 mutations in transmembrane dmain result in constitutive autophosphorylation of HER2)

    諏澤 憲, 阪口 政清, 山本 寛斉, 宗 淳一, 牧 佑歩, 橋田 真輔, 大塚 智昭, 渡邉 元嗣, 浅野 博昭, 佃 和憲, 三好 新一郎, 豊岡 伸一

    日本癌学会総会記事   73回   P - 1328   2014年9月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • Extract of Cordyceps militaris inhibits angiogenesis and suppresses tumor growth of human malignant melanoma cells 査読

    I. Made Winarsa Ruma, Endy Widya Putranto, Eisaku Kondo, Risayo Watanabe, Ken Saito, Yusuke Inoue, Ken-Ichi Yamamoto, Susumu Nakata, Masaji Kaihata, Hitoshi Murata, Masakiyo Sakaguchi

    INTERNATIONAL JOURNAL OF ONCOLOGY   45 ( 1 )   209 - 218   2014年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPANDIDOS PUBL LTD  

    Angiogenesis is essential for tumor development and metastasis. Among several angiogenic factors, vascular endothelial growth factor receptor (VEGF) is important for tumor-derived angiogenesis and commonly overexpressed in solid tumors. Thus, many antitumor strategies targeting VEGF have been developed to inhibit cancer angiogenesis, offering insights into the successful treatment of solid cancers. However, there are a number of issues such as harmful effects on normal vascularity in clinical trials. Taking this into consideration, we employed Cordyceps militaris as an antitumor approach due to its biological safety in vivo. The herbal medicinal mushroom Cordyceps militaris has been reported to show potential anticancer properties including anti-angiogenic capacity; however, its concrete properties have yet to be fully demonstrated. In this study, we aimed to elucidate the biological role of Cordyceps militaris extract in tumor cells, especially in regulating angiogenesis and tumor growth of a human malignant melanoma cell line. We demonstrated that Cordyceps militaris extract remarkably suppressed tumor growth via induction of apoptotic cell death in culture that links to the abrogation of VEGF production in melanoma cells. This was followed by mitigation of Akt1 and GSK-3 beta activation, while p38 alpha phosphorylation levels were increased. Extract treatment in mouse model xenografted with human melanoma cells resulted in a dramatic antitumor effect with downregulation of VEGF expression. The results suggest that suppression of tumor growth by Cordyceps militaris extract is, at least, mediated by its anti-angiogenicity and apoptosis induction capacities. Cordyceps militaris extract may be a potent antitumor herbal drug for solid tumors.

    DOI: 10.3892/ijo.2014.2397

    Web of Science

    PubMed

    researchmap

  • Dramatic Increase in Expression of a Transgene by Insertion of Promoters Downstream of the Cargo Gene 査読

    Masakiyo Sakaguchi, Masami Watanabe, Rie Kinoshita, Haruki Kaku, Hideo Ueki, Junichiro Futami, Hitoshi Murata, Yusuke Inoue, Shun-Ai Li, Peng Huang, Endy Widya Putranto, I. Made Winarsa Ruma, Yasutomo Nasu, Hiromi Kumon, Nam-ho Huh

    MOLECULAR BIOTECHNOLOGY   56 ( 7 )   621 - 630   2014年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:HUMANA PRESS INC  

    For expression of genes in mammalian cells, various vectors have been developed using promoters including CMV, EF-1 alpha, and CAG promoters and have been widely used. However, such expression vectors sometimes fail to attain sufficient expression levels depending on the nature of cargo genes and/or on host cell types. In the present study, we aimed to develop a potent promoter system that enables high expression levels of cargo genes ubiquitously in many different cell types. We found that insertion of an additional promoter downstream of a cargo gene greatly enhanced the expression levels. Among the constructs we tested, C-TSC cassette (C: CMV-RU5' located upstream; TSC: another promoter unit composed of triple tandem promoters, hTERT, SV40, and CMV, located downstream of the cDNA plus a polyadenylation signal) had the most potent capability, showing far higher efficiency than that of potent conventional vector systems. The results indicate that the new expression system is useful for production of recombinant proteins in mammalian cells and for application as a gene therapeutic measure.

    DOI: 10.1007/s12033-014-9738-0

    Web of Science

    PubMed

    researchmap

  • S100A11 is required for efficient plasma membrane repair and survival of invasive cancer cells 査読

    Jyoti K. Jaiswal, Stine P. Lauritzen, Luana Scheffer, Masakiyo Sakaguchi, Jakob Bunkenborg, Sanford M. Simon, Tuula Kallunki, Marja Jaattela, Jesper Nylandsted

    NATURE COMMUNICATIONS   5   3795   2014年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:NATURE PUBLISHING GROUP  

    Cell migration and invasion require increased plasma membrane dynamics and ability to navigate through dense stroma, thereby exposing plasma membrane to tremendous physical stress. Yet, it is largely unknown how metastatic cancer cells acquire an ability to cope with such stress. Here we show that S100A11, a calcium-binding protein upregulated in a variety of metastatic cancers, is essential for efficient plasma membrane repair and survival of highly motile cancer cells. Plasma membrane injury-induced entry of calcium into the cell triggers recruitment of S100A11 and Annexin A2 to the site of injury. We show that S100A11 in a complex with Annexin A2 helps reseal the plasma membrane by facilitating polymerization of cortical F-actin and excision of the damaged part of the plasma membrane. These data reveal plasma membrane repair in general and S100A11 and Annexin A2 in particular as new targets for the therapy of metastatic cancers.

    DOI: 10.1038/ncomms4795

    Web of Science

    PubMed

    researchmap

  • A novel gene expression system strongly enhances the anticancer effects of a REIC/Dkk-3-encoding adenoviral vector 査読

    Masami Watanabe, Masakiyo Sakaguchi, Rie Kinoshita, Haruki Kaku, Yuichi Ariyoshi, Hideo Ueki, Ryuta Tanimoto, Shin Ebara, Kazuhiko Ochiai, Junichiro Futami, Shun-Ai Li, Peng Huang, Yasutomo Nasu, Nam-Ho Huh, Hiromi Kumon

    ONCOLOGY REPORTS   31 ( 3 )   1089 - 1095   2014年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPANDIDOS PUBL LTD  

    Gene expression systems with various promoters, including the cytomegalovirus (CMV) promoter, have been developed to increase the gene expression in a variety of normal and cancer cells. In particular, in the clinical trials of cancer gene therapy, a more efficient and robust gene expression system is required to achieve sufficient therapeutic outcomes. By inserting the triple translational enhancer sequences of human telomerase reverse transcriptase (hTERT), Simian virus 40 (SV40) and CMV downstream of the sequence of the BGH polyA, we were able to develop a novel gene expression system that significantly enhances the expression of the genes of interest. We termed this novel gene expression cassette the super gene expression (SGE) system, and herein verify the utility of the SGE cassette for a replication-deficient adenoviral vector. We newly developed an adenoviral vector expressing the tumor suppressor, reduced expression in immortalized cells (REIC)/Dickkopf-3 (Dkk-3), based on the CMV promoter-driven SGE system (Ad-SGE-REIC) and compared the therapeutic utility of Ad-SGE-REIC with that of the conventional adenoviral vectors (Ad-CMV-REIC or Ad-CAG-REIC). The results demonstrated that the CMV promoter-SGE system allows for more potent gene expression, and that the Ad-SGE-REIC is superior to conventional adenoviral systems in terms of the REIC protein expression and therapeutic effects. Since the SGE cassette can be applied for the expression of various therapeutic genes using various vector systems, we believe that this novel system will become an innovative tool in the field of gene expression and gene therapy.

    DOI: 10.3892/or.2013.2958

    Web of Science

    PubMed

    researchmap

  • Anti-Cancer Effects of REIC/Dkk-3-encoding Adenoviral Vector for the Treatment of Non-small Cell Lung Cancer 査読

    Kazuhiko Shien, Norimitsu Tanaka, Masami Watanabe, Junichi Soh, Masakiyo Sakaguchi, Keitaro Matsuo, Hiromasa Yamamoto, Masashi Furukawa, Hiroaki Asano, Kazunori Tsukuda, Yasutomo Nasu, Nam-Ho Huh, Shinichiro Miyoshi, Hiromi Kumon, Shinichi Toyooka

    PLOS ONE   9 ( 2 )   e87900   2014年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PUBLIC LIBRARY SCIENCE  

    Objectives: REIC/Dkk-3 is down-regulated in a broad range of human cancer cells and is considered to function as a tumor suppressor. We previously reported that REIC/Dkk-3-expressing adenovirus vector (Ad-REIC) induced endoplasmic reticulum (ER) stress and cancer-specific apoptosis in human prostate cancer. In this study, we examined the therapeutic impact of Ad-REIC on non-small cell lung cancer (NSCLC).
    Materials and Methods: We examined the anti-tumor effect of Ad-REIC on 25 NSCLC cell lines in vitro and A549 cells in vivo. Two of these cell lines were artificially established as EGFR-tyrosine kinase inhibitor (TKI) resistant sublines.
    Results: Ad-REIC-treatment inhibited the cell viability by 40% or more in 13 (52%) of the 25 cell lines at multiplicity of infection (MOI) of 20 (20 MOI). These cell lines were regarded as being highly sensitive cells. The cell viability of a nonmalignant immortalized cell line, OUMS-24, was not inhibited at 200 MOI of Ad-REIC. The effects of Ad-REIC on EGFR-TKI resistant sublines were equivalent to those in the parental cell lines. Here, we demonstrated that Ad-REIC treatment activated c-Jun N-terminal kinase (JNK) in NSCLC cell lines, indicating the induction of ER stress with GRP78/BiP (GRP78) up-regulation and resulting in apoptosis. A single intratumoral injection of Ad-REIC significantly inhibited the tumorigenic growth of A549 cells in vivo. As predictive factors of sensitivity for Ad-REIC treatment in NSCLC, we examined the expression status of GRP78 and coxsackievirus and adenovirus receptor (CAR). We found that the combination of the GRP78 and CAR expressional statuses may be used as a predictive factor for Ad-REIC sensitivity in NSCLC cells.
    Conclusion: Ad-REIC induced JNK activation and subsequent apoptosis in NSCLC cells. Our study indicated that Ad-REIC has therapeutic potential against NSCLC and that the expression statuses of GRP78 and CAR may predict a potential therapeutic benefit of Ad-REIC.

    DOI: 10.1371/journal.pone.0087900

    Web of Science

    PubMed

    researchmap

  • Preclinical Evaluation of MicroRNA-34b/c Delivery for Malignant Pleural Mesothelioma 査読

    Tsuyoshi Ueno, Shinichi Toyooka, Takuya Fukazawa, Takafumi Kubo, Junichi Soh, Hiroaki Asano, Takayuki Muraoka, Norimitsu Tanaka, Yuho Maki, Kazuhiko Shien, Masashi Furukawa, Masakiyo Sakaguchi, Hiromasa Yamamoto, Kazunori Tsukuda, Shinichiro Miyoshi

    ACTA MEDICA OKAYAMA   68 ( 1 )   23 - 26   2014年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:OKAYAMA UNIV MED SCHOOL  

    The microRNA-34s (miR-34s) have p53 response elements in their 5'-flanking regions and demonstrate tumor-suppressive functions. In malignant pleural mesothelioma (MPM), we previously reported that expression of miR-34b and miR-34c (miR-34b/c) was frequently downregulated by methylation in MPM cell lines and primary tumors. The forced overexpression of miR-34b/c showed significant antitumor effects with the induction of apoptosis in MPM cells. In this study, we examined the in vivo antitumor effects of miR-34b/c using adenovirus vector on MPM. We subcutaneously transplanted NCI-H290, a human MPM cell line, into BALB/C mice and injected adenovirus vector expressing miR-34b/c, luciferase driven by the cytomegalovirus promoter (Ad-miR-34b/c or Ad-Luc), or PBS control into tumors over 5mm in diameter. A statistically significant growth inhibition of the tumor volume was observed in the Ad-miR-34b/c group from day 6 onward compared to the Ad-Luc group. The inhibition rate of Ad-miR-34b/c, compared to the tumor volume treated with Ad-Luc, was 58.6% on day 10 and 54.7% on day13. Our results indicate that adenovirus-mediated miR-34b/c gene therapy could be useful for the clinical treatment of MPM.

    DOI: 10.18926/AMO/52140

    Web of Science

    PubMed

    researchmap

  • Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas 査読

    Hiromasa Yamamoto, Koichiro Higasa, Masakiyo Sakaguchi, Kazuhiko Shien, Junichi Soh, Koichi Ichimura, Masashi Furukawa, Shinsuke Hashida, Kazunori Tsukuda, Nagio Takigawa, Keitaro Matsuo, Katsuyuki Kiura, Shinichiro Miyoshi, Fumihiko Matsuda, Shinichi Toyooka

    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE   106 ( 1 )   djt338   2014年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:OXFORD UNIV PRESS INC  

    We encountered a family of Japanese descent in which multiple members developed lung cancer. Using whole-exome sequencing, we identified a novel germline mutation in the transmembrane domain of the human epidermal growth factor receptor 2 (HER2) gene (G660D). A novel somatic mutation (V659E) was also detected in the transmembrane domain of HER2 in one of 253 sporadic lung adenocarcinomas. Because the transmembrane domain of HER2 is considered to be responsible for the dimerization and subsequent activation of the HER family and downstream signaling pathways, we performed functional analyses of these HER2 mutants. Mutant HER2 G660D and V659E proteins were more stable than wild-type protein. Both the G660D and V659E mutants activated Akt. In addition, they activated p38, which is thought to promote cell proliferation in lung adenocarcinoma. Our findings strongly suggest that mutations in the transmembrane domain of HER2 may be oncogenic, causing hereditary and sporadic lung adenocarcinomas.

    DOI: 10.1093/jnci/djt338

    Web of Science

    PubMed

    researchmap

  • Histidine-rich glycoprotein prevents septic lethality through neutrophil regulation 査読

    Nishibori M, Wake H, Mori S, Liu K, Morioka Y, Teshigawara K, Sakaguchi M, Kuroda K, Takahashi H, Ohtsuka A, Yoshino T, Morimatsu H

    Critical Care   1 - 53   2014年

  • Draft genome sequence of Clostridium botulinum type B strain Osaka05, isolated from an infant patient with botulism in Japan 査読

    Yoshihiko Sakaguchi, Koji Hosomi, Jumpei Uchiyama, Yoshitoshi Ogura, Kaoru Umeda, Masakiyo Sakaguchi, Tomoko Kohda, Masafumi Mukamoto, Naoaki Misawa, Shigenobu Matsuzaki, Tetsuya Hayashi, Shunji Kozaki

    Genome Announcements   2 ( 1 )   2014年

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:1  

    © 2014 Sakaguchi et al. Clostridium botulinum strain Osaka05, which has been isolated from an infant patient with botulism in Japan, is the first strain producing botulinum neurotoxin subtype B6. Here, we report the draft genome sequence of C. botulinum Osaka05.

    DOI: 10.1128/genomeA.e01010-13

    Scopus

    PubMed

    researchmap

  • Inhibition of RAGE signaling through the intracellular delivery of inhibitor peptides by PEI cationization 査読

    Endy Widya Putranto, Hitoshi Murata, Ken-Ichi Yamamoto, Ken Kataoka, Hidenori Yamada, Jun-Ichiro Futami, Masakiyo Sakaguchi, Nam-Ho Huh

    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE   32 ( 4 )   938 - 944   2013年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPANDIDOS PUBL LTD  

    The receptor for advanced glycation end products (RAGE) is a multi-ligand cell surface receptor and a member of the immunoglobulin superfamily. RAGE is involved in a wide range of inflammatory, degenerative and hyper-proliferative disorders which span over different organs by engaging diverse ligands, including advanced glycation end products, S100 family proteins, high-mobility group protein B1 (HMGB1) and amyloid beta. We previously demonstrated that the cytoplasmic domain of RAGE is phosphorylated upon the binding of ligands, enabling the recruitment of two distinct pairs of adaptor proteins, Toll-interleukin 1 receptor domain-containing adaptor protein (TIRAP) and myeloid differentiation protein 88 (MyD88). This engagement allows the activation of downstream effector molecules, and thereby mediates a wide variety of cellular processes, such as inflammatory responses, apoptotic cell death, migration and cell growth. Therefore, inhibition of the binding of TIRAP to RAGE may abrogate intracellular signaling from ligand-activated RAGE. In the present study, we developed inhibitor peptides for RAGE signaling (RAGE-I) by mimicking the phosphorylatable cytosolic domain of RAGE. RAGE-I was efficiently delivered into the cells by polyethylenimine (PEI) cationization. We demonstrated that RAGE-I specifically bound to TIRAP and abrogated the activation of Cdc42 induced by ligand-activated RAGE. Furthermore, we were able to reduce neuronal cell death induced by an excess amount of S100B and to inhibit the migration and invasion of glioma cells in vitro. Our results indicate that RAGE-I provides a powerful tool for therapeutics to block RAGE-mediated multiple signaling.

    DOI: 10.3892/ijmm.2013.1467

    Web of Science

    PubMed

    researchmap

  • SARM1 and TRAF6 bind to and stabilize PINK1 on depolarized mitochondria 査読

    Hitoshi Murata, Masakiyo Sakaguchi, Ken Kataoka, Nam-ho Huh

    MOLECULAR BIOLOGY OF THE CELL   24 ( 18 )   2772 - 2784   2013年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:AMER SOC CELL BIOLOGY  

    Mutations in PTEN-induced putative kinase 1 (PINK1) or parkin cause autosomal recessive forms of Parkinson's disease. Recent work suggests that loss of mitochondrial membrane potential stabilizes PINK1 and that accumulated PINK1 recruits parkin from the cytoplasm to mitochondria for elimination of depolarized mitochondria, which is known as mitophagy. In this study, we find that PINK1 forms a complex with sterile alpha and TIR motif containing 1 (SARM1) and tumor necrosis factor receptor-associated factor 6 (TRAF6), which is important for import of PINK1 in the outer membrane and stabilization of PINK1 on depolarized mitochondria. SARM1, which is known to be an adaptor protein for Toll-like receptor, binds to PINK1 and promotes TRAF6-mediated lysine 63 chain ubiquitination of PINK1 at lysine 433. Down-regulation of SARM1 and TRAF6 abrogates accumulation of PINK1, followed by recruitment of parkin to damaged mitochondria. Some pathogenic mutations of PINK1 reduce the complex formation and ubiquitination. These results indicate that association of PINK1 with SARM1 and TRAF6 is an important step for mitophagy.

    DOI: 10.1091/mbc.E13-01-0016

    Web of Science

    PubMed

    researchmap

  • DOCK7 is a critical regulator of the RAGE-Cdc42 signaling axis that induces formation of dendritic pseudopodia in human cancer cells 査読

    Ken-Ichi Yamamoto, Hitoshi Murata, Endy Widya Putranto, Ken Kataoka, Akira Motoyama, Toshihiko Hibino, Yusuke Inoue, Masakiyo Sakaguchi, Nam-Ho Huh

    ONCOLOGY REPORTS   29 ( 3 )   1073 - 1079   2013年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPANDIDOS PUBL LTD  

    Cellular migration is a fundamental process linked to cancer metastasis. Growing evidence indicates that the receptor for advanced glycation end products (RAGE) plays a pivotal role in this process. With regard to downstream signal transducers of RAGE, diaphanous-1 and activated small guanine nucleotide triphosphatases, Rac1 and Cdc42, have been identified. To obtain precise insight into the direct downstream signaling mechanism of RAGE, we screened for proteins interacting with the cytoplasmic domain of RAGE employing an immunoprecipitation-liquid chromatography coupled with an electrospray tandem mass spectrometry system. In the present study, we found that the cytoplasmic domain of RAGE interacted with an atypical DOCK180-related guanine nucleotide exchange factor, dedicator of cytokinesis protein 7 (DOCK7). DOCK7 bound to the RAGE cytoplasmic domain and transduced a signal to Cdc42, resulting in the formation of abundant highly branched filopodia-like protrusions, dendritic pseudopodia. Blocking of the function of DOCK7 greatly abrogated the formation of dendritic pseudopodia and suppressed cellular migration. These results indicate that DOCK7 functions as an essential and downstream regulator of RAGE-mediated cellular migration through the formation of dendritic pseudopodia.

    DOI: 10.3892/or.2012.2191

    Web of Science

    PubMed

    researchmap

  • S100A9 is a novel ligand of EMMPRIN that promotes melanoma metastasis 査読

    Toshihiko Hibino, Masakiyo Sakaguchi, Shoko Miyamoto, Mami Yamamoto, Akira Motoyama, Junichi Hosoi, Tadashi Shimokata, Tomonobu Ito, Ryoji Tsuboi, Nam-Ho Huh

    Cancer Research   73 ( 1 )   172 - 183   2013年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:1  

    The calcium-binding proteins S100A8 and S100A9 can dimerize to form calprotectin, the release of which during tissue damage has been implicated in inflammation and metastasis. However, receptor(s) mediating the physiologic and pathophysiologic effects of this damage-associated "danger signal" are uncertain. In this study, searching for candidate calprotectin receptors by affinity isolation-mass spectrometry, we identified the cell surface glycoprotein EMMPRIN/BASIGIN (CD147/BSG). EMMPRIN specifically bound to S100A9 but not S100A8. Induction of cytokines and matrix metalloproteases (MMP) by S100A9 was markedly downregulated in melanoma cells by attenuation of EMMPRIN. We found that EMMPRIN signaling used the TNF receptor-associated factor TRAF2 distinct from the known S100-binding signaling pathway mediated by RAGE (AGER). S100A9 strongly promoted migration when EMMPRIN was highly expressed, independent of RAGE, whereas EMMPRIN blockade suppressed migration by S100A9. Immunohistologic analysis of melanomas revealed that EMMPRIN was expressed at both the invasive edge of lesions and the adjacent epidermis, where S100A9 was also strongly expressed. In epidermal-specific transgenic mice, tail vein-injected melanoma accumulated in skin expressing S100A9 but not S100A8. Together, our results establish EMMPRIN as a receptor for S100A9 and suggest the therapeutic use in targeting S100A9-EMMPRIN interactions. ©2012 AACR.

    DOI: 10.1158/0008-5472.CAN-11-3843

    Scopus

    PubMed

    researchmap

  • Preclinical biodistribution and safety study of reduced expression in immortalized cells/Dickkopf-3-encoding adenoviral vector for prostate cancer gene therapy 査読

    Morito Sugimoto, Masami Watanabe, Haruki Kaku, Shun-Ai Li, Hirofumi Noguchi, Hideo Ueki, Masakiyo Sakaguchi, Nam-Ho Huh, Yasutomo Nasu, Hiromi Kumon

    ONCOLOGY REPORTS   28 ( 5 )   1645 - 1652   2012年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPANDIDOS PUBL LTD  

    The biodistribution and safety of adenoviral vectors encoding the human REIC/Dkk-3 tumor suppressor gene (Ad-REIC) were examined in this preclinical study for in situ prostate cancer gene therapy. First, the in vitro apoptotic effects of Ad-REIC in normal and cancer cells derived from the prostate and liver were examined. Significant apoptotic effects were observed at 100 MOI (multiplicity of infection) in prostate cancer cells (LNCaP, PC3) and hepatoma cells (HEP3B and HEPG2); however, no effects were seen in normal cells. To analyze the safety of intraprostatic Ad-REIC administration, the biodistribution and histology after Ad-REIC injection were evaluated in various organs of normal male C57BL6 mice. In a supporting study, vector dissemination following intravenous injection of Ad-REIC into tail veins was determined. To evaluate whether Ad-REIC was present in the collected tissue specimens, human REIC gene detection was performed using DNA-PCR. Intraprostatic treatment administered at lower doses showed vector biodistribution into the colon, urinary bladder and prostate. At higher doses, vector dissemination was observed in tissues more distant from the prostate, including the lung, thymus, heart, liver and adrenal gland. After intravenous injection a: Ad-REIC, dissemination was observed in the liver and spleen. These results indicate that the biodistribution of Ad-REIC is determined by the dose and route of administration. Although acute inflammatory effects were observed in the prostate after intraprostatic administration at higher doses, no abnormal histological findings were noted in the other tissues, including those of intravenously treated mice. Regarding the safety of Ad-REIC administration, no deaths and no signs of toxicity or unusual behavior were observed in the mice in any treatment group. Based on these preclinical experiments, adenovirus-mediated in situ REIC/Dkk-3 gene therapy is considered to be safe for use as a treatment for human prostate cancer.

    DOI: 10.3892/or.2012.2001

    Web of Science

    PubMed

    researchmap

  • DIRECT THERAPEUTIC EFFECT OF REIC/DKK-3-ENCODING ADENOVIRAL VECTOR FOR NON-SMALL CELL LUNG CANCER 査読

    Yamamoto Hiromasa, Tanaka Norimitsu, Toyooka Shinichi, Watanabe Masami, Sakaguchi Masakiyo, Soh Junichi, Shien Kazuhiko, Furukawa Masashi, Asano Hiroaki, Tsukuda Kazunori, Nasu Yasutomo, Huh Nam-ho, Kumon Hiromi, Miyoshi Shinichirou

    JOURNAL OF THORACIC ONCOLOGY   7 ( 11 )   S463   2012年11月

  • REIC/Dkk-3-encoding adenoviral vector as a potentially effective therapeutic agent for bladder cancer 査読

    Takeshi Hirata, Masami Watanabe, Haruki Kaku, Yasuyuki Kobayashi, Hiroshi Yamada, Masakiyo Sakaguchi, Kohji Takei, Nam-Ho Huh, Yasutomo Nasu, Hiromi Kumon

    INTERNATIONAL JOURNAL OF ONCOLOGY   41 ( 2 )   559 - 564   2012年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPANDIDOS PUBL LTD  

    Bladder cancer is one of the most common urogenital malignancies. The intravesical instillation of anticancer agents is an attractive strategy to treat a superficial lesion or floating/disseminated cancer cells after transurethral operation. An adenovirus carrying REIC/Dkk-3, a tumor suppressor gene (Ad-REIC), exhibits cancer-specific apoptotic effects in various types of cancer cells. The aim of the present study was to examine the potential of Ad-REIC as a therapeutic agent for bladder cancer. KK47 and RT4 human bladder cancer cells were sensitive to the Ad-REIC treatment for apoptosis induction, but some human bladder cancer cell lines (T24, J82 and TccSup) were resistant. Significant cell growth inhibition was observed when these resistant cancer cell lines were treated with Ad-REIC in a condition of floating cells, which is clinically observed after transurethral operation and becomes a cause of intravesical cancer dissemination. The therapeutic potential of Ad-REIC for the treatment of multidrug-resistant bladder cancer was investigated. The adriamycin-resistant KK47 bladder cancer cells (KK47/ADM), which also present multidrug resistance, showed induction of significant apoptosis following Ad-REIC treatment. The Ad-REIC treatment induced downregulation of P-glycoprotein in KK47/ADM cells and restored the sensitivity to doxorubicin (adriamycin). Ad-REIC suppressed P-glycoprotein expression in a c-Jun-NH2-kinase (JNK)-dependent manner. Therefore, the current study indicated two therapeutic aspects of the Ad-REIC agent against human bladder cancer cells, as an apoptosis inducer/cell growth inhibitor and as a sensitizer of chemotherapeutic agents in multidrug-resistant cancer cells. The intravesical instillation of Ad-REIC could be an attractive therapeutic method in human bladder cancer where the treatment of superficial lesions and floating/disseminated or multidrug-resistant cancer cells is necessary.

    DOI: 10.3892/ijo.2012.1503

    Web of Science

    PubMed

    researchmap

  • S100A7 promotes the migration and invasion of osteosarcoma cells via the receptor for advanced glycation end products 査読

    Ken Kataoka, Tomoyuki Ono, Hitoshi Murata, Mika Morishita, Ken-Ichi Yamamoto, Masakiyo Sakaguchi, Nam-Ho Huh

    ONCOLOGY LETTERS   3 ( 5 )   1149 - 1153   2012年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPANDIDOS PUBL LTD  

    Osteosarcoma is the most common malignant tumor of bone in childhood and adolescence. Despite intensive research for new therapies, the outcome in patients with metastasis remains extremely poor. S100 proteins are involved in the proliferation, cell cycle progression and metastasis of numerous malignant tumors, including osteosarcoma. In the present study, we identified S100A7 as a candidate to promote the migration of osteosarcoma cells. S100A7 promoted the migration and invasion of osteosarcoma cells as assayed in vitro. An in vitro pull-down assay revealed the binding of the recombinant S100A7 protein with its putative receptor, the receptor for advanced glycation end products (RAGE). The downregulation of RAGE by a specific siRNA markedly suppressed the migration and invasion of osteosarcoma cells. Furthermore, the matrix metalloproteinase activity of osteosarcoma cells was enhanced by S100A7 and suppressed by the downregulation of RAGE. These results indicate that S100A7 promotes the migration and invasion of osteosarcoma cells through RAGE. The S100A7-RAGE axis may thus be a new target for preventing the invasion and/or metastasis of osteosarcoma.

    DOI: 10.3892/ol.2012.612

    Web of Science

    PubMed

    researchmap

  • 非小細胞肺癌に対する新たな個別化治療戦略 REIC/Dkk-3遺伝子治療の可能性

    宗 淳一, 豊岡 伸一, 田中 則光, 渡部 昌実, 山本 寛斉, 阪口 政清, 許 南浩, 那須 保友, 公文 裕巳, 三好 新一郎

    日本呼吸器外科学会雑誌   26 ( 3 )   P17 - 01   2012年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本呼吸器外科学会  

    researchmap

  • Partial sensitization of human bladder cancer cells to a gene-therapeutic adenovirus carrying REIC/Dkk-3 by downregulation of BRPK/PINK1 査読

    Yu Jin, Hitoshi Murata, Masakiyo Sakaguchi, Ken Kataoka, Masami Watanabe, Yasutomo Nasu, Hiromi Kumon, Nam-Ho Huh

    ONCOLOGY REPORTS   27 ( 3 )   695 - 699   2012年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPANDIDOS PUBL LTD  

    REIC/Dkk-3 is a tumor suppressor gene that was first identified as a gene downregulated in association with immortalization of normal human fibroblasts. We have demonstrated that an adenovirus carrying REIC/Dkk-3 (Ad-REIC) showed a tumor-specific killing effect on a wide range of cancers. However, some human cancers, bladder cancers in particular, are resistant to Ad-REIC. In this study, we investigated the combination effect of downregulation of BRPK/PINK1 (PINK1) and Ad-REIC on bladder cancer cells. Five bladder cancer cell lines among six cell lines examined were resistant to Ad-REIC. Among the cell lines, the resistance of two cell lines was probably due to low infection efficiency of the adenovirus. PINK1-specific siRNA remarkably downregulated Bcl-x(L) and TRAP1 proteins and upregulated BAX protein expression. Finally, downregulation of PINK1 partially sensitized the other three cell lines that were resistant to Ad-REIC. This sensitization was associated with increasing production of reactive oxygen species (ROS). These results indicate that PINK1 is one of the key molecules for the mitochondrial protection system and that PINK1 can be a new target molecule to sensitize bladder cancer cells that are resistant to Ad-REIC.

    DOI: 10.3892/or.2011.1543

    Web of Science

    PubMed

    researchmap

  • Preclinical Safety and Efficacy of in Situ REIC/Dkk-3 Gene Therapy for Prostate Cancer 査読

    Keiichiro Kawauchi, Masami Watanabe, Haruki Kaku, Peng Huang, Kasumi Sasaki, Masakiyo Sakaguchi, Kazuhiko Ochiai, Nam-ho Huh, Yasutomo Nasu, Hiromi Kumon

    ACTA MEDICA OKAYAMA   66 ( 1 )   7 - 16   2012年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:OKAYAMA UNIV MED SCHOOL  

    The preclinical safety and therapeutic efficacy of adenoviral vectors that express the REIC/Dkk-3 tumor suppressor gene (Ad-REIC) was examined for use in prostate cancer gene therapy. The Ad-human (h) and mouse (m) REIC were previously demonstrated to induce strong anti-cancer effects in vitro and in vivo, and we herein report the results of two in vivo studies. First, intra-tumor Ad-hREIC administration was examined for toxicity and therapeutic effects in a subcutaneous tumor model using the PC3 prostate cancer cell line. Second, intra-prostatic Ad-mREIC administration was tested for toxicity in normal mice. The whole-body and spleen weights, hematological and serum chemistry parameters, and histological evaluation of tissues from throughout the body were analyzed. Both experiments indicated that there was no significant difference in the examined parameters between the Ad-REIC-treated group and the control (PBS- or Ad-LacZ-treated) group. In the in vitro analysis using PC3 cells, a significant apoptotic effect was observed after Ad-hREIC treatment. Confirming this observation, the robust anti-tumor efficacy of Ad-hREIC was demonstrated in the in vivo subcutaneous prostate cancer model. Based on the results of these preclinical experiments, we consider the adenovirus-mediated REIC/Dkk-3 in situ gene therapy to be safe and useful for the clinical treatment of prostate cancer.

    DOI: 10.18926/AMO/48076

    Web of Science

    PubMed

    researchmap

  • A Novel Tumor Suppressor, REIC/Dkk-3 Gene Identified by Our In Vitro Transformation Model of Normal Human Fibroblasts Works as a Potent Therapeutic Anti-tumor Agent 査読

    Masakiyo Sakaguchi, Nam-ho Huh, Masayoshi Namba

    HUMAN CELL TRANSFORMATION: ROLE OF STEM CELLS AND THE MICROENVIRONMENT   720   209 - 215   2012年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER-VERLAG BERLIN  

    Reduced Expression in Immortalized Cell (REIC) was cloned by subtractive hybridization method as a gene whose expression is reduced in many human immortalized and neoplastic tumor cells. The REIC, when overexpressed by an adenovirus (Ad-REIC), exhibited a dramatic therapeutic effect on a wide variety of human cancers through a mechanism triggered by ER-stress-mediated JNK activation. In addition to this direct effect on cancer cells, Ad-REIC exerted another cytotoxicity on human cancers, an indirect host-mediated effect due to overproduction of IL-7 by mis-targeted normal cells. This "one-bullet two-arms" finding may lead to a powerful new therapeutic approach to the treatment of human cancers.

    DOI: 10.1007/978-1-4614-0254-1_17

    Web of Science

    PubMed

    researchmap

  • S100A11, a dual growth regulator of epidermal keratinocytes 査読

    Masakiyo Sakaguchi, Nam-ho Huh

    AMINO ACIDS   41 ( 4 )   797 - 807   2011年10月

     詳細を見る

    記述言語:英語   出版者・発行元:SPRINGER  

    S100A11, a member of the family of S100 proteins, is a dimmer, each monomer of which has two EF-hands. Expression of S100A11 is ubiquitous in various tissues at different levels, with a high expression level in the skin. We have analyzed functions of S100A11 mainly in normal human keratinocytes (NHK) as a model cell system of human epithelial cells. High Ca(2+) and transforming growth factor-beta (TGF-beta), two representative growth suppressors for NHK, need a common S100A11-mediated pathway in addition to unique pathways (NFAT1-mediated pathway for high Ca(2+) and Smad-mediated pathway for TGF-beta) for exhibiting a growth inhibitory effect. S100A11 has another action point for growth suppression in NHK. Annexin A1 (ANXA1) complexed with S100A11 efficiently binds to and inhibits cytosolic phospholipase A2 (cPLA2), the activity of which is needed for the growth of NHK. On exposure of NHK to epidermal growth factor (EGF), ANXA1 is cleaved at 12Trp, and this truncated ANXA1 loses binding capacity to S100A11, resulting in maintenance of an active state of cPLA2. On the other hand, we found that S100A11 is actively secreted by NHK. Extracellular S100A11 acts on NHK to enhance the production of EGF family proteins, resulting in growth stimulation. These findings indicate that S100A11 plays a dual role in growth regulation, being suppressive in cells and being promotive from outside of cells.

    DOI: 10.1007/s00726-010-0747-4

    Web of Science

    PubMed

    researchmap

  • 悪性胸膜中皮腫に対するマイクロRNA34b/cを用いたアデノウイルス遺伝子治療の可能性(Anti-proliferative effect of microRNA-34b/c adenoviral gene transfer on malignant pleural mesotheliomas)

    宗 淳一, 豊岡 伸一, 久保 孝文, 上野 剛, 深澤 拓也, 阪口 政清, 佃 和憲, 浅野 博昭, 山本 寛斉, 許 南浩, 三好 新一郎

    日本癌学会総会記事   70回   267 - 267   2011年9月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • Tumor suppressor REIC/Dkk-3 interacts with the dynein light chain, Tctex-1 査読

    Kazuhiko Ochiai, Masami Watanabe, Hideo Ueki, Peng Huang, Yasuyuki Fujii, Yasutomo Nasu, Hirofumi Noguchi, Takeshi Hirata, Masakiyo Sakaguchi, Nam-ho Huh, Yuji Kashiwakura, Haruki Kaku, Hiromi Kumon

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   412 ( 2 )   391 - 395   2011年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    REIC/Dkk-3 is a member of the Dickkopf family proteins known as Wnt-antagonists, and REIC/Dkk-3 expression is downregulated in a broad range of cancer types. REIC/Dkk-3 acts as a tumor suppressor in multiple cancer cell lines by inducing apoptosis through endoplasmic reticulum (ER) stress signaling. However, the intracellular interaction partners of REIC/Dkk-3 have not been fully elucidated. By employing yeast two-hybrid screening, we identified the human dynein light chain, Tctex-1, as a novel interaction partner of REIC/Dkk-3. We further disclosed that the interaction involves the 136-157 amino acid region of REIC/Dkk-3 by using the mammalian two-hybrid system. Interestingly, this binding region of REIC/Dkk-3 with Tctex-1 contains an amino acid sequence motif [-(E) under bar -X-(G) under bar-(R) under bar-(R) under bar -X-(H) under bar-] which was previously reported as the Tctex-1 binding domain of dynein intermediate chain (DIC). Immunocytochemistry demonstrated that both REIC/Dkk-3 and Tctex-1 were localized around the ER of human fibroblasts, and the similar distribution pattern of the proteins suggests that their interaction occurs around the ER. This is the first study showing the interaction of a Dickkopf family protein with a dynein motor complex protein. The link between REIC/Dkk-3 and Tctex-1 may be of significance for understanding the molecular functions of the proteins in ER stress signaling and intracellular dynein motor dynamics, respectively. (C) 2011 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.bbrc.2011.07.109

    Web of Science

    PubMed

    researchmap

  • The impact of adenoviral gene transfer of microRNA-34b/c on malignant pleural mesotheliomas 査読

    Junichi Soh, Shinichi Toyooka, Takafumi Kubo, Takuya Fukazawa, Masakiyo Sakaguchi, Tsuyoshi Ueno, Kazunori Tsukuda, Hiroaki Asano, Hiromasa Yamamoto, Nam-ho Huh, Shinichiro Miyoshi

    CANCER RESEARCH   71   2011年4月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2011-4944

    Web of Science

    researchmap

  • マイクロRNA34b/cのメチル化による発現低下は悪性胸膜中皮腫の重要な分子病態である(Epigenetic silencing of microRNA-34b/c plays a pivotal role in pathogenesis of malignant mesothelioma pathogenesis)

    久保 孝文, 豊岡 伸一, 佃 和憲, 阪口 政清, 深澤 拓也, 宗 淳一, 浅野 博昭, 那須 保友, 岸本 卓巳, 松井 秀樹, 許 南浩, 三好 新一郎

    日本癌学会総会記事   69回   44 - 44   2010年8月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • Frequent silencing of tumor suppressive MicroRNA-34b/c by aberrant methylation in malignant mesothelioma 査読

    Takafumi Kubo, Shinichi Toyooka, Kazunori Tsukuda, Hiroaki Asano, Masakiyo Sakaguchi, Junichi Soh, Tsuyoshi Ueno, Hiromasa Yamamoto, Masaomi Yamane, Takahiro Oto, Yasutomo Nasu, Hideki Matsui, Nam Ho Huh, Shinichro Miyoshi

    CANCER RESEARCH   70   2010年4月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM10-2081

    Web of Science

    researchmap

  • REIC/Dkk-3 stable transfection reduces the malignant phenotype of mouse prostate cancer RM9 cells 査読

    Jie Chen, Masami Watanabe, Peng Huang, Masakiyo Sakaguchi, Kazuhiko Ochiai, Yasutomo Nasu, Mamoru Ouchida, Nam-Ho Huh, Kenji Shimizu, Yuji Kashiwakura, Haruki Kaku, Hiromi Kumon

    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE   24 ( 6 )   789 - 794   2009年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPANDIDOS PUBL LTD  

    The reduced expression in immortalized cells (REIC)/Dickkopf (Dkk)-3. a member of the Dkk gene family, is a tumor suppressor in a broad range of cancers. REIC/Dkk-3 transfected stable clones of mouse prostate cancer RM9 cells (RM9-REIC) and the empty vector-transfected control clone cells (RM9-EV) were established. Clones were used to evaluate the anti-cancer effects and a proteomics analysis of REIC/Dkk-3 continuous expression was performed. The RM9-REIC cells show a feeble appearance and the cell membrane shows irregular buds known as blebs. In vitro cell proliferation was significantly suppressed in RM9-REIC clones in comparison to the control. The apoptosis assay was done under standard culture conditions and RM9-REIC showed a higher incidence of apoptosis. The RM9-EV and RM9-REIC cells were orthotopically implanted into a C57BL/6 mouse prostate. After 2 weeks, the tumor growth was significantly inhibited in RM9-REIC cells in comparison to the control. Two-dimensional gel electrophoresis was used to examine the modification of protein expression by the gene transfection. The analysis with mass spectrometry disclosed that expression of peroxiredoxin-l, GST-P1. transgelin-2, MRP-L12, ARD, GRP78 and Sorcin were increased and eEF1A-1 and cyclophilin-40 protein were decreased in RM9-REIC cells. Therefore, REIC/Dkk-3 stable transfectants show a reduction of malignancy in mouse prostate cancer RM9 cells in vitro and in vivo. The result of the proteomics analysis might provide important clues to clarify the anti-cancer molecular mechanism of REIC/Dkk-3 gene transfer.

    DOI: 10.3892/ijmm_00000293

    Web of Science

    PubMed

    researchmap

  • S100A11, a dual mediator for growth regulation of normal human keratinocytes 査読

    Masakiyo Sakaguchi, Nam-ho Huh

    AMINO ACIDS   37 ( 1 )   77 - 77   2009年7月

     詳細を見る

    記述言語:英語   出版者・発行元:SPRINGER WIEN  

    Web of Science

    researchmap

  • Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor (TAE226) leads to apoptosis in esophageal cancer by inhibiting AKT-mTOR survival signaling 査読

    Huifang Hao, Zhigang Wang, Xiaohong Bao, Nobuyuki Watanabe, Kazufumi Sakurama, Yasuko Tomono, Takuya Fukazawa, Shinji Hatakeyama, Osamu Omori, Seishi Nishitani, Toshiaki Ohara, Munenori Takaoka, Yasuhiro Shirakawa, Tomoki Yamatsuji, Junji Matsuoka, Masakiyo Sakaguchi, Noriaki Tanaka, Yoshio Naomoto

    CANCER RESEARCH   69   2009年5月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    Web of Science

    researchmap

  • REIC/DKK-3 as a potential gene therapeutic agent against human testicular cancer 査読

    Ryuta Tanimoto, Fernando Abarzua, Masakiyo Sakaguchi, Yasutomo Nasu, Hiromi Kumon, Nam-Ho Huh

    JOURNAL OF GENE MEDICINE   10 ( 4 )   454 - 454   2008年4月

     詳細を見る

    記述言語:英語   出版者・発行元:JOHN WILEY & SONS LTD  

    Web of Science

    researchmap

  • Adenovirus-mediated REIC/DKK-3 gene transfer prevented mesothelioma tumor progressions in orthotopic mice model 査読

    Yuji Kashiwakura, Masami Watanabe, Fernando Abarzua, Masakiyo Sakaguchi, Munenori Takaoka, Ryuta Tanimoto, Yasutomo Nasu, Nam-ho Huh, Hiromi Kumon

    JOURNAL OF GENE MEDICINE   10 ( 4 )   469 - 470   2008年4月

     詳細を見る

    記述言語:英語   出版者・発行元:JOHN WILEY & SONS LTD  

    Web of Science

    researchmap

  • Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase 査読

    F Abarzua, M Sakaguchi, M Takaishi, Y Nasu, K Kurose, S Ebara, M Miyazaki, M Namba, H Kumon, N Huh

    CANCER RESEARCH   65 ( 21 )   9617 - 9622   2005年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    Alteration in genes which takes place during malignant conversion and progression could be potential targets for gene therapy. We previously identified REIC/Dkk-3 as a gene whose expression is reduced in many human cancers. Here, we showed that expression of REIC/Dkk-3 was consistently reduced in human prostate cancer tissues in a stage-dependent manner. Forced expression of REIC/Dkk-3 induced apoptosis in human prostate cancer cell lines lacking endogenous REIC/Dkk-3 expression but not in REIC/Dkk3-proficient normal prostate epithelial and stromal cells. The apoptosis involved c-jun-NH2-kinase activation, mitochondrial translocation of Bax, and reduction of Bcl-2. A single injection of an adenovirus vector carrying REIC/Dkk-3 showed a dramatic antitumor effect on a xenotransplanted human prostate cancer. Thus, REIC/Dkk-3 could be a novel target for gene-based therapy of prostate cancer.

    DOI: 10.1158/0008-5472.CAN-05-0829

    Web of Science

    PubMed

    researchmap

  • NMR studies of the N-terminal segment of S100C/A11 protein 査読

    Takahide Kouno, Mineyuki Mizuguchi, Masakiyo Sakaguchi, Eiichi Makino, Nam-ho Huh, Keiichi Kawano

    Peptides 2004, Proceedings   1025 - 1026   2005年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(国際会議プロシーディングス)   出版者・発行元:KENES INT  

    Web of Science

    researchmap

  • Expression of CYP3A4 by an immortalized human hepatocyte line in a three-dimensional culture using a radial-flow bioreactor 査読

    Akiyama, I, K Tomiyama, M Sakaguchi, M Takaishi, M Mori, M Hosokawa, S Nagamori, N Shimizu, NH Huh, M Miyazaki

    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE   14 ( 4 )   663 - 668   2004年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PROFESSOR D A SPANDIDOS  

    Cytochrome P450 (CYP) 3A is responsible for about 50% of drug metabolizing activity in the liver. The present study was undertaken to establish a CYP3A4-active model for in vitro analysis of human drug metabolism. The cells used were immortalized normal human fetal hepatocytes (OUMS-29) and its HNF4alpha-introduced subline (OUMS-29/H-11). The cells were cultivated under high-density three-dimensional conditions in a radial-flow bioreactor (RFB). The number of OUMS-29 cells increased 15-fold over 49 days and their apical surfaces were covered with abundant microvilli, a characteristic of hepatocytes in vivo. The amount of albumin secreted by OUMS-29 cells in the three-dimensional RFB culture was 6-fold higher than those in a monolayer culture. CYP3A4 protein and an intermediate metabolite of testosterone by CYP3A4 were detected in OUMS-29/H11 cells cultivated in RFB &gt;29 days. These results indicate that the RFB; culture of OUMS-29/H-11 cells is useful for screening and developing new drugs.

    Web of Science

    PubMed

    researchmap

  • Involvement of interferon regulatory factor 1 and S100C/A11 in growth inhibition by transforming growth factor beta 1 in human hepatocellular carcinoma cells 査読

    M Miyazaki, M Sakaguchi, Akiyama, I, Y Sakaguchi, S Nagamori, NH Huh

    CANCER RESEARCH   64 ( 12 )   4155 - 4161   2004年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    Growth inhibition by transforming growth factor (TGF)-beta1 has been attributed to the induction of cyclin-dependent kinase inhibitors, among which p21/Waf1 plays a major role in many biological contexts. In the present study, two new intracellular mediators for the induction of p21/Waf1 by TGF-beta1 were identified in a human hepatocellular carcinoma cell line (JHH-5) expressing mutant-type p53. After addition of TGF-beta1 to JHH-5 cells, a marked increase of the p21/Waf1 expression preceded the inhibition of DNA synthesis. Expression of IFN regulatory factor (IRF)-1, a known transacting factor for p21/Waf1 promoter, was elevated just before or in parallel with the increase of p21/Waf1. Transduction of antisense IRF-1 inhibited the increase in p21/Waf1 in JHH-5 cells treated with TGF-beta1 and partially released the cells from the growth arrest by TGF-beta1. Expression of S100C/A11, a member of the Ca2+-binding S100 protein family, also markedly increased after addition of TGF-beta1. S100C/A11 protein was translocated to and accumulated in nuclei of TGF-beta1-treated JHH-5 cells, where p21/Waf1 was concomitantly accumulated. When a recombinant S100C/A11 protein was introduced into nuclei of JHH-5 cells, DNA synthesis was markedly inhibited in a dose-dependent manner in the absence of TGF-beta1. Prior transfection of p21/Waf1-targeted small interfering RNA efficiently blocked decrease of DNA synthesis in JHH-5 cells caused by TAT-S100C/A11 or TGF-beta1 and markedly inhibited expression of p21/Waf1 protein in the cells. These results indicate that IRF-1 and S100C/A11 mediate growth inhibition by TGF-beta1 via induction of p21/Waf1.

    DOI: 10.1158/0008-5472.CAN-03-2750

    Web of Science

    PubMed

    researchmap

  • Differential expression of S100C in thyroid lesions 査読

    C Torres-Cabala, A Panizo-Santos, HC Krutzsch, H Barazi, M Namba, M Sakaguchi, DD Roberts, MJ Merino

    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY   12 ( 2 )   107 - 115   2004年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WESTMINSTER PUBL INC  

    Identification of new potential markers that may help in the diagnosis of benign and malignant thyroid lesions is needed. By comparative 2-dimensional gel electrophoresis of microdissected cells from tumors and normal thyroid tissue, we identified a new protein, S100C, which is highly expressed in papillary carcinomas. In order to validate this finding, we investigated the immunohistochemical expression and the potential role in diagnosis of these markets in 94 specimens representing the spectrum of malignant and benign thyroid lesions. Normal thyroid tissue was evaluated in 57 specimens. Galectin-3, a marker reported as specific for malignant lesions, was also evaluated in the same lesions. S100C protein was expressed in the nuclei of normal tissue, hyperplastic nodules, and follicular adenomas and carcinomas. Papillary carcinomas showed a strong, but cytoplasmic, pattern of staining. Galectin-3 immunostaining was strongly positive in papillary carcinomas, and negative in benign lesions, confirming its value in differential diagnosis. These findings Suggest that immunohistochemical Staining of S100C could be helpful in the pathological study of thyroid lesions, especially in cases in which follicular variants of papillary carcinoma and follicular carcinoma are considered in the differential diagnosis.

    DOI: 10.1177/106689690401200203

    Web of Science

    PubMed

    researchmap

  • PKC alpha mediates TGF beta-induced growth inhibition of human keratinocytes via phosphorylation of S100C/A11 査読

    M Sakaguchi, M Miyazaki, H Sonegawa, M Kashiwagi, M Ohba, T Kuroki, M Namba, N Huh

    JOURNAL OF CELL BIOLOGY   164 ( 7 )   979 - 984   2004年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ROCKEFELLER UNIV PRESS  

    Growth regulation of epithelial cells is of major concern because most human cancers arise from them. We demonstrated previously a novel signal pathway involving S100C/A11 for high Ca2+-induced growth inhibition of normal human keratinocytes (Sakaguchi, M., M. Miyazaki, M. Takaishi, Y. Sakaguchi, E. Makino, N. Kataoka, H. Yamada, M. Namba, and N.H. Huh. 2003.J. Cell Biol. 163:825-835). This paper addresses a question whether transforming growth factor beta (TGFbeta) shares the pathway with high Ca2+. On exposure of the cells to TGFbeta1, S100C/A11 was phosphorylated, bound to nucleolin, and transferred to the nucleus, resulting in induction of p21(WAF1/CIP1) and p15(INK4B) through activation of Sp1. Protein kinase C alpha (PKCalpha) was shown to phosphorylate. (10)Thr of S100C/A11, which is a critical event for the signal transduction. The TGFbeta1-induced growth inhibition was almost completely mitigated when PKCalpha activity was blocked or when S100C/A11 was functionally sequestered. These results indicate that, in addition to the well-characterized Smad-mediated pathway, the PKCalpha-S100C/A11-mediated pathway is involved in and essential for the growth inhibition of normal human keratinocytes cells by TGFbeta1.

    DOI: 10.1083/jcb.200312041

    Web of Science

    PubMed

    researchmap

  • Lentiviral vector: A useful tool for transduction of human liver endothelial cells 査読

    T Totsugawa, N Kobayashi, M Maruyama, Y Kosaka, T Okitsu, T Arata, M Sakaguchi, T Ueda, Y Kurabayashi, N Tanaka

    ASAIO JOURNAL   49 ( 6 )   635 - 640   2003年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS  

    Endothelial cells play multiple roles in pathophysiologic processes and are increasingly being recognized as target cells of gene therapy. Lentiviral vectors derived from human immunodeficiency virus type 1 have an ability to infect both dividing and nondividing cells and currently receive a great deal of attention as an innovative tool for transduction of target cells. The purpose of the present work was to evaluate the efficacy of a lentiviral vector for transducing human liver endothelial cells (HLECs) in vitro. For the present study, a pseudotyped lentiviral vector encoding a green fluorescent protein (GFP) gene, LtV-GFP, was generated by means of FuGENE 6 method and allowed to infect HLECs. Approximately 95% of HLECs were positive for GFP expression after LtV-GFP infection at a multiplicity of infection of 10. Notably, LtV-GFP transduced HLECs had stable and long term GFP expression, showed gene expression of endothelial markers including CD 34, factor VIII, flt-1, KDR/flk-1 and HGF, and maintained in vitro angiogenic potential in a Matrigel assay to the same extent as primarily cultured HLECs. These findings provide evidence that lentivirus based gene delivery is an efficient tool for transduction of endothelial cells that could be considered for cell and gene therapies and hybrid artificial organs.

    DOI: 10.1097/01.MAT.0000093747.89681.4C

    Web of Science

    PubMed

    researchmap

  • BRPK, a novel protein kinase showing increased expression in mouse cancer cell lines with higher metastatic potential 査読

    A Nakajima, K Kataoka, M Hong, M Sakaguchi, N Huh

    CANCER LETTERS   201 ( 2 )   195 - 201   2003年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCI IRELAND LTD  

    A novel protein kinase named BRPK was isolated and partially characterized. BRPK was expressed at a higher level in three carcinoma cell lines with higher metastatic potential. Mouse and human BRPK cDNAs are well conserved and encode 580 and 581 amino acids, respectively. BRPK has a serine/threonine-type protein kinase domain, and the recombinant proteins of BRPK were capable of autophosphorylation. The results of a comparative sequence analysis indicated a possible link of BRPK to BRAP2. BRAP2 is known to bind the nuclear localization signal of BRCA1. We cloned mouse BRAP2 cDNA and showed the presence of isoforms. (C) 2003 Elsevier Ireland Ltd. All rights reserved.

    DOI: 10.1016/S0304-3835(03)00443-9

    Web of Science

    PubMed

    researchmap

  • Establishment of immortalized human hepatic stellate scavenger cells to develop bioartificial livers 査読

    T Watanabe, N Shibata, KA Westerman, T Okitsu, JE Allain, M Sakaguchi, T Totsugawa, M Maruyama, T Matsumura, H Noguchi, S Yamamoto, M Hikida, A Ohmori, M Reth, A Weber, N Tanaka, P Leboulch, N Kobayashi

    TRANSPLANTATION   75 ( 11 )   1873 - 1880   2003年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS  

    Background. Maintenance of liver-specific functions has been shown to be stabilized by co-cultivation of hepatocytes with hepatic stellate cells (HSC). Because the limited lifespan of human HSC is a major hurdle to their use, the authors report here the amplification of human HSC populations in vitro by retroviral transfer of human telomerase reverse transcriptase (hTERT).
    Methods. Human HSC strain LI 90 cells were transduced with a retroviral vector SSR#197 expressing hTERT and green fluorescent protein (GFP) cDNA flanked by a pair of loxP. TWNT-1, one of SSR#197-immortalized HSC, was characterized. Differentiated liver functions were evaluated in an immortalized human hepatocyte NKNT-3-TWNT-1 co-culture system.
    Results. TWNT-1 cells showed differential functions of HSC, including uptake of acetylated low-density lipoproteins and synthesis of collagen type I and hepatocyte growth factor. Efficient excision of the retro-virally transferred hTERT and GFP cDNAs was achieved by TAT-mediated expression of the Cre recombinase and subsequent GFP-negative cell sorting. When co-cultured with TWNT-1 cells, NKNT-3 increased protein expression of the detoxifying cytochrome P450-associated protein isoenzymes 3A4 and 2C9 and urea synthesis.
    Conclusions. TWNT-1 cells could be valuable in the study of integrated liver functions and contribute to the optimization of liver cell therapies and bioartificial livers.

    DOI: 10.1097/01.TP.0000064621.50907.A6

    Web of Science

    PubMed

    researchmap

  • Involvement of arachidonic acid in nonimmunologic production of superoxide in mast cells 査読

    M Sakaguchi, N Fukuishi, K Teramoto, M Miyazaki, NH Huh, M Namba, M Akagi

    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY   130 ( 4 )   288 - 299   2003年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:KARGER  

    Background: A number of different molecules are known to be involved in the signal pathway to release histamine from mast cells, among which arachidonic acid (AA) is one of the key mediators. On the other hand, we found that the application of compound 48/80, a typical histamine liberator, generated superoxide in mast cells. In the present study, we investigated the mechanism of superoxide production in mast cells with respect to AA signaling in conjunction with a fine structural analysis. Methods: Superoxide production was monitored by chemiluminescence in rat peritoneal mast cells and their subfractions after various treatments. For scanning electron micrography, the conditions for fixation and freeze-fracture were optimized to get natural fine images. Results: Compound 48/80 induced superoxide production in the isolated mast cells and some of their subfractions possibly through intracellular increase in Ca2+ concentration, activation of cytosolic phospholipase A(2), and release of AA. Discussion: The present results indicate the critical role of AA in the signal pathway to generate superoxide from mast cells in response to compound 48/80. Copyright (C) 2003 S. Karger AG, Basel.

    DOI: 10.1159/000070216

    Web of Science

    researchmap

  • Establishment of an immortalized human hepatic stellate cell line to develop antifibrotic therapies 査読

    Norikuni Shibata, Takamasa Watanabe, Teru Okitsu, Masakiyo Sakaguchi, Michihiko Takesue, Takemi Kunieda, Kenji Omoto, Shinichiro Yamamoto, Noriaki Tanaka, Naoya Kobayashi

    Cell Transplantation   12 ( 5 )   499 - 507   2003年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Cognizant Communication Corporation  

    Because human hepatic stellate cells (HSCs) perform a crucial role in the progress of hepatic fibrosis, it is of great value to establish an immortalized human cell line that exhibits HSC characteristics and grows well in tissue cultures for the development of antifibrotic therapies. Thus, we engineered an immortalized human hepatic stellate cell (HSC) line TWNT-4 by retrovirally inducing human telomerase reverse transcriptase (hTERT) into LI 90 cells established from a human liver mesenchymal tumor. Parental LI 90 entered replicative senescence, whereas TWNT-4 showed telomerase activity and proliferated for more than population doubling level (PDL) 200 without any crisis. TWNT-4 expressed platelet-derived growth factor-β receptor (PDGF-βR), α-smooth muscle actin (α-SMA), and type I collagen (α1) and was considered to be an activated form of HSCs. Treatment of TWNT-4 cells with either 100 U/ml of IFN-γ or 1 ng/ml of rapamycin (Rapa) for 14 days led to lower expression of type I collagen (α1) at RNA and protein levels. Exposure of TWNT-4 cells to both of IFN-γ (10 U/ml) and Rapa (0.1 ng/ml) for 14 days effectively decreased the expression of type I collagen (α1), PDGF-βR, and α-SMA expression and suppressed TGF-β1 secretion of TWNT-4 cells. We successfully induced apoptosis by transducing TNF-related apoptosis-inducing ligand (TRAIL) into TWNT-4 cells using adenovirus vectors Ad/GT-TRAIL and Ad/PGK-GV-17. These findings suggested that immortalized activated HSC line TWNT-4 would be a useful means to develop antifibrotic therapies.

    DOI: 10.3727/000000003108747064

    Scopus

    PubMed

    researchmap

  • Active expression of p21 facilitates differentiation of immortalized human hepatocytes 査読

    N. Kobayashi, T. Kunieda, M. Sakaguchi, T. Okitsu, T. Totsugawa, M. Maruyama, Y. Kosaka, M. Takesue, N. Shibata, N. Tanaka

    Transplantation Proceedings   35 ( 1 )   433 - 434   2003年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(国際会議プロシーディングス)   出版者・発行元:Elsevier Inc.  

    DOI: 10.1016/S0041-1345(02)03784-3

    Scopus

    PubMed

    researchmap

  • Maintenance of cold-preserved porcine hepatocyte function with UW solution and ascorbic acid-2 glucoside

    M Takesue, M Maruyama, N Shibata, T Kunieda, T Okitsu, M Sakaguchi, T Totsugawa, Y Kosaka, A Arata, H Ikeda, J Matsuoka, T Oyama, M Kodama, K Ohmoto, S Yamamoto, Y Kurabayashi, Yamamoto, I, N Tanaka, N Kobayashi

    CELL TRANSPLANTATION   12 ( 6 )   599 - 606   2003年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SAGE PUBLICATIONS INC  

    Normal human hepatocytes are an ideal source of liver-targeted cell therapies, such as hepatocyte transplantation and bioartificial livers, but availability of human donor livers for liver cell isolation is severely limited. To effectively utilize scarce donor organs for cell therapies, it is of extreme importance to establish an efficient isolation technique and an effective cold preservation solution for transportation of isolated cells. A lateral segment of the liver was surgically resected from pigs weighing 10 kg and a four-step collagenase and dispase digestion was conducted. Isolated hepatocytes were subjected to 8-h cold storage on ice. The following preservation solutions were tested: 1) University of Wisconsin (UW) solution, 2) UW with 100 mug/ml of ascorbic acid-2 glucoside (AA2G), 3) 100% fetal bovine serum (FBS), and 4) Dulbecco's modified Eagle's medium (DMEM) supplemented with 100% FBS. The mean viability of porcine hepatocytes was 95.5 +/- 2.5% when isolated in three independent experiments. Viability, plating efficiency, membrane stability, and ammonia metabolic capacity of cold-preserved hepatocytes were significantly better maintained by the use of UW solution. When AA2G (100 mug/ml) was combined with UW solution, such parameters were further improved. It was explained by inhibition of caspase-3 activation and retention of ATP at high levels of hepatocytes preserved with UW solution containing AA2G. The present work demonstrates that a combination of UW solution with AA2G (100 mug/ml) would be a useful cold preservation means for the development of cell therapies.

    DOI: 10.3727/000000003108747208

    Web of Science

    researchmap

  • Improved conditions to induce hepatocytes from rat bone marrow cells in culture 査読

    M Miyazaki, Akiyama, I, M Sakaguchi, E Nakashima, M Okada, K Kataoka, NH Huh

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   298 ( 1 )   24 - 30   2002年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    Recent studies have revealed that bone marrow cells can develop into hepatocytes by in vivo transplantation under certain circumstances. However, little is known about the mechanism of bone marrow cell differentiation into hepatocytes. It is important to determine suitable culture conditions in which bone marrow cells will be differentiated into hepatocytes not only for understanding differentiation mechanisms but also for efficient amplification of hepatocyte-progenitor cells of bone marrow origin, this being a prerequisite for potential therapeutic use. In the present study, we found that hepatocyte growth factor (HGF) receptor (c-Met)- and a-fetoprotein-expressing cells were present in adult rat bone marrow. We also found that these cells also express hematopoietic stem cell markers, such as CD34, Thy-1, and c-Kit. Using an HGM medium with HGF and EGF, we succeeded in propagating hepatocyte-like cells induced from adult rat bone marrow in culture. These cells were immunocytochemically stained for albumin. By RT-PCR analysis of cultures containing the hepatocyte-like cells, we detected mRNAs of tryptophan-2,3-dioxygenase and tyrosine aminotransferase, markers of hepatocytes at a terminal differentiation stage. The present culture therefore can be a useful resource for cell transplantation therapy for liver diseases. (C) 2002 Elsevier Science (USA). All rights reserved.

    DOI: 10.1016/S0006-291X(02)02340-9

    Web of Science

    PubMed

    researchmap

  • Localization of S100C immunoreactivity in various human tissues 査読

    A Kondo, M Sakaguchi, E Makino, M Namba, S Okada, NH Huh

    ACTA MEDICA OKAYAMA   56 ( 1 )   31 - 34   2002年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:OKAYAMA UNIV MED SCHOOL  

    Using 2-dimensional gel electrophoresis, we previously demonstrated that the S100C protein remarkably decreased after immortalization of normal human fibroblasts, and that this protein caused growth inhibition of human tumor cells when forcibly expressed in these cells, suggesting that S100C plays a significant role in tumor suppression. The present study was carried out to determine what type of human tissues express S100C protein,, and, subsequently, whether the S100C content in these tissues changes after normal cells have been transformed into cancer cells. We found that ductal cells in various tissues were positively stained with the S100C protein. In comparison, epithelial cells in digestive organs such as, the stomach, small intestine, and colon were not stained as strongly. When 14 pairs of human normal and cancerous tissues were stained with the antibody, decreases in the staining levels of S100C were observed in 6 kinds of:cancerous tissues-from the bronchus, mammary duct, renal tubule, prostate, uterus, and testis-in comparison with staining in their normal counterparts. These results suggest that S100C is a new tumor marker protein, the expression of which significantly decreases after malignant transformation of human tissues.

    Web of Science

    researchmap

  • Antiproliferative activity of REIC/Dkk-3 and its significant down-regulation in non-small-cell lung carcinomas 査読

    T Tsuji, Nozaki, I, M Miyazaki, M Sakaguchi, H Pu, Y Hamazaki, O Iijima, M Namba

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   289 ( 1 )   257 - 263   2001年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ACADEMIC PRESS INC  

    We recently reported the cloning of the REIC/Dkk-3 gene, whose expression was shown to be downregulated in many human immortalized and tumor-derived cell lines [T. Tsuji et al. (2000) Biochem. Biophys. Res. Commun. 268, 20-24]. In the present study, we demonstrated that expression of the exogenous REIC/Dkk-3 gene in tumor cells inhibited cell growth. Furthermore, the level of REIC/Dkk-3 mRNA in normal human cells was lowest in the late G, phase during the cell cycle. Then we found that the expression of REIC/Dkk-3 was significantly down-regulated in surgically resected non-small-cell lung carcinomas. We determined the REIC/Dkk-3 locus on chromosome 11p15, where loss of heterozygosity has frequently been observed in human tumors. These findings indicate that REIC/Dkk-3 may function as a tumor suppressor. (C) 2001 Academic Press.

    Web of Science

    researchmap

  • Up-regulation of S100C in normal human fibroblasts in the process of aging in vitro 査読

    M Sakaguchi, M Miyazaki, T Kondo, M Namba

    EXPERIMENTAL GERONTOLOGY   36 ( 8 )   1317 - 1325   2001年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PERGAMON-ELSEVIER SCIENCE LTD  

    S100 proteins belonging to the EF-hand Ca2+ -binding protein family regulate a variety of cellular processes via interaction with different target proteins. Several diseases, including cancer and Alzheimer's disease, are related to a disorder of multifunctional S100 proteins, which are expressed in cell- and tissue-specific manners. We previously demonstrated that S100C could move to and accumulate in the nuclei of normal human fibroblasts but not in the nuclei of immortalized and neoplastic cells. In addition, we found that its nuclear accumulation resulted in suppression of DNA synthesis in normal cells at a confluent stage. In the present study, we investigated whether S100C was associated with cellular senescence in vitro. We found that S100C expression increased in normal human fibroblasts in the process of aging in culture and was accompanied by accumulation of its protein in the nuclei of senescent fibroblasts. In addition, the nuclear accumulation of S100C increased expression of a cyclin-dependent kinase inhibitor p21 (Sdil), a strong inhibitor of cell growth. These findings suggest that an increase in the cells having nuclear accumulation of S100C is closely related to the process of cellular senescence of normal human fibroblasts. (C) 2001 Elsevier Science Inc. All rights reserved.

    Web of Science

    researchmap

  • Establishment of a human hepatocyte line (OUMS-29) having CYP 1A1 and 1A2 activities from fetal liver tissue by transfection of SV-10 LT 査読

    KI Fukaya, S Asahi, S Nagamori, M Sakaguchi, C Gao, M Miyazaki, M Namba

    IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL   37 ( 5 )   266 - 269   2001年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SOC IN VITRO BIOLOGY  

    Immortalized human hepatocytes that can retain functions of drug-metabolizing enzymes would be useful for medical and pharmacological studies and for constructing an artificial liver. The aim of this study wa. to establish immortalized human hepatocyte lines having differentiated liver-specific functions. pSVneo deoxyribonucleic acid, which contains large and small T genes in the early region of simian virus 40, was introduced into hepatocytes that had been obtained from the liver of a 21-wk-old fetus. Neomycin-resistant immortalized colonies were cloned and expanded to mass cultures to examine hepatic functions. Cells were cultured in a chemically defined serum-free medium, ASF101, which contains no peptides other than recombinant human transferrin and insulin. As a result, air immortal human hepatocyte cell line (OUMS-29) having li er-specific functions was established from one of the 13 clones. Expression of CYP 1A1 arid 1A2 messenger ribonucleic acid by the cells was induced by treatment with benz[a]pyrene, 3-methylcholanthrene, and benz[a]anthracene. OUMS-29 cells had both the polycyclic aromatic hydrocarbon receptor (AhR) arid AhR nuclear translocator. Consequently, 7-ethoxyresorufin deethylase activity of the cells was induced time- and dose-dependent by these polycyclic aromatic hydrocarbons. This cell line is expected to he instrumental as an alternative method in animal experiments for studying hepatocarcinogenesis. drug metabolisms of liver cells, and hepatic toxicology,.

    Web of Science

    researchmap

  • Overexpression of platelet-derived growth factor B and downregulation of PDGF-receptor alpha in human immortalized fibroblasts 査読

    C Gao, M Miyazaki, T Kondo, T Tsuji, M Sakaguchi, M Namba

    INTERNATIONAL JOURNAL OF ONCOLOGY   18 ( 4 )   871 - 875   2001年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PROFESSOR D A SPANDIDOS  

    Since immortalization of cells is critical in multistep carcinogenesis, efforts should be made to elucidate the mechanisms of the immortalization. To determine whether platelet-derived growth factor (PDGF) signal pathways play a role in immortalization of cells, we compared mRNA expressions of PDGFs and their receptors in three immortalized human fibroblast cell lines (SUSM-1, OUMS-24F, and KMST-6) with their normal parent cells. As a result, mRNA expression of PDGF-B (oncogene: c-sis) was upregulated in these immortalized cells. Unexpectedly, the expression of alpha- and beta -PDGF receptor genes was downregulated. PDGFR-alpha mRNA was remarkably decreased. When exogenous PDGFR-a was expressed transiently in the KMST-6 cells, the morphology of the cells resembled that of normal cells. These results suggest that the overexpression of PDGF-B (c-sis) and downregulation of PDGFR-alpha are related to the phenotypic characteristics of immortalized human cells.

    Web of Science

    researchmap

  • Two-dimensional gel electrophoretic studies on the cellular aging: accumulation of alpha-2-macroglobulin in human fibroblasts with aging

    T. Kondo, M. Sakaguchi, M. Namba

    Experimental Gerontology   36 ( 3 )   487 - 495   2001年3月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    DOI: 10.1016/s0531-5565(00)00256-4

    researchmap

  • Identification of a phosphoprotein that is downregulated in immortalized human fibroblasts 査読

    M Sakaguchi, M Miyazaki, T Kondo, T Tsuji, H Kouchi, M Namba

    ELECTROPHORESIS   22 ( 1 )   155 - 160   2001年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-V C H VERLAG GMBH  

    Many lines of evidence indicate that the immortalization step is critical for the neoplastic transformation of normal human cells. Once normal human cells have been immortalized, they are relatively easily transformed into neoplastic cells. In order to understand these phenomena, patterns of protein phosphorylation in proliferating normal human fibroblast cell strains and their immortalized cell lines were compared by using two-dimensional polyacrylamide gel electrophoresis. It was found that the expression and phosphorylation levels of the human heat shock protein 27 (HSP27) were predominantly downregulated in the immortalized cells compared with those in their normal counterparts. In the normal cells, HSP27 expression and phosphorylation were markedly increased by physiological and nonphysiological stresses, such as serum addition, treatment with a carcinogenic agent like 4-nitroquinoline-1-oxide, and a high osmotic pressure. This may be a normal defense against acute changes of cellular environment and cytotoxic effects. However, these stresses had no effects on the expression and phosphorylation of HSP27 in the immortalized cells. These results suggest that an abnormal regulation of HSP27 expression and phosphorylation may be one of the reasons for easy neoplastic transformation of the immortalized cells by the treatment with carcinogenic agents.

    Web of Science

    researchmap

  • Loss of nuclear localization of the S100C protein in immorialized human fibroblasts 査読

    M Sakaguchi, H Yamada, T Tsuji, Y Inoue, M Miyazaki, T Tanaka, M Namba

    RADIATION RESEARCH   155 ( 1 )   208 - 214   2001年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:RADIATION RESEARCH SOC  

    It is well known that cancer develops through a multistep process, lit vitro transformation studies of normal human cells have shown that the immortalization step is critical for neoplastic transformation of cells. Furthermore, studies of cell fusion between normal and immortalized cells have indicated that the normal phenotype is dominant and the immortal phenotype is recessive. Thus we looked for cellular proteins that were down-regulated in immortalized human cells by two-dimensional gel electrophoresis to elucidate the mechanisms of immortalization of human cells. We found that the S100C protein was down-regulated in immortalized cells. This protein was localized in the cytoplasm of cells at the semiconfluent stage, while at the confluent stage it moved into the nuclei of normal cells but not into those of immortalized cells. Microinjection of an S100C antibody into normal confluent cells diminished the level of nuclear S100C protein, resulting in DNA synthesis. Taken together, loss of nuclear localization of the S100C protein, which may be related to DNA synthesis, is thought to be one of the mechanisms of immortalization, (C) 2001 by Radiation Research Society.

    Web of Science

    researchmap

  • Hepatocyte growth factor induces differentiation of adult rat bone marrow cells into a hepatocyte lineage in vitro 査読

    SH Oh, M Miyazaki, H Kouchi, Y Inoue, M Sakaguchi, T Tsuji, N Shima, K Higashio, M Namba

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   279 ( 2 )   500 - 504   2000年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ACADEMIC PRESS INC  

    Bone marrow (BM) cells originally include alpha-fetoprotein (AFP)- and c-Met [a receptor for hepatocyte growth factor (HGF)]-expressing cells. In vitro treatment of BM cells with HGF induced albumin-expressing hepatocyte-like cells. Furthermore, those hepatocyte-like cells expressed cytokeratins 8 and 18, which are typically expressed in normal adult hepatocytes. These findings demonstrate that BM cells include AFP-expressing hepatic progenitor cells that can be differentiated into hepatocytes by HGF in culture, indicating that such cultures are useful resources for cell transplantation therapy for liver diseases. (C) 2000 Academic Press.

    DOI: 10.1006/bbrc.2000.3985

    Web of Science

    researchmap

  • Treatment of surgically induced acute liver failure with transplantation of highly differentiated immortalized human hepatocytes 査読

    N Kobayashi, M Miyazaki, K Fukaya, Y Inoue, M Sakaguchi, H Noguchi, T Matsumura, T Watanabe, T Totsugawa, N Tanaka, M Namba

    CELL TRANSPLANTATION   9 ( 5 )   733 - 735   2000年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:COGNIZANT COMMUNICATION CORP  

    Primary human hepatocytes are an ideal source of hepatic function in bioartficial liver (BAL), but the shortage of human livers available for hepatocyte isolation limits this modality. To resolve this issue, primary human fetal hepatocytes were immortalized using simian virus 40 large T antigen. One of the immortal cell lines, OUMS-29, showed highly differentiated liver functions. Intrasplenic transplantation of OUMS-29 cells protected 90% hepatectomized rats from hyperammonemia and significantly prolonged their survival. Essentially unlimited availability of OUMS-29 cells supports their clinical use for BAL treatment.

    Web of Science

    researchmap

  • Relationship between contact inhibition and intranuclear S100C of normal human fibroblasts 査読

    M Sakaguchi, M Miyazaki, Y Inoue, T Tsuji, H Kouchi, T Tanaka, H Yamada, M Namba

    JOURNAL OF CELL BIOLOGY   149 ( 6 )   1193 - 1206   2000年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ROCKEFELLER UNIV PRESS  

    Many lines of evidence indicate that neoplastic transformation of cells occurs by a multistep process. For neoplastic transformation of normal human cells, they must be first immortalized and then be converted into neoplastic cells. It is well known that the immortalization is a critical step for the neoplastic transformation of cells and that the immortal phenotype is recessive. Thus, we investigated proteins downregulated in immortalized cells by two-dimensional gel electrophoresis. As a result, S100C, a Ca2+-binding protein, was dramatically downregulated in immortalized human fibroblasts compared with their normal counterparts. When the cells reached confluence, S100C was phosphorylated on threonine 10. Then the phosphorylated S100C moved to and accumulated in the nuclei of normal cells, whereas in immortalized cells it was not phosphorylated and remained in the cytoplasm. Microinjection of the anti-S100C antibody into normal confluent quiescent cells induced DNA synthesis. Furthermore, when exogenous S100C was compelled to localize in the nuclei of HeLa cells, their DNA synthesis was remarkably inhibited with increase in cyclin-dependent kinase inhibitors such as p16(Ink4a) and p21(Waf1) These data indicate the possible involvement of nuclear S100C in the contact inhibition of cell growth.

    Web of Science

    researchmap

  • In vitro aging research in Japan 査読

    T Tsuji, M Miyazaki, M Sakaguchi, M Namba

    EXPERIMENTAL GERONTOLOGY   35 ( 3 )   291 - 298   2000年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PERGAMON-ELSEVIER SCIENCE LTD  

    Web of Science

    researchmap

  • Establishment of a highly differentiated immortalized human hepatocyte cell line as a source of hepatic function in the bioartificial liver 査読

    N Kobayashi, M Miyazaki, K Fukaya, Y Inoue, M Sakaguchi, H Noguchi, N Tanaka, M Namba

    TRANSPLANTATION PROCEEDINGS   32 ( 2 )   237 - 241   2000年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCIENCE INC  

    Web of Science

    researchmap

  • Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes 査読

    N Kobayashi, T Fujiwara, KA Westerman, Y Inoue, M Sakaguchi, H Noguchi, M Miyazaki, J Cai, N Tanaka, IJ Fox, P Leboulch

    SCIENCE   287 ( 5456 )   1258 - 1262   2000年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:AMER ASSOC ADVANCEMENT SCIENCE  

    Because of a critical shortage in suitable organs, many patients with terminal liver disease die each year before liver transplantation can be performed. Transplantation of isolated hepatocytes has been proposed for the temporary metabolic support of patients awaiting liver transplantation or spontaneous reversion of their liver disease. A major limitation of this form of therapy is the present inability to isolate an adequate number of transplantable hepatocytes. A highly differentiated cell line, NKNT-3, was generated by retroviral transfer in normal primary adult human hepatocytes of an immortalizing gene that can be subsequently and completely excised by Cre/Lox site-specific recombination. When transplanted into the spleen of rats under transient immunosuppression, reversibly immortalized NKNT-3 cells provided life-saving metabolic support during acute liver failure induced by 90% hepatectomy.

    Web of Science

    researchmap

  • A REIC gene shows down-regulation in human immortalized cells and human tumor-derived cell lines 査読

    T Tsuji, M Miyazaki, M Sakaguchi, Y Inoue, M Namba

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   268 ( 1 )   20 - 24   2000年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ACADEMIC PRESS INC  

    Normal human cells stop proliferation after a certain number of cell divisions. This phenomenon is called cellular aging. The fact that the senescence phenotype is dominant and the immortal one is recessive indicates that immortalization of human cells may be caused by loss of functions of certain genes in normal cells. Based on this evidence, several cDNA clones whose expression was down-regulated during the immortalization process of human cells were isolated by the representative difference analysis (RDA) system in our laboratory. One of them, which was named REIC, was expressed to a lower degree in three human immortalized cell lines as compared with their parental normal counterparts, In addition, the expression of REIC was markedly lower in eight human tumor-derived cell lines (Hep3B and HuH-7 hepatocellular carcinomas, HuH-6 Clone 5 hepatoblastoma, HuCCT-1 cholangiocarcinoma, A549 lung cancer, HaCaT immortalized keratinocyte, HeLa cervical carcinoma, and Saos-2 osteosarcoma). In contrast, among the human tissues examined, the heart and brain, which contain a large number of post-mitotic cells, showed the highest expression of REIC. The full-length REIC cDNA revealed that the predicted protein is 350 amino acids in length and possesses coiled-coil tertiary structures in each of the amino- and carboxyl-termini. Furthermore, a search of the protein database revealed a match of this gene product with Dkk-3, which is a novel inhibitor of Wnt oncogene. These results indicate that the REIC cloned by us may function as a tumor suppressor. (C) 2000 Academic Press.

    Web of Science

    researchmap

  • Transplantation of highly differentiated immortalized human hepatocytes to treat acute liver failure 査読

    N Kobayashi, M Miyazaki, K Fukaya, Y Inoue, M Sakaguchi, T Uemura, H Noguchi, A Kondo, N Tanaka, M Namba

    TRANSPLANTATION   69 ( 2 )   202 - 207   2000年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS  

    Background. Temporary support of a damaged liver by a bioartificial liver (BAL) devise is a promising approach for the treatment of acute liver failure. Although human primary hepatocytes are an ideal source of hepatic function in BAL, shortage of human livers available for hepatocyte isolation is the limiting factor for the use of this modality. A clonal human hepatocyte cell line that can grow economically in culture and exhibit liver-specific functions should be an attractive solution to this problem.
    Methods. To test this alternative, primary human fetal hepatocytes were immortalized using Simian virus 40 large T antigen. To investigate the potential of the immortalized cells for BAL, we transplanted the cells into the spleen of adult rats and performed a 90% hepatectomy 12 hr later.
    Results, One of the cloned human liver cell lines, OUMS-29, showed highly differentiated liver functions. Intrasplenic transplanting of 20x10(6) OUMS-29 cells protected the animals from hyperammonemia and the associated hepatic encephalopathy, Survival was significantly prolonged in 90% of hepatectomized rats receiving GUMS-29 cells.
    Conclusions. A highly differentiated immortalized human hepatocyte cell line, OUMS-29, was able to provide metabolic support during acute liver failure induced by 90% hepatectomy in rats. Essentially unlimited availability of OUMS-29 cells may be clinically useful for BAL treatment.

    Web of Science

    PubMed

    researchmap

  • Establishment of a human hepatoma cell line, HLE/2E1, suitable for detection of P450 2E1-related cytotoxicity 査読

    Isao Nozaki, Toshiya Tsuji, Masakiyo Sakaguchi, Yusuke Inoue, Ryuji Hirai, Akio Andou, Masahiro Miyazaki, Nobuyoshi Shimizu, Masayoshi Namba

    In Vitro Cellular and Developmental Biology - Animal   36 ( 9 )   566 - 570   2000年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    By transfection of an expression vector of human cytochrome P450 2E1 (CYP2E1) into a human hepatoma cell line (HLE), a new cell line (HLE/2E1) that stably expresses activity of CYP2E1 has been established. The HLE/2E1 cell line expressed a higher level of CYP2E1 messenger ribonucleic acid than did the mother HLE cell line. CYP2E1 enzyme activity determined by a p-nitrophenol oxidation assay was also higher in HLE/2E1 cells than in HLE cells. In addition, the enzyme activity of the HLE/2E1 cells was increased by ethanol treatment. Exposure to acetaminophen (APAP) or buthionine sulfoximine (BSO) caused a greater decrease in viability of the HLE/2E1 cells than that of the HLE cells, as determined by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay. The cytotoxicity of APAP or BSO to HLE/2E1 cells was inhibited by the addition of ethanol or vitamin E. However, the cytotoxicity of both APAP and BSO was enhanced by 24-h preincubation of HLE/2E1 cells with ethanol. These results show that this cell line provides a useful model for studying catalytic properties of CYP2E1 and cytotoxic mechanisms of chemicals metabolized by CYP2E1.

    DOI: 10.1007/BF02577524

    Scopus

    PubMed

    researchmap

  • Manumycin A, inhibitor of ras farnesyltransferase, inhibits proliferation and migration of rat vascular smooth muscle cells 査読

    H Kouchi, K Nakamura, K Fushimi, M Sakaguchi, M Miyazaki, T Ohe, M Namba

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   264 ( 3 )   915 - 920   1999年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ACADEMIC PRESS INC  

    Restenosis after angioplasty is thought to be caused by proliferation and migration of vascular smooth muscle cells (VSMCs), and it is a most serious problem in medical treatment. A low dose (50 ng/ml) of manumycin A, an inhibitor of p21(ras) (ras) farnesylation, significantly inhibited proliferation of rat VSMCs stimulated by the platelet-derived growth factor (PDGF). The mitoinhibitory effect of manumycin A was dose- and time-dependent but was independent of cell density. Western blot analysis showed that manumycin A reduced the amount of functional ras localized at the cytoplasmic membrane and inhibited the phosphorylation of p42/44 mitogen-activated protein kinase (MAPK). Manumycin A also inhibited VSMC migration and disorganized alpha actin fibers, as shown by immnofluorecence staining. These results indicate that the interruption of the ras/MAPK signal transduction pathway and the disorganization of alpha actin fibers are the main cause of manumycin A inhibition of VSMC proliferation and migration induced by PDGF. (C) 1999 Academic Press.

    Web of Science

    researchmap

  • Transferrin synthesized in cultured human fibroblasts is associated with tubulins and has iron binding capacity 査読

    Masakiyo Sakaguchi, Tadashi Kondo, Hong Pu, Masayoshi Namba

    Cell Structure and Function   24 ( 1 )   5 - 9   1999年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    In a previous report, using immunocytochemical and fluorescence-labeling techniques, we demonstrated that transferrin is synthesized in cultured human fibroblasts and that it is associated with tubulins in the cells. These morphological findings led us to attempt to elaborate those issues in more detail by biochemical methods. In this report, we were able to prove the association of transferrin produced in cells with tubulins. In addition, the transferrin associated with tubulins was found to bind to iron. These results suggest that endogenous transferrin plays a role in preventing damage caused by free radicals which can be induced by the interaction of iron with the hydrogen peroxide produced in cells.

    DOI: 10.1247/csf.24.5

    Scopus

    PubMed

    researchmap

  • Characteristics of intracellular transferrin produced by human fibroblasts: Its posttranscriptional regulation and association with tubulin 査読

    Tadashi Kondo, Masakiyo Sakaguchi, Masayoshi Namba

    Experimental Cell Research   242 ( 1 )   38 - 44   1998年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Academic Press Inc.  

    Transferrin (Tf), an iron-binding protein, was investigated in the cultured human fibroblast which is a major cell type in connective tissues. Tf is a major iron-transporting protein and has an important role in iron metabolism. Using two-dimensional gel electrophoresis, we demonstrated the eight subtypes of Tf produced by cultured normal human fibroblasts and their down-regulation after the immortalization of human cells, an essential early step of in vitro transformation. However, the amount of Tf mRNA in the immortalized cells was equal to that in the normal human fibroblasts, suggesting that the down-regulation occurred at the posttranscriptional level. The amount of Tf receptor increased in the immortalized cells in spite of a decrease in the amount of intracellular Tf. Interestingly the produced Tf associated with microtubules. These findings suggest a novel aspect of Tf characteristics in human fibroblasts.

    DOI: 10.1006/excr.1998.4080

    Scopus

    PubMed

    researchmap

  • Two-dimensional gel electrophoretic analysis of the changes after immortalization of human cells: Decrease of intracellular alpha-2-macroglobulin fragment 査読

    T Kondo, M Sakaguchi, H Yamada, M Namba

    ELECTROPHORESIS   19 ( 10 )   1836 - 1840   1998年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-V C H VERLAG GMBH  

    To study the mechanisms of immortalization of human cells, an early step in cancer development, we compared the cellular proteins of normal and immortalized human fibroblasts. Two-dimensional gel electrophoresis showed that one spot with a molecular mass 20 kDa and an isoelectric point of 6.0, became significantly smaller after immortalization of human cells. Further, the spot was rarely observed in four human liver cancer cell lines. Investigation of the N-terminal amino acids revealed that the spot was a fragment of alpha-2-macroglobulin. Although the 20 kDa fragment contains methionine, the spot was not labeled with [S-35]methionine. Thus we concluded that the spot might be derived from the culture medium. These results indicated that intracellular metabolism of alpha-2-macroglobulin, which is a multifunctional protease inhibitor, changed after the cells were transformed.

    Web of Science

    researchmap

  • Differential localization of two types of transferrin: Produced by human fibroblasts or incorporated from culture medium 査読

    Masakiyo Sakaguchi, Tadashi Kondo, Hong Pu, Masayoshi Namba

    Cell Structure and Function   23 ( 2 )   69 - 72   1998年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Japan Society for Cell Biology  

    In a previous paper, we demonstrated that cultured human fibroblasts synthesize transferrin (Tf). Two types of Tf are present
    one is produced by the cells and the other is internalized from the culture medium. To study the metabolism of intracellular Tf, we investigated the subcellular localization of the two types of Tf in human fibroblasts by immunocytochemical and fluorescence-labeling techniques. The internalized Tf was found to be localized in the perinuclear area, and the synthesized Tf was associated with microtubules, forming a fibrous structure in the cytoplasm. When the cells were treated with colchicine which depolymerizes microtubules irreversibly, the synthesized Tf lost its fibrous structure and spread out in cytoplasm, but the internalized Tf remained around the nucleus. These results suggest that the two types of Tf are regulated differently in the cells.

    DOI: 10.1247/csf.23.69

    Scopus

    PubMed

    researchmap

▼全件表示

書籍等出版物

  • 動物細胞培養・自動化におけるトラブル発生原因と対策

    技術情報協会  2017年 

     詳細を見る

  • 培養細胞実験ハンドブック

    羊土社  2009年 

     詳細を見る

  • 培養細胞実験ハンドブック

    羊土社  2009年 

     詳細を見る

  • 培養細胞実験ハンドブック

    羊土社  2009年 

     詳細を見る

  • 培養細胞実験ハンドブック

    羊土社  2004年 

     詳細を見る

  • 培養細胞実験ハンドブック

    羊土社  2004年 

     詳細を見る

  • 培養細胞実験ハンドブック

    羊土社  2004年 

     詳細を見る

▼全件表示

MISC

  • Inhibiting S100A8/A9 Attenuates Airway Obstruction in a Mouse Heterotopic Tracheal Transplantation Model

    D. Shimizu, M. Okazaki, S. Sugimoto, R. Kinoshita, S. Kawana, Y. Kubo, K. Matsubara, K. Nakata, A. Matsukawa, M. Sakaguchi, S. Toyooka

    The Journal of Heart and Lung Transplantation   41 ( 4 )   2022年4月

     詳細を見る

    記述言語:英語   出版者・発行元:Elsevier {BV}  

    DOI: 10.1016/j.healun.2022.01.191

    researchmap

  • Anti-S100A8/A9 Neutralizing Monoclonal Antibody Ameliorates Lung Injury Induced by Lung Ischemia Reperfusion Injury

    K. Nakata, M. Okazaki, K. Miyoshi, S. Sugimoto, M. Sakaguchi, S. Toyooka

    The Journal of Heart and Lung Transplantation   41 ( 4 )   2022年4月

     詳細を見る

    記述言語:英語   出版者・発行元:Elsevier {BV}  

    DOI: 10.1016/j.healun.2022.01.040

    researchmap

  • HSP90 inhibition suppresses not only cell proliferation but also chemotaxis in esophageal squamous cell carcinoma

    Masahiro Yamamura, Akira Yamauchi, Naoki Katase, Shuichiro Okamoto, Masakiyo Sakaguchi, Yoshiyuki Yamaguchi

    CANCER SCIENCE   112   477 - 477   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:WILEY  

    Web of Science

    researchmap

  • NOX4 on lymphatic endothelial cells (LEC) plays an important role on the migration of pancreatic cancer cells.

    Akira Yamauchi, Masahiro Yamamura, Naoki Katase, Nahoko Tomonobu, Rie Kinoshita, Masakiyo Sakaguchi, Shuichiro Okamoto

    CANCER SCIENCE   112   347 - 347   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:WILEY  

    Web of Science

    researchmap

  • 細胞外S100A11によりがん間質線維芽細胞が加速する膵がん進展のメカニズムの解明

    合原勇馬, 光井洋介, 友信奈保子, 木下理恵, 山内明, 山村真弘, 近藤英作, 豊岡伸一, 豊岡伸一, 那須保友, 阪口政清

    日本癌学会学術総会抄録集(Web)   79th   2020年

     詳細を見る

  • S100A11は筋浸潤性膀胱癌細胞と線維芽細胞のクロストークに関与し腫瘍進行に寄与する(S100A11 contributes to tumor progression with cross talking between muscle invasive bladder cancer cells and fibroblasts)

    光井 洋介, 定平 卓也, 渡部 昌実, 丸山 雄樹, 荒木 元朗, 渡邉 豊彦, 阪口 政清, 那須 保友

    西日本泌尿器科   81 ( 増刊 )   138 - 138   2019年10月

     詳細を見る

    記述言語:英語   出版者・発行元:西日本泌尿器科学会  

    researchmap

  • Comparing effects of small molecular weight compounds on proliferation and chemotaxis of pancreatic cancer cells

    Masahiro Yamamura, Akira Yamauchi, Naoki Katase, Masakiyo Sakaguchi, Yosuke Katata, Hiroaki Tanioka, Makoto Okawaki, Takeshi Nagasaka, Yoshiyuki Yamaguchi

    CANCER RESEARCH   79 ( 13 )   2019年7月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2019-2188

    Web of Science

    researchmap

  • メラノーマ原発巣における転移機構に関わるMCAM-S100A8/A9シグナル経路の分子学的解析

    友信奈保子, 木下理恵, 近藤英作, 山内明, 二見淳一郎, 豊岡伸一, 阪口政清

    日本癌学会学術総会抄録集(Web)   78th   2019年

     詳細を見る

  • S100タンパク質に着眼したがん転移機構の解明とその制御.

    阪口 政清

    岡山医学会雑誌   130   135 - 139   2018年10月

     詳細を見る

    記述言語:日本語  

    researchmap

  • 膵がん進展に導く膵がん細胞 間質線維芽細胞クロストークを介在する分泌性S100A11 受容体RAGE連携の役割

    光井 洋介, 山本 健一, Sumardika I Wayan, 木下 理恵, 村田 等, 二見 淳一郎, 高松 仁, 山本 靖彦, 西堀 正洋, 豊岡 伸一, 渡部 昌実, 那須 保友, 阪口 政清

    日本がん免疫学会総会プログラム・抄録集   22回   156 - 156   2018年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本がん免疫学会  

    researchmap

  • 分泌性S100A11-受容体RAGEシグナルに着眼した膵がん間質増大のメカニズムの解明

    山本 健一, 高松 仁, 光井 洋介, 木下 理恵, 村田 等, 二見 淳一郎, 山本 靖彦, 西堀 正洋, 豊岡 伸一, 阪口 政清

    日本がん免疫学会総会プログラム・抄録集   22回   117 - 117   2018年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本がん免疫学会  

    researchmap

  • Signal Diversity of Receptor for Advanced Glycation End Products

    Masakiyo Sakaguchi, Rie Kinoshita, Endy Widya Putranto, I. Made Winarsa Ruma, I. Wayan Sumardika, Chen Youyi, Naoko Tomonobu, Ken-ichi Yamamoto, Hitoshi Murata

    ACTA MEDICA OKAYAMA   71 ( 6 )   459 - 465   2017年12月

     詳細を見る

    記述言語:英語   掲載種別:書評論文,書評,文献紹介等   出版者・発行元:OKAYAMA UNIV MED SCHOOL  

    The receptor for advanced glycation end products (RAGE) is involved in inflammatory pathogenesis. It functions as a receptor to multiple ligands such as AGEs, HMGB1 and S100 proteins, activating multiple intracellular signaling pathways with each ligand binding. The molecular events by which ligand-activated RAGE controls diverse signaling are not well understood, but some progress was made recently. Accumulating evidence revealed that RAGE has multiple binding partners within the cytoplasm and on the plasma membrane. It was first pointed out in 2008 that RAGE's cytoplasmic tail is able to recruit Diaphanous-1 (Dia-1), resulting in the acquisition of increased cellular motility through Rac1/Cdc42 activation. We also observed that within the cytosol, RAGE's cytoplasmic tail behaves similarly to a Toll-like receptor (TLR4)-TIR domain, interacting with TIRAP and MyD88 adaptor molecules that in turn activate multiple downstream signals. Subsequent studies demonstrated the presence of an alternative adaptor molecule, DAP10, on the plasma membrane. The coupling of RAGE with DAP10 is critical for enhancing the RAGE-mediated survival signal. Interestingly, RAGE interaction on the membrane was not restricted to DAP10 alone. The chemotactic G-protein-coupled receptors (GPCRs) formyl peptide receptors1 and 2 (FPR1 and FPR2) also interacted with RAGE on the plasma membrane. Binding interaction between leukotriene B4 receptor 1 (BLT1) and RAGE was also demonstrated. All of the interactions affected the RAGE signal polarity. These findings indicate that functional interactions between RAGE and various molecules within the cytoplasmic area or on the membrane area coordinately regulate multiple ligand-mediated RAGE responses, leading to typical cellular phenotypes in several pathological settings. Here we review RAGE's signaling diversity, to contribute to the understanding of the elaborate functions of RAGE in physiological and pathological contexts.

    Web of Science

    researchmap

  • Exogenous DKK-3/REIC inhibits Wnt/β-catenin signaling and cell proliferation in human kidney cancer KPK1

    Jiaqi Xu, Takuya Sadahira, Rie Kinoshita, Shun Ai Li, Peng Huang, Koichiro Wada, Motoo Araki, Kazuhiko Ochiai, Hirofumi Noguchi, Masakiyo Sakaguchi, Yasutomo Nasu, Masami Watanabe

    Oncology Letters   14 ( 5 )   5638 - 5642   2017年11月

     詳細を見る

  • Promising therapeutic efficacy of a novel reduced expression in immortalized cells/dickkopf-3 expressing adenoviral vector for hepatocellular carcinoma

    Hiroaki Sawahara, Hidenori Shiraha, Daisuke Uchida, Hironari Kato, Ryo Kato, Atsushi Oyama, Teruya Nagahara, Masaya Iwamuro, Shigeru Horiguchi, Koichiro Tsutsumi, Mari Mandai, Tetsushige Mimura, Nozomu Wada, Yasuto Takeuchi, Kenji Kuwaki, Hideki Onishi, Shinichiro Nakamura, Masami Watanabe, Masakiyo Sakaguchi, Akinobu Takaki, Kazuhiro Nouso, Takahito Yagi, Yasutomo Nasu, Hiromi Kumon, Hiroyuki Okada

    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY   32 ( 10 )   1769 - 1777   2017年10月

     詳細を見る

    記述言語:英語   出版者・発行元:WILEY  

    Background and Aim: Reduced expression in immortalized cells (REIC)/dickkopf-3 (Dkk-3) is a tumor suppressor gene that is downregulated in various cancers. In our previous study of prostate cancer, the REIC/Dkk-3-expressing adenoviral vector (Ad-REIC) was found to induce cancer-selective apoptosis. This study recently developed a novel super gene expression (SGE) system and used this system to re-construct an Ad-REIC vector, termed the Ad-SGE-REIC, to achieve more effective therapeutic outcomes. In this study, the therapeutic effects of Ad-SGE-REIC on hepatocellular carcinoma (HCC) was assessed.
    Methods: Human HCC cell lines (HLE, Huh7, HepG2, HLF, SK-Hep1, and PLC), human HCC tissues, and mouse HCC cell line (Hepa1-6) were used in this study. REIC/Dkk-3 expression was assessed by immunoblotting and immunohistochemistry. The relative cell viability and the apoptotic effect were examined in vitro, and the anti-tumor effects of Ad-SGE-REIC treatment were analyzed in the mouse xenograft model. This study additionally assessed anti-tumor immunological effects on the immunocompetent mice.
    Results: REIC/Dkk-3 expression was decreased in HCC cell lines and HCC tissues. Ad-SGE-REIC reduced cell viability and induced apoptosis in HCC cell lines (HLE and Huh7), inhibited tumor growth in the mouse xenograft model, and demonstrated in vivo anti-cancer immunostimulatory effects on the HCC cell line (Hepa1-6).
    Conclusions: Ad-SGE-REIC treatment not only enhanced cell killing effects in vitro but also elicited significant therapeutic effects, with tumor growth suppression, in vivo. REIC/Dkk-3 gene therapy using Ad-SGE-REIC potentially represents an innovative new therapeutic tool for HCC.

    DOI: 10.1111/jgh.13757

    Web of Science

    researchmap

  • Identification of a novel component leading to anti-tumor activity besides the major ingredient cordycepin in Cordyceps militaris extract

    Takeharu Wada, I. Wayan Sumardika, Shingo Saito, I. Made Winarsa Ruma, Eisaku Kondo, Masami Shibukawa, Masakiyo Sakaguchi

    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES   1061   209 - 219   2017年9月

     詳細を見る

    記述言語:英語   出版者・発行元:ELSEVIER SCIENCE BV  

    In accordance with our previous study that was carried out to identify novel anti-tumor ingredients, chromatographic separation in combination with an anti-tumor activity assay was used for analysis of Cordyceps militaris extract in this study. Various modes of chromatography including reversed-phase, cation-exchange and anion exchange were used to separate components of Cordyceps militaris, which showed various chemical properties. Anti-tumor activity of each fraction was assessed by a Hoechst staining-based apoptosis assay using malignant melanoma MeWo cells. By these repeated approaches through chromatographic segregation and cell biological assay, we finally succeeded in identifying the target substance from a certain fraction that included neutral hydrophilic components using a pre-column and post-column chlorine adduct ionization LC APCI MS method. The target substance was a mono-carbohydrate, xylitol, that induced apoptotic cell death in MeWo cells but not in normal human OUMS-24 fibroblasts. This is the first study showing that Cordyceps militaris extract contains a large amount of xylitol. Thus, our results will contribute greatly to uncovering the mysterious multifunctional herbal drug Cordyceps militaris as an anti-tumor agent.

    DOI: 10.1016/j.jchromb.2017.07.022

    Web of Science

    researchmap

  • Robust cancer-specific gene expression by a novel cassette with hTERT and CMV promoter elements

    Masakiyo Sakaguchi, Takuya Sadahira, Hideo Ueki, Rie Kinoshita, Hitoshi Murata, Ken-Ichi Yamamoto, Junichiro Futami, Yasutomo Nasu, Kazuhiko Ochiai, Hiromi Kumon, Nam-Ho Huh, Masami Watanabe

    ONCOLOGY REPORTS   38 ( 2 )   1108 - 1114   2017年8月

     詳細を見る

    記述言語:英語   出版者・発行元:SPANDIDOS PUBL LTD  

    We developed and validated a novel hTERT/CMV promoter element-driven gene expression cassette that can robustly enhance cancer-specific gene expression. The following gene expressional elements were located in tandem within the plasmid construct: [hTERT core promoter, cytomegalovirus (CMV) minimized promoter, RU5' sequence, an inserted gene, BGH polyA, hTERT enhancer]; this is hereafter referred to as the hT/Cm-R-hT construct. Using various human cancer cell lines and normal cells, the cancer-specific transcription of the green fluorescent protein (GFP) gene was examined by western blotting and fluorescence microscopy. Cancer-specific gene expression was robustly achieved in the hT/Cm-R-hT plasmid in comparison to the other control hT/Cm-driven construct. Notably, the expression level of GFP observed in the hT/Cm-RhT-driven construct was superior to that of the control plasmid with the conventional CMV promoter in HEK293 cells, which are known to possess higher hTERT activity than normal cells. We next examined the availability of hT/Cm-R-hT in detecting the target GFP expressing cancer cells from human peripheral blood mononuclear cells (PBMCs). The hT/Cm-R-hT plasmid successfully induced cancer-specific gene expression; the robust expression of GFP was observed in target HeLa cancer cells, whereas GFP was not visibly expressed in normal PBMCs. The plasmid allowed for the selective visualization of viable HeLa cancer cells in mixed cell cultures containing up to 10000-fold more PBMCs. These findings indicate that the hT/Cm-R-hT expressional system is a valuable tool for detecting viable cancer cells mixed with normal cells. The current system can therefore be applied to the in vitro detection of cancer cells that are disseminated in the blood and other types of body fluid in vivo. Since the current system can also be applied to other types of vectors, including virus vectors, this approach using the hTERT promoter-based construct is expected to become a valuable tool for enhancing cancer specific gene expression.

    DOI: 10.3892/or.2017.5710

    Web of Science

    researchmap

  • Expression of tumor suppressor REIC/Dkk-3 by a newly improved adenovirus vector with insertion of a hTERT promoter at the 3'-side of the transgene

    Endy Widya Putranto, Rie Kinoshita, Masami Watanabe, Takuya Sadahira, Hitoshi Murata, Ken-Ichi Yamamoto, Junichiro Futami, Ken Kataoka, Yusuke Inoue, I. Made Winarsa Ruma, I. Wayan Sumardika, Chen Youyi, Miyoko Kubo, Yoshihiko Sakaguchi, Kenji Saito, Yasutomo Nasu, Hiromi Kumon, Nam-Ho Huh, Masakiyo Sakaguchi

    ONCOLOGY LETTERS   14 ( 1 )   1041 - 1048   2017年7月

     詳細を見る

    記述言語:英語   出版者・発行元:SPANDIDOS PUBL LTD  

    Reduced expression in immortalized cells (REIC)/Dickkopf-3 (Dkk-3) overexpression, induced using an adenovirus (Ad)-REIC, has been revealed to have a dramatic therapeutic effect on multiple types of cancer. To achieve an improved therapeutic effect from Ad-REIC on cancer, our group previously developed an enhanced gene expression system, the C-TSC cassette [cytomegalovirus (CMV)-RU5' located upstream (C); another promoter unit composed of triple tandem promoters, human telomerase reverse transcriptase (hTERT), simian virus 40 and CMV, located downstream of the cDNA (TSC); plus a polyadenylation (polyA) signal]. When applied to the conventional Ad-REIC, this novel system induced the development of an enhanced product, Ad-C-TSC-REIC, which exhibited a noticeable anticancer effect. However, there were difficulties in terms of Ad-C-TSC-REIC productivity in HEK293 cells, which are a widely used donor cell line for viral production. Productivity of Ad-C-TSC-REIC was significantly reduced compared with the conventional Ad-REIC, as the Ad-C-TSC-REIC had a significantly higher ability to induce apoptotic cell death of not only various types of cancer cell, but also HEK293 cells. The present study aimed to overcome this problem by modifying the C-TSC structure, resulting in an improved candidate: A C-T cassette (C: CMV-RU5' located upstream; T: another promoter unit composed of a single hTERT promoter, located downstream of the cDNA plus a polyA signal), which demonstrated gene expression comparable to that of the C-TSC system. The improved adenovirus REIC/Dkk-3 product with the C-T cassette, named Ad-C-T-REIC, exhibited a higher expression level of REIC/Dkk3, similar to that of Ad-C-TSC-REIC. Notably, the vector mitigated the cell death of donor HEK293 cells, resulting in a higher rate of production of its adenovirus. These results indicated that Ad-C-T-REIC has the potential to be a useful tool for application in cancer gene therapy.

    DOI: 10.3892/ol.2017.6201

    Web of Science

    researchmap

  • An HNF4α-microRNA-194/192 signaling axis maintains hepatic cell function

    Aoi Morimoto, Mana Kannari, Yuichi Tsuchida, Shota Sasaki, Chinatsu Saito, Tsuyoshi Matsuta, Tsukasa Maeda, Megumi Akiyama, Takahiro Nakamura, Masakiyo Sakaguchi, Nobukazu Nameki, Frank J. Gonzalez, Yusuke Inoue

    Journal of Biological Chemistry   292 ( 25 )   10574 - 10585   2017年6月

     詳細を見る

  • Topics from special edition 転移先臓器を感知する受容体群の分子制御機構の解明とその応用

    阪口 政清, 木下 理恵, 村田 等, 山本 健一, 許 南浩, 日比野 利彦

    細胞   49 ( 7 )   359 - 362   2017年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:ニューサイエンス社  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2017264472

  • Topics from special edition 転移先臓器を感知する受容体群

    阪口 政清, 木下 理恵, 村田 等, 山本 健一, 許 南浩, 日比野 利彦

    細胞   49 ( 3 )   143 - 146   2017年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:ニューサイエンス社  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2017181594

  • Distant Bystander Effect of REIC/DKK3 Gene Therapy Through Immune System Stimulation in Thoracic Malignancies

    Ken Suzawa, Kazuhiko Shien, Huang Peng, Masakiyo Sakaguchi, Masami Watanabe, Shinsuke Hashida, Yuho Maki, Hiromasa Yamamoto, Shuta Tomida, Junichi Soh, Hiroaki Asano, Kazunori Tsukuda, Yasutomo Nasu, Hiromi Kumon, Shinichiro Miyoshi, Shinichi Toyooka

    ANTICANCER RESEARCH   37 ( 1 )   301 - 307   2017年1月

     詳細を見る

    記述言語:英語   出版者・発行元:INT INST ANTICANCER RESEARCH  

    Background: Reduced expression in immortalized cell (REIC)/Dickkoph-3 (DKK3) is a tumor-suppressor gene, and its overexpression by adenovirus vector (Ad-REIC) exhibits a remarkable therapeutic effect on various human cancer types through a mechanism triggered by endoplasmic reticulum stress. Materials and Methods: We examined the direct anti-tumor effect of Ad-REIC gene therapy on lung cancer and malignant mesothelioma cell lines in vitro, and the distant bystander effect using immunocompetent mouse allograft models with bilateral flank tumors. Results: Ad-REIC treatment showed antitumor effect in many lung cancer and malignant mesothelioma cell lines in vitro. In an in vivo model, Ad-REIC treatment inhibited the growth not only of directly treated tumors but also of distant untreated tumors. By immunohistochemical analysis, infiltration of T-cells and natural killer (NK) cells and expression of the major histocompatibility complex (MHC) class I molecules were observed in bilateral tumors. Conclusion: Ad-REIC treatment not only had a direct antitumor effect but also an indirect bystander effect through stimulation of the immune system.

    DOI: 10.21873/anticanres.11321

    Web of Science

    researchmap

  • Neuroplastinβとextracellular matrix metalloprotease inducerはS100A8/A9に対する機能的な受容体であり,ケラチノサイトの増殖とアトピーの皮膚炎症の増強に関与している. Critical role of novel receptors to S100A8/A9, EMMPRIN and NPTNβ, on keratinocyte growth and inflammation in atopic dermatitis.

    阪口政清, 山本真実, 宮井雅史, 松元 有羽子, 木下理恵, 村田 等, 山本健一, 森実 真, 岩月啓氏, 許 南浩, 坪井良治, 日比野 利彦

    臨床免疫   49 ( 6 )   594 - 598   2017年

     詳細を見る

    記述言語:日本語   出版者・発行元:科学評論社  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2017265401

  • 転移先臓器を感知する受容体群の分子制御機構の解明とその応用. Advanced approach to prevent cancer metastasis based on S100A8/A9-mediated seed and soil theory Innovative approach to prevent cancer metastasis based on S100A8/A9-mediated seed and soil theory.

    阪口政清, 木下理恵, 村田 等, 山本健一, 許 南浩, 日比野 利彦

    月刊「細胞」6月号   49 ( 7 )   43 - 46   2017年

     詳細を見る

  • 転移先臓器を感知する受容体群Innovative approach to prevent cancer metastasis based on S100A8/A9-mediated seed and soil theory.

    阪口政清, 木下理恵, 村田 等, 山本健一, 許 南浩, 日比野 利彦

    月刊「細胞」3月号   49 ( 3 )   39 - 42   2017年

     詳細を見る

  • S100-SPECT uncovers cellular and molecular events of pre-metastatic niche formation and following organ-specific cancer metastasis.

    Sakaguchi M

    Theranostics   7 ( 10 )   2649 - 2651   2017年

     詳細を見る

  • ß-1,3-galactosyl-O-glycosyl-glycoprotein ß-1,6-N-acetylglucosaminyltransferase 3 Increases MCAM Stability, Which Enhances S100A8/A9-Mediated Cancer Motility.

    Sumardika IW, Youyi C, Kondo E, Inoue Y, Ruma IMW, Murata H, Kinoshita R, Yamamoto KI, Tomida S, Shien K, Satoh H, Yamauchi A, Futami J, Putranto EW, Hibino T, Toyooka S, Nishibori M, Sakaguchi M

    Oncol Res   2017年

     詳細を見る

  • 【アトピー性皮膚炎の病態研究】 Neuroplastin βとextracellular matrix metallo-protease inducerはS100A8/A9に対する機能的な受容体であり、ケラチノサイトの増殖とアトピーの皮膚炎症の増強に関与している

    阪口 政清, 山本, 真実, 宮井 雅史, 木下 理恵, 村田 等, 山本 健一, 森実 真, 岩月 啓氏, 許 南浩, 坪井 良治, 日比野 利彦

    臨床免疫・アレルギー科   67 ( 6 )   594 - 598   2017年

     詳細を見る

  • Active Secretion of Dimerized S100A11 Induced by the Peroxisome in Mesothelioma Cells. 国際誌

    Satomi Saho, Hiroki Satoh, Eisaku Kondo, Yusuke Inoue, Akira Yamauchi, Hitoshi Murata, Rie Kinoshita, Ken-Ichi Yamamoto, Junichiro Futami, Endy Widya Putranto, I Made Winarsa Ruma, I Wayan Sumardika, Chen Youyi, Ken Suzawa, Hiromasa Yamamoto, Junichi Soh, Shuta Tomida, Yoshihiko Sakaguchi, Ken Saito, Hidekazu Iioka, Nam-Ho Huh, Shinichi Toyooka, Masakiyo Sakaguchi

    Cancer microenvironment : official journal of the International Cancer Microenvironment Society   9 ( 2-3 )   93 - 105   2016年12月

     詳細を見る

    記述言語:英語  

    S100A11, a small Ca2+ binding protein, acts extracellularly as a mediator of cancer progression. That raises the question of how a protein that lacks the classical secretory signal is able to be secreted outside cells without being damaged. Some insights into this question have been obtained, and there has been accumulating evidence indicating a pivotal role of a non-classical vesicle-mediated pathway using lysosomes or peroxisomes for the protein secretion. To obtain a more precise insight into the secretory mechanism of S100A11, we first screened representative cancer cells exhibiting significantly active secretion of S100A11. From the results of profiling, we turned our attention to aggressive cancer mesothelioma cells. In mesothelioma cells, we found that abundant dimeric S100A11 was produced selectively in the peroxisome after transportation of monomeric S100A11 through an interaction with PEX14, a peroxisome membrane protein, resulting in peroxisomal secretion of dimerized S100A11. In an extracellular environment in vitro, dimerized S100A11 promoted mesothelial cell invasion indirectly with the help of fibroblast cells. Overall, the results indicate that the peroxisome functions as an essential vesicle for the production of dimerized S100A11 and the subsequent secretion of the protein from mesothelioma cells and that peroxisome-mediated secretion of dimerized S100A11 might play a critical role in mesothelioma progression in a tumor microenvironment.

    DOI: 10.1007/s12307-016-0185-2

    PubMed

    researchmap

  • Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway

    Tomoaki Ohtsuka, Masakiyo Sakaguchi, Hiromasa Yamamoto, Shuta Tomida, Katsuyoshi Takata, Kazuhiko Shien, Shinsuke Hashida, Tomoko Miyata-Takata, Mototsugu Watanabe, Ken Suzawa, Junichi Soh, Chen Youyi, Hiroki Sato, Kei Namba, Hidejiro Torigoe, Kazunori Tsukuda, Tadashi Yoshino, Shinichiro Miyoshi, Shinichi Toyooka

    SCIENTIFIC REPORTS   6   39557 - 39557   2016年12月

     詳細を見る

    記述言語:英語   出版者・発行元:NATURE PUBLISHING GROUP  

    HER2 is a receptor tyrosine kinase and its upregulation via activating mutations or amplification has been identified in some malignant tumors, including lung cancers. Because HER2 can be a therapeutic target in HER2-driven malignancies, it is important to understand the molecular mechanisms of HER2 activation. In the current study, we identified that cytokeratin 19 (KRT19) binds to HER2 at the inside face of plasma membrane. HER2 and KRT19, which were concurrently introduced to a human embryonic kidney 293 T cells, revealed an association with each other and resulted in phosphorylation of HER2 with the subsequent activation of a downstream Erk-associated pathway. A binding assay revealed that both the NH2-terminal head domain of KRT19 and the COOH-terminal domain of HER2 were essential for their binding. To investigate the impact of the interaction between HER2 and KRT19 in lung cancer, we examined their expressions and localizations in lung cancers. We found that KRT19 was highly expressed in HER2-positive lung cancer cells, and KRT19 and HER2 were co-localized at the cell membrane. In conclusion, we found that KRT19 intracellularly binds to HER2, playing a critical role in HER2 activation.

    DOI: 10.1038/srep39557

    Web of Science

    researchmap

  • Identification of an S100A8 Receptor Neuroplastin-β and its Heterodimer Formation with EMMPRIN

    Masakiyo Sakaguchi, Mami Yamamoto, Masashi Miyai, Tatsuo Maeda, Junichiro Hiruma, Hitoshi Murata, Rie Kinoshita, I. Made, Winarsa Ruma, ndy Widya Putranto, Yusuke Inoue, Shin Morizane, Nam Ho Huh, Ryoji Tsuboi, Toshihiko Hibino

    Journal of Investigative Dermatology, Advances in biology of skin   136 ( 11 )   2240 - 2250   2016年11月

     詳細を見る

  • RAGEはロイコトリエンB4第一受容体BLT1と機能的に相互作用する

    市木 貴子, 古賀 友紹, 奥野 利明, 佐伯 和子, 阪口 政清, 山本 靖彦, 横溝 岳彦

    日本生化学会大会プログラム・講演要旨集   89回   [2P - 089]   2016年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本生化学会  

    researchmap

  • A super gene expression system enhances the anti-glioma effects of adenovirus-mediated REIC/Dkk-3 gene therapy

    Tetsuo Oka, Kazuhiko Kurozumi, Yosuke Shimazu, Tomotsugu Ichikawa, Joji Ishida, Yoshihiro Otani, Toshihiko Shimizu, Yusuke Tomita, Masakiyo Sakaguchi, Masami Watanabe, Yasutomo Nasu, Hiromi Kumon, Isao Date

    SCIENTIFIC REPORTS   6   33319 - 33319   2016年9月

     詳細を見る

    記述言語:英語   出版者・発行元:NATURE PUBLISHING GROUP  

    Reduced expression in immortalized cells/Dickkopf-3 (REIC/Dkk-3) is a tumor suppressor and therapeutic gene in many human cancers. Recently, an adenovirus REIC vector with the super gene expression system (Ad-SGE-REIC) was developed to increase REIC/Dkk-3 expression and enhance therapeutic effects compared with the conventional adenoviral vector (Ad-CAG-REIC). In this study, we investigated the in vitro and in vivo effects of Ad-SGE-REIC on malignant glioma. In U87 Delta EGFR and GL261 glioma cells, western blotting confirmed that robust upregulation of REIC/Dkk-3 expression occurred in Ad-SGE-REIC-transduced cells, most notably after transduction at a multiplicity of infection of 10. Cytotoxicity assays showed that Ad-SGE-REIC resulted in a time-dependent and significant reduction in the number of malignant glioma cells attaching to the bottom of culture wells. Xenograft and syngeneic mouse intracranial glioma models treated with Ad-SGE-REIC had significantly longer survival than those treated with the control vector Ad-LacZ or with Ad-CAG-REIC. This study demonstrated the anti-glioma effect of Ad-SGE-REIC, which may represent a promising strategy for the treatment of malignant glioma.

    DOI: 10.1038/srep33319

    Web of Science

    researchmap

  • Novel REIC/Dkk-3-encoding adenoviral vector as a promising therapeutic agent for pancreatic cancer

    H. Sawahara, H. Shiraha, D. Uchida, H. Kato, T. Nagahara, M. Iwamuro, J. Kataoka, S. Horiguchi, M. Watanabe, M. Sakaguchi, A. Takaki, K. Nouso, Y. Nasu, H. Kumon, H. Okada

    CANCER GENE THERAPY   23 ( 8 )   278 - 283   2016年8月

     詳細を見る

    記述言語:英語   出版者・発行元:NATURE PUBLISHING GROUP  

    Reduced expression in immortalized cells (REIC)/dickkopf-3 (Dkk-3), a tumor suppressor gene, is downregulated in various cancers. We previously reported the tumor-inhibitory effects of the REIC/Dkk-3 gene, delivered by a conventional adenoviral vector (Ad-CAG-REIC) in pancreatic cancer. Here, we developed an Ad-REIC vector with a novel gene expression system, termed the super gene expression (SGE) system, and assessed its therapeutic effects relative to those of Ad-CAG-REIC in pantreatic cancer cells. Human pancreatic cancer cell lines ASPC1 and MIAPaCa2 were used. REIC/Dkk-3 expression was assessed by western blot analysis. Relative cell viability and apoptotic effects were examined in vitro. The anti-tumor effects of Ad-REIC treatment were assessed in the mouse xenograft model. Compared with Ad-CAG-REIC, Ad-SGE-REIC elicited a significant increase in REIC protein expression in the cells studied, Relative to Ad-CAG-REIC, Ad-SGE-REIC reduced cell viability and induced apoptosis in the ASPC1 and MIAPaCa2 cell lines in vitro, and achieved superior tumor growth inhibition in the mouse xenograft model. Compared with conventional Ad-REIC agents, Ad-SGE-REIC provided enhanced inhibitory effects against tumor growth. Our results indicate that Ad-SGE-REIC is an innovative therapeutic tool for pancreatic cancer.

    DOI: 10.1038/cgt.2016.31

    Web of Science

    researchmap

  • MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-κB and ROS formation upon ligand binding 国際誌

    I. Made, Winarsa Ruma, ndy Widya Putranto, Eisaku Kondo, Hitoshi Murata, Masami Watanabe, Peng Huang, Rie Kinoshita, Junichiro Futami, Yusuke Inoue, Akira Yamauchi, I. Wayan, Sumardika,Chen Youyi, Ken Ichi Yamamoto, Yasutomo Nasu, Masahiro Nishibori, Toshihiko H

    Clinical and Experimental Metastasis   33 ( 6 )   609 - 27   2016年8月

     詳細を見る

  • An efficient method for the preparation of preferentially heterodimerized recombinant S100A8/A9 coexpressed in Escherichia coli

    Junichiro Futami, Yuki Atago, Akari Azuma, Endy Widya Putranto, Rie Kinoshita, Hitoshi Murata, Masakiyo Sakaguchi

    Biochemistry and Biophysics Reports   6   94 - 100   2016年7月

     詳細を見る

    記述言語:英語   出版者・発行元:Elsevier B.V.  

    It is now known that multicomponent protein assemblies strictly regulate many protein functions. The S100 protein family is known to play various physiological roles, which are associated with alternative complex formations. To prepare sufficient amounts of heterodimeric S100A8 and S100A9 proteins, we developed a method for bicistronic coexpression from a single-vector system using Escherichia coli cells as a host. The complex formation between S100A8 and S100A9 appears to be dependent on the thermodynamic stability of the protein during expression. The stable S100A8/A9 heterodimer complex spontaneously formed during coexpression, and biologically active samples were purified by cation-exchange chromatography. Semi-stable homodimers of S100A8 and S100A9 were also formed when expressed individually. These results suggest that the assembly of S100 protein complexes might be regulated by expression levels of partner proteins in vivo. Because protein assembly occurs rapidly after protein synthesis, coexpression of relevant proteins is crucial for the design of multicomponent recombinant protein expression systems.

    DOI: 10.1016/j.bbrep.2016.03.009

    Scopus

    researchmap

  • Histidine-Rich Glycoprotein Prevents Septic Lethality through Regulation of Immunothrombosis and Inflammation

    Hidenori Wake, Shuji Mori, Keyue Liu, Yuta Morioka, Kiyoshi Teshigawara, Masakiyo Sakaguchi, Kosuke Kuroda, Yuan Gao, Hideo Takahashi, Aiji Ohtsuka, Tadashi Yoshino, Hiroshi Morimatsu, Masahiro Nishibori

    EBIOMEDICINE   9   180 - 194   2016年7月

     詳細を見る

    記述言語:英語   出版者・発行元:ELSEVIER SCIENCE BV  

    Sepsis is a major cause of death worldwide. We show that a plasma protein histidine-rich glycoprotein (HRG) was decreased significantly in septic mice with cecal ligation and puncture (CLP) and supplementary treatment of septic mice with exogenous HRG improved survival, with strong inhibition of tight attachment of neutrophils to pulmonary vasculatures, subsequent immunothrombosis, DIC state, lung inflammation, hypercytokinemia, and activation of vascular endothelial cells (VECs). In contrast, knockdown of HRG by siRNA exacerbated lethality. Purified human HRG reversibly induced morphological changes in human neutrophils in vitro; induction of spherical shape with reduced microvilli and adhesiveness to VECs. HRG maintained the passage of neutrophils through microcapillaries and abolished production of reactive oxygen species. These results suggested that the supplementary therapy with HRG may provide a novel strategy for the treatment of sepsis through suppression of excessive systemic inflammation and immunothrombosis by keeping circulating neutrophils quiescent and preventing uncontrolled activation of VECs. (C) 2016 The Authors. Published by Elsevier B.V.

    DOI: 10.1016/j.ebiom.2016.06.003

    Web of Science

    researchmap

  • Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations

    Ken Suzawa, Shinichi Toyooka, Masakiyo Sakaguchi, Mizuki Morita, Hiromasa Yamamoto, Shuta Tomida, Tomoaki Ohtsuka, Mototsugu Watanabe, Shinsuke Hashida, Yuho Maki, Junichi Soh, Hiroaki Asano, Kazunori Tsukuda, Shinichiro Miyoshi

    CANCER SCIENCE   107 ( 1 )   45 - 52   2016年1月

     詳細を見る

    記述言語:英語   出版者・発行元:WILEY  

    Human epidermal growth factor receptor 2 (HER2) is a member of the HER family of proteins containing four receptor tyrosine kinases. It plays an important role in the pathogenesis of certain human cancers. In non-small-cell lung cancer (NSCLC), HER2 amplification or mutations have been reported. However, little is known about the benefit of HER2-targeted therapy for NSCLCs harboring HER2 alterations. In this study, we investigated the antitumor effect of afatinib, an irreversible epidermal growth factor receptor (EGFR)-HER2 dual inhibitor, in lung cancers harboring HER2 oncogene alterations, including novel HER2 mutations in the transmembrane domain, which we recently identified. Normal bronchial epithelial cells, BEAS-2B, ectopically overexpressing wild-type HER2 or mutants (A775insYVMA, G776VC, G776LC, P780insGSP, V659E, and G660D) showed constitutive autophosphorylation of HER2 and activation of downstream signaling. They were sensitive to afatinib, but insensitive to gefitinib. Furthermore, we examined the antitumor activity of afatinib and gefitinib in several NSCLC cell lines, and investigated the association between their genetic alterations and sensitivity to afatinib treatment. In HER2-altered NSCLC cells (H2170, Calu-3, and H1781), afatinib downregulated the phosphorylation of HER2 and EGFR as well as their downstream signaling, and induced an antiproliferative effect through G(1) arrest and apoptotic cell death. In contrast, HER2- or EGFR-non-dependent NSCLC cells were insensitive to afatinib. In addition, these effects were confirmed in vivo by using a xenograft mouse model of HER2-altered lung cancer cells. Our results suggest that afatinib is a therapeutic option as a HER2-targeted therapy for NSCLC harboring HER2 amplification or mutations.

    DOI: 10.1111/cas.12845

    Web of Science

    researchmap

  • Modulation of leukotriene B4 receptor 1 signaling by receptor for advanced glycation end products (RAGE).

    Ichiki T, Koga T, Okuno T, Saeki K, Yamamoto Y, Yamamoto H, Sakaguchi M, Yokomizo T

    FASEB J   30 ( 5 )   1811 - 1822   2016年

     詳細を見る

  • Hepatocyte Nuclear Factor 4α Controls Iron Metabolism and Regulates Transferrin Receptor 2 in Mouse Liver.

    Matsuo S, Ogawa M, Muckenthaler MU, Mizui Y, Sasaki S, Fujimura T, Takizawa M, Ariga N, Ozaki H, Sakaguchi M, Gonzalez FJ, Inoue Y

    J Biol Chem   290 ( 52 )   30855 - 30865   2015年12月

     詳細を見る

  • NRF2 Regulates PINK1 Expression under Oxidative Stress Conditions

    Hitoshi Murata, Hitoshi Takamatsu, Sulai Lie, Ken Kataoka, Nam-ho Huh, Masakiyo Sakaguchi

    PLoS One   10 ( 11 )   e0142438-e0142438   2015年11月

     詳細を見る

    記述言語:英語   出版者・発行元:PUBLIC LIBRARY SCIENCE  

    Mutations of the PTEN-induced putative kinase 1 (PINK1) gene are a cause of autosomal recessive forms of Parkinson's disease. Recent studies have revealed that PINK1 is an essential factor for controlling mitochondrial quality, and that it protects cells from oxidative stresses. Although there has been considerable progress in the elucidation of various aspects of PINK1 protein regulation such as activation, stability and degradation, the transcriptional regulation of PINK1 mRNA under stress conditions remains unclear. In this study, we found that nuclear factor (erythroid-derived 2)-like 2 (NRF2), an antioxidant transcription factor, regulates PINK1 expression under oxidative stress conditions. Damaged mitochondria arising from stress conditions induced NRF2-dependent transcription of the PINK1 gene through production of reactive oxygen species (ROS). Either an ROS scavenger or forced expression of KEAP1, a potent inhibitory partner to NRF2, restricted PINK1 expression induced by activated NRF2. Transcriptionally up-regulated PINK1 diminished oxidative stress-associated cell death. The results indicate that PINK1 expression is positively regulated by NRF2 and that the NRF2-PINK1 signaling axis is deeply involved in cell survival.

    DOI: 10.1371/journal.pone.0142438

    Web of Science

    researchmap

  • TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells

    Hiroki Otani, Hiromasa Yamamoto, Munenori Takaoka, Masakiyo Sakaguchi, Junichi Soh, Masaru Jida, Tsuyoshi Ueno, Takafumi Kubo, Hiroaki Asano, Kazunori Tsukuda, Katsuyuki Kiura, Shinji Hatakeyama, Eiji Kawahara, Yoshio Naomoto, Shinichiro Miyoshi, Shinichi Toyooka

    PLOS ONE   10 ( 6 )   e0129838-e0129838   2015年6月

     詳細を見る

    記述言語:英語   出版者・発行元:PUBLIC LIBRARY SCIENCE  

    TAE226, a bis-anilino pyrimidine compound, has been developed as an inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor-I receptor (IGF-IR). In this study, we investigated the effect of TAE226 on non-small-cell lung cancer (NSCLC), especially focusing on the EGFR mutational status. TAE226 was more effective against cells with mutant EGFR, including the T790M mutant, than against cells with wild-type one. TAE226 preferentially inhibited phospho-EGFR and its downstream signaling mediators in the cells with mutant EGFR than in those with wild-type one. Phosphorylation of FAK and IGF-IR was not inhibited at the concentration at which the proliferation of EGFR-mutant cells was inhibited. Results of the in vitro binding assay indicated significant differences in the affinity for TAE226 between the wild-type and L858R (or delE746_A750) mutant, and the reduced affinity of ATP to the L858R (or delE746_A750) mutant resulted in good responsiveness of the L858R (or delE746_A750) mutant cells to TAE226. Of interest, the L858R/T790M or delE746_A750/T790M mutant enhanced the binding affinity for TAE226 compared with the L858R or delE746_A750 mutant, resulting in the effectiveness of TAE226 against T790M mutant cells despite the T790M mutation restoring the ATP affinity for the mutant EGFR close to that for the wild-type. TAE226 also showed higher affinity of about 15-fold for the L858R/T790M mutant than for the wild-type one by kinetic interaction analysis. The antitumor effect against EGFR-mutant tumors including T790M mutation was confirmed in mouse models without any significant toxicity. In summary, we showed that TAE226 inhibited the activation of mutant EGFR and exhibited anti-proliferative activity against NSCLCs carrying EGFR mutations, including T790M mutation.

    DOI: 10.1371/journal.pone.0129838

    Web of Science

    researchmap

  • The cysteine-rich core domain of REIC/Dkk-3 is critical for its effect on monocyte differentiation and tumor regression

    Rie Kinoshita, Masami Watanabe, Peng Huang, Shun-Ai Li, Masakiyo Sakaguchi, Hiromi Kumon, Junichiro Futami

    ONCOLOGY REPORTS   33 ( 6 )   2908 - 2914   2015年6月

     詳細を見る

    記述言語:英語   出版者・発行元:SPANDIDOS PUBL LTD  

    Reduced expression in immortalized cells (REIC)/Dickkopf (Dkk)-3 is a tumor-suppressor gene and has been studied as a promising therapeutic gene for cancer gene therapy. Intratumoral injection of an adenovirus vector carrying the human REIC/Dkk-3 gene (Ad-REIC) elicits cancer cell-specific apoptosis and anticancer immune responses. The cytokine-like effect of secretory REIC/Dkk-3 on the induction of dendritic cell (DC)-like cell differentiation from monocytes plays a role in systemic anticancer immunity. In the present study, we generated recombinant full-length and N-terminally truncated REIC/Dkk-3 to characterize the biological activity of the protein. During the purification procedure, we identified a 17 kDa cysteine-rich stable product (C17-REIC) showing limited degradation. Further analysis showed that the C17-REIC domain was sufficient for the induction of DC-like cell differentiation from monocytes. Concomitant with the differentiation of DCs, the REIC/Dkk-3 protein induced the phosphorylation of glycogen synthase kinase 3 beta (GSK-3 beta) and signal transducers and activators of transcription (STAT) at a level comparable to that of granulocyte/macrophage colony-stimulating factor. In a mouse model of subcutaneous renal adenocarcinoma, intraperitoneal injection of full-length and C17-REIC proteins exerted anticancer effects in parallel with the activation of immunocompetent cells such as DCs and cytotoxic T lymphocytes in peripheral blood. Taken together, our results indicate that the stable cysteine-rich core region of REIC/Dkk-3 is responsible for the induction of anticancer immune responses. Because REIC/Dkk-3 is a naturally circulating serum protein, the upregulation REIC/Dkk-3 protein expression could be a promising option for cancer therapy.

    DOI: 10.3892/or.2015.3885

    Web of Science

    researchmap

  • Antitumor effect of afatinib, as a HER2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.

    Suzawa K, Toyooka S, Sakaguchi M, Morita M, Yamamoto H, Tomida S, Ohtsuka T, Watanabe M, Hashida S, Maki Y, Soh J, Asano H, Tsukuda K, Miyoshi S

    Cancer Sci   cas.12845-cas.12845   2015年

     詳細を見る

  • Potential role of tumor suppressor gene REIC/Dkk-3 as a regulator of skin tissue inflammation

    Y. Ayabe, T. Tsuruda, M. Sakaguchi, K. Kataoka

    MOLECULAR BIOLOGY OF THE CELL   26   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:AMER SOC CELL BIOLOGY  

    Web of Science

    researchmap

  • 肺腺癌におけるHER2膜貫通領域の遺伝子変異と機能解析

    山本寛斉, 阪口政清, 諏澤憲, 大塚智昭, 枝園和彦, 橋田真輔, 渡邉元嗣, 牧佑歩, 宗淳一, 岡田真典, 伊賀徳周, 三好健太郎, 杉本誠一郎, 山根正修, 大藤剛宏, 三好新一郎, 豊岡伸一

    日本肺癌学会総会号   55th ( 5 )   362 - 362   2014年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    J-GLOBAL

    researchmap

  • Anti-cancer effects of REIC/Dkk-3-encoding adenoviral vector for the treatment of non-small cell lung cancer

    Ken Suzawa, Shinichi Toyooka, Kazuhiko Shien, Norimitsu Tanaka, Masami Watanabe, Junichi Soh, Masakiyo Sakaguchi, Keitaro Matsuo, Hiromasa Yamamoto, Masashi Furukawa, Hiroaki Asano, Kazunori Tsukuda, Yasutomo Nasu, Nam-Ho Huh, Shinichiro Miyoshi, Hiromi Kumon

    CANCER RESEARCH   74 ( 19 )   2014年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2014-2879

    Web of Science

    researchmap

  • DNAX-activating Protein 10 (DAP10) Membrane Adaptor Associates with Receptor for Advanced Glycation End Products (RAGE) and Modulates the RAGE-triggered Signaling Pathway in Human Keratinocytes

    Masakiyo Sakaguchi, Hitoshi Murata, Yumi Aoyama, Toshihiko Hibino, Endy Widya Putranto, I. Made Winarsa Ruma, Yusuke Inoue, Yoshihiko Sakaguchi, Ken-ichi Yamamoto, Rie Kinoshita, Junichiro Futami, Ken Kataoka, Keiji Iwatsuki, Nam-ho Huh

    JOURNAL OF BIOLOGICAL CHEMISTRY   289 ( 34 )   23389 - 23402   2014年8月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC  

    Background: RAGE receptor plays a critical role in many inflammatory disorders. Results: Functional interaction between RAGE and DAP10 coordinately regulates S100A8/A9-mediated cell survival. Conclusion: DAP10 membrane adaptor is critically involved in RAGE-mediated survival signaling upon S100A8/A9 binding. Significance: This is the first report demonstrating that RAGE-mediated survival signaling is critically regulated by DAP10 interaction.
    The receptor for advanced glycation end products (RAGE) is involved in the pathogenesis of many inflammatory, degenerative, and hyperproliferative diseases, including cancer. Previously, we revealed mechanisms of downstream signaling from ligand-activated RAGE, which recruits TIRAP/MyD88. Here, we showed that DNAX-activating protein 10 (DAP10), a transmembrane adaptor protein, also binds to RAGE. By artificial oligomerization of RAGE alone or RAGE-DAP10, we found that RAGE-DAP10 heterodimer formation resulted in a marked enhancement of Akt activation, whereas homomultimeric interaction of RAGE led to activation of caspase 8. Normal human epidermal keratinocytes exposed to S100A8/A9, a ligand for RAGE, at a nanomolar concentration mimicked the pro-survival response of RAGE-DAP10 interaction, although at a micromolar concentration, the cells mimicked the pro-apoptotic response of RAGE-RAGE. In transformed epithelial cell lines, A431 and HaCaT, in which endogenous DAP10 was overexpressed, and S100A8/A9, even at a micromolar concentration, led to cell growth and survival due to RAGE-DAP10 interaction. Functional blocking of DAP10 in the cell lines abrogated the Akt phosphorylation from S100A8/A9-activated RAGE, eventually leading to an increase in apoptosis. Finally, S100A8/A9, RAGE, and DAP10 were overexpressed in the psoriatic epidermis. Our findings indicate that the functional interaction between RAGE and DAP10 coordinately regulates S100A8/A9-mediated survival and/or apoptotic response of keratinocytes.

    DOI: 10.1074/jbc.M114.573071

    Web of Science

    researchmap

  • Extract of Cordyceps militaris inhibits angiogenesis and suppresses tumor growth of human malignant melanoma cells

    I. Made Winarsa Ruma, Endy Widya Putranto, Eisaku Kondo, Risayo Watanabe, Ken Saito, Yusuke Inoue, Ken-Ichi Yamamoto, Susumu Nakata, Masaji Kaihata, Hitoshi Murata, Masakiyo Sakaguchi

    INTERNATIONAL JOURNAL OF ONCOLOGY   45 ( 1 )   209 - 218   2014年7月

     詳細を見る

    記述言語:英語   出版者・発行元:SPANDIDOS PUBL LTD  

    Angiogenesis is essential for tumor development and metastasis. Among several angiogenic factors, vascular endothelial growth factor receptor (VEGF) is important for tumor-derived angiogenesis and commonly overexpressed in solid tumors. Thus, many antitumor strategies targeting VEGF have been developed to inhibit cancer angiogenesis, offering insights into the successful treatment of solid cancers. However, there are a number of issues such as harmful effects on normal vascularity in clinical trials. Taking this into consideration, we employed Cordyceps militaris as an antitumor approach due to its biological safety in vivo. The herbal medicinal mushroom Cordyceps militaris has been reported to show potential anticancer properties including anti-angiogenic capacity; however, its concrete properties have yet to be fully demonstrated. In this study, we aimed to elucidate the biological role of Cordyceps militaris extract in tumor cells, especially in regulating angiogenesis and tumor growth of a human malignant melanoma cell line. We demonstrated that Cordyceps militaris extract remarkably suppressed tumor growth via induction of apoptotic cell death in culture that links to the abrogation of VEGF production in melanoma cells. This was followed by mitigation of Akt1 and GSK-3 beta activation, while p38 alpha phosphorylation levels were increased. Extract treatment in mouse model xenografted with human melanoma cells resulted in a dramatic antitumor effect with downregulation of VEGF expression. The results suggest that suppression of tumor growth by Cordyceps militaris extract is, at least, mediated by its anti-angiogenicity and apoptosis induction capacities. Cordyceps militaris extract may be a potent antitumor herbal drug for solid tumors.

    DOI: 10.3892/ijo.2014.2397

    Web of Science

    researchmap

  • Dramatic Increase in Expression of a Transgene by Insertion of Promoters Downstream of the Cargo Gene

    Masakiyo Sakaguchi, Masami Watanabe, Rie Kinoshita, Haruki Kaku, Hideo Ueki, Junichiro Futami, Hitoshi Murata, Yusuke Inoue, Shun-Ai Li, Peng Huang, Endy Widya Putranto, I. Made Winarsa Ruma, Yasutomo Nasu, Hiromi Kumon, Nam-ho Huh

    MOLECULAR BIOTECHNOLOGY   56 ( 7 )   621 - 630   2014年7月

     詳細を見る

    記述言語:英語   出版者・発行元:HUMANA PRESS INC  

    For expression of genes in mammalian cells, various vectors have been developed using promoters including CMV, EF-1 alpha, and CAG promoters and have been widely used. However, such expression vectors sometimes fail to attain sufficient expression levels depending on the nature of cargo genes and/or on host cell types. In the present study, we aimed to develop a potent promoter system that enables high expression levels of cargo genes ubiquitously in many different cell types. We found that insertion of an additional promoter downstream of a cargo gene greatly enhanced the expression levels. Among the constructs we tested, C-TSC cassette (C: CMV-RU5' located upstream; TSC: another promoter unit composed of triple tandem promoters, hTERT, SV40, and CMV, located downstream of the cDNA plus a polyadenylation signal) had the most potent capability, showing far higher efficiency than that of potent conventional vector systems. The results indicate that the new expression system is useful for production of recombinant proteins in mammalian cells and for application as a gene therapeutic measure.

    DOI: 10.1007/s12033-014-9738-0

    Web of Science

    researchmap

  • S100A11 is required for efficient plasma membrane repair and survival of invasive cancer cells

    Jyoti K. Jaiswal, Stine P. Lauritzen, Luana Scheffer, Masakiyo Sakaguchi, Jakob Bunkenborg, Sanford M. Simon, Tuula Kallunki, Marja Jaattela, Jesper Nylandsted

    NATURE COMMUNICATIONS   5   a3795-a3795   2014年5月

     詳細を見る

    記述言語:英語   出版者・発行元:NATURE PUBLISHING GROUP  

    Cell migration and invasion require increased plasma membrane dynamics and ability to navigate through dense stroma, thereby exposing plasma membrane to tremendous physical stress. Yet, it is largely unknown how metastatic cancer cells acquire an ability to cope with such stress. Here we show that S100A11, a calcium-binding protein upregulated in a variety of metastatic cancers, is essential for efficient plasma membrane repair and survival of highly motile cancer cells. Plasma membrane injury-induced entry of calcium into the cell triggers recruitment of S100A11 and Annexin A2 to the site of injury. We show that S100A11 in a complex with Annexin A2 helps reseal the plasma membrane by facilitating polymerization of cortical F-actin and excision of the damaged part of the plasma membrane. These data reveal plasma membrane repair in general and S100A11 and Annexin A2 in particular as new targets for the therapy of metastatic cancers.

    DOI: 10.1038/ncomms4795

    Web of Science

    researchmap

  • 超高効率遺伝子発現システムを用いた次世代REIC遺伝子治療の開発

    渡部 昌実, 阪口 政清, 賀来 春紀, 佐々木 克己, 高本 篤, 有吉 勇一, 杉本 盛人, 江原 伸, 渡辺 豊彦, 許 南浩, 那須 保友, 公文 裕巳

    日本泌尿器科学会総会   102回   621 - 621   2014年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本泌尿器科学会総会事務局  

    researchmap

  • A novel gene expression system strongly enhances the anticancer effects of a REIC/Dkk-3-encoding adenoviral vector

    Masami Watanabe, Masakiyo Sakaguchi, Rie Kinoshita, Haruki Kaku, Yuichi Ariyoshi, Hideo Ueki, Ryuta Tanimoto, Shin Ebara, Kazuhiko Ochiai, Junichiro Futami, Shun-Ai Li, Peng Huang, Yasutomo Nasu, Nam-Ho Huh, Hiromi Kumon

    ONCOLOGY REPORTS   31 ( 3 )   1089 - 1095   2014年3月

     詳細を見る

    記述言語:英語   出版者・発行元:SPANDIDOS PUBL LTD  

    Gene expression systems with various promoters, including the cytomegalovirus (CMV) promoter, have been developed to increase the gene expression in a variety of normal and cancer cells. In particular, in the clinical trials of cancer gene therapy, a more efficient and robust gene expression system is required to achieve sufficient therapeutic outcomes. By inserting the triple translational enhancer sequences of human telomerase reverse transcriptase (hTERT), Simian virus 40 (SV40) and CMV downstream of the sequence of the BGH polyA, we were able to develop a novel gene expression system that significantly enhances the expression of the genes of interest. We termed this novel gene expression cassette the super gene expression (SGE) system, and herein verify the utility of the SGE cassette for a replication-deficient adenoviral vector. We newly developed an adenoviral vector expressing the tumor suppressor, reduced expression in immortalized cells (REIC)/Dickkopf-3 (Dkk-3), based on the CMV promoter-driven SGE system (Ad-SGE-REIC) and compared the therapeutic utility of Ad-SGE-REIC with that of the conventional adenoviral vectors (Ad-CMV-REIC or Ad-CAG-REIC). The results demonstrated that the CMV promoter-SGE system allows for more potent gene expression, and that the Ad-SGE-REIC is superior to conventional adenoviral systems in terms of the REIC protein expression and therapeutic effects. Since the SGE cassette can be applied for the expression of various therapeutic genes using various vector systems, we believe that this novel system will become an innovative tool in the field of gene expression and gene therapy.

    DOI: 10.3892/or.2013.2958

    Web of Science

    researchmap

  • Coxsackie and adenovirus receptor is a critical regulator for the survival and growth of oral squamous carcinoma cells

    K. Saito, M. Sakaguchi, H. Iioka, M. Matsui, H. Nakanishi, N. H. Huh, E. Kondo

    ONCOGENE   33 ( 10 )   1274 - 1286   2014年3月

     詳細を見る

    記述言語:英語   出版者・発行元:NATURE PUBLISHING GROUP  

    Coxsackie and adenovirus receptor (CAR) is essential for adenovirus infection to target cells, and its constitutive expression in various cancerous and normal tissues has been reported. Recently, the biological role of CAR in human cancers of several different origins has been investigated with respect to tumor progression, metastasis and tumorigenesis. However, its biological function in tumor cells remains controversial. Here we report the critical role of CAR in growth regulation of oral squamous cell carcinomas (SCCs) in vitro and in vivo via the specific interaction with Rho-associated protein kinase (ROCK). Loss of endogenous CAR expression by knockdown using specific small interfering RNA (siRNA) against CAR facilitates growth suppression of SCC cells due to cell dissociation, followed by apoptosis. The consequent morphological reaction was reminiscent of anoikis, rather than epithelial-mesenchymal transition, and the dissociation of oral SCC cells was triggered not by lack of contact with extracellular matrix, but by loss of cell-to-cell contact caused by abnormal translocation of E-cadherin from surface membrane to cytoplasm. Immunoprecipitation assays of the CAR-transfected oral SCC cell line, HSC-2, with or without ROCK inhibitor (Y-27632) revealed that CAR directly associates with ROCK! and ROCKII, which results in inhibition of ROCK activity and contributes to maintenance of cell-to-cell adhesion for their growth and survival. Based on these findings, in vivo behavior of CAR-downregulated HSC-2 cells from siRNA knockdown was compared with that of normally CAR-expressing cells in intraperitoneally xenografted mouse models. The mice engrafted with CAR siRNA-pretreated HSC-2 cells showed poor formation of metastatic foci in contrast to those implanted with the control siRNA-pretreated cells. Thus, CAR substantially has an impact on growth and survival of oral SCC cells as a negative regulator of ROCK in vitro and in vivo.

    DOI: 10.1038/onc.2013.66

    Web of Science

    researchmap

  • Anti-Cancer Effects of REIC/Dkk-3-encoding Adenoviral Vector for the Treatment of Non-small Cell Lung Cancer

    Kazuhiko Shien, Norimitsu Tanaka, Masami Watanabe, Junichi Soh, Masakiyo Sakaguchi, Keitaro Matsuo, Hiromasa Yamamoto, Masashi Furukawa, Hiroaki Asano, Kazunori Tsukuda, Yasutomo Nasu, Nam-Ho Huh, Shinichiro Miyoshi, Hiromi Kumon, Shinichi Toyooka

    PLOS ONE   9 ( 2 )   e87900-e87900   2014年2月

     詳細を見る

    記述言語:英語   出版者・発行元:PUBLIC LIBRARY SCIENCE  

    Objectives: REIC/Dkk-3 is down-regulated in a broad range of human cancer cells and is considered to function as a tumor suppressor. We previously reported that REIC/Dkk-3-expressing adenovirus vector (Ad-REIC) induced endoplasmic reticulum (ER) stress and cancer-specific apoptosis in human prostate cancer. In this study, we examined the therapeutic impact of Ad-REIC on non-small cell lung cancer (NSCLC).
    Materials and Methods: We examined the anti-tumor effect of Ad-REIC on 25 NSCLC cell lines in vitro and A549 cells in vivo. Two of these cell lines were artificially established as EGFR-tyrosine kinase inhibitor (TKI) resistant sublines.
    Results: Ad-REIC-treatment inhibited the cell viability by 40% or more in 13 (52%) of the 25 cell lines at multiplicity of infection (MOI) of 20 (20 MOI). These cell lines were regarded as being highly sensitive cells. The cell viability of a nonmalignant immortalized cell line, OUMS-24, was not inhibited at 200 MOI of Ad-REIC. The effects of Ad-REIC on EGFR-TKI resistant sublines were equivalent to those in the parental cell lines. Here, we demonstrated that Ad-REIC treatment activated c-Jun N-terminal kinase (JNK) in NSCLC cell lines, indicating the induction of ER stress with GRP78/BiP (GRP78) up-regulation and resulting in apoptosis. A single intratumoral injection of Ad-REIC significantly inhibited the tumorigenic growth of A549 cells in vivo. As predictive factors of sensitivity for Ad-REIC treatment in NSCLC, we examined the expression status of GRP78 and coxsackievirus and adenovirus receptor (CAR). We found that the combination of the GRP78 and CAR expressional statuses may be used as a predictive factor for Ad-REIC sensitivity in NSCLC cells.
    Conclusion: Ad-REIC induced JNK activation and subsequent apoptosis in NSCLC cells. Our study indicated that Ad-REIC has therapeutic potential against NSCLC and that the expression statuses of GRP78 and CAR may predict a potential therapeutic benefit of Ad-REIC.

    DOI: 10.1371/journal.pone.0087900

    Web of Science

    researchmap

  • Preclinical Evaluation of MicroRNA-34b/c Delivery for Malignant Pleural Mesothelioma

    Tsuyoshi Ueno, Shinichi Toyooka, Takuya Fukazawa, Takafumi Kubo, Junichi Soh, Hiroaki Asano, Takayuki Muraoka, Norimitsu Tanaka, Yuho Maki, Kazuhiko Shien, Masashi Furukawa, Masakiyo Sakaguchi, Hiromasa Yamamoto, Kazunori Tsukuda, Shinichiro Miyoshi

    ACTA MEDICA OKAYAMA   68 ( 1 )   23 - 26   2014年2月

     詳細を見る

    記述言語:英語   出版者・発行元:OKAYAMA UNIV MED SCHOOL  

    The microRNA-34s (miR-34s) have p53 response elements in their 5'-flanking regions and demonstrate tumor-suppressive functions. In malignant pleural mesothelioma (MPM), we previously reported that expression of miR-34b and miR-34c (miR-34b/c) was frequently downregulated by methylation in MPM cell lines and primary tumors. The forced overexpression of miR-34b/c showed significant antitumor effects with the induction of apoptosis in MPM cells. In this study, we examined the in vivo antitumor effects of miR-34b/c using adenovirus vector on MPM. We subcutaneously transplanted NCI-H290, a human MPM cell line, into BALB/C mice and injected adenovirus vector expressing miR-34b/c, luciferase driven by the cytomegalovirus promoter (Ad-miR-34b/c or Ad-Luc), or PBS control into tumors over 5mm in diameter. A statistically significant growth inhibition of the tumor volume was observed in the Ad-miR-34b/c group from day 6 onward compared to the Ad-Luc group. The inhibition rate of Ad-miR-34b/c, compared to the tumor volume treated with Ad-Luc, was 58.6% on day 10 and 54.7% on day13. Our results indicate that adenovirus-mediated miR-34b/c gene therapy could be useful for the clinical treatment of MPM.

    DOI: 10.18926/AMO/52140

    Web of Science

    researchmap

  • Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas

    Hiromasa Yamamoto, Koichiro Higasa, Masakiyo Sakaguchi, Kazuhiko Shien, Junichi Soh, Koichi Ichimura, Masashi Furukawa, Shinsuke Hashida, Kazunori Tsukuda, Nagio Takigawa, Keitaro Matsuo, Katsuyuki Kiura, Shinichiro Miyoshi, Fumihiko Matsuda, Shinichi Toyooka

    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE   106 ( 1 )   djt338-djt338   2014年1月

     詳細を見る

    記述言語:英語   出版者・発行元:OXFORD UNIV PRESS INC  

    We encountered a family of Japanese descent in which multiple members developed lung cancer. Using whole-exome sequencing, we identified a novel germline mutation in the transmembrane domain of the human epidermal growth factor receptor 2 (HER2) gene (G660D). A novel somatic mutation (V659E) was also detected in the transmembrane domain of HER2 in one of 253 sporadic lung adenocarcinomas. Because the transmembrane domain of HER2 is considered to be responsible for the dimerization and subsequent activation of the HER family and downstream signaling pathways, we performed functional analyses of these HER2 mutants. Mutant HER2 G660D and V659E proteins were more stable than wild-type protein. Both the G660D and V659E mutants activated Akt. In addition, they activated p38, which is thought to promote cell proliferation in lung adenocarcinoma. Our findings strongly suggest that mutations in the transmembrane domain of HER2 may be oncogenic, causing hereditary and sporadic lung adenocarcinomas.

    DOI: 10.1093/jnci/djt338

    Web of Science

    researchmap

  • Draft genome sequence of Clostridium botulinum type B strain Osaka05, isolated from an infant patient with botulism in Japan

    Yoshihiko Sakaguchi, Koji Hosomi, Jumpei Uchiyama, Yoshitoshi Ogura, Kaoru Umeda, Masakiyo Sakaguchi, Tomoko Kohda, Masafumi Mukamoto, Naoaki Misawa, Shigenobu Matsuzaki, Tetsuya Hayashi, Shunji Kozaki

    Genome Announcements   2 ( 1 )   e01010-e01013   2014年

     詳細を見る

    © 2014 Sakaguchi et al. Clostridium botulinum strain Osaka05, which has been isolated from an infant patient with botulism in Japan, is the first strain producing botulinum neurotoxin subtype B6. Here, we report the draft genome sequence of C. botulinum Osaka05.

    DOI: 10.1128/genomeA.e01010-13

    Scopus

    researchmap

  • Inhibition of RAGE signaling through the intracellular delivery of inhibitor peptides by PEI cationization

    Endy Widya Putranto, Hitoshi Murata, Ken-Ichi Yamamoto, Ken Kataoka, Hidenori Yamada, Jun-Ichiro Futami, Masakiyo Sakaguchi, Nam-Ho Huh

    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE   32 ( 4 )   938 - 944   2013年10月

     詳細を見る

    記述言語:英語   出版者・発行元:SPANDIDOS PUBL LTD  

    The receptor for advanced glycation end products (RAGE) is a multi-ligand cell surface receptor and a member of the immunoglobulin superfamily. RAGE is involved in a wide range of inflammatory, degenerative and hyper-proliferative disorders which span over different organs by engaging diverse ligands, including advanced glycation end products, S100 family proteins, high-mobility group protein B1 (HMGB1) and amyloid beta. We previously demonstrated that the cytoplasmic domain of RAGE is phosphorylated upon the binding of ligands, enabling the recruitment of two distinct pairs of adaptor proteins, Toll-interleukin 1 receptor domain-containing adaptor protein (TIRAP) and myeloid differentiation protein 88 (MyD88). This engagement allows the activation of downstream effector molecules, and thereby mediates a wide variety of cellular processes, such as inflammatory responses, apoptotic cell death, migration and cell growth. Therefore, inhibition of the binding of TIRAP to RAGE may abrogate intracellular signaling from ligand-activated RAGE. In the present study, we developed inhibitor peptides for RAGE signaling (RAGE-I) by mimicking the phosphorylatable cytosolic domain of RAGE. RAGE-I was efficiently delivered into the cells by polyethylenimine (PEI) cationization. We demonstrated that RAGE-I specifically bound to TIRAP and abrogated the activation of Cdc42 induced by ligand-activated RAGE. Furthermore, we were able to reduce neuronal cell death induced by an excess amount of S100B and to inhibit the migration and invasion of glioma cells in vitro. Our results indicate that RAGE-I provides a powerful tool for therapeutics to block RAGE-mediated multiple signaling.

    DOI: 10.3892/ijmm.2013.1467

    Web of Science

    researchmap

  • SARM1 and TRAF6 bind to and stabilize PINK1 on depolarized mitochondria

    Hitoshi Murata, Masakiyo Sakaguchi, Ken Kataoka, Nam-ho Huh

    MOLECULAR BIOLOGY OF THE CELL   24 ( 18 )   2772 - 2784   2013年9月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER SOC CELL BIOLOGY  

    Mutations in PTEN-induced putative kinase 1 (PINK1) or parkin cause autosomal recessive forms of Parkinson's disease. Recent work suggests that loss of mitochondrial membrane potential stabilizes PINK1 and that accumulated PINK1 recruits parkin from the cytoplasm to mitochondria for elimination of depolarized mitochondria, which is known as mitophagy. In this study, we find that PINK1 forms a complex with sterile alpha and TIR motif containing 1 (SARM1) and tumor necrosis factor receptor-associated factor 6 (TRAF6), which is important for import of PINK1 in the outer membrane and stabilization of PINK1 on depolarized mitochondria. SARM1, which is known to be an adaptor protein for Toll-like receptor, binds to PINK1 and promotes TRAF6-mediated lysine 63 chain ubiquitination of PINK1 at lysine 433. Down-regulation of SARM1 and TRAF6 abrogates accumulation of PINK1, followed by recruitment of parkin to damaged mitochondria. Some pathogenic mutations of PINK1 reduce the complex formation and ubiquitination. These results indicate that association of PINK1 with SARM1 and TRAF6 is an important step for mitophagy.

    DOI: 10.1091/mbc.E13-01-0016

    Web of Science

    researchmap

  • Tumor Necrosis Factor-alpha Down-regulates a Tumor Suppressor Gene, REIC/Dkk-3, in Normal Skin Keratinocytes

    K. Kataoka, M. Sakaguchi, H. Murata, N. Hashikawa, N. Huh

    IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL   49   S43 - S43   2013年6月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:SPRINGER  

    Web of Science

    researchmap

  • DOCK7 is a critical regulator of the RAGE-Cdc42 signaling axis that induces formation of dendritic pseudopodia in human cancer cells

    Ken-Ichi Yamamoto, Hitoshi Murata, Endy Widya Putranto, Ken Kataoka, Akira Motoyama, Toshihiko Hibino, Yusuke Inoue, Masakiyo Sakaguchi, Nam-Ho Huh

    ONCOLOGY REPORTS   29 ( 3 )   1073 - 1079   2013年3月

     詳細を見る

    記述言語:英語   出版者・発行元:SPANDIDOS PUBL LTD  

    Cellular migration is a fundamental process linked to cancer metastasis. Growing evidence indicates that the receptor for advanced glycation end products (RAGE) plays a pivotal role in this process. With regard to downstream signal transducers of RAGE, diaphanous-1 and activated small guanine nucleotide triphosphatases, Rac1 and Cdc42, have been identified. To obtain precise insight into the direct downstream signaling mechanism of RAGE, we screened for proteins interacting with the cytoplasmic domain of RAGE employing an immunoprecipitation-liquid chromatography coupled with an electrospray tandem mass spectrometry system. In the present study, we found that the cytoplasmic domain of RAGE interacted with an atypical DOCK180-related guanine nucleotide exchange factor, dedicator of cytokinesis protein 7 (DOCK7). DOCK7 bound to the RAGE cytoplasmic domain and transduced a signal to Cdc42, resulting in the formation of abundant highly branched filopodia-like protrusions, dendritic pseudopodia. Blocking of the function of DOCK7 greatly abrogated the formation of dendritic pseudopodia and suppressed cellular migration. These results indicate that DOCK7 functions as an essential and downstream regulator of RAGE-mediated cellular migration through the formation of dendritic pseudopodia.

    DOI: 10.3892/or.2012.2191

    Web of Science

    researchmap

  • S100A9 is a novel ligand of EMMPRIN that promotes melanoma metastasis

    Toshihiko Hibino, Masakiyo Sakaguchi, Shoko Miyamoto, Mami Yamamoto, Akira Motoyama, Junichi Hosoi, Tadashi Shimokata, Tomonobu Ito, Ryoji Tsuboi, Nam-Ho Huh

    Cancer Research   73 ( 1 )   172 - 183   2013年1月

     詳細を見る

    記述言語:英語  

    The calcium-binding proteins S100A8 and S100A9 can dimerize to form calprotectin, the release of which during tissue damage has been implicated in inflammation and metastasis. However, receptor(s) mediating the physiologic and pathophysiologic effects of this damage-associated "danger signal" are uncertain. In this study, searching for candidate calprotectin receptors by affinity isolation-mass spectrometry, we identified the cell surface glycoprotein EMMPRIN/BASIGIN (CD147/BSG). EMMPRIN specifically bound to S100A9 but not S100A8. Induction of cytokines and matrix metalloproteases (MMP) by S100A9 was markedly downregulated in melanoma cells by attenuation of EMMPRIN. We found that EMMPRIN signaling used the TNF receptor-associated factor TRAF2 distinct from the known S100-binding signaling pathway mediated by RAGE (AGER). S100A9 strongly promoted migration when EMMPRIN was highly expressed, independent of RAGE, whereas EMMPRIN blockade suppressed migration by S100A9. Immunohistologic analysis of melanomas revealed that EMMPRIN was expressed at both the invasive edge of lesions and the adjacent epidermis, where S100A9 was also strongly expressed. In epidermal-specific transgenic mice, tail vein-injected melanoma accumulated in skin expressing S100A9 but not S100A8. Together, our results establish EMMPRIN as a receptor for S100A9 and suggest the therapeutic use in targeting S100A9-EMMPRIN interactions. ©2012 AACR.

    DOI: 10.1158/0008-5472.CAN-11-3843

    Scopus

    PubMed

    researchmap

  • TRAF6 ubiquitinates and stabilizes PINK1 on the outer membrane of depolarized mitochondria through interaction with SARM1

    H. Murata, M. Sakaguchi, K. Kataoka, N-H. Huh

    MOLECULAR BIOLOGY OF THE CELL   24   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:AMER SOC CELL BIOLOGY  

    Web of Science

    researchmap

  • Identification of RAGE-coupled membran adaptor that modulates RAGE-triggered signaling pathway

    M. Sakaguchi, H. Murata, T. Hibino, Y. Aoyama, K. Iwatsuki, N-H. Huh

    MOLECULAR BIOLOGY OF THE CELL   24   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:AMER SOC CELL BIOLOGY  

    Web of Science

    researchmap

  • Preclinical biodistribution and safety study of reduced expression in immortalized cells/Dickkopf-3-encoding adenoviral vector for prostate cancer gene therapy

    Morito Sugimoto, Masami Watanabe, Haruki Kaku, Shun-Ai Li, Hirofumi Noguchi, Hideo Ueki, Masakiyo Sakaguchi, Nam-Ho Huh, Yasutomo Nasu, Hiromi Kumon

    ONCOLOGY REPORTS   28 ( 5 )   1645 - 1652   2012年11月

     詳細を見る

    記述言語:英語   出版者・発行元:SPANDIDOS PUBL LTD  

    The biodistribution and safety of adenoviral vectors encoding the human REIC/Dkk-3 tumor suppressor gene (Ad-REIC) were examined in this preclinical study for in situ prostate cancer gene therapy. First, the in vitro apoptotic effects of Ad-REIC in normal and cancer cells derived from the prostate and liver were examined. Significant apoptotic effects were observed at 100 MOI (multiplicity of infection) in prostate cancer cells (LNCaP, PC3) and hepatoma cells (HEP3B and HEPG2); however, no effects were seen in normal cells. To analyze the safety of intraprostatic Ad-REIC administration, the biodistribution and histology after Ad-REIC injection were evaluated in various organs of normal male C57BL6 mice. In a supporting study, vector dissemination following intravenous injection of Ad-REIC into tail veins was determined. To evaluate whether Ad-REIC was present in the collected tissue specimens, human REIC gene detection was performed using DNA-PCR. Intraprostatic treatment administered at lower doses showed vector biodistribution into the colon, urinary bladder and prostate. At higher doses, vector dissemination was observed in tissues more distant from the prostate, including the lung, thymus, heart, liver and adrenal gland. After intravenous injection a: Ad-REIC, dissemination was observed in the liver and spleen. These results indicate that the biodistribution of Ad-REIC is determined by the dose and route of administration. Although acute inflammatory effects were observed in the prostate after intraprostatic administration at higher doses, no abnormal histological findings were noted in the other tissues, including those of intravenously treated mice. Regarding the safety of Ad-REIC administration, no deaths and no signs of toxicity or unusual behavior were observed in the mice in any treatment group. Based on these preclinical experiments, adenovirus-mediated in situ REIC/Dkk-3 gene therapy is considered to be safe for use as a treatment for human prostate cancer.

    DOI: 10.3892/or.2012.2001

    Web of Science

    researchmap

  • REIC/Dkk-3-encoding adenoviral vector as a potentially effective therapeutic agent for bladder cancer

    Takeshi Hirata, Masami Watanabe, Haruki Kaku, Yasuyuki Kobayashi, Hiroshi Yamada, Masakiyo Sakaguchi, Kohji Takei, Nam-Ho Huh, Yasutomo Nasu, Hiromi Kumon

    INTERNATIONAL JOURNAL OF ONCOLOGY   41 ( 2 )   559 - 564   2012年8月

     詳細を見る

    記述言語:英語   出版者・発行元:SPANDIDOS PUBL LTD  

    Bladder cancer is one of the most common urogenital malignancies. The intravesical instillation of anticancer agents is an attractive strategy to treat a superficial lesion or floating/disseminated cancer cells after transurethral operation. An adenovirus carrying REIC/Dkk-3, a tumor suppressor gene (Ad-REIC), exhibits cancer-specific apoptotic effects in various types of cancer cells. The aim of the present study was to examine the potential of Ad-REIC as a therapeutic agent for bladder cancer. KK47 and RT4 human bladder cancer cells were sensitive to the Ad-REIC treatment for apoptosis induction, but some human bladder cancer cell lines (T24, J82 and TccSup) were resistant. Significant cell growth inhibition was observed when these resistant cancer cell lines were treated with Ad-REIC in a condition of floating cells, which is clinically observed after transurethral operation and becomes a cause of intravesical cancer dissemination. The therapeutic potential of Ad-REIC for the treatment of multidrug-resistant bladder cancer was investigated. The adriamycin-resistant KK47 bladder cancer cells (KK47/ADM), which also present multidrug resistance, showed induction of significant apoptosis following Ad-REIC treatment. The Ad-REIC treatment induced downregulation of P-glycoprotein in KK47/ADM cells and restored the sensitivity to doxorubicin (adriamycin). Ad-REIC suppressed P-glycoprotein expression in a c-Jun-NH2-kinase (JNK)-dependent manner. Therefore, the current study indicated two therapeutic aspects of the Ad-REIC agent against human bladder cancer cells, as an apoptosis inducer/cell growth inhibitor and as a sensitizer of chemotherapeutic agents in multidrug-resistant cancer cells. The intravesical instillation of Ad-REIC could be an attractive therapeutic method in human bladder cancer where the treatment of superficial lesions and floating/disseminated or multidrug-resistant cancer cells is necessary.

    DOI: 10.3892/ijo.2012.1503

    Web of Science

    researchmap

  • S100A8およびS100A9タンパク質の新規受容体の探索とそのがん進展における役割(Identification of novel receptors for pro-inflammatory S100A8/A9 proteins and their potential roles in tumor progression)

    阪口 政清, 日比野 利彦, 村田 等, 井上 裕介, 山本 健一, 片岡 健, 許 南浩

    日本癌学会総会記事   71回   59 - 59   2012年8月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • Expression pattern of REIC/Dkk-3 in mouse squamous epithelia

    K. Kataoka, G. Du, N. Maehara, H. Murata, M. Sakaguchi, N. Huh

    CLINICAL AND EXPERIMENTAL DERMATOLOGY   37 ( 4 )   428 - 431   2012年6月

     詳細を見る

    記述言語:英語   出版者・発行元:WILEY-BLACKWELL  

    The REIC/Dkk (reduced expression in immortalized cells/Dickkopf-3) gene was originally identified as a tumour-suppressor gene with reduced expression in immortalized cells, cancer-cell lines and tumour tissues. Of the four members of the Dkk family, the REIC/Dkk-3 protein is unique in terms of DNA sequence, expression profiles and biological functions. In this study, we investigated and compared the expression patterns of the REIC/Dkk-3 protein in mouse squamous epithelia. Expression of REIC/Dkk-3 in the back skin was localized to the upper layer of the interfollicular epidermis, and the inner root sheath of hair follicles. Expression of REIC/Dkk-3 was detected in the ear skin, oral mucosa, tongue, oesophagus, uterine cervix, footpad and tail skin, but not in the cornea. Interestingly, expression was localized to the upper layers of these epithelial tissues. The physiological function of REIC/Dkk-3 is still unclear, but our detailed observation highlight its unique expression pattern in squamous epithelia.

    DOI: 10.1111/j.1365-2230.2011.04301.x

    Web of Science

    researchmap

  • S100A7 promotes the migration and invasion of osteosarcoma cells via the receptor for advanced glycation end products

    Ken Kataoka, Tomoyuki Ono, Hitoshi Murata, Mika Morishita, Ken-Ichi Yamamoto, Masakiyo Sakaguchi, Nam-Ho Huh

    ONCOLOGY LETTERS   3 ( 5 )   1149 - 1153   2012年5月

     詳細を見る

    記述言語:英語   出版者・発行元:SPANDIDOS PUBL LTD  

    Osteosarcoma is the most common malignant tumor of bone in childhood and adolescence. Despite intensive research for new therapies, the outcome in patients with metastasis remains extremely poor. S100 proteins are involved in the proliferation, cell cycle progression and metastasis of numerous malignant tumors, including osteosarcoma. In the present study, we identified S100A7 as a candidate to promote the migration of osteosarcoma cells. S100A7 promoted the migration and invasion of osteosarcoma cells as assayed in vitro. An in vitro pull-down assay revealed the binding of the recombinant S100A7 protein with its putative receptor, the receptor for advanced glycation end products (RAGE). The downregulation of RAGE by a specific siRNA markedly suppressed the migration and invasion of osteosarcoma cells. Furthermore, the matrix metalloproteinase activity of osteosarcoma cells was enhanced by S100A7 and suppressed by the downregulation of RAGE. These results indicate that S100A7 promotes the migration and invasion of osteosarcoma cells through RAGE. The S100A7-RAGE axis may thus be a new target for preventing the invasion and/or metastasis of osteosarcoma.

    DOI: 10.3892/ol.2012.612

    Web of Science

    researchmap

  • PS-109-6 REIC/Dickkopf-3 shows anti-proliferative effect for non-small cell lung cancer cells with negative phosphorylated-Akt status

    Tanaka Norimitsu, Toyooka Shinichi, Watanabe Masami, Soh Junichi, Sakaguchi Masakiyo, Tsukuda Kazunori, Asano Hiroaki, Shien Kazuhiko, Furukawa Masashi, Maki Yuho, Muraoka Takayuki, Huh Nam-ho, Nasu Yasutomo, Kumon Hiromi, Miyoshi Shinichiro

    日本外科学会雑誌   113 ( 2 )   710 - 710   2012年3月

     詳細を見る

    記述言語:英語   出版者・発行元:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • Partial sensitization of human bladder cancer cells to a gene-therapeutic adenovirus carrying REIC/Dkk-3 by downregulation of BRPK/PINK1

    Yu Jin, Hitoshi Murata, Masakiyo Sakaguchi, Ken Kataoka, Masami Watanabe, Yasutomo Nasu, Hiromi Kumon, Nam-Ho Huh

    ONCOLOGY REPORTS   27 ( 3 )   695 - 699   2012年3月

     詳細を見る

    記述言語:英語   出版者・発行元:SPANDIDOS PUBL LTD  

    REIC/Dkk-3 is a tumor suppressor gene that was first identified as a gene downregulated in association with immortalization of normal human fibroblasts. We have demonstrated that an adenovirus carrying REIC/Dkk-3 (Ad-REIC) showed a tumor-specific killing effect on a wide range of cancers. However, some human cancers, bladder cancers in particular, are resistant to Ad-REIC. In this study, we investigated the combination effect of downregulation of BRPK/PINK1 (PINK1) and Ad-REIC on bladder cancer cells. Five bladder cancer cell lines among six cell lines examined were resistant to Ad-REIC. Among the cell lines, the resistance of two cell lines was probably due to low infection efficiency of the adenovirus. PINK1-specific siRNA remarkably downregulated Bcl-x(L) and TRAP1 proteins and upregulated BAX protein expression. Finally, downregulation of PINK1 partially sensitized the other three cell lines that were resistant to Ad-REIC. This sensitization was associated with increasing production of reactive oxygen species (ROS). These results indicate that PINK1 is one of the key molecules for the mitochondrial protection system and that PINK1 can be a new target molecule to sensitize bladder cancer cells that are resistant to Ad-REIC.

    DOI: 10.3892/or.2011.1543

    Web of Science

    researchmap

  • Preclinical Safety and Efficacy of in Situ REIC/Dkk-3 Gene Therapy for Prostate Cancer

    Keiichiro Kawauchi, Masami Watanabe, Haruki Kaku, Peng Huang, Kasumi Sasaki, Masakiyo Sakaguchi, Kazuhiko Ochiai, Nam-ho Huh, Yasutomo Nasu, Hiromi Kumon

    ACTA MEDICA OKAYAMA   66 ( 1 )   7 - 16   2012年2月

     詳細を見る

    記述言語:英語   出版者・発行元:OKAYAMA UNIV MED SCHOOL  

    The preclinical safety and therapeutic efficacy of adenoviral vectors that express the REIC/Dkk-3 tumor suppressor gene (Ad-REIC) was examined for use in prostate cancer gene therapy. The Ad-human (h) and mouse (m) REIC were previously demonstrated to induce strong anti-cancer effects in vitro and in vivo, and we herein report the results of two in vivo studies. First, intra-tumor Ad-hREIC administration was examined for toxicity and therapeutic effects in a subcutaneous tumor model using the PC3 prostate cancer cell line. Second, intra-prostatic Ad-mREIC administration was tested for toxicity in normal mice. The whole-body and spleen weights, hematological and serum chemistry parameters, and histological evaluation of tissues from throughout the body were analyzed. Both experiments indicated that there was no significant difference in the examined parameters between the Ad-REIC-treated group and the control (PBS- or Ad-LacZ-treated) group. In the in vitro analysis using PC3 cells, a significant apoptotic effect was observed after Ad-hREIC treatment. Confirming this observation, the robust anti-tumor efficacy of Ad-hREIC was demonstrated in the in vivo subcutaneous prostate cancer model. Based on the results of these preclinical experiments, we consider the adenovirus-mediated REIC/Dkk-3 in situ gene therapy to be safe and useful for the clinical treatment of prostate cancer.

    DOI: 10.18926/AMO/48076

    Web of Science

    researchmap

  • TRAF6とSARM1によるPINK1のユビキチン化はマイトファジーの誘導に必須である

    村田等, 阪口政清, 片岡健, HUH Nam‐ho

    日本分子生物学会年会プログラム・要旨集(Web)   35th   4P-0506 (WEB ONLY)   2012年

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • C型ボツリヌス毒素変換ファージのゲノム情報を基盤とした偽溶原性メカニズムの解析

    阪口義彦, OLIVA Maria A, MARTIN‐GALIANO Antonio J, ANDREU Jose M, 阪口政清, 内山淳平, 小椋義俊, 山本由弥子, 鈴木智典, 織田華絵, 津田千秋, 松崎茂展, 林哲也, 小熊惠二

    日本分子生物学会年会プログラム・要旨集(Web)   35th   WEB ONLY 3W3III-2   2012年

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 多機能受容体RAGEの下流信号伝達機構の解明(TIRAP is a critical transducer of RAGE-mediated inflammatory signaling)

    阪口 政清, 村田 等, 山本 健一, 阪口 義彦, 本山 晃, 日比野 利彦, 片岡 健, 許 南浩

    日本癌学会総会記事   70回   225 - 225   2011年9月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • PINK1発現抑制によるミトコンドリア機能不全はREIC/Dkk-3のアポトーシス誘導効果を増強する(Mitochondrial malfunction by PINK1 knockdown augments apoptosis induced by adenovirus carrying REIC/Dkk-3)

    村田 等, 金 玉, 阪口 政清, 片岡 健, 許 南浩

    日本癌学会総会記事   70回   51 - 51   2011年9月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • S100A7による骨肉腫細胞の遊走・浸潤の多機能受容体RAGEを介した制御機構(Promotion of migration and invasion of osteosarcoma cells by S100A7 through RAGE)

    片岡 健, 阪口 政清, 小野 智之, 森下 美加, 山本 健一, 村田 等, 許 南浩

    日本癌学会総会記事   70回   79 - 79   2011年9月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • Tumor suppressor REIC/Dkk-3 interacts with the dynein light chain, Tctex-1

    Kazuhiko Ochiai, Masami Watanabe, Hideo Ueki, Peng Huang, Yasuyuki Fujii, Yasutomo Nasu, Hirofumi Noguchi, Takeshi Hirata, Masakiyo Sakaguchi, Nam-ho Huh, Yuji Kashiwakura, Haruki Kaku, Hiromi Kumon

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   412 ( 2 )   391 - 395   2011年8月

     詳細を見る

    記述言語:英語   出版者・発行元:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    REIC/Dkk-3 is a member of the Dickkopf family proteins known as Wnt-antagonists, and REIC/Dkk-3 expression is downregulated in a broad range of cancer types. REIC/Dkk-3 acts as a tumor suppressor in multiple cancer cell lines by inducing apoptosis through endoplasmic reticulum (ER) stress signaling. However, the intracellular interaction partners of REIC/Dkk-3 have not been fully elucidated. By employing yeast two-hybrid screening, we identified the human dynein light chain, Tctex-1, as a novel interaction partner of REIC/Dkk-3. We further disclosed that the interaction involves the 136-157 amino acid region of REIC/Dkk-3 by using the mammalian two-hybrid system. Interestingly, this binding region of REIC/Dkk-3 with Tctex-1 contains an amino acid sequence motif [-(E) under bar -X-(G) under bar-(R) under bar-(R) under bar -X-(H) under bar-] which was previously reported as the Tctex-1 binding domain of dynein intermediate chain (DIC). Immunocytochemistry demonstrated that both REIC/Dkk-3 and Tctex-1 were localized around the ER of human fibroblasts, and the similar distribution pattern of the proteins suggests that their interaction occurs around the ER. This is the first study showing the interaction of a Dickkopf family protein with a dynein motor complex protein. The link between REIC/Dkk-3 and Tctex-1 may be of significance for understanding the molecular functions of the proteins in ER stress signaling and intracellular dynein motor dynamics, respectively. (C) 2011 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.bbrc.2011.07.109

    Web of Science

    researchmap

  • Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma

    Takafumi Kubo, Shinichi Toyooka, Kazunori Tsukuda, Masakiyo Sakaguchi, Takuya Fukazawa, Junichi Soh, Hiroaki Asano, Tsuyoshi Ueno, Takayuki Muraoka, Hiromasa Yamamoto, Yasutomo Nasu, Takumi Kishimoto, Harvey I. Pass, Hideki Matsui, Nam-ho Huh, Shinichiro Miyoshi

    CLINICAL CANCER RESEARCH   17 ( 15 )   4965 - 4974   2011年8月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    Purpose: Malignant pleural mesothelioma (MPM) is an aggressive tumor with a dismal prognosis. Unlike other malignancies, TP53 mutations are rare in MPM. Recent studies have showed that altered expression of microRNA (miRNA) is observed in human malignant tumors. In this study, we investigated the alterations of miR-34s, a direct transcriptional target of TP53, and the role of miR-34s on the pathogenesis of MPM.
    Experimental Design: Aberrant methylation and expression of miR-34s were examined in MPM cell lines and tumors. miR-34b/c was transfected to MPM cells to estimate the protein expression, cell proliferation, invasion, and cell cycle.
    Results: Aberrant methylation was present in 2 (33.3%) of 6 MPM cell lines and 13 (27.7%) of 47 tumors in miR-34a and in all 6 MPM cell lines (100%) and 40 (85.1%) of 47 tumors in miR-34b/c. Expression of miR-34a and 34b/c in all methylated cell lines was reduced and restored with 5-aza-2&apos;-deoxycytidine treatment. Because epigenetic silencing was the major event in miR-34b/c, we investigated the functional role of miR-34b/c in MPM. miR-34b/c-transfected MPM cells with physiologic miR-34b/c expression exhibited antiproliferation with G(1) cell cycle arrest and suppression of migration, invasion, and motility. The forced overexpression of miR-34b/c, but not p53, showed a significant antitumor effect with the induction of apoptosis in MPM cells.
    Conclusions: We show that the epigenetic silencing of miR-34b/c by methylation is a crucial alteration and plays an important role in the tumorigenesis of MPM, suggesting potential therapeutic options for MPM. Clin Cancer Res; 17(15); 4965-74. (C)2011 AACR.

    DOI: 10.1158/1078-0432.CCR-10-3040

    Web of Science

    researchmap

  • TIRAP, an Adaptor Protein for TLR2/4, Transduces a Signal from RAGE Phosphorylated upon Ligand Binding

    Masakiyo Sakaguchi, Hitoshi Murata, Ken-ichi Yamamoto, Tomoyuki Ono, Yoshihiko Sakaguchi, Akira Motoyama, Toshihiko Hibino, Ken Kataoka, Nam-ho Huh

    PLOS ONE   6 ( 8 )   23132 - 23132   2011年8月

     詳細を見る

    記述言語:英語   出版者・発行元:PUBLIC LIBRARY SCIENCE  

    The receptor for advanced glycation end products (RAGE) is thought to be involved in the pathogenesis of a broad range of inflammatory, degenerative and hyperproliferative diseases. It binds to diverse ligands and activates multiple intracellular signaling pathways. Despite these pivotal functions, molecular events just downstream of ligand-activated RAGE have been surprisingly unknown. Here we show that the cytoplasmic domain of RAGE is phosphorylated at Ser391 by PKCf upon binding of ligands. TIRAP and MyD88, which are known to be adaptor proteins for Toll-like receptor-2 and -4 (TLR2/4), bound to the phosphorylated RAGE and transduced a signal to downstream molecules. Blocking of the function of TIRAP and MyD88 largely abrogated intracellular signaling from ligand-activated RAGE. Our findings indicate that functional interaction between RAGE and TLRs coordinately regulates inflammation, immune response and other cellular functions.

    DOI: 10.1371/journal.pone.0023132

    Web of Science

    researchmap

  • Markedly elevated serum levels of calcium-binding S100A8/A9 proteins in psoriatic arthritis are due to activated. monocytes/macrophages

    Seiko Aochi, Kazuhide Tsuji, Masakiyo Sakaguchi, Namho Huh, Tatsuya Tsuda, Kiyofumi Yamanishi, Mayumi Komine, Keiji Iwatsuki

    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY   64 ( 5 )   879 - 887   2011年5月

     詳細を見る

    記述言語:英語   出版者・発行元:MOSBY-ELSEVIER  

    Background: Serum levels of S100A8/A9 may correlate with disease activity in psoriasis.
    Objective: We sought to elucidate the association of serum levels of S100A8/A9 heterodimers with the clinical subtypes of psoriasis and the major cell source.
    Methods: Serum samples were collected from patients with psoriasis vulgaris (n = 30), psoriatic arthritis (PA) (n = 16),. pustular psoriasis (n = 24), and atopic dermatitis (n = 14) and from healthy control subjects (n = 21). Serum concentrations of S100A8/A9 were measured, and the expression levels were examined in psoriatic lesions. The messenger RNA levels were quantified in circulating monocytes and neutrophils.
    Results: Serum levels of S100A8/A9 were significantly increased in all subtypes of psoriasis as compared with healthy controls and atopic dermatitis. Among the psoriatic subtypes, PA and pustular psoriasis showed remarkably high concentrations of S100A8/A9 heterodimers. The higher serum levels were associated with the presence of articular symptoms, but not significantly correlated with body surface areas of psoriatic lesions. S100A8 was expressed by both keratinocytes and infiltrating mononuclear cells, whereas S100A9 was predominantly expressed by neutrophils. The expression levels of S100A8 and S100A9 messenger RNA in monocytes were increased by approximately 2.25- and 1.91-fold in PA, respectively, whereas no significant increase was observed in psoriasis vulgaris and pustular psoriasis.
    Limitations: Difficulty in acquisition of clinical and laboratory samples in untreated patients, and of a sufficient number of subjects, were limitations.
    Conclusions: Although serum levels of S100A8/A9 were increased in all types of psoriasis examined, patients with PA had higher levels of S100A8/A9, probably because of an activated monocyte/macrophage system. (J Am Acad Dermatol 2011;64:879-87.)

    DOI: 10.1016/j.jaad.2010.02.049

    Web of Science

    researchmap

  • Multiple functions of PINK1 at different intracellular locations Beyond neurodegenerative diseases

    Hitoshi Murata, Masakiyo Sakaguchi, Ken Kataoka, Nam-ho Huh

    CELL CYCLE   10 ( 10 )   1518 - 1519   2011年5月

     詳細を見る

    記述言語:英語   出版者・発行元:LANDES BIOSCIENCE  

    DOI: 10.4161/cc.10.10.15445

    Web of Science

    researchmap

  • Intraperitoneal administration of an adenovirus vector carrying REIC/Dkk-3 suppresses peritoneal dissemination of scirrhous gastric carcinoma

    Swe Swe Than, Ken Kataoka, Masakiyo Sakaguchi, Hitoshi Murata, Fernando Abarzua, Chika Taketa, Gang Du, Masakazu Yashiro, Kazuyoshi Yanagihara, Yasutomo Nasu, Hiromi Kumon, Nam-Ho Huh

    ONCOLOGY REPORTS   25 ( 4 )   989 - 995   2011年4月

     詳細を見る

    記述言語:英語   出版者・発行元:SPANDIDOS PUBL LTD  

    Expression levels of the novel tumor suppressor gene REIC/Dkk-3 are reduced in many human cancers. We have previously showed that an adenovirus vector carrying REIC/Dkk-3 (Ad-REIC) induced apoptosis of cancer cells selectively and exerted bystander antitumor effects via ER stress. We examined possible effects of Ad-REIC in a peritoneal dissemination model of scirrhous gastric carcinoma (SGC). Among various types of gastric cancer, SGC continues to be associated with the worst prognosis due to a high incidence of metastases in the peritoneal cavity. We found that a single intraperitoneal injection of Ad-REIC suppressed tumor dissemination and disease progression. Immunomodulation by Ad-REIC led to recruitment of natural killer cells inside tumor nodules. We conclude that Ad-REIC gene therapy may be a potential tool in combinatorial approaches to achieve curative effects in SGC.

    DOI: 10.3892/or.2011.1149

    Web of Science

    researchmap

  • Identification of EMMPRIN as a novel receptor for S100A9: Its involvement in melanoma metastasis

    T. Hibino, S. Miyamoto, M. Sakaguchi, A. Motoyama, M. Yamamoto, R. Tsuboi, N. Huh

    JOURNAL OF INVESTIGATIVE DERMATOLOGY   131   S126 - S126   2011年4月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:NATURE PUBLISHING GROUP  

    Web of Science

    researchmap

  • Expression of REIC/Dkk-3 in normal and hyperproliferative epidermis

    Gang Du, Ken Kataoka, Masakiyo Sakaguchi, Fernando Abarzua, Swe Swe Than, Hiroyuki Sonegawa, Teruhiko Makino, Tadamichi Shimizu, Nam-Ho Huh

    EXPERIMENTAL DERMATOLOGY   20 ( 3 )   273 - 277   2011年3月

     詳細を見る

    記述言語:英語   出版者・発行元:WILEY-BLACKWELL  

    Dickkopf (Dkk) family members are known as Wnt modulators involved in the development, cell growth/differentiation and cancer. REIC/Dkk-3, which does not interfere with Wnt signalling, has been proposed to be a tumor suppressor gene, but its physiological function has remained unclear. In this study, we analysed the expression of REIC/Dkk-3 in normal interfollicular epidermis (IFE) and hyperproliferative epidermis. REIC/Dkk-3 was expressed in human and mouse IFE, being localized at the interface of upper spinous layer and granular layer. Skin cancer cell lines lost REIC/Dkk-3 expression as reported previously. When we analysed patient samples, REIC/Dkk-3 expression was down-regulated in the hyperproliferative epidermis including skin cancers and non-cancerous proliferative diseases. REIC/Dkk-3 expression was also suppressed in the regenerative and inflammative epidermis of model mice. These findings will certainly contribute to the extension of studies on REIC/Dkk-3.

    DOI: 10.1111/j.1600-0625.2010.01244.x

    Web of Science

    researchmap

  • REIC/Dkk-3の扁平上皮における発現とその制御因子の探索

    片岡 健, 阪口 政清, 杜 剛, 前原 奈都美, 村田 等, 許 南浩

    組織培養研究   30 ( 1 )   99 - 99   2011年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本組織培養学会  

    researchmap

  • A New Cytosolic Pathway from a Parkinson Disease-associated Kinase, BRPK/PINK1 ACTIVATION OF AKT VIA MTORC2

    Hitoshi Murata, Masakiyo Sakaguchi, Yu Jin, Yoshihiko Sakaguchi, Jun-ichiro Futami, Hidenori Yamada, Ken Kataoka, Nam-ho Huh

    JOURNAL OF BIOLOGICAL CHEMISTRY   286 ( 9 )   7182 - 7189   2011年3月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC  

    Accumulating evidence indicates that dysfunction of mitochondria is a common feature of Parkinson disease. Functional loss of a familial Parkinson disease-linked gene, BRPK/PINK1 (PINK1), results in deterioration of mitochondrial functions and eventual neuronal cell death. A mitochondrial chaperone protein has been shown to be a substrate of PINK1 kinase activity. In this study, we demonstrated that PINK1 has another action point in the cytoplasm. Phosphorylation of Akt at Ser-473 was enhanced by overexpression of PINK1, and the Akt activation was crucial for protection of SH-SY5Y cells from various cytotoxic agents, including oxidative stress. Enhanced Akt phosphorylation was not due to activation of phosphatidylinositol 3-kinase but due to activation of mammalian target of rapamycin complex 2 (mTORC2) by PINK1. Rictor, a specific component of mTORC2, was phosphorylated by overexpression of PINK1. Furthermore, overexpression of PINK1 enhanced cell motility. These results indicate that PINK1 exerts its cytoprotective function not only in mitochondria but also in the cytoplasm through activation of mTORC2.

    DOI: 10.1074/jbc.M110.179390

    Web of Science

    researchmap

  • A novel tumor suppressor, REIC/Dkk-3 gene identified by our in vitro transformation model of normal human fibroblasts works as a potent therapeutic anti-tumor agent

    Masakiyo Sakaguchi, Nam-Ho Huh, Masayoshi Namba

    Advances in Experimental Medicine and Biology   720   209 - 215   2011年

     詳細を見る

    記述言語:英語  

    Reduced Expression in Immortalized Cell (REIC) was cloned by subtractive hybridization method as a gene whose expression is reduced in many human immortalized and neoplastic tumor cells. The REIC, when over-expressed by an adenovirus (Ad-REIC), exhibited a dramatic therapeutic effect on a wide variety of human cancers through a mechanism triggered by ER-stress-mediated JNK activation. In addition to this direct effect on cancer cells, Ad-REIC exerted another cytotoxicity on human cancers, an indirect host-mediated effect due to overproduction of IL-7 by mis-targeted normal cells. This "one-bullet two-arms" finding may lead to a powerful new therapeutic approach to the treatment of human cancers. © 2011 Springer Science+Business Media, LLC.

    DOI: 10.1007/978-1-4614-0254-1_17

    Scopus

    PubMed

    researchmap

  • 正常皮膚におけるREIC/Dkk‐3の発現制御因子の検索

    前原奈都美, 片岡健, DU Gang, 村田等, 山本健一, 阪口政清, HUH Nam‐Ho

    日本分子生物学会年会プログラム・要旨集(Web)   34th   1P-0254 (WEB ONLY)   2011年

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • S100タンパク質受容体の結合解析

    森下美加, 村田等, 山本健一, 片岡健, 阪口政清, HUH Nam‐Ho

    日本分子生物学会年会プログラム・要旨集(Web)   34th   4P-0293 (WEB ONLY)   2011年

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • Expression pattern of REIC/Dkk-3 in various cell types and the implications of the soluble form in prostatic acinar development

    Kai Zhang, Masami Watanabe, Yuji Kashiwakura, Shun-Al Li, Kohei Edamura, Peng Huang, Ken Yamaguchi, Yasutomo Nasu, Yasuyuki Kobayashi, Masakiyo Sakaguchi, Kazuhiko Ochiai, Hiroshi Yamada, Kohji Takei, Hideo Ueki, Nam-Ho Huh, Ming Li, Haruki Kaku, Yanqun Na, Hiromi Kumon

    INTERNATIONAL JOURNAL OF ONCOLOGY   37 ( 6 )   1495 - 1501   2010年12月

     詳細を見る

    記述言語:英語   出版者・発行元:SPANDIDOS PUBL LTD  

    The tumor suppressor REIC/Dkk-3 is a secretory protein which was originally identified to be downregulated in human immortalized cells In the present study, we investigated the expression pattern of REIC/Dkk-3 in various cell types to characterize its physiological functions We first examined the expression level of REIC/Dkk-3 in a broad range of cancer cell types and confirmed that it was significantly downregulated in all of the cell types We also examined the tissue distribution pattern in a variety of normal mouse organs Ubiquitous REIC/Dkk-3 protein expression was observed in the organs The expression was abundant in the liver, heart and brain tissue, but was absent in the spleen and peripheral blood mononuclear cells The immunohistochemical analyses revealed that the subcellular localization of REIC/Dkk-3 had a punctate pattern around the nucleus, indicating its association with secretory vesicles In cancer cells stably transfected with REIC/Dkk-3 the protein was predominantly localized to the endoplasmic reticulum (ER) under observation with confocal microscopy Because REIC/ Dkk-3 was found to be abundantly expressed in the acinar epithelial cells of the mouse prostate, we analyzed the effects of recombinant REIC/Dkk-3 protein on the acinar morphogenesis of RWPE-1 cells, which are derived from human normal prostate epithelium Statistically significant acinar growth was observed in the culture condition with 10 mu g/m1 REIC/Dkk-3 protein, implicating the soluble form m prostatic acinar development Current results suggest that REIC/Dkk-3 may play a role in regulating the morphological process of normal tissue architecture through an autocrine and/or paracrine manner

    DOI: 10.3892/ijo_00000802

    Web of Science

    researchmap

  • KLF11とKLF15によるUCP1の発現制御

    山本 健一, 阪口 政清, 片岡 健, 許 南浩

    日本生化学会大会・日本分子生物学会年会合同大会講演要旨集   83回・33回   2P - 0822   2010年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本生化学会  

    researchmap

  • BRPK/PINK1のmTORC2経路活性化を介したがん進展への寄与(BRPK/PINK1 promotes tumor progression through activation of mTORC2 pathway)

    村田 等, 阪口 政清, 金 玉, 片岡 健, 許 南浩

    日本生化学会大会・日本分子生物学会年会合同大会講演要旨集   83回・33回   4P - 0934   2010年12月

     詳細を見る

    記述言語:英語   出版者・発行元:(公社)日本生化学会  

    researchmap

  • Internalization of REIC/Dkk-3 protein by induced pluripotent stem cell-derived embryoid bodies and extra-embryonic tissues

    Ken Kataoka, Masakiyo Sakaguchi, Kun Peng Li, Chika Taketa, Ken-Ichi Yamamoto, Gang Du, Hiroaki Funahashi, Hitoshi Murata, Nam-Ho Huh

    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE   26 ( 6 )   853 - 859   2010年12月

     詳細を見る

    記述言語:英語   出版者・発行元:SPANDIDOS PUBL LTD  

    REIC/Dkk-3 was first identified as a down-regulated gene in a number of human immortalized cells and human tumor-derived cell lines. Overexpression of the REIC/Dkk-3 gene using an adenovirus vector (Ad-REIC) has showed a potent selective therapeutic effect on various human cancers through induction of ER stress. Furthermore, we recently showed that Ad-REIC has an indirect host-mediated anti-tumor activity by induction of IL-7. However, the physiological function of REIC/Dkk-3 is still unclear. As a first step to study the possible receptor(s) for secreted REIC/Dkk-3, we analyzed the internalization of Cy3-labeled recombinant REIC/Dkk-3 protein. Among the cell lines screened, mouse induced pluripotent stem (iPS) cells showed a unique pattern of internalization. The internalization was observed in peripheral cells of spherical colonies formed spontaneously, but not in undifferentiated iPS cells. When we analyzed embryoid bodies (EBs) derived from iPS cells, REIC/Dkk-3 protein was internalized specifically by differentiated cells located at the periphery of EBs. Interestingly, Dkk-1 was internalized by undifferentiated cells at the center of the EBs. When developmental tissue was analyzed, internalization of REIC/Dkk-3 protein was strictly limited to extra-embryonic tissue, such as the trophectoderm layer of 4.5 days post-coitus (dpc) blastocysts and the chorionic membrane at 16.5 dpc. The mechanism of the internalization was confirmed to be endocytosis. These findings will contribute to knowledge on the interaction of REIC/Dkk-3 with a possible receptor(s).

    DOI: 10.3892/ijmm_00000534

    Web of Science

    researchmap

  • Transcriptional regulation of a brown adipocyte-specific gene, UCP1, by KLF11 and KLF15

    Ken-ichi Yamamoto, Masakiyo Sakaguchi, Reinhold J. Medina, Aya Niida, Yoshihiko Sakaguchi, Masahiro Miyazaki, Ken Kataoka, Nam-ho Huh

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   400 ( 1 )   175 - 180   2010年9月

     詳細を見る

    記述言語:英語   出版者・発行元:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    Several growth factors and transcription factors have been reported to play important roles in brown adipocyte differentiation and modulation of thermogenic gene expression, especially the expression of UCP1. In this study, we focused on KLF11 and KLF15, which were expressed highly in brown adipose tissue. Our data demonstrated that KLF11 and KLF15 interacted directly with the UCP1 promoter using GC-box and GT-boxes, respectively. Co-transfection of KLF11 and KLF15 in the mesenchymal stem cell line muBM3.1 during brown adipocyte differentiation enhanced the expression level of UCP1. KLF11, but not KLF15, was essential for UCP1 expression during brown adipocyte differentiation of muBM3.1. (C) 2010 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.bbrc.2010.08.039

    Web of Science

    researchmap

  • 新規がん抑制遺伝子REIC/Dkk-3の増殖性皮膚疾患での発現減少(Reduced expression of REIC/Dkk-3, a putative tumor suppressor gene, in hyperproliferative epidermis)

    杜 剛, 片岡 健, 阪口 政清, 牧野 輝彦, 清水 忠道, 許 南浩

    日本癌学会総会記事   69回   316 - 316   2010年8月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • アデノウイルス受容体(CAR;CXADR)の固形癌細胞の増殖制御における役割の解析(Biological role of Coxsackievirus and Adenovirus Receptor (CXADR) in cancer cell proliferation)

    小屋 恵理子, 阪口 政清, 松井 誠, 冨田 勇樹, 許 南浩, 近藤 英作

    日本癌学会総会記事   69回   268 - 268   2010年8月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • スキルス胃がん腹膜播種へのREIC/Dkk-3遺伝子治療の効果(REIC/Dkk-3 gene therapy suppresses peritoneal dissemination of scirrhous gastric carcinoma)

    片岡 健, タン・スエスエ, 阪口 政清, アバルスァ・フェルナンド, 村田 等, 八代 正和, 那須 保友, 公文 裕巳, 許 南浩

    日本癌学会総会記事   69回   252 - 253   2010年8月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • マウス骨髄間葉系幹細胞の褐色脂肪分化をKLF11およびKLF15は促進する

    片岡健, 山本健一, 阪口政清, HUH Nam‐ho

    硬組織再生生物学会学術大会・総会プログラム・抄録集   19th   40   2010年7月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • Down-regulation of BiP/GRP78 sensitizes resistant prostate cancer cells to gene-therapeutic overexpression of REIC/Dkk-3

    Ryuta Tanimoto, Masakiyo Sakaguchi, Fernando Abarzua, Ken Kataoka, Kaoru Kurose, Hitoshi Murata, Yasutomo Nasu, Hiromi Kumon, Nam-Ho Huh

    INTERNATIONAL JOURNAL OF CANCER   126 ( 7 )   1562 - 1569   2010年4月

     詳細を見る

    記述言語:英語   出版者・発行元:JOHN WILEY & SONS INC  

    We have recently shown that an adenovirus carrying REIC/Dkk-3 (Ad-REIC) exhibits a potent tumor-specific cell-killing function for various human cancers. It has also become evident that some human cancers are resistant to Ad-REIC-induced apoptosis. The aim of the present study was to determine the molecular mechanisms of resistance to Ad-REIC. First, we isolated resistant clones from a human prostate cancer cell line, PC3, after repeated exposure to Ad-REIC. Infection efficiency of the adenovirus vector and expression level of REIC/Dkk-3 in the resistant clones were similar to those in the parental PC3 cells. By screening for alteration in levels and functional status of proteins involved in Ad-REIC-induced apoptosis, we found that BiP/GRP78, an ER-residing chaperone protein, was expressed at higher levels consistently among resistant cells. Expression levels of BiP and rates of apoptosis induced by Ad-REIC were inversely correlated. Down-regulation of BiP with siRNA sensitized the resistant cells to Ad-REIC in vivo as well as in culture. These results indicate that BiP is a major determinant of resistance to Ad-REIC-induced apoptosis. Thus BiP is useful for diagnosis of inherent and acquired resistance of cancers and also as a target molecule to overcome resistance to the gene therapeutic Ad-REIC.

    DOI: 10.1002/ijc.24764

    Web of Science

    researchmap

  • 分化誘導したマウスES細胞及びiPS細胞におけるCy3標識REIC/Dkk‐3タンパク質のエンドサートーシスによる取り込み

    片岡健, 阪口政清, LI Kun Peng, DU Gang, 武田千佳, 舟橋弘晃, 村田等, HUH Nam‐Ho

    組織培養研究   29 ( 1 )   74 - 74   2010年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本組織培養学会  

    J-GLOBAL

    researchmap

  • 褐色脂肪細胞分化におけるKLF11とKLF15の役割

    山本健一, 阪口政清, MEDINA Reinhold, 新居田彩, 宮崎正博, 片岡健, HUH Nam‐Ho

    組織培養研究   29 ( 1 )   82   2010年3月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 関節症性乾癬におけるバイオマーカーとしての血清S100A8/A9蛋白

    青地聖子, 辻和英, 阪口政清, 許南浩, 津田達也, 山西清文, 小宮根真弓, 岩月啓氏

    日本皮膚科学会雑誌   120 ( 3 )   691   2010年3月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • S100A11, a dual growth regulator of epidermal keratinocytes.

    Sakaguchi M, Huh NH

    Amino Acids   1111 - 1111   2010年

     詳細を見る

  • BRPK/PINK1のmTORC2経路活性化を介したがん浸潤への寄与(BRPK/PINK1 enhances invasiveness of cancer cells trough activation of mTORC2 pathway)

    村田 等, 阪口 政清, 片岡 健, 許 南浩

    日本癌学会総会記事   68回   205 - 205   2009年8月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • Overexpression of REIC/Dkk-3 in Normal Fibroblasts Suppresses Tumor Growth via Induction of Interleukin-7

    Masakiyo Sakaguchi, Ken Kataoka, Fernando Abarzua, Ryuta Tanimoto, Masami Watanabe, Hitoshi Murata, Swe Swe Than, Kaoru Kurose, Yuji Kashiwakura, Kazuhiko Ochiai, Yasutomo Nasu, Hiromi Kumon, Nam-ho Huh

    JOURNAL OF BIOLOGICAL CHEMISTRY   284 ( 21 )   14236 - 14244   2009年5月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC  

    We previously showed that the tumor suppressor gene REIC/Dkk-3, when overexpressed by an adenovirus (Ad-REIC), exhibited a dramatic therapeutic effect on human cancers through a mechanism triggered by endoplasmic reticulum stress. Adenovirus vectors show no target cell specificity and thus may elicit unfavorable side effects through infection of normal cells even upon intra-tumoral injection. In this study, we examined possible effects of Ad-REIC on normal cells. We found that infection of normal human fibroblasts (NHF) did not cause apoptosis but induced production of interleukin (IL)-7. The induction was triggered by endoplasmic reticulum stress and mediated through IRE1 alpha, ASK1, p38, and IRF-1. When Ad-REIC-infected NHF were transplanted in a mixture with untreated human prostate cancer cells, the growth of the cancer cells was significantly suppressed. Injection of an IL-7 antibody partially abrogated the suppressive effect of Ad-REIC-infected NHF. These results indicate that Ad-REIC has another arm against human cancer, an indirect host-mediated effect because of overproduction of IL-7 by mis-targeted NHF, in addition to its direct effect on cancer cells.

    DOI: 10.1074/jbc.M808002200

    Web of Science

    researchmap

  • BRPK/PINK1のmTORC2活性化を介したがん進展への寄与

    村田 等, 阪口 政清, 片岡 健, 許 南浩

    組織培養研究   28 ( 1 )   66 - 66   2009年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本組織培養学会  

    researchmap

  • Immunological aspects of REIC/Dkk-3 in monocyte differentiation and tumor regression

    Masami Watanabe, Yuji Kashiwakura, Peng Huang, Kazuhiko Ochiai, Junichiro Futami, Shun-Ai Li, Munenori Takaoka, Yasutomo Nasu, Masakiyo Sakaguchi, Nam-Ho Huh, Hiromi Kumon

    INTERNATIONAL JOURNAL OF ONCOLOGY   34 ( 3 )   657 - 663   2009年3月

     詳細を見る

    記述言語:英語   出版者・発行元:SPANDIDOS PUBL LTD  

    The REIC/Dkk-3 gene has been reported to be a tumor suppressor and the expression is significantly down-regulated in a broad range of cancer cell types. The protein is secretory, but the physiological function remains unclear. This study demonstrated that recombinant REIC/Dkk-3 protein induced the differentiation of human CD14(+) monocytes into a novel cell type ((REIC/Dkx-3)Mo). (REIC/Dkk-3)Mo resembles immature dendritic cells generated with IL-4 and GM-CSF. Both these cell populations exhibit similar proportions of CD11c(+), CD40(+), CD86(+) and HLA-DR(+) cells and endocytic capacity, but (REIC/Dkk-3)Mo is negative for CD1a antigen. An analysis of the signal transducers and activators of transcription (STAT) pathways revealed that REIC/Dkk-3 induces phosphorylation of STAT 1 and STAT 3. Furthermore, intratumoral administration of REIC/Dkk-3 protein significantly suppressed tumor growth with CD11c(+) and CD8(+) (dendritic and killer T cell marker, respectively) cell accumulation and enhanced anticancer cytolytic activity of splenocytes. These data indicated a cytokine-like role of REIC/Dkk-3 protein in monocyte differentiation that might be exploited therapeutically.

    DOI: 10.3892/ijo_00000191

    Web of Science

    researchmap

  • 分化したマウスES細胞およびiPS細胞のCy3標識REIC/Dkk‐3タンパク質の取り込み

    片岡健, 阪口政清, 李坤鵬, 武田千佳, 山本健一, 許南浩

    再生医療   8   223   2009年2月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer

    K. Kawasaki, M. Watanabe, M. Sakaguchi, Y. Ogasawara, K. Ochiai, Y. Nasu, H. Doihara, Y. Kashiwakura, N-h Huh, H. Kumon, H. Date

    CANCER GENE THERAPY   16 ( 1 )   65 - 72   2009年1月

     詳細を見る

    記述言語:英語   出版者・発行元:NATURE PUBLISHING GROUP  

    The overexpression of reduced expression in immortalized cells (REIC)/Dickkopf-3 (Dkk-3), a tumor suppressor gene, induced apoptosis in human prostatic and testicular cancer cells. The aim of this study is to examine the potential of REIC/Dkk-3 as a therapeutic target against breast cancer. First, the in vitro apoptotic effect of Ad-REIC treatment was investigated in breast cancer cell lines and the adenovirus-mediated overexpression of REIC/Dkk-3 was thus found to lead to apoptotic cell death in a c-Jun-NH(2)-kinase (JNK) phosphorylaion-dependent manner. Moreover, an in vivo apoptotic effect and MCF/Wt tumor growth inhibition were observed in the mouse model after intratumoral Ad-REIC injection. As multidrug resistance (MDR) is a major problem in the chemotherapy of progressive breast cancer, the in vitro effects of Ad-REIC treatment were investigated in terms of the sensitivity of multidrug-resistant MCF7/ADR cells to doxorubicin and of the P-glycoprotein expression. Ad-REIC treatment in MCF7/ADR cells also downregulated P-glycoprotein expresssion through JNK activation, and sensitized its drug resistance against doxorubicin. Therefore, not only apoptosis induction but also the reversal of anticancer drug resistance was achieved using Ad-REIC. We suggest that REIC/Dkk-3 is a novel target for breast cancer treatment and that Ad-REIC might be an attractive agent against drug-resistant cancer in combination with conventional antineoplastic agents.

    DOI: 10.1038/cgt.2008.58

    Web of Science

    researchmap

  • REIC/Dkk-3 in normal fibroblasts suppresses tumor growth via induction of interleukin-7.

    Chen J, Watanabe M, Huang P, Sakaguchi M, Ochiai K, Nasu Y, Ouchida M, Huh NH, Shimizu K, Kashiwakura Y, Kaku H, Kumon H

    Int J Mol Med   24 ( 6 )   789 - 794   2009年

     詳細を見る

  • Suppression of Carbon Tetrachloride-Induced Liver Fibrosis by Transplantation of a Clonal Mesenchymal Stem Cell Line Derived From Rat Bone Marrow

    Marhaen Hardjo, Masahiro Miyazaki, Masakiyo Sakaguchi, Takuro Masaka, Sukaeni Ibrahim, Ken Kataoka, Narn-ho Huh

    CELL TRANSPLANTATION   18 ( 1 )   89 - 99   2009年

     詳細を見る

    記述言語:英語   出版者・発行元:COGNIZANT COMMUNICATION CORP  

    Transplantation of hepatocytes or bone marrow-derived cells has been shown to ameliorate liver fibrosis in animal models, but no direct comparison of relative efficiency has been made. The aim of this study was to compare the efficiency of a bone marrow-derived clonal mesenchymal stem cell line established by LIS (rBM25/S3) with that of its adipogenic or hepatogenic differentiation derivative for Suppression of rat liver fibrosis. After induction of differentiation of rBM25/S3 cells into adipogenic or hepatogenic cells in Culture, we intrasplenically transplanted the three types of cells into rats (3 x 10(7) cells/rat) before and 4 weeks after initiation of carbon tetrachloride treatment (1 ml/kg body weight twice a week for 8 weeks) to induce liver fibrosis. Undifferentiated rBM25/S3 cells were the most effective for suppression of liver fibrosis, followed by the adipogenic cells and hepatogenic cells. Expression levels of MMP-2 and MMP-9 were also highest in undifferentiated rBM25/S3 cells. These results indicate that bone marrow-derived clonal mesenchymal stem cell lines are useful for further mechanistic studies on cell-mediated suppression of liver fibrosis and that such cell lines will provide information on an appropriate cell source for transplantation therapy for cirrhosis.

    DOI: 10.3727/096368909788237140

    Web of Science

    researchmap

  • Mechanistic Analysis of Resistance to REIC/Dkk-3-induced Apoptosis in Human Bladder Cancer Cells

    Tomoko Kobayashi, Masakiyo Sakaguchi, Ryuta Tanimoto, Fernando Abarzua, Mikiro Takaishi, Haruki Kaku, Ken Kataoka, Takashi Saika, Yasutomo Nasu, Masahiro Miyazaki, Hiromi Kumon, Nam-ho Huh

    ACTA MEDICA OKAYAMA   62 ( 6 )   393 - 401   2008年12月

     詳細を見る

    記述言語:英語   出版者・発行元:OKAYAMA UNIV MED SCHOOL  

    We have recently shown that a new therapeutic modality using the REIC/Dkk-3 gene (Ad-REIC) is effective against various human cancers, including those of prostate, testis and breast origins. The aim of the present study was to examine the sensitivity of bladder cancers to Ad-REIC and to clarify the molecular mechanisms that determine sensitivity/resistance. We found that 2 human bladder cancer cell lines, T24 and J82, are resistant to Ad-REIC. In T24 and J82 cells, the ER stress response and activation of JNK were observed in a manner similar to that in the sensitive PC3 cells. Translocation of Bax to mitochondria occurred in PC3 cells but not in T24 and J82 cells. Bcl-2 was remarkably overexpressed in T24 and J82 compared with the expression levels in sensitive cell lines. Treatment of T24 and J82 cells with a Bcl-2 inhibitor sensitized the cells to Ad-REIC-induced apoptosis. The results indicate that some human bladder cancers are resistant to apoptosis induced by overexpression of REIC/Dkk-3, which is at least in part due to up-regrulation of Bcl-2. These results provide a basis for possible use of Bcl-2 as a marker of sensitive cancers and to try to sensitize resistant cancers to Ad-REIC by down-regrulation of Bcl-2.

    DOI: 10.18926/AMO/30945

    Web of Science

    researchmap

  • Down-regulation of Inhibition of Differentiation-1 via Activation of Activating Transcription Factor 3 and Smad Regulates REIC/Dickkopf-3-Induced Apoptosis

    Yuji Kashiwakura, Kazuhiko Ochiai, Masami Watanabe, Fernando Abarzua, Masakiyo Sakaguchi, Munenori Takaoka, Ryuta Tanimoto, Yasutomo Nasu, Nam-ho Hub, Hiromi Kumon

    CANCER RESEARCH   68 ( 20 )   8333 - 8341   2008年10月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    REIC/Dickkopf-3 (Dkk-3), a tumor suppressor gene, has been investigated in gene therapy studies. Our previous study suggested that REIC/Dkk-3-induced apoptosis mainly resulted from phosphorylation of c-Jun-NH2 kinase (JNK) in prostate cancer cells. However, the precise mechanisms, especially the molecular mechanisms regulating JNK phosphorylation, remain unclear. In this study, we investigated the mechanisms participating in JNK phosphorylation in the context of a refractory cancer disease, malignant mesothelioma (MM). Adenovirus-mediated overexpression of REIC/Dkk-3 induced apoptosis mainly through JNK activation in immortalized MM cells (211H cells). Interestingly, transcriptional down-regulation of inhibition of differentiation-1 (Id-1) was detected in REIC/Dkk-3-overexpressed 211H cells. Moreover, restoration of Id-1 expression antagonized REIC/Dkk-3-induced JNK phosphorylation and apoptosis. Mutagenesis experiments with the 2.1-kb human Id-1 promoter revealed that activating transcription factor 3 (ATF3) and Smad interaction, with their respective binding motifs, was essential for REIC/Dkk-3-mediated suppression of Id-1 promoter activity. ATF3 activation was probably induced by endoplasmic reticulum stress. Finally, we showed strong antitumor effects from REIC/Dkk-3 gene transfer into the pleural cavity in an orthotopic MM mouse model. Relative to control tumor tissue, REIC/Dkk-3-treated tumor tissue showed down-regulated expression of Id-1 mRNA, enhanced expression of phosphorylated JNK, and an increased number of apoptotic cells. In summary, we first showed that both ATF3 and Smad were crucially and synergistically involved in down-regulation of Id-1, which regulated JNK phosphorylation in REIC/Dkk-3-induced apoptosis. Thus, gene therapy with REIC/Dkk-3 may be a promising therapeutic tool for MM. [Cancer Res 2008;68(20):8333-41]

    DOI: 10.1158/0008-5472.CAN-08-0080

    Web of Science

    researchmap

  • The structure of S100A11 fragment explains a local structural change induced by phosphorylation

    Takahide Kouno, Mineyuki Mizuguchi, Masakiyo Sakaguchi, Eiichi Makino, Yoshihiro Mori, Hiroyuki Shinoda, Tomoyasu Aizawa, Makoto Demur, Nam-Ho Huh, Keiichi Kawano

    JOURNAL OF PEPTIDE SCIENCE   14 ( 10 )   1129 - 1138   2008年10月

     詳細を見る

    記述言語:英語   出版者・発行元:JOHN WILEY & SONS LTD  

    S100A11 protein is a member of the S100 family containing two EF-hand motifs. It undergoes phophorylation on residue T10 after cell stimulation such as an increase in Ca2+ concentration. Phosphorylated S100A11 I can be recognized by its target protein, nucleolin. Although S100A11 is initially expressed in the cytoplasm, it is transported to the nucleus by the action of nucleolin. In the nucleus, S100A11 suppresses the growth of keratinocytes through p21(CIP1/WAF1) activation and induces cell differentiation. Interestingly, the N-terminal fragment of S100A11 has the same activity as the full-length protein: i.e. it is phosphorylated in vivo and binds to nucleolin. In addition, this fragment leads to the arrest of cultured keratinocyte growth. We examined the solution structure of this fragment peptide and explored its structural properties before and after phosphorylation. In a trifluoroethanol solution, the peptide adopts the alpha-helical structure just as the corresponding region of the full-length S100A11. Phosphorylation induces a disruption of the N-capping conformation of the alpha-helix, and has a tendency to perturb its surrounding structure. Therefore, the phosphorylated threonine lies in the N-terminal edge of the alpha-helix. This local structural change can reasonably explain why the phosphorylation of a residue that is initially buried in the interior of protein allows it to be recognized by the binding partner. Copyright (C) 2008 European Peptide Society and John Wiley & Sons, Ltd.

    DOI: 10.1002/psc.1050

    Web of Science

    researchmap

  • Intracellular delivery of glutathione S-transferase-fused proteins into mammalian cells by polyethylenimine-glutathione conjugates

    Hitoshi Murata, Junichiro Futami, Midori Kitazoe, Takayuki Yonehara, Hidetaka Nakanishi, Megumi Kosaka, Hiroko Tada, Masakiyo Sakaguchi, Yasuyuki Yagi, Masaharu Seno, Nam-ho Huh, Hidenori Yamada

    JOURNAL OF BIOCHEMISTRY   144 ( 4 )   447 - 455   2008年10月

     詳細を見る

    記述言語:英語   出版者・発行元:OXFORD UNIV PRESS  

    The glutathione S-transferase (GST)-fused protein expression system has been extensively used to generate a large quantity of proteins and has served for functional analysis in vitro. In this study, we developed a novel approach for the efficient intracellular delivery of GST-fused proteins into living cells to expand their usefulness up to in vivo use. Since protein cationization techniques are powerful strategies for efficient intracellular uptake by adsorptive-mediated endocytosis, GST-fused proteins were cationized by forming a complex with a polycationic polyethylenimine (PEI)-glutathione conjugate. On screening of protein transduction, optimized PEI-glutathione conjugate for protein transduction was characterized by a partly oligomerized mixture of PEI with average molecular masses of 600 (PEI600) modified with multiple glutathiones, which could have sufficient avidity for GST. Furthermore, enhanced endosomal escape of transduced GST-fused proteins was observed when they were delivered with a glutathione-conjugated PEI600 derivative possessing a hydroxybutenyl moiety. These results were confirmed by both intracellular confocal imaging of GST-fused green fluorescent protein and activation of an endogenous growth signal transduction pathway by a GST-fused constitutively active mutant of a kinase protein. These PEI-glutathione conjugates seem to be convenient molecular tools for protein transduction of widely used GST-fused proteins.

    DOI: 10.1093/jb/mvn087

    Web of Science

    researchmap

  • Derivation of hepato-pancreatic intermediate progenitor cells from a clonal mesenchymal stem cell line of rat bone marrow origin

    Takuro Masaka, Masahiro Miyazaki, Gang Du, Marhaen Hardjo, Masakiyo Sakaguchi, Mikiro Takaishi, Ken Kataoka, Kazuhide Yamamoto, Nam-Ho Huh

    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE   22 ( 4 )   447 - 452   2008年10月

     詳細を見る

    記述言語:英語   出版者・発行元:PROFESSOR D A SPANDIDOS  

    We have recently established a clonal mesenchymal stem cell line (rBM25/S3) from adult rat bone marrow. The cells have practically unlimited proliferation capacity (over 300 PDL), maintaining multipotency for differentiation. In the present study, we examined the potential for rBM25/S3 cells to differentiate into insulin-secreting cells. When cultured in the presence of HGF and FGF-4 on Matrigel, rBM25/S3 cells expressed genes specific to pancreatic B-cells as well as those specific to hepatocytes. They still maintained proliferation capacity with a doubling time of similar to 30 h. These hepato-pancreatic intermediate progenitor cells, but not the original undifferentiated rBM25/S3 cells, were induced by the overexpression of PDX-1 to produce significant amounts of insulin in a manner responding to glucose concentration in medium. The present culture system indicates a direction for further studies aimed at the realization of cell transplantation therapy for type I diabetes mellitus.

    DOI: 10.3892/ijmm_00000041

    Web of Science

    researchmap

  • An N-terminal 78 amino acid truncation of REIC/Dkk-3 effectively induces apoptosis

    Fernando Abarzua, Yuji Kashiwakura, Munenori Takaoka, Masami Watanabe, Kazuhiko Ochiai, Masakiyo Sakaguchi, Takao Iwawaki, Ryuta Tanimoto, Yasutomo Nasu, Nam-ho Huh, Hiromi Kumon

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   375 ( 4 )   614 - 618   2008年10月

     詳細を見る

    記述言語:英語   出版者・発行元:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    Overexpression of REIC/Dkk-3 (a tumor suppressor gene) induces cancer cell apoptosis through endoplasmic reticulum (ER) stress. Therefore, the identification of the portion of REIC/Dkk-3 that causes ER stress may be essential for the development of cancer treatment based on REIC/Dkk-3. Here, we made several truncated forms of REIC/Dkk-3 and investigated their therapeutic potentials against prostate cancer. Among three truncated forms, a variant comprising the N-terminal 78 amino acid region of REIC/Dkk-3 ((1-78) REIC/Dkk-3) most strongly induced ER stress and apoptosis in human prostate cancer cells (PC3). For in vivo gene expression, we coupled a biodegradable polymer with naked DNA, which attained robust trans-gene expression in PC3-derived subcutaneous tumor. In therapeutic experiments, we demonstrated that multiple direct injections of polymer-conjugated (1-78)REIC/Dkk-3 plasmid provoke ER stress and significantly reduced the subcutaneous tumor volume compared with the control group. We suggest this non-viral strategy may be an effective alternative to viral gene therapy. (C) 2008 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.bbrc.2008.08.079

    Web of Science

    researchmap

  • REIC/Dkk-3遺伝子治療の正常細胞を介する抗腫瘍効果(Transduction of gene therapeutic REIC/Dkk-3 into normal cells provides another arm for tumor suppression in vivo)

    片岡 健, 阪口 政清, Fernando Abarzua, 谷本 竜太, 渡部 昌実, 村田 等, 那須 保友, 公文 裕巳, 許 南浩

    日本癌学会総会記事   67回   93 - 93   2008年9月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • REIC/Dkk-3遺伝子によるアポトーシス耐性メカニズムとその克服(BiP is a determining protein for sensitivity to apoptosis induced by a gene-therapeutic adenovirus carrying REIC/Dkk-3)

    谷本 竜太, 阪口 政清, アバルズア・フェルナンド, 片岡 健, 那須 保友, 公文 裕巳, 許 南浩

    日本癌学会総会記事   67回   238 - 238   2008年9月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • REIC/Dkk-3の強制発現はERストレスを介してIL-7を誘導する(Over-expression of REIC/Dkk-3 induces IL-7 in normal human fibroblasts via ER stress)

    阪口 政清, 片岡 健, アバルスア・フェルナンド, 谷本 竜太, 渡辺 昌実, 村田 等, 那須 保友, 公文 裕己, 許 南浩

    日本癌学会総会記事   67回   238 - 238   2008年9月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • BRPK/PINK1はAktのリン酸化によってがん細胞のアポトーシスを抑制する(BRPK/PINK1 blocks apoptotic cell death of cancer cells by phosphotylation of Akt)

    村田 等, 阪口 政清, 片岡 健, 許 南浩

    日本癌学会総会記事   67回   64 - 64   2008年9月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • S100A8/A9, a key mediator for positive feedback growth stimulation of normal human keratinocytes

    Takamasa Nukui, Ritsuko Ehama, Masakiyo Sakaguchi, Hiroyuki Sonegawa, Chika Katagiri, Toshihiko Hibino, Nam-Ho Huh

    JOURNAL OF CELLULAR BIOCHEMISTRY   104 ( 2 )   453 - 464   2008年5月

     詳細を見る

    記述言語:英語   出版者・発行元:WILEY-LISS  

    S100A8 and S100A9 are known to be up-regulated in hyperproliferative and psoriatic epidermis, but their function in epidermal keratinocytes remains largely unknown. Here we show that (1) S100A8 and S100A9 are secreted by cultured normal human keratinocytes (NHK) in a cytokine-dependent manner, (2) when applied to NHK, recombinant S100A8/A9 (a 1:1 mixture of S100A8 and S100A9) induced expression of a number of cytokine genes such as IL-8/CXCL8, CXCL1, CXCL2, CXCL3, CCL20, IL-6, and TNF alpha that are known to be up-regulated in psoriatic epidermis, (3)the S100A8/ A9-induced cytokines in turn enhanced production and secretion of S100A8 and S100A9 by NHK, and (4) S100A8 and S100A8/A9 stimulated the growth of NHK at a concentration as low as 1 ng/ml. These results indicate the presence of a positive feedback loop for growth stimulation involving S100A8/A9 and cytokines in human epidermal keratinocytes, implicating the relevance of the positive feedback loop to the etiology of hyperproliferative skin diseases, including psoriasis.

    DOI: 10.1002/jcb.21639

    Web of Science

    researchmap

  • S100A11 functions as a dual mediator for growth regulation in normal human keratinocytes

    M. Sakaguchi, H. Murata, N. Huh

    JOURNAL OF INVESTIGATIVE DERMATOLOGY   128   S138 - S138   2008年4月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:NATURE PUBLISHING GROUP  

    Web of Science

    researchmap

  • Serum calcium-binding S100A8/A9 proteins in patients with psoriatic arthritis are derived from not only the skin lesions but also circulating monocytes

    S. Aochi, K. Tsuji, M. Sakaguchi, N. Huh, T. Tsuda, K. Yamanishi, M. Komine, K. Iwatsuki

    JOURNAL OF INVESTIGATIVE DERMATOLOGY   128   S17 - S17   2008年4月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:NATURE PUBLISHING GROUP  

    Web of Science

    researchmap

  • S100A11, an dual mediator for growth regulation of human keratinocytes

    Masakiyo Sakaguchi, Hiroyuki Sonegawa, Hitoshi Murata, Midori Kitazoe, Jun-ichiro Futami, Ken Kataoka, Hidenori Yamada, Nam-ho Huh

    MOLECULAR BIOLOGY OF THE CELL   19 ( 1 )   78 - 85   2008年1月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER SOC CELL BIOLOGY  

    We previously revealed a novel signal pathway involving S100A11 for inhibition of the growth of normal human keratinocytes (NHK) caused by high Ca++ or transforming growth factor beta. Exposure to either agent resulted in transfer of S100A11 to nuclei, where it induced p21(WAF1). In contrast, S100A11 has been shown to be overexpressed in many human cancers. To address this apparent discrepancy, we analyzed possible new functions of S100A11, and we provide herein evidence that 1) S100A11 is actively secreted by NHK; 2) extracellular S100A11 acts on NHK to enhance the production of epidermal growth factor family proteins, resulting in growth stimulation; 3) receptor for advanced glycation end products, nuclear factor-kappa B, Akt, and cAMP response element-binding protein are involved in the S100A11-triggered signal transduction; and 4) production and secretion of S100A11 are markedly enhanced in human squamous cancer cells. These findings indicate that S100A11 plays a dual role in growth regulation of epithelial cells.

    DOI: 10.1091/mbc.E07-07-0682

    Web of Science

    researchmap

  • Truncation of annexin A1 is a regulatory lever for linking epidermal growth factor signaling with cytosolic phospholipase A2 in normal and malignant squamous epithelial cells

    Masakiyo Sakaguchi, Hitoshi Murata, Hiroyuki Sonegawa, Yoshihiko Sakaguchi, Jun-ichiro Futami, Midori Kitazoe, Hidenori Yamada, Nam-ho Huh

    JOURNAL OF BIOLOGICAL CHEMISTRY   282 ( 49 )   35679 - 35686   2007年12月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC  

    Regulation of cell growth and apoptosis is one of the pleiotropic functions of annexin A1 (ANXA1). Although previous reports on the overexpression of ANXA1 in many human cancers and on growth suppression and/or induction of apoptosis by ANXA1 may indicate the tumor-suppressive nature of ANXA1, molecular mechanisms of the function of ANXA1 remain largely unknown. Here we provide evidence that ANXA1 mechanistically links the epidermal growth factor-triggered growth signal pathway with cytosolic phospholipase A(2) (cPLA(2)), an initiator enzyme of the arachidonic acid cascade, through interaction with S100A11 in normal human keratinocytes (NHK). Ca2+ -dependent binding of S100A11 to ANXA1 facilitated the binding of the latter to cPLA2, resulting in inhibition of cPLA2 activity, which is essential for the growth of NHK. On exposure of NHK to epidermal growth factor, ANXA1 was cleaved solely at Trp(12), and this cleavage was executed by cathepsin D. In squamous cancer cells, this pathway was shown to be constitutively activated. The newly found mechanistic intersection may be a promising target for establishing new measures against human cancer and other cell growth disorders.

    DOI: 10.1074/jbc.M707538200

    Web of Science

    researchmap

  • Isolation of a bone marrow-derived stem cell line with high proliferation potential and its application for preventing acute fatal liver failure

    Masahiro Miyazaki, Marhaen Hardjo, Takuro Masaka, Koji Tomiyama, Naila Mahmut, Reinhold J. Medina, Aya Niida, Hiroyuki Sonegawa, Gang Du, Rong Yong, Mikiro Takaishi, Masakiyo Sakaguchi, Nam-Ho Huh

    STEM CELLS   25 ( 11 )   2855 - 2863   2007年11月

     詳細を見る

    記述言語:英語   出版者・発行元:ALPHAMED PRESS  

    Transplantation of hepatocytes or hepatocyte-like cells of extrahepatic origin is a promising strategy for treatment of acute and chronic liver failure. We examined possible utility of hepatocyte-like cells induced from bone marrow cells for such a purpose. Clonal cell lines were established from the bone marrow of two different rat strains. One of these cell lines, rBM25/S3 cells, grew rapidly (doubling time, similar to 24 hours) without any appreciable changes in cell properties for at least 300 population doubling levels over a period of 300 days, keeping normal diploid karyotype. The cells expressed CD29, CD44, CD49b, CD90, vimentin, and fibronectin but not CD45, indicating that they are of mesenchymal cell origin. When plated on Matrigel with hepatocyte growth factor and fibroblast growth factor-4, the cells efficiently differentiated into hepatocyte-like cells that expressed albumin, cytochrome P450 (CYP) 1A1, CYP1A2, glucose 6-phosphatase, tryptophane-2,3-dioxygenase, tyrosine aminotransferase, hepatocyte nuclear factor (HNF)1 alpha, and HNF4 alpha. Intrasplenic transplantation of the differentiated cells prevented fatal liver failure in 90%-hepatectomized rats. In conclusion, a clonal stem cell line derived from adult rat bone marrow could differentiate into hepatocyte-like cells, and transplantation of the differentiated cells could prevent fatal liver failure in 90%-hepatectomized rats. The present results indicate a promising strategy for treating human fatal liver diseases.

    DOI: 10.1634/stemcells.2007-0078

    Web of Science

    researchmap

  • ヒト膀胱癌細胞におけるREIC/Dkk-3誘導性アポトーシスに対する抵抗性の機構解析(Mechanistic Analysis of Resistance to REIC/Dkk-3-induced Apoptosis in Human Bladder Cancer Cell Lines)

    小林 知子, 阪口 政清, 谷本 竜太, 枝村 康平, アバラズア・フェルナンド, 片岡 健, 賀来 春紀, 雑賀 隆史, 宮崎 正博, 那須 保友, 公文 裕巳, 許 南浩

    西日本泌尿器科   69 ( 増刊 )   125 - 125   2007年10月

     詳細を見る

    記述言語:英語   出版者・発行元:西日本泌尿器科学会  

    researchmap

  • Adenovirus-mediated REIC/Dkk-3 gene transfer inhibits tumor growth and metastasis in an orthotopic prostate cancer model

    K. Edamura, Y. Nasu, M. Takaishi, T. Kobayashi, F. Abarzua, M. Sakaguchi, Y. Kashiwakura, S. Ebara, T. Saika, M. Watanabe, N-H Huh, H. Kumon

    CANCER GENE THERAPY   14 ( 9 )   765 - 772   2007年9月

     詳細を見る

    記述言語:英語   出版者・発行元:NATURE PUBLISHING GROUP  

    We had previously reported that REIC/Dkk-3, a member of the Dickkopf ( Dkk) gene family, works as a tumor suppressor. In this study, we evaluated the therapeutic effects of an intratumoral injection with adenoviral vector encoding REIC/Dkk-3 gene ( Ad-REIC) using an orthotopic mouse prostate cancer model of RM-9 cells. We also investigated the in vivo anti-metastatic effect and in vitro anti-invasion effect of Ad-REIC gene delivery. We demonstrated that the Ad-REIC treatment inhibited prostate cancer growth and lymph node metastasis, and prolonged mice survival in the model. These therapeutic responses were consistent with the intratumoral apoptosis induction and in vitro suppression of cell invasion/migration with reduced matrix metalloprotease-2 activity. We thus concluded that in situ Ad-REIC/Dkk-3 gene transfer may be a promising therapeutic intervention modality for the treatment of prostate cancer.

    DOI: 10.1038/sj.cgt.7701071

    Web of Science

    researchmap

  • ヒト膀胱癌細胞株におけるREIC/Dkk-3誘導性アポトーシスに対する抵抗性の機構的解析(Mechanistic Analysis of Resistance to REIC/Dkk-3-induced Apoptosis in Human Bladder Cancer Cell Lines)

    小林 知子, 阪口 政清, 谷本 竜太, アバラズア・フェルナンド, 高石 樹朗, 片岡 健, 賀来 春紀, 雑賀 隆史, 那須 保友, 宮崎 正博, 公文 裕巳, 許 南浩

    日本癌学会総会記事   66回   476 - 476   2007年8月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • Heat shock proteins play a crucial role in tumor-specific apoptosis by REIC/Dkk-3

    Fernando Abarzua, Masakiyo Sakaguchi, Ryuta Tanimoto, Hiroyuki Sonegawa, Dai-Wei L, Kohei Edamura, Tomoko Kobayashi, Masami Watanabe, Yuji Kashiwakura, Haruki Kaku, Takashi Saika, Keiichiro Nakamura, Yasutomo Nasu, Hiromi Kumon, Nam-Ho Huh

    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE   20 ( 1 )   37 - 43   2007年7月

     詳細を見る

    記述言語:英語   出版者・発行元:PROFESSOR D A SPANDIDOS  

    We recently showed that overexpression of REIC/Dickkopf-3 (Dkk-3), a tumor suppressor gene, induced apoptosis in a tumor cell-specific manner. The aim of the present study was to determine the mechanisms underlying the selective induction of apoptosis. At first, we found a mouse renal carcinoma cell line, RENCA, to be extremely sensitive to an adenovirus carrying REIC/Dkk-3 (Ad-REIC), and we showed that activation of c-Jun N-terminal kinase (JNK) was a critical step in cell death, i.e. a process similar to that in human prostate and testicular cancer observed in our previous studies. Among the proteins interfering with the activation of JNK, heat shock protein (Hsp)70/72 was reduced in expression in RENCA cells compared with that in NIH3T3 cells. An Hsp70/72 inducer protected RENCA cells from Ad-REIC-induced apoptosis, while an Hsp70/72 inhibitor sensitized NIH3T3 cells for apoptosis induction. These results indicate that functionally active Hsp70/72 is a key factor in tumor cell-specific induction of apoptotic cell death and that analyses of the expression levels of Hsp70/72 may be essential in determining the significance of Ad-REIC-based gene therapy against human cancer.

    Web of Science

    researchmap

  • Involvement of deterioration in S100C/A11-mediated pathway in resistance of human squamous cancer cell lines to TGF beta-induced growth suppression

    Hiroyuki Sonegawa, Takamasa Nukui, Dai-Wei Li, Mikiro Takaishi, Masakiyo Sakaguchi, Nam-Ho Hub

    JOURNAL OF MOLECULAR MEDICINE-JMM   85 ( 7 )   753 - 762   2007年7月

     詳細を見る

    記述言語:英語   出版者・発行元:SPRINGER  

    Recently, we demonstrated that S100C/A11 comprises an essential pathway for growth suppression by TGF beta in normal human keratinocytes. Nuclear transfer of S 100C/A11 was a hallmark of the activation of the process. In the present study, we examined the possible deterioration in the pathway in human squamous cancer cell lines, focusing on intracellular localization of S100C/A11 and its functional partners Smad3 and Smad4. All four human squamous cancer cell lines examined (A431, BSCC-93, DJM-1, and HSC-5) were resistant to growth suppression by TGF beta. In BSCC-93, DJM-1, and HSC-5 cells exposed to TGF beta, S100C/A11 was not transferred to the nuclei, and p21(WAF1) was not induced. Overexpression of nucleus-targeted S100C/A11 partially recovered induction of p21 (WAF1) and p15(INK4B) and growth suppression by TGF beta 1 in these cells. These results indicate that the deterioration in the S100C/A11-mediated pathway conferred upon the cancer cell lines resistance to TGF beta. In A431 cells, S100C/A11, Smad3, and Smad4 were simultaneously transferred to the nuclei, and p2l(WAF1) was induced upon exposure to TGF beta. We provide evidence to indicate that refractoriness of A431 cells to TGF beta was probably because the amount of p2l(WAF1) induced by TGF beta was insufficient to counteract cyclin A, which is highly overexpressed in A431 cells. Thus, the newly found S100C/A11-mediated pathway is at least partly involved in conferring upon human squamous cell cancers resistant to TGF beta-induced growth suppression, which is considered to play a critical role for the initiation and progression of many human cancers.

    DOI: 10.1007/s00109-007-0180-7

    Web of Science

    researchmap

  • S100A8/A9, a key mediator for positive feedback growth stimulation and inflammation of normal human keratinocytes

    R. Ehama, T. Nukui, C. Katagiri, M. Sakaguchi, H. Sonegawa, N. Huh, T. Hibino

    JOURNAL OF INVESTIGATIVE DERMATOLOGY   127   S98 - S98   2007年4月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:NATURE PUBLISHING GROUP  

    Web of Science

    researchmap

  • TGFβ抵抗性扁平上皮がん細胞におけるS100C/A11信号伝達経路の異常

    曽根川 裕之, 阪口 政清, 許 南浩

    Tissue culture research communications : the journal of experimental & applied cell culture research = 組織培養研究   26 ( 1 )   63 - 63   2007年3月

     詳細を見る

  • REIC/Dkk-3遺伝子による精巣腫瘍に対する遺伝子治療の基礎実験

    谷本 竜太, 阪口 政清, フェルナンド アバラズア, 曽根川 裕之, 那須 保友, 公文 裕巳, 許 南浩

    Tissue culture research communications : the journal of experimental & applied cell culture research = 組織培養研究   26 ( 1 )   88 - 88   2007年3月

     詳細を見る

  • S100C/A11タンパク質による細胞増殖制御機構の新展開-分泌型S100C/A11の機能解明

    阪口 政清, 曽根川 裕之, 許 南浩

    Tissue culture research communications : the journal of experimental & applied cell culture research = 組織培養研究   26 ( 1 )   74 - 74   2007年3月

     詳細を見る

  • S100A8/A9を介するヒト表皮角化細胞の増殖促進機構

    江浜 律子, 温井 孝昌, 阪口 政清, 曽根川 裕之, 片桐 千佳, 日比野 利彦, 許 南浩

    Tissue culture research communications : the journal of experimental & applied cell culture research = 組織培養研究   26 ( 1 )   73 - 73   2007年3月

     詳細を見る

  • REIC/Dkk-3 as a potential gene therapeutic agent against human testicular cancer

    Ryuta Tanimoto, Fernando Abarzua, Masakiyo Sakaguchi, Mikiro Takaishi, Yasutomo Nasu, Hiromi Kumon, Nam-Ho Huh

    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE   19 ( 3 )   363 - 368   2007年3月

     詳細を見る

    記述言語:英語   出版者・発行元:PROFESSOR D A SPANDIDOS  

    Human testicular cancer is very sensitive to chemotherapy and radiation therapy and is regarded as a curable cancer. The cancer prevails in the young reproductive generation and testicular dysfunction is often observed as a side effect, remaining a serious challenge. In the present study, we examined the potential utility of REIC/Dkk-3-based gene therapy against human testicular cancer. Expression of REIC/Dkk-3 was reduced in all of the human seminoma and non-seminomatous germ cell tumor tissues. Overexpression of REIC/Dkk-3 using an adenovirus vector (Ad-REIC) induced apoptosis in a testicular germ cell cancer cell line NCCIT but not in normal human fibroblasts. c-Jun terminal kinase (JNK) was activated by Ad-REIC and the induction of apoptosis was abrogated by a JNK inhibitor. A single intratumoral injection of Ad-REIC markedly inhibited the tumorigenic growth of NCCIT cells in nude mice. These results indicate that Ad-REIC may lead to developing less insulting and non-genotoxic therapeutic measures against human testicular cancer.

    Web of Science

    researchmap

  • Denatured and reversibly cationized p53 readily enters cells and simultaneously folds to the functional protein in the cells

    H Murata, M Sakaguchi, J Futami, M Kitazoe, T Maeda, H Doura, M Kosaka, H Tada, M Seno, N Huh, H Yamada

    BIOCHEMISTRY   45 ( 19 )   6124 - 6132   2006年5月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER CHEMICAL SOC  

    Cationization is a powerful strategy for internalizing a protein into living cells. On the other hand, a reversibly cationized denatured protein through disulfide bonds is not only soluble in water but also able to fold to the native conformation in vitro. When these advantages in cationization were combined, we developed a novel method to deliver a denatured protein into cells and simultaneously let it fold to express its function within cells. This "in-cell folding" method enhances the utility of recombinant proteins expressed in Escherichia coli as inclusion bodies; that is, the recombinant proteins in inclusion bodies are solubilized by reversible cationization through cysteine residues by disulfide bonds with aminopropyl methanethiosulfonate or pyridyldithiopropionylpolyethylenimine and then incubated with cells without an in vitro folding procedure. As a model protein, we investigated human tumor-suppressor p53. Treatment of p53-null Saos-2 cells with reversibly cationized p53 revealed that all events examined as indications of the activation of p53 in cells, such as reduction of disulfide bonds followed by tetramer formation, localization into the nucleus, induction of p53 target genes, and induction of apoptosis of cells, occurred. These results suggest that reversible cationization of a denatured protein through cysteine residues is an alternative method for delivery of a functional protein into cells. This method would be very useful when a native folded protein is not readily available.

    DOI: 10.1021/bi052642a

    Web of Science

    researchmap

  • 新規樹立ラット骨髄間葉系幹細胞から誘導した肝細胞の脾臓内移植による90%肝切除急性肝不全ラットの救命

    宮崎 正博, ハルジョ マルハエン, メディナ レインホルド, 間阪 拓郎, ナイラ マホモティ, 冨山 浩司, 阪口 政清, 高石 樹朗, 許 南浩

    Tissue culture research communications : the journal of experimental & applied cell culture research = 組織培養研究   25 ( 1 )   75 - 75   2006年3月

     詳細を見る

  • ラット骨髄由来肝類似細胞のインスリン産生細胞への分化転換の試み

    間阪 拓郎, 宮崎 正博, ハルジョ マルハエン, メディナ レインホルド, 阪口 政清, 高石 樹朗, 許 南浩

    Tissue culture research communications : the journal of experimental & applied cell culture research = 組織培養研究   25 ( 1 )   77 - 77   2006年3月

     詳細を見る

  • HNF4 転写因子による肝機能制御機構の解明

    阪口政清

    ファルマシア   2006年

     詳細を見る

  • Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase

    F Abarzua, M Sakaguchi, M Takaishi, Y Nasu, K Kurose, S Ebara, M Miyazaki, M Namba, H Kumon, N Huh

    CANCER RESEARCH   65 ( 21 )   9617 - 9622   2005年11月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    Alteration in genes which takes place during malignant conversion and progression could be potential targets for gene therapy. We previously identified REIC/Dkk-3 as a gene whose expression is reduced in many human cancers. Here, we showed that expression of REIC/Dkk-3 was consistently reduced in human prostate cancer tissues in a stage-dependent manner. Forced expression of REIC/Dkk-3 induced apoptosis in human prostate cancer cell lines lacking endogenous REIC/Dkk-3 expression but not in REIC/Dkk3-proficient normal prostate epithelial and stromal cells. The apoptosis involved c-jun-NH2-kinase activation, mitochondrial translocation of Bax, and reduction of Bcl-2. A single injection of an adenovirus vector carrying REIC/Dkk-3 showed a dramatic antitumor effect on a xenotransplanted human prostate cancer. Thus, REIC/Dkk-3 could be a novel target for gene-based therapy of prostate cancer.

    DOI: 10.1158/0008-5472.CAN-05-0829

    Web of Science

    researchmap

  • Bifurcated converging pathways for high Ca2+- and TGF beta-induced inhibition of growth of normal human keratinocytes

    M Sakaguchi, H Sonegawa, T Nukui, Y Sakaguchi, M Miyazaki, M Namba, N Huh

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA   102 ( 39 )   13921 - 13926   2005年9月

     詳細を見る

    記述言語:英語   出版者・発行元:NATL ACAD SCIENCES  

    Growth suppression of normal human keratinocytes by high Ca2+ or TGF beta was shown to be mediated by p2l(WAF1/C1P1) and Sp1 [Pardali, K., et al. (2000) J. Biol. Chem. 275, 29244-29256; Santini, M. P., Talora, C., Seki, T., Bolgan, L. & Dotto, G. P. (2001) Proc. Nat. Acad Sci. USA 98, 9575-9580; Al-Daraji, W. I., Grant, K. R., Ryan, K., Saxton, A., & Reynolds, N. J. (2002) J. Invest. Dermato/. 118, 779-788]. We previously demonstrated that S100C/A11 is a key mediator for growth inhibition of normal human epidermal keratinocytes (NHK) triggered by high Ca2+ or TGF beta [Sakaguchi, M., et al. (2003) J. Cell Biol. 163, 825-835; Sakaguchi, M., et al. (2004) 164, 979-984]. On exposure of NHK cells to either agent, S100C/ All is transferred to nuclei, where it induces p21(WAF1/CIP1) through activation of Sp1/Sp3. In the present study, we found that high Ca2+ activated NFAT1 through calcineurin-dependent dephosphorylation. In growing NHK cells, Krueppel-like factor (KLF)16, a member of the Sp/KLF family, bound to the p21(WAF1/CIP1) promoter and, thereby, inhibited the transcription of p21(WAF1/CIP1). Sp1 complexed with NFAT1 in high Ca2+ -treated cells or with Smad3 in TGF beta 1-treated cells, but not Sp1 alone, replaced KLF16 from the p21(WAF1/CIP1) promoter and transcriptionally activated the p21(WAF1/CIP1) gene. Thus, high Ca2+ and TGF beta 1 have a common S1OOC/A11-mediated pathway in addition to a unique pathway (NFAT1-mediated pathway for high Ca2+ and Smad-mediated pathway for TGF beta 1) for exhibiting a growth inhibitory effect on NHK cells, and both pathways were shown to be indispensable for growth inhibition.

    DOI: 10.1073/pnas.0500630102

    Web of Science

    researchmap

  • Protein transduction assisted by polyethylenimine-cationized carrier proteins

    M Kitazoe, H Murata, J Futami, T Maeda, M Sakaguchi, M Miyazaki, M Kosaka, H Tada, M Seno, N Huh, M Namba, M Nishikawa, Y Maeda, H Yamada

    JOURNAL OF BIOCHEMISTRY   137 ( 6 )   693 - 701   2005年6月

     詳細を見る

    記述言語:英語   出版者・発行元:JAPANESE BIOCHEMICAL SOC  

    Previously, we have reported that cationized-proteins covalently modified with polyethylenimine (PEI) (direct PEI-cationization) efficiently enter cells and function in the cytosol [Futami et al. (2005) J. Biosci. Bioeng. 99,95-1031. However, it may be more convenient if a protein could be delivered into cells just by mixing the protein with a PEI-cationized carrier protein having a specific affinity (indirect PEI-cationization). Thus, we prepared PEI-cationized avidin (PEI-avidin), streptavidin (PEI-streptavidin), and protein G (PEI-protein G), and examined whether they could deliver biotinylated proteins and antibodies into living cells. PEI-avidin (and/or PEI-streptavidin) carried biotinylated GFPs into various mammalian cells very efficiently. A GFP variant containing a nuclear localization signal was found to arrive even in the nucleus. The addition of a biotinylated RNase A derivative mixed with PEI-streptavidin to a culture medium of 3T3-SV-40 cells resulted in remarkable cell growth inhibition, suggesting that the biotinylated RNase A derivative entered cells and digested intracellular RNA molecules. Furthermore, the addition of a fluorescein-labeled antiS100C (beta-actin binding protein) antibody mixed with PEI-protein G to human fibroblasts resulted in the appearance of a fluorescence image of actin-like filamentous structures in the cells. These results indicate that indirect PEI-cationization using non-covalent interaction is as effective as the direct PEI-cationization for the transduction of proteins into living cells and for expression of their functions in the cytosol. Thus, PEI-cationized proteins having a specific affinity for certain molecules such as PEI-streptavidin, PEI-avidin and PEI-protein G are concluded to be widely applicable protein transduction carrier molecules.

    DOI: 10.1093/jb/mvi081

    Web of Science

    researchmap

  • Intracellular delivery of proteins into mammalian living cells by polyethylenimine-cationization

    J Futami, M Kitazoe, T Maeda, E Nukui, M Sakaguchi, J Kosaka, M Miyazaki, M Kosaka, H Tada, M Seno, Y Sasaki, NH Huh, M Namba, H Yamada

    JOURNAL OF BIOSCIENCE AND BIOENGINEERING   99 ( 2 )   95 - 103   2005年2月

     詳細を見る

    記述言語:英語   出版者・発行元:SOC BIOSCIENCE BIOENGINEERING JAPAN  

    In the post-genomic era, there is pressing need for development of protein manipulation methodology to analyze functions of proteins in living cells. For this purpose, techniques to deliver functional proteins into living cells are currently being evaluated as alternative approaches to the introduction of transcriptionally active DNA. Here, we describe a novel method for efficient protein transduction into living cells in which a protein is simply cationized with polyethylenimine (PEI) by limited chemical conjugation. PEI-cationized proteins appear to adhere to the cell surface by ionic charge interaction and then internalize into cells in a receptor- and transporter-independent fashion. Since PEI is an organic macromolecule with a high cationic-charge density, limited coupling with PEI results in endowment of sufficient cationic charge to proteins without causing serious decline in their fundamental functions. A number of PEI-cationized proteins, such as ribonuclease (RNase), green fluorescent protein (GFP) and immunoglobulin (IgG), efficiently entered cells and functioned in the cytosol. Our results suggest that protein cationization techniques using PEI will be useful for the development of protein transduction technology.

    DOI: 10.1263/jbb.99.095

    Web of Science

    researchmap

  • Targeted disruption of transcriptional regulatory function of p53 by a novel efficient method for introducing a decoy oligonucleotide into nuclei

    M Sakaguchi, T Nukui, H Sonegawa, H Murata, J Futami, H Yamada, N Huh

    NUCLEIC ACIDS RESEARCH   33 ( 9 )   2005年

     詳細を見る

    記述言語:英語   出版者・発行元:OXFORD UNIV PRESS  

    Decoy oligonucleotides have been used for functional sequestering of transcription factors. Efficient introduction into cells is a prerequisite for the oligonucleotides to exert their blocking function. Lipofection is the most widely used technique for that purpose because of its convenience and relatively high efficiency. However, the transduction efficiency of lipofection largely depends on cell types and experimental conditions and the introduced nucleotides are not specifically directed to nuclei where they exert their major function. In the present study, we designed a new system for transporting oligonucleotides into cell nuclei. The vehicle is composed of glutathione-S-transferase, 7 arginine residues, the DNA- binding domain of GAL4 and a nuclear localization signal, which are linked with flexible glycine stretches. The p53-responsive element linked to the GAL4 upstream activating sequence was efficiently transferred by the vehicle protein into nuclei of primary cultures of neuronal cells, embryonic stem cells and various human normal cells. Transcriptional activation of p21(WAF1/CIP1) and Bax by p53 on exposure to cisplatin was completely blocked by introducing the p53 decoy oligonucleotide. Thus, the system developed in the present study can be a convenient and powerful tool for specifically disrupting the function of DNA- binding proteins in culture.

    DOI: 10.1093/nar/gni088

    Web of Science

    researchmap

  • siRNAによる遺伝子発現抑制法

    阪口政清, 曽根川裕之, 温井孝昌, 許 南浩

    Surgery Frontier   2005年

     詳細を見る

  • PKCα mediates TGFβ-induced growth inhibition of human keratinocytes via phosphorylation of S100C/A11.

    Sakaguchi M, Miyazaki M, Sonegawa H, Kashiwagi M, Ohba M, Kuroki T, Namba M, Huh N

    The Journal of Cell Biology   15   449A - 449A   2004年11月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)  

    Web of Science

    researchmap

  • Increased expression of calcium-binding protein S100 in human uterine smooth muscle tumours

    T Kanamori, K Takakura, M Mandai, M Kariya, K Fukuhara, M Sakaguchi, NH Huh, K Saito, T Sakurai, J Fujita, S Fujii

    MOLECULAR HUMAN REPRODUCTION   10 ( 10 )   735 - 742   2004年10月

     詳細を見る

    記述言語:英語   出版者・発行元:OXFORD UNIV PRESS  

    S100 proteins belong to the EF-hand Ca2+ -binding protein family and regulate a variety of cellular processes via interaction with different target proteins. Several diseases, including cancer and melanoma, are related to the abnormal expression of S100 proteins, which are expressed in cell- and tissue-specific manners. We investigated the expression of S100 family members in human uterine smooth muscle tumours. Expression of six members of the S100 protein family: S100A1, A4, A6, A7, A10 and A11, was found in human uterine leiomyoma and myometrium tissue, but expression of other members was not detected by RT-PCR. Real-time PCR showed that S100A11 expression was significantly increased in leiomyoma compared with myometrium. Suppression of S100A11 by small interfering RNA (siRNA) led to apoptosis, and the overexpression of S100A11 inhibited apoptosis in human uterine smooth muscle tumour cells. These findings suggest that S100A11 has an anti-apoptotic function and is related to the process of growth of human uterine leiomyoma.

    DOI: 10.1093/molehr/gah100

    Web of Science

    researchmap

  • Expression of CYP3A4 by an immortalized human hepatocyte line in a three-dimensional culture using a radial-flow bioreactor

    Akiyama, I, K Tomiyama, M Sakaguchi, M Takaishi, M Mori, M Hosokawa, S Nagamori, N Shimizu, NH Huh, M Miyazaki

    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE   14 ( 4 )   663 - 668   2004年10月

     詳細を見る

    記述言語:英語   出版者・発行元:PROFESSOR D A SPANDIDOS  

    Cytochrome P450 (CYP) 3A is responsible for about 50% of drug metabolizing activity in the liver. The present study was undertaken to establish a CYP3A4-active model for in vitro analysis of human drug metabolism. The cells used were immortalized normal human fetal hepatocytes (OUMS-29) and its HNF4alpha-introduced subline (OUMS-29/H-11). The cells were cultivated under high-density three-dimensional conditions in a radial-flow bioreactor (RFB). The number of OUMS-29 cells increased 15-fold over 49 days and their apical surfaces were covered with abundant microvilli, a characteristic of hepatocytes in vivo. The amount of albumin secreted by OUMS-29 cells in the three-dimensional RFB culture was 6-fold higher than those in a monolayer culture. CYP3A4 protein and an intermediate metabolite of testosterone by CYP3A4 were detected in OUMS-29/H11 cells cultivated in RFB &gt;29 days. These results indicate that the RFB; culture of OUMS-29/H-11 cells is useful for screening and developing new drugs.

    Web of Science

    researchmap

  • Introduction of an N-terminal peptide of S100C/A11 into human cells induces apoptotic cell death

    E Makino, M Sakaguchi, K Iwatsuki, N Huh

    JOURNAL OF MOLECULAR MEDICINE-JMM   82 ( 9 )   612 - 620   2004年9月

     詳細を見る

    記述言語:英語   出版者・発行元:SPRINGER  

    S100 proteins belong to the EF-hand Ca2+- binding protein family and are involved in the regulation of a variety of cellular processes. Individual S 100 proteins are expressed in cell- and tissue-specific manners, and functional deterioration of S100 proteins leads to a number of human diseases, including cancer. We previously demonstrated that S100C/A11 was translocated to nuclei and inhibited DNA synthesis in human keratinocytes when exposed to high Ca2+. In the present study we examined the effects of synthetic partial peptides of S100C/ A11 on human carcinoma cell lines. Only an N-terminal peptide with 19 amino acid residues (MAK19) showed cytotoxicity to the cell lines in dose- and time-dependent manners when introduced into cells by flanking the HIV-TAT protein transduction domain (TAT-MAK19). Pulse field electrophoresis revealed that DNA of the treated cells was partially degradated. Annexin V, a marker of cellular apoptosis, was detected in the cells treated with TAT-MAK19 by immunostaining and flow cytometry. The induction of apoptotic cell death was apparently independent of p53, p21(WAF1/CIP1), and caspase activity, but treatment with TAT-MAK19 resulted in partial translocation of apoptosis-inducing factor (AIF) from the cytoplasm to nuclei. These results indicate that MAK19 induces apoptosis in human cell lines and may therefore lead to the establishment of a new molecular target for the treatment of human cancer.

    DOI: 10.1007/s00109-004-0560-1

    Web of Science

    researchmap

  • Involvement of interferon regulatory factor 1 and S100C/A11 in growth inhibition by transforming growth factorβ1 in human hepatocellular carcinoma.

    Miyazaki M, Sakaguchi M, Akiyama I, Sakaguchi Y, Nagamori S, Huh N

    Cancer Research   64 ( 12 )   4155 - 4161   2004年6月

     詳細を見る

  • Establishment of an immortalized human-liver endothelial cell line with SV40T and hTERT

    T Matsumura, M Takesue, KA Westerman, T Okitsu, M Sakaguchi, T Fukazawa, T Totsugawa, H Noguchi, S Yamamoto, DB Stolz, N Tanaka, P Leboulch, N Kobayashi

    TRANSPLANTATION   77 ( 9 )   1357 - 1365   2004年5月

     詳細を見る

    記述言語:英語   出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS  

    Background and Aims. Liver endothelial cells (LECs) perform an essential role in important pathophysiologic functions in the liver. Establishment of a human LEC line facilitates advances in LEC research. Here, we present immortalization of human LECs using retroviral gene transfer of simian virus 40 large T antigen (SV40T) and human telomerase reverse transcriptase (hTERT). We also demonstrate excision of SV40T and hTERT with TAT-mediated Cre/loxP recombination and subsequent cell sorting.
    Methods. First, human LECs were transduced with a retroviral vector somatostatin receptor (SSR)#69 expressing SV40T and hygromycin-resistance genes flanked by a pair of loxA recombination targets. Then, cells were retrovirally superinfected with SSR#197 encoding hTERT and green fluorescent protein (GFP) cDNAs that were intervened by two loxBs. One SV40T- and hTERT-immortalized LEC clone, TMNK-1, was established and analyzed for its biologic characteristics.
    Results. The cells were hygromycin-resistant and uniformly positive for GFP expression. TMNK-1 expressed EC markers, including factor VIII, vascular endothelial growth factor receptors (flt-1, KDR/Flk-1), and CD34, showed uptake of Di-I-acetylated-low-density lipoprotein and angiogenic potential in Matrigel assays. After lipopolysaccharide treatment, TMNK-1 produced tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 and exhibited increased expression of intracellular adhesive molecule-1, vascular cellular adhesive molecule-1, and VE-cadherin. After treatment with TAT-Cre recombinase fusion protein, approximately 60% of TMNK-1 was negative for GFP expression, and subsequent cell sorting of this population for GFP allowed for collection of the reverted form of TMNK-1.
    Conclusions. This study demonstrates the utility and efficiency of the reversible immortalization procedure to expand primary human LECs for basic studies.

    DOI: 10.1097/01.TP.0000124286.82961.7E

    Web of Science

    researchmap

  • Differential expression of S100C in thyroid lesions

    C Torres-Cabala, A Panizo-Santos, HC Krutzsch, H Barazi, M Namba, M Sakaguchi, DD Roberts, MJ Merino

    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY   12 ( 2 )   107 - 115   2004年4月

     詳細を見る

    記述言語:英語   出版者・発行元:WESTMINSTER PUBL INC  

    Identification of new potential markers that may help in the diagnosis of benign and malignant thyroid lesions is needed. By comparative 2-dimensional gel electrophoresis of microdissected cells from tumors and normal thyroid tissue, we identified a new protein, S100C, which is highly expressed in papillary carcinomas. In order to validate this finding, we investigated the immunohistochemical expression and the potential role in diagnosis of these markets in 94 specimens representing the spectrum of malignant and benign thyroid lesions. Normal thyroid tissue was evaluated in 57 specimens. Galectin-3, a marker reported as specific for malignant lesions, was also evaluated in the same lesions. S100C protein was expressed in the nuclei of normal tissue, hyperplastic nodules, and follicular adenomas and carcinomas. Papillary carcinomas showed a strong, but cytoplasmic, pattern of staining. Galectin-3 immunostaining was strongly positive in papillary carcinomas, and negative in benign lesions, confirming its value in differential diagnosis. These findings Suggest that immunohistochemical Staining of S100C could be helpful in the pathological study of thyroid lesions, especially in cases in which follicular variants of papillary carcinoma and follicular carcinoma are considered in the differential diagnosis.

    DOI: 10.1177/106689690401200203

    Web of Science

    researchmap

  • TGFβによるヒト正常表皮角化細胞の増殖制御機構 : PKCα、S100C/A11を介する新しい信号伝達経路

    阪口 政清, 宮崎 正博, 曽根川 裕之, 柏木 麻里子, 大場 基, 黒木 登志夫, 難波 正義, 許 南浩

    Tissue culture research communications : the journal of experimental & applied cell culture research = 組織培養研究   23 ( 1 )   38 - 38   2004年3月

     詳細を見る

  • Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma

    K Kurose, M Sakaguchi, Y Nasu, S Ebara, H Kaku, R Kariyama, Y Arao, M Miyazaki, T Tsushima, M Namba, H Kumon, NH Huh

    JOURNAL OF UROLOGY   171 ( 3 )   1314 - 1318   2004年3月

     詳細を見る

    記述言語:英語   出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS  

    Purpose: We examined the expression of REIC/Dkk-3, a possible candidate for a tumor suppressor gene, in human renal clear cell carcinoma (RCCC) cell lines and sporadic RCCC surgical specimens.
    Materials and Methods: Human RCCC cell lines (Caki-1, Caki-2, ACHN and KPK-1) and several control cell lines were used to examine the expression of REIC/Dkk-3 mRNA and characterize a newly raised antibody specific for REIC/Dkk-3 protein. Pairs of cancerous and adjacent noncancerous tissues were obtained from 20 patients with RCCC. Of them 17 and 7 cases were analyzed by real-time quantitative reverse transcriptase-polymerase chain reaction, and by Western blot analysis and/or immunohistochemical analysis, respectively.
    Results: The decreased expression of REIC/Dkk-3 mRNA and protein in human RCCC cell lines, and the specificity of the new antibody were confirmed. In a real-time quantitative reverse transcriptase-polymerase chain reaction study using 17 pairs of RCCC and adjacent normal tissues REIC/Dkk-3 mRNA levels were significantly decreased in carcinoma tissues (by 25% to approximately 95% in 15 pairs). Western blot analysis and immunohistochemistry revealed a significant decrease in REIC/Dkk-3 protein levels in 6 of the 7 and 13 of the 14 RCCC cases analyzed, respectively.
    Conclusions: The decrease in REIC/Dkk-3 mRNA and protein levels was observed irrespective of tumor grade and stage, indicating the involvement of REIC/Dkk-3 in an initial step of malignant conversion. Consequently REIC/Dkk-3 could be a new molecular target for therapeutic measures against RCCC.

    DOI: 10.1097/01.ju.0000101047.64379.d4

    Web of Science

    researchmap

  • Establishment of a highly differentiated immortalized human cholangiocyte cell line with SV40T and hTERT

    M Maruyama, N Kobayashi, KA Westerman, M Sakaguchi, JE Allain, T Totsugawa, T Okitsu, T Fukazawa, A Weber, DB Stolz, P Leboulch, N Tanaka

    TRANSPLANTATION   77 ( 3 )   446 - 451   2004年2月

     詳細を見る

    記述言語:英語   出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS  

    Background. Cholangiocytes perform an essential role in important pathophysiologic functions in the liver. Establishment of a human cholangiocyte line facilitates advances in cholangiocyte research and clinical applications for cell therapies. Here, we describe the immortalization of human cholangiocytes using serial transfection of simian virus 40 large T (SV40T) followed by human telomerase reverse transcriptase (hTERT).
    Methods. SV40T-transduced human liver OUMS-21 cells were superinfected with a retroviral vector SSR#197 encoding hTERT and green fluorescent protein (GFP) cDNAs. Resulting cell lines were evaluated for gene expression, functional cholangiogenic characteristics in vitro and in vivo, and response to lipopolysaccharide (LPS).
    Results. One of the SV40T- and hTERT-immortalized cholangiocyte clones, MMNK-1, was established. MMNK-1 expressed cholangiocyte markers, including cytokeratin (CK)-7 and -19 and exhibited cholangiogenic tubule formation in a Matrigel assay. When transplanted into the immunodeficient mice, MMNK-1 cells developed bile duct-like structures in the spleen. After LPS treatment, MMNK-1 cells produced interleukin-6 and failed to form well-developed tubular structures in Matrigel.
    Conclusion. We have established an immortalized cholangiocyte cell line, MMNK-1, using SV40T and hTERT transduction.

    DOI: 10.1097/01.TP.0000110292.73873.25

    Web of Science

    researchmap

  • Transplantation of reversibly immortalized insulin-secreting human hepatocytes controls diabetes in pancreatectomized pigs

    T Okitsu, N Kobayashi, HS Jun, S Shin, SJ Kim, J Han, H Kwon, M Sakaguchi, T Totsugawa, M Kohara, KA Westerman, N Tanaka, P Leboulch, JW Yoon

    DIABETES   53 ( 1 )   105 - 112   2004年1月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER DIABETES ASSOC  

    Type 1 diabetes results from the destruction of insulin-producing pancreatic beta-cells by a beta-cell-specific autoimmune process. Although converting other cell types into insulin-producing cells may compensate for the loss of the beta-cell mass while evading beta-cell-specific T-cell responses, proof-of-principle of this approach in large animal models is lacking. This investigation was initiated to determine whether an insulin-producing human hepatocyte line can control diabetes when transplanted into totally pancreatectomized diabetic pigs. We established a reversibly immortalized human hepatocyte line, YOCK-13, by transferring a human telomerase reverse transcriptase cDNA and a drug-inducible Cre recombinase cassette, followed by cDNA for a modified insulin under the control of the L-type pyruvate kinase (L-PK) promoter. YOCK-13 cells produced small amounts of modified insulin and no detectable endogenous L-PK at low glucose concentrations, whereas they produced large amounts of both modified insulin and L-PK in response to high glucose concentrations. Xenotransplantation of YOCK-13 cells via the portal vein into immunosuppressed, totally pancreatectomized pigs decreased hyperglycemia and prolonged survival without adverse effects such as portal thrombosis, liver necrosis, pulmonary embolism, and tumor development. We suggest that this reversibly immortalized, insulin-secreting human hepatocyte line may overcome the shortage of donor pancreata for islet transplantation into patients with type 1 diabetes.

    DOI: 10.2337/diabetes.53.1.105

    Web of Science

    researchmap

  • Propagation of adult rat bone marrow-derived hepatocyte-like cells by serial passages in vitro

    M Miyazaki, T Masaka, Akiyama, I, E Nakashima, M Sakaguchi, NH Huh

    CELL TRANSPLANTATION   13 ( 4 )   385 - 391   2004年

     詳細を見る

    記述言語:英語   出版者・発行元:COGNIZANT COMMUNICATION CORP  

    Previously, we found that hepatocyte growth factor receptor (c-Met)-and alpha-fetoprotein (AFP)-expressing cells were present in adult rat bone marrow, and that these cells also expressed hematopoietic stem cell markers, such as CD34, Thy-1, and c-Kit. When bone marrow cells were cultured in a hepatocyte growth medium (HGM) with HGF and EGF, colonies composed of polygonal cells resembling mature hepatocytes appeared by 2 weeks and grew very slowly because of overgrowth of stromal cells. At days 34-41, 2-mm(2) sheets of hepatocyte-like cells were cut out of their colonies by scratching with an injection needle under observation with a phase contrast microscope, transferred into wells of 24-well plates, and cultured in the HGM medium in the presence or absence of HGF and EGF. When cells reached confluence, cells were detached with trypsin and EDTA and transferred step by step into bigger culture vessels. Thus, hepatocyte-like cells were expanded 1000-fold during less than 4 months. These cells were immunocytochemically stained for albumin and also for AFP and the hematopoietic stem cell markers described above, showing characteristics of oval cells. By RT-PCR, we detected mRNAs of tryptophan-2,3-dioxygenase and tyrosine aminotransferase, markers of hepatocytes at a terminal differentiation stage. The present culture system may be useful for supply of hepatocyte resources for cell transplantation therapy.

    Web of Science

    researchmap

  • S100C/A11 is a key mediator of Ca2+-induced growth inhibition of human epidermal keratinocytes

    M Sakaguchi, M Miyazaki, M Takaishi, Y Sakaguchi, E Makino, N Kataoka, H Yamada, M Namba, NH Huh

    JOURNAL OF CELL BIOLOGY   163 ( 4 )   825 - 835   2003年11月

     詳細を見る

    記述言語:英語   出版者・発行元:ROCKEFELLER UNIV PRESS  

    An increase in extracellular Ca2+ induces growth arrest and differentiation of human keratinocytes in culture. We examined possible involvement of S100C/A11 in this growth regulation. On exposure of the cells to high Ca2+, S100C/A11 was specifically phosphorylated at (10)Thr and (94)Ser. Phosphorylation facilitated the binding of S100C/A11 to nucleolin, resulting in nuclear translocation of S100C/A11. In nuclei, S100C/A11 liberated Sp1/3 from nucleolin. The resulting free Sp1/3 transcriptionally activated p21(CIP1/WAF1), a representative negative regulator of cell growth. Introduction of anti-S100C/A11 antibody into the cells largely abolished the growth inhibition induced by Ca2+ and the induction of p21(CIP1/WAF1). In the human epidermis, S100C/A11 was detected in nuclei of differentiating cells in the suprabasal layers, but not in nuclei of proliferating cells in the basal layer. These results indicate that S100C/A11 is a key mediator of the Ca2+-induced growth inhibition of human keratinocytes in culture, and that it may be possibly involved in the growth regulation in vivo as well.

    DOI: 10.1083/jcb.200304017

    Web of Science

    researchmap

  • 新規タンパク質リン酸化酵素BRPKの解析

    阪口 政清, 洪 梅, 片岡 健, 宮崎 正博, 許 南浩

    日本癌学会総会記事   61回   81 - 81   2002年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本癌学会  

    researchmap

  • Dynamic alteration of human beta-defensin 2 localization from cytoplasm to intercellular space in psoriatic skin

    WK Huh, T Oono, Y Shirafuji, H Akiyama, J Arata, M Sakaguchi, NH Huh, K Iwatsuki

    JOURNAL OF MOLECULAR MEDICINE-JMM   80 ( 10 )   678 - 684   2002年10月

     詳細を見る

    記述言語:英語   出版者・発行元:SPRINGER-VERLAG  

    Defensins are cationic antimicrobial peptides with a broad spectrum. Recently human P-defensin 2 (hBD-2) has been isolated from psoriatic skin; however, its exact localization and fate have not been fully under,stood. We studied the distribution pattern of hBD-2 in skin tissues of psoriasis and other inflammatory skin diseases. In the upper spinous and granular layer of psoriasis vulgaris hBD-2 was present in the cytoplasm. In the horny layer the positive signals were in a basket-weave pattern, indicating possible accumulation of hBD-2 in the intercellular space. The similar pattern of hBD-2 distribution was observed in the lesions of nummular eczema and atopic dermatitis. hBD-2 was not detected in the section of normal elbow and knee skin. When isolated psoriatic scales were stained. hBD-2 was detected in a wrapping paper-like distribution pattern surrounding the corneocytes. In horny layer of psoriatic skin hBD-2 was closely associated or c localized with elafin, which is known to be in extracellular space, as demonstrated by double staining. Western blot analysis using cultured human keratinocytes detected hBD-2 with an expected size in the conditioned medium and in the cell lysates when stimulated with 5% FCS or IL-alpha. These results indicate that hBD-2 was synthesized and remained in cytoplasm in the upper spinous and granular layer, and then secreted into intercellular space in the horny layer. This dynamic change in hBD-2 distribution in epidermis is certainly relevant to function as an innate host defense mechanism against invading microorganisms.

    DOI: 10.1007/s00109-002-0373-z

    Web of Science

    researchmap

  • Improvement in the differentiated hepatic phenotype of immortalized human hepatocytes by adenovirus mediated p21 gene transfer

    N Kobayashi, M Sakaguchi, T Okitsu, T Totsugawa, M Maruyama, T Matsumura, T Watanabe, H Noguchi, Y Kosaka, T Fujiwara, N Tanaka

    ASAIO JOURNAL   48 ( 4 )   355 - 359   2002年7月

     詳細を見る

    記述言語:英語   出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS  

    The p21 molecule, a potent cyclin dependent kinase inhibitor, regulates the transition from the G1 phase to the S phase of the cell cycle and is involved in terminal cellular differentiation. The overexpression of p21 has been shown to induce differentiation in various cell lines. We have made an effort to establish a reliable human hepatocyte cell line as a source of hepatic function in bioartificial liver (BAL) therapy. In this work, we investigated the effect of p21 on the differential phenotype of simian virus 40 large T antigen (SV40Tag) immortalized human hepatocytic NKNT-3 cells. A recombinant adenoviral vector expressing a p21 gene under control of the cytomegalovirus (CMV) promoter (Ad-p21) was used to efficiently transfer genes into NKNT-3 cells. The morphologic alterations, the cell cycle progression, and the expression of p-450 associated enzymes (CYPs) were carefully examined in NKNT-3 cells that had been infected with Ad-p21. Adenovirus mediated gene delivery of p21 was efficiently achieved in NKNT-3 cells without affecting cellular structure. After Ad-p21 infection, NKNT-3 cells were GO/G1 arrested in cell cycle analysis. NKNT-3 cells that had been infected with Ad-p21 showed differentiated hepatic phenotypes in morphology and improvement in protein expression of CYP 3A4 and CYP 2C9. In the present work, we demonstrate that the exogenous expression of p21 enhances the differential phenotype of immortalized hepatocytic NKNT-3 cells.

    DOI: 10.1097/00002480-200207000-00005

    Web of Science

    researchmap

  • Reversible immortalization of human hepatocytes using the Cre/Loxp system for cell therapies

    T Totsugawa, N Kobayashi, T Okitsu, H Noguchi, T Watanabe, T Matsumura, M Maruyama, M Hikida, A Ohmori, M Sakaguchi, KA Westerman, P Leboulch, N Tanaka

    GASTROENTEROLOGY   123 ( 1 )   54 - 54   2002年7月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:W B SAUNDERS CO  

    Web of Science

    researchmap

  • Controlled expansion of human endothelial cell Populations by cre-loxP-based reversible immortalization

    H Noguchi, N Kobayashi, KA Westerman, M Sakaguchi, T Okitsu, T Totsugawa, T Watanabe, T Matsumura, T Fujiwara, T Ueda, M Miyazaki, N Tanaka, P Leboulch

    HUMAN GENE THERAPY   13 ( 2 )   321 - 334   2002年1月

     詳細を見る

    記述言語:英語   出版者・発行元:MARY ANN LIEBERT INC PUBL  

    Endothelial cells (ECs) play multiple physiological functions and are central to many pathological processes. Various biological studies as well as cell and gene therapy applications would benefit substantially from a procedure that would result in the expansion in culture of large numbers of highly differentiated human ECs. Here, we report the amplification in vitro of human EC populations, which occurred during the first phase of reversible immortalization resulting from the retroviral transfer of an oncogene that was subsequently excised by Cre-loxP-mediated site-specific recombination. Human umbilical vein endothelial cells (HUVECs) and human liver sinusoidal endothelial cells (HLSECs) were transduced with a retroviral vector that expresses the simian virus 40 large T (SV40T) gene flanked by positive and negative selectable markers and a pair of loxP recombination targets. Transduced HUVECs and HLSECs yielded clones with greatly extended life spans, referred to as HNNT-1 and HNNT-2 cells, respectively. HNNT-1 and HNNT-2 cells showed morphological characteristics of ECs and were maintained in culture up to population doubling level (PDL) 80 for HNNT-1 and PDL 65 for HNNT-2 cells. HNNT-1 and HNNT-2 cells were not tumorigenic when transplanted into severe combined immunodeficiency mice and were sensitive to ganciclovir as well as G418. Both cell clones expressed EC markers, which include factor VIII, VEGF receptors (Flt-1 and KDR/Flk-1), and CD34, and endocytosed acetylated low-density lipoproteins. Formation of capillary-like structures in a Matrigel assay was observed with HNNT-1 and HNNT-2 cells until at least PDL 50. Complete elimination of the transferred SV40T gene was achieved in virtually 100% of HNNT-1 and HNNT-2 cells after infection with a recombinant adenovirus expressing the Cre recombinase fused to a nuclear localization signal and subsequent selection with G418. Reverted cells maintained their differentiated EC phenotype. This study extends the utility of the reversible immortalization procedure and provides a means to expand primary human ECs of various sources for basic studies and possible cell and gene therapies.

    DOI: 10.1089/10430340252769833

    Web of Science

    researchmap

  • レンチウイルスベクターシステム樹立に伴う安全配慮.

    都津川敏範, 小林直哉, 丸山昌伸, 小坂芳和, 興津 輝, 荒田 尚, 阪口政清, 藤原俊義, 倉林 譲, 田中紀章

    Organ Biology   9,4,357-364   2002年

     詳細を見る

  • Lentiviral transfer of the LacZ gene into human endothelial cells and human bone marrow mesenchymal stem cells

    T Totsugawa, N Kobayashi, T Okitsu, H Noguchi, T Watanabe, T Matsumura, M Maruyama, T Fujiwara, M Sakaguchi, N Tanaka

    CELL TRANSPLANTATION   11 ( 5 )   481 - 488   2002年

     詳細を見る

    記述言語:英語   出版者・発行元:COGNIZANT COMMUNICATION CORP  

    Because one of the attractive characteristics of human immunodeficiency virus type 1 (HIV-1)-based lentiviral vectors is that it can infect even nondividing cells, a lentivirus-mediated gene delivery system is currently being paid a great deal of attention as an innovative tool for gene transfer into target cells. The purpose of the work was to investigate the efficacy of lentiviral transfer of the LacZ gene into human umbilical vein endothelial cells (HUVECs) and human bone marrow mesenchymal stem cells (HMSCs) in vitro. For the present study, a vesicular stomatitis virus G-protein (VSV-G)-pseudotyped lentiviral vector encoding the E. coli LacZ gene tagged with nuclear localization signal (NLS) was generated in 293T cells by means of the three-plasmid system. The resulting lentiviral vector, LtV-NLS/LacZ, was allowed to infect HUVECs and HMSCs. Approximately 70% of HUVECs were positive for LacZ expression and 50% of HMSCs showed LacZ activity. There was no significant difference in transduction efficacy between early and late-passage phases in both cells. LtV-NLS/LacZ-transduced HUVECs showed gene expression of endothelial markers including CD34 and flt-1 and KDR/flk-1 of vascular endothelial growth factor (VEGF) receptors and had angiogenic potential as efficiently as primarily cultured HUVECs in a Matrigel assay. These findings provide evidence that lentiviral vectors are efficient tools for gene transfer and expression in human endothelial cells and stem cells that could be useful for tissue engineering.

    Web of Science

    researchmap

  • Transduction of immortalized human hepatocytes with p21 to enhance differentiated phenotypes

    T Kunieda, N Kobayashi, M Sakaguchi, T Okitsu, T Totsugawa, T Watanabe, T Matsumura, M Maruyama, H Noguchi, M Takesue, N Shibata, K Ohmoto, T Fujiwara, S Yamamoto, N Tanaka

    CELL TRANSPLANTATION   11 ( 5 )   421 - 428   2002年

     詳細を見る

    記述言語:英語   出版者・発行元:COGNIZANT COMMUNICATION CORP  

    We previously constructed an immortal human hepatocyte line NKNT-3 with a simian virus 40 T antigen (SV40T) to develop cell-based biological therapies. p21 is a molecule that regulates the transition from the G, phase to the S phase of the cell cycle. Investigators have demonstrated that overexpression of p21 induces differentiation in various cell lines. In the current study we examined the effect of p21 on differentiated phenotypes of SV40T-immortalized NKNT-3 cells. A replication-deficient adenovirus vector expressing a human wild-type p21 cDNA under the control of the CMV promoter (Ad5CMVp21) and a human wild-type p21 protein fused to the protein transduction domain from the human immunodeficiency virus (HIV) TAT protein (TAT/p21) were utilized to achieve efficient delivery of p21 into NKNT-3 cells. Morphological alterations, cell cycle progression, and expression of albumin and p-450 associated enzymes (CYPs) 3A4 and 2C9 were evaluated in NKNT-3 cells treated with Ad5CMVp21 and TAT/p21. Efficient adenovirus-based p21 transfer and TAT-mediated p21 protein delivery were confirmed in NKNT-3 cells in an immunofluorescence study and Western blotting analysis. Transduction of NKNT-3 cells with p21 predominantly arrested the cell cycle at the G, checkpoint, resulting in differentiated hepatic phenotypes in morphology and improvement in protein expression of albumin, CYP 3A4, and CYP C29. We here show that exogenous expression of p21 augments cellular differentiation in immortalized human NKNT-3 cells.

    Web of Science

    researchmap

  • Reactivation of liver-specific gene expression in an immortalized human hepatocyte cell line by introduction of the human HNF4 alpha 2 gene

    Y Inoue, M Miyazaki, T Tsuji, M Sakaguchi, K Fukaya, NH Huh, M Namba

    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE   8 ( 5 )   481 - 487   2001年11月

     詳細を見る

    記述言語:英語   出版者・発行元:PROFESSOR D A SPANDIDOS  

    An immortalized human hepatocyte cell line (OUMS-29) was established from fetal liver by transfection with the SV-40 large T antigen gene that has certain liver-specific functions such as albumin production and enzyme activities of CYP1A1, 1A2, and 2E1. To make OUMS-29 cells express other liver-specific functions, the human hepatocyte nuclear factor 4 alpha2 (HNF4 alpha2) gene was introduced into the cells, because this gene was found to be markedly down-regulated. The transduced HNF4 alpha2 was overexpressed in the nuclei of the transfected cells, and its DNA-binding activity was also detected. The liver-specific genes such as apolipoprotein AI, CII, CIII, blood coagulation factor X, alpha1-antitrypsin, and HNF1 alpha were up-regulated. Thus, this cell line is expected to be a useful tool for studying the differentiated human hepatocyte, functions.

    Web of Science

    researchmap

  • Adenovirus-mediated p21 gene transfer enhances differentiated hepatic phenotypes of immortalized human hepatocytes.

    N Kobayashi, H Noguchi, T Totsugawa, T Watanabe, T Matsumura, M Maruyama, T Matsumoto, T Fujimara, N Tanaka, M Sakaguchi

    HEPATOLOGY   34 ( 4 )   305A - 305A   2001年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:W B SAUNDERS CO  

    Web of Science

    researchmap

  • Construction of a differentiated human hepatocyte cell line expressing the herpes simplex virus-thymidine kinase gene

    N Kobayashi, M Miyazaki, KA Westerman, H Noguchi, M Sakaguchi, T Totsugawa, T Watanabe, T Matsumura, T Fujiwara, P Leboulch, N Tanaka, M Namba

    ASAIO JOURNAL   47 ( 5 )   476 - 480   2001年9月

     詳細を見る

    記述言語:英語   出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS  

    Transient support using a hybrid artificial liver (HAL) device is a promising treatment for the patients with acute liver failure. Primary human hepatocytes are an ideal source for HAL therapy; however, the number of human livers available for hepatocyte isolation is limited by competition for use in whole organ transplantation. To overcome this problem, we previously established a highly differentiated human fetal hepatocyte cell line OUMS-29. Considering the potential risk when using these genetically engineered cells in humans, additional safeguards should be added to make the cells more clinically useful. In this work, the herpes simplex virus thymidine kinase (HSVtk) gene was retrovirally introduced into OUMS-29 cells. One of the HSVtk-expressed clones, OUMS-29/thymidine kinase (TK), grew in chemically defined serum free medium and expressed the genes of albumin, asialoglycoprotein receptor, glutamine synthetase, glutathione-S-transferase pi, and blood coagulation factor X. In vitro sensitivity of the cells to ganciclovir was evaluated. Intrasplenic transplantation of 50 X 10(6) OUMS-29/TK cells prolonged the survival of 90% hepatectomized rats compared with medium injection alone (control). In the present study, we have established highly differentiated immortalized human hepatocytes with tight regulation. The cells may be clinically useful for HAL treatment.

    DOI: 10.1097/00002480-200109000-00016

    Web of Science

    researchmap

  • Expansion of human hepatocyte populations by a retroviral gene transfer of simian virus 40 large T antigen

    N Kobayashi, KA Westerman, T Taguchi, M Sakaguchi, T Fujiwara, H Urata, N Kishimoto, N Hayashi, S Nakaji, T Murakami, P Leboulch, N Tanaka

    ASAIO JOURNAL   47 ( 5 )   481 - 485   2001年9月

     詳細を見る

    記述言語:英語   出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS  

    A hybrid artificial liver (HAL) could be used to treat acute liver failure or to serve as a temporary support until orthotopic liver transplantation is available. Primary human hepatocytes are ideal as a source of hepatic function in a HAL device. However, the worldwide shortage of human livers available for hepatocyte isolation severely limits this form of therapy. A possible alternative is to use a tightly regulated cell line that can be economically grown in culture to have differentiated liver function. In this work, human hepatocytes were immortalized with a retroviral vector SSR#69 expressing the genes of simian virus 40 large T antigen and herpes simplex virus-thymidine kinase. One of the resulting clones, NKNT-3, showed the gene expression of differentiated liver function and were sensitive to the antiviral agent ganciclovir. When transplanted into the spleen of rats subjected to 90% hepatectomy, NKNT-3 cells prolonged the survival of 90% hepatectomized rats. The cells provide the advantages of unlimited availability, sterility, uniformity, and freedom from pathogens. This work represents a potential novel strategy for resolving the organ shortage that currently limits the use of primary human hepatocytes to develop a HAL.

    DOI: 10.1097/00002480-200109000-00017

    Web of Science

    researchmap

  • S100Cタンパク質のアクチンとの結合及びその意義

    阪口 政清, 宮崎 正博, 難波 正義, 許 南浩

    Tissue culture research communications : the journal of experimental & applied cell culture research = 組織培養研究   20 ( 2 )   108 - 108   2001年7月

     詳細を見る

  • レンチウイルスベクターによるヒト血管内皮細胞への効果的な遺伝子導入.

    都津川敏範, 小林直哉, 丸山昌伸, 興津 輝, 野口洋文, 松村年久, 渡辺剛正, 阪口政清, 藤原俊義, 田中紀章

    Organ Biology   2001年

     詳細を見る

  • ヒト線維芽細胞の不死化, 癌化にともなう細胞内タンパク質の変化 : 酸化還元系酵素の発現の変化について

    近藤 格, 阪口 政清, 難波 正義

    生物物理化学 = Journal of Electrophoresis   44   35 - 35   2000年10月

     詳細を見る

  • 培養環境中の酸素濃度に依存するヒト線維芽細胞に対する鉄毒性

    濮 紅, 阪口 政清, 近藤 格, 近藤 麻美, 姜 海行, 川端 晃幸, 難波 正義

    Tissue culture research communications : the journal of experimental & applied cell culture research = 組織培養研究   19 ( 2 )   78 - 78   2000年6月

     詳細を見る

  • S100Cタンパク質の細胞密度依存性増殖抑制シグナル

    阪口 政清, 宮崎 正博, 河内 裕輔, 近藤 格, 難波 正義

    Tissue culture research communications : the journal of experimental & applied cell culture research = 組織培養研究   19 ( 2 )   87 - 87   2000年6月

     詳細を見る

  • 【臓器移植と医工学 その現況と展望】 急性肝不全に対する不死化ヒト肝細胞の移植

    小林 直哉, 野口 洋文, 田中 紀章, 深谷 憲一, 阪口 政清, 井上 祐介, 宮崎 正博, 難波 正義

    今日の移植   13 ( 3 )   216 - 221   2000年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)日本医学館  

    researchmap

  • SF10-3 不死化ヒト臍帯静脈内皮細胞株(HNKT-1)の樹立

    野口 洋文, 小林 直哉, 宮崎 正博, 井上 祐介, 阪口 政清, 藤原 俊義, 田中 紀章

    日本外科学会雑誌   101   129 - 129   2000年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • ペプシンを産生するラット胃粘膜上皮細胞株(OUMS-37)の樹立と分化誘導の検討

    濮 紅, 湯浅 貴恵, 近藤 麻美, 阪口 政清, 高 崇, 稲田 憲一, 難波 正義

    Tissue culture research communications : the journal of experimental & applied cell culture research = 組織培養研究   18 ( 1 )   63 - 63   1999年3月

     詳細を見る

  • 細胞外ATPは不死化ヒト線維芽細胞の増殖をヒト正常線維芽細胞に比べより強く抑制する

    井上 裕介, 阪口 政清, 難波 正義

    Tissue culture research communications : the journal of experimental & applied cell culture research = 組織培養研究   18 ( 1 )   67 - 67   1999年3月

     詳細を見る

  • P-986 ラット急性肝不全モデルにおける不死化胎児肝細胞OUMS-29の脾臓内移植の効果

    小林 直哉, 宮崎 正博, 井上 裕介, 阪口 政清, 近藤 麻美, 田中 紀章, 難波 正義

    日本外科学会雑誌   100   558 - 558   1999年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • ATP inhibition of proliferation of immortalized human fibroblasts is greater than that of normal human diploid fibroblasts

    B Katayama, M Sakaguchi, JW Li, H Pu, Y Inoue, M Namba

    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE   2 ( 5 )   603 - 606   1998年11月

     詳細を見る

    記述言語:英語   出版者・発行元:PROFESSOR D A SPANDIDOS  

    It is known that cancers develop by a multi-step process. Normal cells are first immortalized, and then transformed into tumorigenic cells. Normal human cells are very rarely immortalized, but once they are, they are relatively easily transformed into tumorigenic cells. This indicates that the immortalization step plays a critical part in the development of human cancers. Thus, elucidation of the mechanisms of this step would shed light on the process of carcinogenesis in human cells. To understand the causes of immortalization, it is important to determine the differences in cellular phenotype between immortalized and normal human cells. In this study, we found that immortalized human fibroblasts were more sensitive to the growth inhibitory effects of ATP than normal human fibroblasts. ADP was as effective as ATP, but AMP, adenosine, and phosphoric acid were not. These results indicate that a high-energy bound of ATP and ADP may contribute to the growth inhibition of the cells. When the immortalized cells were pulse-labeled with [P-32]-ATP, 30-, 31-, 33- and 40-kDa membrane fraction proteins were more prominently labeled in the immortalized cells than in the normal cells. At present, the characteristics of these proteins are being investigated.

    Web of Science

    researchmap

  • ヒト線維芽細胞の産生するトランスフェリンと培地由来の細胞内トランスフェリンの細胞内局在は異なる

    阪口 政清, 近藤 格, 難波 正義

    Tissue culture research communications : the journal of experimental & applied cell culture research = 組織培養研究   17 ( 1 )   46 - 46   1998年3月

     詳細を見る

▼全件表示

講演・口頭発表等

  • 血漿タンパク受容体をターゲットとした創薬プラン 招待

    阪口政清

    第 44 回日本臨床薬理学会学術総会  2023年12月16日 

     詳細を見る

    開催年月日: 2023年12月14日 - 2023年12月16日

    記述言語:日本語   会議種別:口頭発表(招待・特別)  

    researchmap

  • STAT1/3シグナル経路によるNAD+代謝酵素制御を介した軸索変性と神経細胞死の抑制

    村田 等, 安井 優, 越智 俊樹, 友信 奈保子, 山本 健一, 木下 理恵, 阪口 政清

    第46回日本分子生物学会年会  2023年12月8日 

     詳細を見る

    開催年月日: 2023年12月6日 - 2023年12月8日

    記述言語:日本語   会議種別:ポスター発表  

    researchmap

  • 膀胱がんの進行における S100A8/A9 に関わる分子機構の解明

    友信 奈保子, 木下 理恵, 合原 勇馬, Yoni Komalasari, 二見 淳 一郎, 山内 明, 近藤 英作, 豊岡 伸一, 阪口 政清

    第82回日本癌学会学術総会  2023年9月23日 

     詳細を見る

    開催年月日: 2023年9月21日 - 2023年9月23日

    記述言語:日本語   会議種別:ポスター発表  

    researchmap

  • 核内 PD-L1 は MCRIP1 を抑制することでトリプルネガティブ乳がん細胞の浸潤能を促進する

    合原 勇馬, 友信 奈保子, 木下 理恵, 山本 建一, 村田 等, 阪口 政清

    第82回日本癌学会学術総会  2023年9月22日 

     詳細を見る

    開催年月日: 2023年9月21日 - 2023年9月23日

    記述言語:日本語   会議種別:ポスター発表  

    researchmap

  • 膵がん進展における S100A8/A9 の役割解明と治療方法の開発

    木下 理恵, 友信 奈保子, 山内 明, 二見 淳一郎, 豊岡 伸一, 阪口 政清

    第82回日本癌学会学術総会  2023年9月21日 

     詳細を見る

    開催年月日: 2023年9月21日 - 2023年9月23日

    記述言語:日本語   会議種別:ポスター発表  

    researchmap

  • Lysyl oxidase-like 4 exerts an atypical role in breast cancer progression that targets the cell-surface annexin A2

    Yoni Komalasari, Nahoko Tomonobu, Rie Kinoshita, Yuma Gohara, Kenichi Yamamoto, Hitoshi Murata, Akira Yamauchi, Futoshi Kuribayashi, Yusuke Inoue, Shinichi Toyooka, Masakiyo Sakaguchi

    第82回日本癌学会学術総会  2023年9月20日 

     詳細を見る

    開催年月日: 2023年9月21日 - 2023年9月23日

    記述言語:英語   会議種別:ポスター発表  

    researchmap

  • STAT1/3 シグナル経路によるNAD+代謝酵素制御を介した神経軸索変性と細胞死の抑制

    安井優, 村田等, 大磯和真, 越智俊樹, 友信奈保子, 山本健一, 木下理恵, 阪口政清

    日本組織培養学会第95回大会  2023年9月1日 

     詳細を見る

    開催年月日: 2023年8月31日 - 2023年9月1日

    記述言語:日本語   会議種別:ポスター発表  

    researchmap

  • 細胞表面アネキシンA2/S100A11 結合に着目した 乳がん進行の機序解明

    髙橋徹多, 友信奈保子, Ni LuhGede, Yoni Komalasari, 合原勇馬, 山本健一, 木下理恵, 村田等, 阪口政清

    日本組織培養学会第95回大会  2023年9月1日 

     詳細を見る

    開催年月日: 2023年8月31日 - 2023年9月1日

    記述言語:日本語   会議種別:ポスター発表  

    researchmap

  • 癌転移抑制を目指した細胞動態解析と創薬

    山内明, 町支臣成, 岡本秀一郎, 片瀬直樹, 山村真弘, 友信奈保子, 木下理恵, 阪口政清, 栗林太

    日本組織培養学会第95回大会  2023年9月1日 

     詳細を見る

    開催年月日: 2023年8月31日 - 2023年9月1日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 糞便微生物移植治療から見出した腸内の放線菌の 生理活性評価

    阪口義彦, 武晃, 後藤和義, 原正也, 友信奈保子, 山本健一, 菊池雄太, 坂本光央, 加藤はる, 大宮直木, 阪口政清, 永浜政博

    日本組織培養学会第95回大会  2023年9月1日 

     詳細を見る

    開催年月日: 2023年8月31日 - 2023年9月1日

    記述言語:日本語   会議種別:ポスター発表  

    researchmap

  • 亜鉛結合により活性化されるZEB1 転写因子の 乳がん進展における意義の解明

    山本健一, 平林大輔, 丸山顕嘉, 友信奈保子, 木下理恵, Ni Luh Gade, Yoni Komalasari, 村田等, 合原勇馬, 江帆, 山内明, 栗林太, 豊岡伸一, 井上裕介, 阪口政清

    日本組織培養学会第95回大会  2023年9月1日 

     詳細を見る

    開催年月日: 2023年8月31日 - 2023年9月1日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • TLR4 accelerates bladder cancer progression upon interaction with S100A8/A9

    Fan Jiang, Acosta Gonzalez, Herik Rodrigo, Nahoko Tomonobu, Rie Kinoshita, Yuma Gohara, Ni Luh Gede, Yoni Komalasari, Ken-ichi Yamamoto, Hitoshi Murata, Akira Yamauchi, Shinichi Toyooka, Masami Watanabe, Yasutomo Nasu, Masakiyo Sakaguchi

    日本組織培養学会第95回大会  2023年9月1日 

     詳細を見る

    開催年月日: 2023年8月31日 - 2023年9月1日

    記述言語:英語   会議種別:口頭発表(一般)  

    researchmap

  • ヒトメラノーマ細胞の増殖と血管新生における冬虫夏草の抗腫瘍作用評価 国際共著

    長﨑直也, 堀井聡, I Wayan Sumardika, I Made Winarsa Ruma, 友信奈保子, 木下理恵, 山本健一, 村田等, 阪口政清

    日本組織培養学会第95回大会  2023年9月1日 

     詳細を見る

    開催年月日: 2023年8月31日 - 2023年9月1日

    記述言語:日本語   会議種別:ポスター発表  

    researchmap

  • S100A8/A9 とその新制御分子のバランスで成立するがん転移の機序解明

    友信奈保子, 木下理恵, 合原勇馬, Ni Luh Gede, Yoni Komalasari, Fan Jiang, 村田等, 山本健一, 山内明, 近藤英作, 豊岡伸一, 西堀正洋, 阪口政清

    日本組織培養学会第95回大会  2023年9月1日 

     詳細を見る

    開催年月日: 2023年8月31日 - 2023年9月1日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • ヒトiPS 細胞由来神経細胞と動物モデルを用いた 軸索変性誘導分子SARM1 の阻害剤開発

    村田等, 安藤隆幸, 安井優, 越智俊樹, 友信奈保子, 山本健一, 木下理恵, 阪口政清

    日本組織培養学会第95回大会  2023年9月1日 

     詳細を見る

    開催年月日: 2023年8月31日 - 2023年9月1日

    記述言語:日本語   会議種別:ポスター発表  

    researchmap

  • 膵がん進展におけるS100A8/A9 の機能解析と抗体による治療への応用

    宮本航大, 木下理恵, 小林和子, 友信奈保子, 山本健一, 村田等, 許南浩, 豊岡伸一, 阪口政清

    日本組織培養学会第95回大会  2023年9月1日 

     詳細を見る

    開催年月日: 2023年8月31日 - 2023年9月1日

    記述言語:日本語   会議種別:ポスター発表  

    researchmap

  • β3 インテグリン遺伝子導入ヒト表皮角化細胞を用いた難治性潰瘍に対する新 規再生医療の開発

    久保美代子, 山本健一, 木下理恵, 米澤朋子, 大橋俊孝, 阪口政清

    第55回日本結合組織学会学術大会  2023年6月24日 

     詳細を見る

    開催年月日: 2023年6月24日 - 2023年6月25日

    記述言語:日本語   会議種別:ポスター発表  

    researchmap

  • REIC/Dkk-3の受容体への結合はトリプルネガティブ乳がんのPD-L1の発現を抑制する

    吉澤 智香子, 合原 勇馬, 友信 奈保子, 木下 理恵, 二見 淳一郎, 村田 等, 山本 健一, 阪口 政清

    第45回日本分子生物学会年会  2022年12月1日 

     詳細を見る

    開催年月日: 2022年11月30日 - 2022年12月2日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:千葉市  

    researchmap

  • A critical role of;A;NPTNb axis in;the;lung cancer dissemination

    山本 健一, 友信 奈保子, 木下 理恵, 二見 淳一郎, 山内 明, 豊岡 伸一, 近藤 栄作, 阪口 政清

    第81回日本癌学会学術総会  2022年10月1日 

     詳細を見る

    開催年月日: 2022年9月29日 - 2022年10月1日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:横浜市  

    researchmap

  • Lysyl Oxidase-Like 4 (LOXL4) Exerts an Atypical Role in Breast Cancer Progression Dependent on the Enzymatic ctivity

    Yoni Komalasari, Nahoko Tomonobu, Yuma Gohara, Rie Kinoshita, Masakiyo Sakaguchi

    第81回日本癌学会学術総会  2022年9月30日 

     詳細を見る

    開催年月日: 2022年9月29日 - 2022年10月1日

    記述言語:英語   会議種別:ポスター発表  

    開催地:横浜市  

    researchmap

  • 腫瘍微小環境を悪性化する S100A8/A9 を標的としたがん治療薬の開発

    木下 理恵, 友信 奈保子, 山内 明, 二見 淳一郎, 近藤 英作, 豊岡 伸一, 阪口 政清

    第81回日本癌学会学術総会  2022年9月29日 

     詳細を見る

    開催年月日: 2022年9月29日 - 2022年10月1日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:横浜市  

    researchmap

  • 細胞動態アッセイデバイス TAXIScan で見出された化合物は腫瘍増大と転移の両方を抑える

    山内 明, 山村 真弘, 片瀬 直樹, 友信 奈保子, 木下 理恵, 阪口 政清, 岡本 秀一郎

    第81回  2022年9月29日 

     詳細を見る

    開催年月日: 2022年9月29日 - 2022年10月1日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:横浜市  

    researchmap

  • S100A8/A9-NPTNb シグナルによる肺がん転移メカニズムの解析

    友信 奈保子, Yoni Komalasari, 合原 勇馬, 木下 理恵, 山本 健一, 山内 明, 近藤 英作, 豊岡 伸一, 阪口 政清

    第81回日本癌学会学術総会  2022年9月29日 

     詳細を見る

    開催年月日: 2022年9月29日 - 2022年10月1日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:横浜市  

    researchmap

  • 炎症性疾患に対する抗S100A8/A9抗体療法におけるマクロファージの役割

    木下理恵, 小林和子, 荒木恒太, 佐藤博紀, 友信奈保子, 村田等, 許南浩, 豊岡伸一, 阪口政清

    日本組織培養学会第94回大会  2022年7月8日 

     詳細を見る

    開催年月日: 2022年7月7日 - 2022年7月8日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:大阪府豊中市  

    researchmap

  • REIC protein suppresses tumor progression through PD-L1 regulation in cancer cells

    Yuma Gohara, Nahoko Tomonobu, Rie Kinoshita, Hitoshi Murata, Ken-ichi Yamamoto, Masayoshi Namba, Nam-ho Huh, Hiromi Kumon, Masakiyo Sakaguchi

    日本組織培養学会第94回大会  2022年7月8日 

     詳細を見る

    開催年月日: 2022年7月7日 - 2022年7月8日

    記述言語:英語   会議種別:口頭発表(一般)  

    開催地:大阪府豊中市  

    researchmap

  • Lysyl oxidase-like 4 is prominent in breast cancer progression through its en]ymatic activities

    Ni Luh Gede, Yoni Komalasari, Nahoko Tomonobu, Fan Jiang, Acosta Gonzalez, Herik Rodrigo, Yuma Gohara, Ken-ichi Yamamoto, Rie Kinoshita, Hitoshi Murata, Yusuke Inoue, Masakiyo Sakaguchi

    日本組織培養学会第94回大会  2022年7月8日 

     詳細を見る

    開催年月日: 2022年7月7日 - 2022年7月8日

    記述言語:英語   会議種別:口頭発表(一般)  

    開催地:大阪府豊中市  

    researchmap

  • 軸索変性誘導分子 SARM1の阻害剤開発

    村田 等, 安藤 隆幸, 大磯 和真, 友信 奈保子, 山本 健一, 木下 理恵, 阪口 政清

    NEURO2022  2022年6月30日 

     詳細を見る

    開催年月日: 2022年6月30日 - 2022年7月3日

    会議種別:ポスター発表  

    開催地:沖縄県宜野湾市  

    researchmap

  • がん転移におけるS100A8/A9の機能解明とその制御 ーHRGの発見による新展開ー 招待

    阪口政清

    がん転移におけるS100A8/A9の機能解明とその制御 ーHRGの発見による新展開ー  2022年4月20日  日本血液製剤機構中央研究所

     詳細を見る

    開催年月日: 2022年4月20日

    会議種別:口頭発表(招待・特別)  

    researchmap

  • キシリトールのグルタチオン制御を介したがん選択的抗がん作用の解析

    友信 奈保子, 合原 勇馬, 木下 理恵, 阪口 政清

    第80回日本癌学会学術総会  2021年10月1日 

     詳細を見る

    開催年月日: 2021年9月30日 - 2021年10月2日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:横浜市  

    researchmap

  • S100A8/A9を標的とした炎症性疾患に対する治療法の開発

    木下 理恵, 荒木 恒太, 佐藤 博紀, 友信 奈保子, 村田 等, 山本 健一, 許 南浩, 豊岡 伸一, 阪 口 政清

    日本組織培養学会第93会大会  2021年9月3日 

     詳細を見る

    開催年月日: 2021年9月2日 - 2021年9月3日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:広島市  

    researchmap

  • 培養肝細胞を用いたプラスチックラップによる細胞傷害性の解析

    山本 健一, Xian Wen Tan, 有元 佐賀恵, 押木 俊之, 難波 正義, 阪口 政清

    日本組織培養学会第93会大会  2021年9月3日 

     詳細を見る

    開催年月日: 2021年9月2日 - 2021年9月3日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:広島市  

    researchmap

  • 疾患特異的iPS細胞と動物モデルを用いたパーキンソン病における軸索変性誘導分子 SARM1のリン酸化制御解析

    村田 等, 越智俊樹, 友信奈保子, 山本健一, 木下理恵, 阪口政清

    日本組織培養学会第93会大会  2021年9月3日 

     詳細を見る

    開催年月日: 2021年9月2日 - 2021年9月3日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:広島市  

    researchmap

  • キシリトールの細胞内グルタチオン調節によるがん選択的細胞死誘導機序の解明 招待

    友信 奈保子, 木下 理恵, 山本 健一, 村田 等, 阪口 政清

    日本組織培養学会第93会大会  2021年9月2日 

     詳細を見る

    開催年月日: 2021年9月2日 - 2021年9月3日

    記述言語:日本語   会議種別:口頭発表(招待・特別)  

    開催地:広島市  

    researchmap

  • がんの転移制御を目指して 招待

    阪口政清

    岡山肺癌基礎研究会  2021年6月11日 

     詳細を見る

    開催年月日: 2021年6月11日

    記述言語:日本語   会議種別:口頭発表(招待・特別)  

    開催地:岡山市  

    researchmap

  • HNF4αとCREBHによる肝臓のFsp27bの相乗的な発現制御

    笠野 一郎, 瀧澤 将行, 岩崎 若菜, 佐々木 翔太, 濱田 夢芽, 守本 葵, 阪口 政清, GONZALEZ Frank J, 井上 裕介

    第44回日本分子生物学会年会  2020年12月2日 

     詳細を見る

    開催年月日: 2020年12月2日 - 2020年12月4日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:オンライン  

    researchmap

  • HNF4γ2に相互作用するタンパク質の探索

    江原 伸哉, 佐々木 翔太, 浦部 瑞穂, 前田 つかさ, 鈴木 淳子, 入江 亮太, 鈴木 正則, 外丸 靖浩, 阪口 政清, FRANK Gonzalez J, 井上 裕介

    第44回日本分子生物学会年会  2020年12月2日 

     詳細を見る

    開催年月日: 2020年12月2日 - 2020年12月4日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:オンライン  

    researchmap

  • ロテノン誘発パーキンソニズムの病態形成におけるSARM1リン酸化制御の意義

    村田 等, 越智 俊樹, 山本 健一, 木下 理恵, 阪口 政清

    第43回日本分子生物学会年会  2020年12月2日 

     詳細を見る

    開催年月日: 2020年12月2日 - 2020年12月4日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:オンライン  

    researchmap

  • 分泌性S100A11は膵臓癌の細胞運動性を高める腫瘍周囲の線維芽細胞を活性化する

    合原 勇馬, 光井 洋介, 友信 奈保子, 木下 理恵, 山本 健一, 山内 明, 山村 真弘, 近藤 英作, 豊岡 伸一, 那須 保友, 村田 等, 阪口 政清

    第43回日本分子生物学会年会  2020年12月2日 

     詳細を見る

    開催年月日: 2020年12月2日 - 2020年12月4日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:オンライン  

    researchmap

  • 細胞外S100A11 によりがん間質線維芽細胞が加速する膵がん進展のメカニズムの解明

    合原 勇馬, 光井 洋介, 友信 奈保子, 木下 理恵, 山内 明, 山村 真弘, 近藤 英作, 豊岡 伸一, 那須 保友, 阪口 政清

    第79回日本癌学会学術総会  2020年10月1日 

     詳細を見る

    開催年月日: 2020年10月1日 - 2020年10月3日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:広島市  

    researchmap

  • リンパ内皮細胞上のN;は癌細胞のリンパ系への遊走に重要な役割を果たす

    山内 明, 山村 真弘, 片瀬 直樹, 友信 奈保子, 木下 理恵, 阪口 政清, 岡本 秀一郎

    第79回日本癌学会学術総会  2020年10月1日 

     詳細を見る

    開催年月日: 2020年10月1日 - 2020年10月3日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:広島市  

    researchmap

  • キシリトールによるがん細胞選択的抗がん作用の分子機構の解明ならびにキシリトールの生体における抗がん効能の検討

    友信 奈保子, 合原 勇馬, 木下 理恵, 阪口 政清

    第79回日本癌学会学術総会  2020年10月1日 

     詳細を見る

    開催年月日: 2020年10月1日 - 2020年10月3日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:広島市  

    researchmap

  • HSP90 阻害は食道扁平上皮癌において細胞増殖だけでなく走化性も抑制する

    山村 真弘, 山内 明, 片瀬 直樹, 岡本 秀一郎, 阪口 政清, 山口 佳之

    第79回日本癌学会学術総会  2020年10月1日 

     詳細を見る

    開催年月日: 2020年10月1日 - 2020年10月3日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:広島市  

    researchmap

  • Heat shock protein 90 inhibition suppresses not only proliferation but also migration towards lysophosphatidic acid and Sphingosine-1-phosphate in esophageal squamous cell carcinoma

    Masahiro Yamamura, Akira Yamauchi, Naoki Katase, Masakiyo Sakaguchi, Yosuke Katata, Fuminori Sano, Hiroaki Tanioka, Makoto Okawaki, Takeshi Nagasaka, Yoshiyuki Yamaguchi

    AACR Annual Meeting 2020  2020年4月24日 

     詳細を見る

    開催年月日: 2020年4月24日 - 2020年4月29日

    記述言語:英語  

    開催地:オンライン  

    researchmap

  • S100 family protein: its role in inflammation associated with aging, Specific title: Prevention of cancer metastasis on the basis of identification of novel S100 protein sensor receptors 招待

    阪口政清

    National Symposium and Workshop in Anti-Aging Medicine (NASWAAM)  2020年2月7日 

     詳細を見る

    開催年月日: 2020年2月7日 - 2020年2月9日

    記述言語:英語   会議種別:口頭発表(一般)  

    researchmap

  • Prevention of Aging Process: Biomolecular insight, Specific title: A Novel Tumor Suppressor, REIC/Dkk-3 Gene Identified by Our In Vitro Transformation Model of Normal Human Fibroblasts Works as a Potent Therapeutic Anti-tumor Agent 招待

    阪口政清

    National Symposium and Workshop in Anti-Aging Medicine (NASWAAM)  2020年2月7日 

     詳細を見る

    開催年月日: 2020年2月7日 - 2020年2月9日

    記述言語:英語   会議種別:口頭発表(招待・特別)  

    researchmap

  • 肺腺がん細胞における核内受容体HNF4αの機能解析と標的遺伝子の同定

    亀井めぐみ, 濱田真輝, 阪口政清, 井上裕介

    第42回日本分子生物学会年会  2019年12月5日 

     詳細を見る

    開催年月日: 2019年12月3日 - 2019年12月6日

    会議種別:ポスター発表  

    開催地:福岡市  

    researchmap

  • Development of exSSSRs(extracellular S100 soil sensor receptors)-Fc fusion proteins and S100A8/A9 antibody for suppression of cancer metastasis

    Rie Kinoshita, Hiroki Sato, Akira Yamauchi, Yuta Takahashi, Yusuke Inoue, I Wayan Sumardika, Youyi Chen, Nahoko Tomonobu, Kota Araki, Kazuhiko Shien, Shuta Tomida, Hidejiro Torigoe, Kei Namba, Eisuke Kurihara, Yusuke Ogoshi, Hitoshi Murata, Ken-ichi Yamamoto, Junichiro Futami, Endy Widya PutrantoI, I Made Winarsa Ruma, Hiromasa Yamamoto, Junichi Soh, Toshihiko Hibino, Masahiro Nishibori, Eisaku Kondo, Shinichi Toyooka, Masakiyo Sakaguchi

    第9回International DAMPs and Alarmins Symposium (9th iDEAs)  2019年11月6日 

     詳細を見る

    開催年月日: 2019年11月6日 - 2019年11月8日

    記述言語:英語   会議種別:ポスター発表  

    開催地:岡山市  

    researchmap

  • メラノーマ原発巣における転移機構に関わるMCAM-S100A8/A9シグナル経路の分子学的解析

    友信 奈保子, 木下 理恵, 近藤 英作, 山内 明, 二見 淳一郎, 豊岡 伸一, 阪口 政清

    第78回日本癌学会学術総会  2019年9月28日 

     詳細を見る

    開催年月日: 2019年9月26日 - 2019年9月28日

    会議種別:ポスター発表  

    開催地:京都市  

    researchmap

  • 転移がんに有効なS100A8/A9阻害薬の開発

    木下 理恵, 友信 奈保子, 山内 明, 枝園 和彦, 冨田 秀太, 村田 等, 二見 淳一郎, 近藤 英作, 豊岡 伸一, 阪口 政清

    第78回日本癌学会学術総会第  2019年9月27日 

     詳細を見る

    開催年月日: 2019年9月26日 - 2019年9月28日

    会議種別:ポスター発表  

    開催地:京都市  

    researchmap

  • JNKによるリン酸化を介したSARM1のNAD+代謝と軸索変性への寄与 招待

    村田 等, 阪口政清

    第92回日本生化学会大会  2019年9月18日 

     詳細を見る

    開催年月日: 2019年9月18日 - 2019年9月20日

    会議種別:シンポジウム・ワークショップ パネル(指名)  

    開催地:横浜市  

    researchmap

  • JNKによるリン酸化を介したSARM1のNAD+分解活性とミトコンドリア機能制御

    村田等, 山本健一, 木下理恵, 阪口政清

    NEURO2019(第42回日本神経科学大会、第62回日本神経化学会大会)  2019年7月25日 

     詳細を見る

    開催年月日: 2019年7月25日 - 2019年7月28日

    会議種別:ポスター発表  

    開催地:新潟市  

    researchmap

  • 新規HNF4γバリアントによる肝機能の誘導

    佐々木 翔太, 浦部瑞穂, 前田つかさ, 鈴木淳子, 入江亮太, 阪口政清, Frank J. Gonzalez, 井上裕介

    第  2018年11月30日 

     詳細を見る

    開催年月日: 2018年11月28日 - 2018年11月30日

    会議種別:ポスター発表  

    researchmap

  • 分泌性S100A11-受容体RAGEシグナルを介した膵臓がん周辺微小環境における間質線維芽細胞の増殖誘導の解明

    山本 健一, 高松 仁志, 友信 奈保子, 光井 洋介, 二見 淳一郎, 木下 理恵, 村田 等, 阪口 政清

    第41回日本分子生物学会年会  2018年11月30日 

     詳細を見る

    開催年月日: 2018年11月28日 - 2018年11月30日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:横浜市  

    researchmap

  • JNKによるリン酸化はSARM1のNAD分解活性を制御し、ミトコンドリア呼吸阻害を誘導する

    村田 等, 山本健一, 木下理恵, 阪口政清

    第41回日本分子生物学会年会  2018年11月30日 

     詳細を見る

    開催年月日: 2018年11月28日 - 2018年11月30日

    会議種別:ポスター発表  

    開催地:横浜市  

    researchmap

  • Development of novel biologics to prevent lung tropic cancer metastasis. 招待

    阪口政清

    The First International Symposium on Immunology and Cancer in Okayama / 13th URA International Symposium  2018年10月31日 

     詳細を見る

    開催年月日: 2018年10月31日

    記述言語:英語   会議種別:口頭発表(招待・特別)  

    開催地:岡山市  

    researchmap

  • がん転移抑制剤として効果を有するS100A8/A9中和抗体の開発

    木下理恵, 山内明, 枝園和彦, 富田秀太, 村田等, 豊岡伸一, 近藤英作, 阪口政清

    第77回日本癌学会学術総会  2018年9月28日 

     詳細を見る

    開催年月日: 2018年9月27日 - 2018年9月29日

    記述言語:英語   会議種別:ポスター発表  

    開催地:大阪市  

    researchmap

  • EGFR変異陽性肺癌におけるLRIG1の抗腫瘍効果

    鳥越英次郎, 山本寛斎, 阪口政清, 難波圭, 佐藤博紀, 枝園和彦, 諏澤憲, 宗淳一, 冨田秀太, 佃和憲, 三好新一郎, 豊岡伸一

    第77回日本癌学会学術総会  2018年9月28日 

     詳細を見る

    開催年月日: 2018年9月27日 - 2018年9月29日

    記述言語:英語   会議種別:口頭発表(一般)  

    開催地:大阪市  

    researchmap

  • 浸潤性膵管がんの転移におけるPODXL1の生物学的役割

    近藤英作, 阪口政清, 飯岡英和, 齋藤憲

    第77回日本癌学会学術総会  2018年9月27日 

     詳細を見る

    開催年月日: 2018年9月27日 - 2018年9月29日

    記述言語:英語   会議種別:口頭発表(一般)  

    開催地:大阪市  

    researchmap

  • 分泌性S100A11-受容体RAGEシグナルに着眼した膵がん間質増大のメカニズムの解明分泌性S100A11-受容体RAGEシグナルに着眼した膵がん間質増大のメカニズムの解明

    本健一, 高松仁志, 光井洋介, 木下理恵, 村田 等, 二見淳一郎, 山本靖彦, 西堀正洋, 豊岡伸一, 阪口政清

    第22回日本がん免疫学会総会  2018年8月3日 

     詳細を見る

    開催年月日: 2018年8月1日 - 2018年8月3日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 膵がん進展に導く膵がん細胞−間質線維芽細胞クロストークを介在する分泌性 S100A11−受容体RAGE連携の役割

    光井洋介, 山本健一, Sumardika I Wayan, 木下理恵, 村田等, 二見淳一郎, 高松仁, 山本靖彦, 西堀正洋, 豊岡伸一, 渡部昌実, 那須保友, 阪口政清

    第22回日本がん免疫学会総会  2018年8月2日 

     詳細を見る

    開催年月日: 2018年8月1日 - 2018年8月3日

    記述言語:日本語   会議種別:ポスター発表  

    researchmap

  • Novel biologics to prevent cancer metastasis 招待

    第9回International DAMPs and Alarmins Symposium  2019年 

     詳細を見る

    記述言語:日本語  

    researchmap

  • Therapeutic Strategies for suppression of cancer metastasis on the basis of finding novel S100A8/A9 receptors

    2017年 

     詳細を見る

  • Development of novel biologics for cancer metastasis via prevention of extracellular S100A8/A9 function

    The 76th Annual Meeting of the Japanese Cancer Association  2017年 

     詳細を見る

  • Crumbs3 promotes metastasis of colon cancer by regulating focal adhesion components

    The 76th Annual Meeting of the Japanese Cancer Association  2017年 

     詳細を見る

  • Identification of novel receptors for pro-inflammatory S100A8/A9 protein and its role(s) in cancer metastasis

    2017年 

     詳細を見る

  • SARM1 induces neuronal cell death by inhibition of mitochondrial respiration

    2017年 

     詳細を見る

  • S100タンパク質を基軸とした乾癬病態増悪の分子メカニズムとその制御

    第16回皮膚科スプリングセミナー  2017年 

     詳細を見る

  • S100A8を標的としたがん転移制御法の開発

    日本組織培養学会第90回大会  2017年 

     詳細を見る

  • 転移先臓器を感知する受容体

    日本組織培養学会第90回大会  2017年 

     詳細を見る

  • Anti-glioma mechanism of the Ad-REIC vector with the super gene expression system.

    第24回日本遺伝子細胞治療学会学術総会  2017年 

     詳細を見る

  • S100A8/A9 とその受容体との結合遮断を目指した転移抑制タンパク質製剤の開発

    第76回日本癌学会学術総会  2017年 

     詳細を見る

  • ミトコンドリア呼吸鎖複合体への作用を介したSARM1の神経細胞死誘導

    日本組織培養学会第90回大会  2017年 

     詳細を見る

  • A super gene expression system enhances the anti-glioma effects of adenovirus-mediated REIC/Dkk-3 gene therapy.

    第23回日本遺伝子細胞治療学会学術総会  2017年 

     詳細を見る

  • 核内受容体HNF4γによる肝がん細胞の再分化誘導

    第39回日本分子生物学会年会  2017年 

     詳細を見る

  • ゲノムと遺伝情報-5) RNAプロセシング、輸送、翻訳、非コードRNA

    第39回日本分子生物学会年会  2017年 

     詳細を見る

  • Crumbs3 は焦点接着構成因子を制御することで大腸癌の転移を促進する

    第76回日本癌学会学術総会  2017年 

     詳細を見る

  • 健常者及びパーキンソン病患者iPS細胞由来の神経細胞を用いたミトコンドリア機能解析

    第39回日本分子生物学会年会  2017年 

     詳細を見る

  • s100a8/A9タンパク質と臓器指向性転移

    第28回創薬・薬理フォーラム岡山  2017年 

     詳細を見る

  • 神経細胞死・軸索変性に関与するSARM1のリン酸化制御

    第39回日本分子生物学会年会  2016年 

     詳細を見る

  • HNF4αによるmiRNAを介した遺伝子発現制御機構の解析

    第39回日本分子生物学会年会  2016年 

     詳細を見る

  • 核内受容体HNF4γの機能解析

    第39回日本分子生物学会年会  2016年 

     詳細を見る

  • Development of a novel biologics for suppression of S100A8/A9-induced cancer metastasis

    The 76th Annual Meeting of the Japanese Cancer Association  2016年 

     詳細を見る

  • Beta3 integrin cDNA-transduced human keratinocytes grow far better on fibrin gels as compared to normal human keratinocytes

    2016年 

     詳細を見る

  • Extract of Cordyceps militaries inhibits angiogenesis and suppresses tumor growth of human malignant melanoma cells

    2016年 

     詳細を見る

  • Functional Interplay between the Leukotriene B4 receptor BLT1 and RAGE

    6th international conference on Phospholipase A2 and Lipid Mediators(PLM2015)  2016年 

     詳細を見る

  • Regulation of Cellular Stress Response By Mitochondrial Kinase Pink1

    日本組織培養学会第89回大会  2016年 

     詳細を見る

  • Interaction between Pancreatic cancer cells and MSC for cancer progression

    The 76th Annual Meeting of the Japanese Cancer Association  2016年 

     詳細を見る

  • The cell polarity regulator Crumbs3 promotes adenocarcinoma metastasis through the regulation of glycolipid dynamics

    The 76th Annual Meeting of the Japanese Cancer Association  2016年 

     詳細を見る

  • PINK1 regulation of mitochondrial homeostasis and cell survival.

    the 2016 World Congress on In Vitro Biology  2016年 

     詳細を見る

  • 肺動脈性肺高血圧症におけるRAGEシグナルの亢進

    第4回日本肺循環学会・第3回日本肺高血圧学会 合同学術集会  2016年 

     詳細を見る

  • 冬虫夏草抽出溶液による悪性メラノーマ細胞の増殖と血管新生の抑制

    日本組織培養学会第89回大会  2016年 

     詳細を見る

  • Beta3インテグリンcDNA導入ヒトケラチノサイトは正常ヒトケラチノサイトに比べてフィブリンゲル上で細胞増殖が増加する

    日本組織培養学会第89回大会  2016年 

     詳細を見る

  • 癌転移抑制を目指した新規タンパク質製剤の開発

    第75回日本癌学会学術総会  2016年 

     詳細を見る

  • 浸潤性膵管癌におけるがん-間質相互反応の増殖・浸潤における役割

    第75回日本癌学会学術総会  2016年 

     詳細を見る

  • 細胞極性制御因子Crumbs3 は糖脂質動態を制御することで腺癌の転移を促進する

    第75回日本癌学会学術総会  2016年 

     詳細を見る

  • NOD2 inflammasome is up-regulated in the skin with atopic dermatitis.

    日本研究皮膚科学会 第40回年次学術大会・総会  2015年 

     詳細を見る

  • Identification of a novel binding protein playing a critical role in HER2 activation in lung cancer cells

    AACR Annual Meeting 2015  2015年 

     詳細を見る

  • RegulationofREIC/Dkk-3expressionbyTNF-alphaanditseffecton normal human keratinocytes

    2015年 

     詳細を見る

  • NRF2 pathway activation as a target to counteract mitochondrial dysfunction in Parkinson’s disease

    第9回ICME国際複合医工学会議  2015年 

     詳細を見る

  • TNF-αによるREIC/Dkk-3の発現制御とケラチノサイトの挙動への影響

    日本組織培養学会第88回大会  2015年 

     詳細を見る

  • TIR/BB-loop mimetic AS-1 Inhibits Proliferation of Pulmonary Artery Smooth Muscle Cells from Patients with Pulmonary Arterial Hypertension

    第79回日本循環器学会  2015年 

     詳細を見る

  • S100A8/A9 induces skin inflammation and keratinocyte proliferation via neuroplasatin-beta/EMMPRIN heterodimer receptor in atopic dermatitis

    日本研究皮膚科学会 第40回年次学術大会・総会  2015年 

     詳細を見る

  • S100A8 promoted Th1-related gene expression and S100A9 induced Th2 differentiation via activation of GATA-3

    日本研究皮膚科学会 第40回年次学術大会・総会  2015年 

     詳細を見る

  • Mechanism of S100A9 induction in the skin with atopic dermatitis―involvement of NOD2 inflammasome

    日本研究皮膚科学会 第40回年次学術大会・総会  2015年 

     詳細を見る

  • Regulation of PINK1 expression through the NRF2 transcription factor under mitochondrial stress conditions

    PINK1-Parkin Signalling in Parkinson’s Disease and Beyond  2014年 

     詳細を見る

  • Novel functional mutations in the transmembrane domain of HER2 gene in familial and sporadic lung adenocarcinomas

    2014年 

     詳細を見る

  • Novel HER2 mutations in transmembrane dmain result in constitutive autophosphorylation of HER2

    2014年 

     詳細を見る

  • 新開発超高効率遺伝子発現プラスミドベクターによる抗体大量産出技術の確立

    大学研究力強化支援情報交換ワークショップ  2014年 

     詳細を見る

  • IgG4関連疾患:病態形成機序ならび腫瘍との関連性

    第17回がんと免疫セミナー  2014年 

     詳細を見る

  • 炎症を感知する新規内因性リガンドセンサ―の作動機構解明とがん進展における役割

    新学術領域平成25年度第4回領域班会議  2014年 

     詳細を見る

  • Critical role of Cytokeratin-19 in an oncogenic activation of HER2

    2014年 

     詳細を見る

  • S100タンパク質によるケラチノサイトの増殖、死の分子制御機構、阪口政清

    資生堂新領域研究センター特別講演  2014年 

     詳細を見る

  • 家族性・孤発性肺腺癌におけるHER2 膜貫通領域の新規遺伝子変異

    第73回日本癌学会学術総会  2014年 

     詳細を見る

  • 新規HER2 膜貫通部領域遺伝子変異の機能解析

    第73回日本癌学会学術総会  2014年 

     詳細を見る

  • HNF4γの機能解析

    第37回日本分生生物学会年会  2014年 

     詳細を見る

  • ロイコトリエンB4第一受容体BLT1とRAGEの相互作用

    第87回日本生化学会大会  2014年 

     詳細を見る

  • 高機能REIC 遺伝子発現アデノウイルスベクターの開発

    岡山大学機能強化戦略プロジェクト-難治固形がんの遺伝子治療- 第2回シンポジウム  2014年 

     詳細を見る

  • HER2がんマーカー,サイトケラチン19 (CK19) 機能の新展開― HER2活性化におけるCK19 の役割―

    第73回日本癌学会学術総会  2014年 

     詳細を見る

  • Histidine-rich glycoprotein prevents septic lethality through neutrophil regulation

    Sepsis Symposium at Pasteur Institute in Paris  2014年 

     詳細を見る

  • Identification of RAGE-coupled membran adaptor that modulates RAGE-triggered signaling pathway

    2013年アメリカ細胞生物学会総会  2013年 

     詳細を見る

  • Regulation of Cellular Stress Response By Mitochondrial Kinase Pink1

    日本組織培養学会第86回大会  2013年 

     詳細を見る

  • S100A8/A9 targets oncogenic survival pathway via RAGE that critically enhanced by a RAGE co-receptor. 多機能受容体RAGE の共役受容体の発見とその意義

    第72回日本癌学会学術総会  2013年 

     詳細を見る

  • 膿疱性乾癬の病態解明とその対策に向けて - S100A8およびS100A9タンパク質の新規受容体の探索とその機能解析-

    稀少難治性皮膚疾患に関する調査研究班平成24年度第1回総会  2013年 

     詳細を見る

  • 多機能受容体RAGEの共役受容体の発見とその意義

    新学術領域研究「自然炎症」+「脂質マシナリー」合同若手ワークショップ  2013年 

     詳細を見る

  • S100タンパク質機能解析の新展開―分泌性S100タンパク質とその受容体ファミリーによる「炎症―腫瘍進展」応答ネットワーク形成の分子機構の解明とその制御

    徳島文理大学大学院特別講演  2013年 

     詳細を見る

  • SARM1and TRAF6 bind to and stabilizes PINK1 on the outer membrane of depolarized mitochondria for mitophagy through interaction with SARM1

    第36回日本分子生物学会年会  2013年 

     詳細を見る

  • TRAF6 and SARM1 regulate PINK1 ubiquitination and stabilization on

    第1回国際ミトコンドリア学術集会  2013年 

     詳細を見る

  • 肝臓特異的HNF4α欠損マウスにおけるHNF4γの機能解析

    第36回日本分子生物学会年会  2013年 

     詳細を見る

  • TRAF6 ubiquitinates and stabilizes PINK1 on the outer membrane of depolarized mitochondria through interaction with SARM1

    2013年アメリカ細胞生物学会総会  2013年 

     詳細を見る

  • Analysis of Pseudolysogenic Lifecycle of Clostridium botulinum Phage c-st, Based on Comparative Genomics of Wild-type and Long-term-incubated Mutants Phages

    2012年 

     詳細を見る

  • Identification of novel receptors for pro-inflammatory S100A8/A9 proteins and their potential

    2012年 

     詳細を見る

  • Development of RAGE-inhibitor delivered into cells

    2012年 

     詳細を見る

  • Analysis of Pseudolysogenic Lifecycle of Clostridium botulinum Phage c-st, Based on Comparative Genomics of Wild-type and Long-term-incubated Mutants Phages

    2012年 

     詳細を見る

  • TRAF6 Ubiquitinates and Stabilizes PINK1 on Damaged Mitochondria Through Interaction with SARM1

    2012年 

     詳細を見る

  • DOCK7 is a critical regulator of the RAGE-Cdc42 signaling axis that induces formation of dendritic pseudopodia in human cancer cells

    2012年 

     詳細を見る

  • 膿疱性乾癬の病態解明とその対策に向けて - S100A8およびS100A9タンパク質の新規受容体の探索とその機能解析-

    稀少難治性皮膚疾患に関する調査研究班平成24年度第1回総会  2012年 

     詳細を見る

  • A Novel Tumor Suppressor, REIC/Dkk-3 Gene Identified by our in Vitro Transformation Model of Normal Human Fibroblasts Works as a Potent Therapeutic Anti-tumor Agent

    2012 World Congress on In Vitro Biology  2012年 

     詳細を見る

  • 細胞内導入型RAGE阻害剤の開発

    日本組織培養学会第85回大会  2012年 

     詳細を見る

  • 細胞遊走に関わるRAGE膜直下信号伝達機構の解析―RAGE細胞質領域結合タンパク質Dock7の発見―

    第35回日本分子生物学会年会  2012年 

     詳細を見る

  • Identification of novel receptors for pro-inflammatory S100A8/A9 proteins and their roles inmelanoma metastasis

    IEIIS2012. Homeostatic Inflammation Symposium  2012年 

     詳細を見る

  • S100A8およびS100A9タンパク質の新規受容体の探索とそのがん進展における役割

    第71回日本癌学会学術総会  2012年 

     詳細を見る

  • 細胞内導入型RAGE阻害ペプチドの開発

    日本生物工学会西日本支部創立30周年記念シンポジウム・講演会  2012年 

     詳細を見る

  • C型ポツリヌス毒素変換ファージのゲノム情報を基盤とした偽溶原性メカニズムの解析

    第35回日本分子生物学会年会  2012年 

     詳細を見る

  • TRAF6とSARM1によるPINK1のユビキチン化はマイトファジーの誘導に必須である

    第35回日本分子生物学会年会  2012年 

     詳細を見る

  • RAGE高発現がもたらす細胞形態変化と細胞運動亢進の分子機構の解析

    第34回日本分子生物学会年会  2011年 

     詳細を見る

  • Mitochondral malfunction by PINK1 kn0ckdown augments apoptosis induced by adenoviirus carrying REIC/Dkk-3

    2011年 

     詳細を見る

  • Promotion of migration and invasion of osteosarcoma cells by S100A7 through RAGE

    2011年 

     詳細を見る

  • PINK1 knockdown increases the apoptosis induced by adenovirus-mediated REIC/Dkk-3

    日本組織培養学会第84回大会  2011年 

     詳細を見る

  • REIC/Dkk-3 の扁平上皮における発現とその制御因子の探索

    日本組織培養学会第84回大会  2011年 

     詳細を見る

  • Anti-proliferative effect of microRNA-34b/c adenoviral gene transfer on malignant pleural mesotheliomas

    2011年 

     詳細を見る

  • TIRAP is a critical transducer of RAGE-mediated inflammatory signaling

    2011年 

     詳細を見る

  • 膿疱性乾癬の病態解明とその対策に向けて - S100A8およびS100A9タンパク質の新規受容体の探索とその機能解析-

    稀少難治性皮膚疾患に関する調査研究班平成23年度第1回総会  2011年 

     詳細を見る

  • PINK1発現抑制によるミトコンドリア機能不全はREIC/Dkk-3のアポトーソシス誘導効果を増強する

    第70回日本癌学会学術総会  2011年 

     詳細を見る

  • S100A7による骨肉腫細胞の遊走・浸潤の多機能受容体RAGEを介した制御機構

    第70回日本癌学会学術総会  2011年 

     詳細を見る

  • Mitochondrial dysfunction by PINK1 knockdown augments apotosis induced by a gene-therspeutic adenovirus carrying REIC/Dkk-3

    第34回日本分子生物学会年会  2011年 

     詳細を見る

  • 正常皮膚におけるREIC/Dkk-3の発現制御因子の検索

    第34回日本分子生物学会年会  2011年 

     詳細を見る

  • 悪性胸膜中皮腫に対するマイクロRNA34b/cを用いたアデノウイルス遺伝子治療の可能性

    第70回日本癌学会学術総会  2011年 

     詳細を見る

  • 多機能受容体RAGEの下流信号伝達機構の解明

    第70回日本癌学会学術総会  2011年 

     詳細を見る

  • S100タンパク質受容体の統合解析

    第34回日本分子生物学会年会  2011年 

     詳細を見る

  • REIC/Dkk-3 gene therapy suppresses peritoneal dissemination of scirrhous gastric carcinoma

    2010年 

     詳細を見る

  • TAE226, a bis-anilino pyrimidine compound, specifically inhibits the EGFR mutant kinase to show anti-tumor effect on non-small cell lung cancer with EGFR mutation

    2010年 

     詳細を見る

  • Frequent silencing of tumor suppressive miR-34b/c by aberrant methylation in malignant pleural mesothelioma

    2010年 

     詳細を見る

  • Role of KLF11 and KLF15 in brown adipocyte differentiation

    2010年 

     詳細を見る

  • TIRAP, an adaptor protein for TLR-2/-4, transduces a signal from RAGE phosphorylated upon ligand bindi

    2010年 

     詳細を見る

  • biologial relw of coxsactievirus and Adenovirus receptor (CXADR) in cancer cell proliferqtion

    2010年 

     詳細を見る

  • Epigenetic silencing of microRNA-34b/c plays a pivotal role in pathogenesis of malignant mesothelioma pathogenesis

    2010年 

     詳細を見る

  • 悪性胸膜中皮腫の新しい分子生物学的異常と治療応用の可能性

    日本組織培養学会第83回大会  2010年 

     詳細を見る

  • Effect of Adenovirus-mediated Overexpression of REIC/Dkk-3 on Scirrhous Gastric Carcinoma Cells

    日本組織培養学会第83回大会  2010年 

     詳細を見る

  • 褐色脂肪細胞分化におけるKLF11とKLF15の役割

    日本組織培養学会第83回大会  2010年 

     詳細を見る

  • 分化誘導したマウスES細胞及びiPS細胞におけるCy3標識REIC/Dkk-3タンパク質のエンドサートーシスによる取り込み

    日本組織培養学会第83回大会  2010年 

     詳細を見る

  • マイクロRNA34b/cのメチル化による発現低下は悪性胸膜中皮腫の重要な分子病態である

    第69回日本癌学会学術総会  2010年 

     詳細を見る

  • スキルス胃がん腹膜播種へにREIC/Dkk-3遺伝子治療の効果

    第69回日本癌学会学術総会  2010年 

     詳細を見る

  • 膿疱性乾癬の病態解明とその対策に向けて - 多機能受容体RAGEの信号伝達経路の解析

    稀少難治性皮膚疾患に関する調査研究班平成22年度第1回総会  2010年 

     詳細を見る

  • 肺癌細胞株におけるTAE226の変異型EGFRチロシンキナーゼ特異的な不活化作用とその抗腫瘍効果の検討

    日本組織培養学会第83回大会  2010年 

     詳細を見る

  • PINK1/BRPK inhibits apoptotic cell death and enahances cellular invasiveness through an activation of mTORC2 pathway

    The 16th International Charles Heidelberger Symposium on Cancer Research  2010年 

     詳細を見る

  • アデノウイルス受容体(CAR;CXADR)の固形癌細胞の増殖制御における役割の解析

    第69回日本癌学会学術総会  2010年 

     詳細を見る

  • 多機能受容体RAGEの下流信号伝達機構の解明

    第33回日本分子生物学会年会・第83回日本生化学会大会 合同大会  2010年 

     詳細を見る

  • BRPK/PINK1 promotes tumor progression through activation of mTORC2 pathway

    第33回日本分子生物学会年会・第83回日本生化学会大会 合同大会  2010年 

     詳細を見る

  • KFL11とKLF15によるUCP1の発現制御

    第33回日本分子生物学会年会・第83回日本生化学会大会 合同大会  2010年 

     詳細を見る

  • Endocytotic internalization of Cy3-labeled REIC/Dkk-3 protein by differentiated ES cells and iPS cells

    2010年 

     詳細を見る

  • 分化したマウスES細胞およびiPS細胞のCy3標識REIC/Dkk-3タンパク質の取り込み

    第8回日本再生医療学会  2009年 

     詳細を見る

  • BRPK/PINK1 enhances invasiveness of cancer cells through activation of mTCRC2 pathway (RPK/PINK1のmTORC2経路活性化を介したがん浸潤への寄与

    第68回日本癌学会学術総会  2009年 

     詳細を見る

  • KLF11およびKLF15による褐色脂肪特異的遺伝子UCP1の転写制御

    第14回アディポサイエンス研究会シンポジウム  2009年 

     詳細を見る

  • 膿疱性乾癬の病態解明とその対策に向けて-多機能受容体RAGEの信号伝達経路の解析

    希少難治性皮膚疾患に関する調査研究班平成21年度第1回総会  2009年 

     詳細を見る

  • BRPK/PINK1のmTORC2活性化を介したがん進展への寄与

    日本組織培養学会第82回大会  2009年 

     詳細を見る

  • Normal human fibroblasts mis-targetedly infected with adenovirus REIC have a tumorsuppressive ability in vivo

    第32回日本分子生物学会年会参加費  2009年 

     詳細を見る

  • Promoter-badsed improvement of gene expression in cancer therapeutic advenovirus vecter carrying 超高効率発現ベクターの開発とがん遺伝子治療薬としてのREIC/Dkk-3REIC/Dkk-3アデノウイルス

    第68回日本癌学会学術総会  2009年 

     詳細を見る

  • Over-expression of REIC/Dkk-3 induces IL-7 in normal human fibroblasts via ER stress

    第67回日本癌学会学術総会  2008年 

     詳細を見る

  • INVOLVEMENT OF DECLINE IN S100C/A11-MEDIATED PATHWAY IN RESISTANCE OF CANCER CELLS TO TGFb-INDUCED GROWTH SUPPRESSION

    The 66th Annual meeting of the Japanease Cancer Association (第66回日本癌学会学術総会)  2007年 

     詳細を見る

  • Autocrine growth-stimulation of normal human keratinocytes by secreted S100C/A11

    The 66th Annual meeting of the Japanease Cancer Association (第66回日本癌学会学術総会)  2007年 

     詳細を見る

  • S100A11,a Ca++-binding protein showing pleiotropic growth regulating functions in normal human keratinocytes

    第30回分子生物学会年会・第80回日本生化学会大会合同大会  2007年 

     詳細を見る

  • S100A11,an ambivalent mediator for growth regulation of human keratinocytes.

    American Society for Cell Biology 47th Annual Meeting  2007年 

     詳細を見る

  • S100C/A11による細胞増殖制御機構の新展開-分泌型S100C/A11の機能解明

    第80回日本組織培養学会大会  2007年 

     詳細を見る

  • Molecular mechanism of growth-regulation of normal human keratinocytes by S100C/A11

    がん研究に係わる特定領域研究-若手研究者ワークショップ  2007年 

     詳細を見る

  • Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of JNK

    The 11th International Charles Heidelberger Symposium on Cancer Research  2006年 

     詳細を見る

  • ヒト正常表皮角化細胞におけるS100C/A11を介した細胞増殖制御シグナル

    第13回岡山研究皮膚科フォーラム  2006年 

     詳細を見る

  • ヒト正常表皮角化細胞におけるS100C/A11を介した細胞増殖制御シグナル

    第64回日本癌学会  2005年 

     詳細を見る

  • Bifurcated converging pathways for high Ca++- and TGFb-induced inhibition of growth of normal human keratinocytes

    第28回日本分子生物学会  2005年 

     詳細を見る

  • TGFbによるヒト正常表皮角化細胞の増殖制御機構:PKCa、S100C/A11を介する新しい信号伝達経路

    第77回日本組織培養学会  2004年 

     詳細を見る

  • PKCa mediates TGFb-induced growth inhibition of human keratinocytes via phosphorylation of S100C/A11

    2004 The American Society for Cell Biology (ASCB) annual meeting (44th)  2004年 

     詳細を見る

  • TGFb-induced growth inhibition of human keratinocytes via phosphorylation of S100C/A11

    第27回日本分子生物学会  2004年 

     詳細を見る

  • TGFbによる細胞増殖抑制の新しい信号伝達経路:PKCa、S100C/A11の関与

    第63回日本癌学会  2004年 

     詳細を見る

▼全件表示

産業財産権

  • 肺炎症性疾患の予防及び/又は治療剤

    阪口政清, 豊岡伸一, 木下理恵, 荒木恒太

     詳細を見る

    出願人:岡山大学

    出願番号:EP 2088259.6  出願日:2022年5月30日

    researchmap

  • 肺炎症性疾患の予防及び/又は治療剤

    阪口政清, 豊岡伸一, 木下理恵, 荒木恒太

     詳細を見る

    出願人:岡山大学

    出願番号:AU 2020376350  出願日:2022年5月9日

    researchmap

  • 肺炎症性疾患の予防及び/又は治療剤

    阪口政清, 豊岡伸一, 木下理恵, 荒木恒太

     詳細を見る

    出願人:岡山大学

    出願番号:CA 3155346  出願日:2022年4月20日

    出願国:外国  

    researchmap

  • 肺炎症性疾患の予防及び/又は治療剤

    阪口政清, 豊岡伸一, 木下理恵, 荒木恒太

     詳細を見る

    出願人:岡山大学

    出願番号:US 17/768865  出願日:2022年4月14日

    出願国:外国  

    researchmap

  • 肺炎症性疾患の予防及び/又は治療剤

    阪口政清, 豊岡伸一, 木下理恵, 荒木恒太

     詳細を見る

    出願人:岡山大学

    出願番号:CN 202080071786.X  出願日:2022年4月13日

    出願国:外国  

    researchmap

  • 化合物、神経系疾患の予防又は治療薬

    村田 等, 阪口 政清, 安藤 隆幸, 福田 達也, 中村 仁

     詳細を見る

    出願人:国立大学法人岡山大学

    出願番号:特願2021-135934  出願日:2021年8月23日

    公開番号:特開2023-30679  公開日:2023年3月8日

    researchmap

  • 抗体薬物コンジュゲート及び抗体の薬物送達のための使用

    西堀正洋, 森秀治, 高尚澤, 阪口政清

     詳細を見る

    出願人:岡山大学

    出願番号:PCT/JP2020/047157  出願日:2020年12月18日

    出願国:外国  

    researchmap

  • 抗体薬物コンジュゲート及び抗体の薬物送達のための使用

    西堀正洋, 森秀治, 高尚澤, 阪口政清, 友野靖子

     詳細を見る

    出願人:岡山大学

    出願番号:特願2021-523530  出願日:2020年12月17日

    特許番号/登録番号:特許6949343  登録日:2021年9月27日 

    出願国:国内  

    researchmap

  • 抗S100A8/A9抗体とその用途

    阪口政清, 豊岡伸一, 木下理恵, 冨田秀太, 枝園和彦, 佐藤博紀, 二見淳一郎, 近藤英作, 井上裕介, 山内明

     詳細を見る

    出願人:国立大学法人岡山大学 国立大学法人新潟大学 国立大学法人群馬大学 学校法人川崎学園

    出願番号:19792052. 3  出願日:2020年11月20日

    公開番号:3791894  公開日:2021年2月25日

    出願国:外国  

    researchmap

  • 肺炎症性疾患の予防及び/又は治療剤

    阪口政清, 豊岡伸一, 木下理恵, 荒木恒太

     詳細を見る

    出願人:国立大学法人岡山大学

    出願番号:PCT/JP2020/39460  出願日:2020年10月30日

    researchmap

  • 肺炎症性疾患の予防及び/又は治療剤

    阪口政清, 豊岡伸一, 木下理恵, 荒木恒太

     詳細を見る

    出願人:国立大学法人岡山大学

    出願番号:TW 110110562  出願日:2020年10月30日

    出願国:外国  

    researchmap

  • 抗S100A8/A9抗体とその用途

    阪口政清, 豊岡伸一, 木下理恵, 冨田秀太, 枝園和彦, 佐藤博紀, 二見淳一郎, 近藤英作, 井上裕介, 山内明

     詳細を見る

    出願人:国立大学法人岡山大学 国立大学法人新潟大学 国立大学法人群馬大学 学校法人川崎学園

    出願番号:201980028619.4  出願日:2020年10月27日

    公開番号:CN11204090982 A  公開日:2020年12月4日

    出願国:外国  

    researchmap

  • 抗S100A8/A9抗体とその用途

    阪口政清, 豊岡伸一, 木下理恵, 冨田秀太, 枝園和彦, 佐藤博紀, 二見淳一郎, 近藤英作, 井上裕介, 山内明

     詳細を見る

    出願人:国立大学法人岡山大学,国立大学法人新潟大学,国立大学法人群馬大学,学校法人川崎学園

    出願番号:17/050384  出願日:2020年10月23日

    公開番号:us2021/0054061  公開日:2021年2月25日

    researchmap

  • 抗S100A8/A9抗体とその用途

    阪口政清, 豊岡伸一, 冨田秀太, 枝園和彦, 佐藤博紀, 木下理恵, 二見淳一郎, 荒木恒太, 岡﨑幹夫, 近藤英作, 井上裕介, 山内明

     詳細を見る

    出願人:国立大学法人岡山大学 国立大学法人新潟大学 国立大学法人群馬大学 学校法人川崎学園

    出願番号:JP2020-516238  出願日:2020年10月6日

    出願国:国内  

    researchmap

  • 肺炎症性疾患の予防及び/又は治療剤

    阪口政清, 豊岡伸一, 木下理恵, 荒木恒太

     詳細を見る

    出願人:国立大学法人岡山大学 国立大学法人新潟大学 国立大学法人群馬大学 学校法人川崎学園

    出願番号:特願2019-197222  出願日:2019年10月30日

    researchmap

  • 好中球貪食機能増強剤

    西堀正洋, 和氣秀徳, 高橋陽平, 森秀治, 阪口政清

     詳細を見る

    出願人:岡山大学

    出願番号:PCT/JP2019/022812  出願日:2019年6月7日

    出願国:外国  

    researchmap

  • 抗S100A8/A9抗体とその用途

    阪口政清, 豊岡伸一, 冨田秀太, 枝園和彦, 佐藤博紀, 木下理恵, 二見淳一郎, 荒木恒太, 岡?幹夫, 近藤英作, 井上裕介, 山内明

     詳細を見る

    出願人:国立大学法人岡山大学 国立大学法人新潟大学 国立大学法人群馬大学 学校法人川崎学園

    出願番号:PCT/JP2019/16100  出願日:2019年4月15日

    researchmap

  • 好中球貪食機能増強剤

    西堀正洋, 和氣秀徳, 高橋陽平, 森秀治, 阪口政清

     詳細を見る

    出願人:岡山大学

    出願番号:特願2018-123626  出願日:2018年6月28日

    researchmap

  • 抗S100A8/A9抗体

    阪口政清, 豊岡伸一, 冨田秀太, 枝園和彦, 佐藤博紀, 木下理恵, 二見淳一郎, 近藤英作, 井上裕介, 山内明

     詳細を見る

    出願人:国立大学法人岡山大学 国立大学法人新潟大学 国立大学法人群馬大学 学校法人川崎学園

    出願番号:特願2018-087576  出願日:2018年4月27日

    出願国:国内  

    researchmap

  • リン酸化SARM1、抗体、SARM1リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、SARM1改変体及び使用

    村田 等, 阪口政清, 木下理恵, 山本健一

     詳細を見る

    出願人:国立大学法人岡山大学

    出願番号:特願2018-507366  出願日:2018年4月2日

    researchmap

  • リン酸化SARM1、抗体、SARM1リン酸化阻害剤、神経変性患者の予防または治療薬、スクリーニング方法、SARM1改変体及び使用

    村田 等, 阪口政清, 木下理恵, 山本健一

     詳細を見る

    出願人:国立大学法人岡山大学

    出願番号:特願2018-507366  出願日:2018年4月2日

    公開番号:特開WO2017/164230  公開日:2017年9月27日

    特許番号/登録番号:特許7198489  登録日:2022年12月21日 

    出願国:国内  

    researchmap

  • 赤血球保存剤

    西堀正洋, 和氣秀徳, 衷輝, 森秀治, 阪口政清

     詳細を見る

    出願人:岡山大学

    出願番号:特願2018-568621  出願日:2018年2月16日

    公開番号:特開WO2018/151243 

    特許番号/登録番号:特許6983420  登録日:2021年11月26日 

    researchmap

  • リン酸化SARM1、抗体、SARM1リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、SARM1改変体及び使用

    村田 等, 阪口政清, 木下理恵, 山本健一

     詳細を見る

    出願人:国立大学法人岡山大学

    出願番号:PCT/JP2017/011418  出願日:2017年3月22日

    公開番号:WO2017/164230  公開日:2017年9月28日

    researchmap

  • 遺伝子発現用カセット及びその産生物

    阪口政清, 西堀正洋, 公文裕巳, 村田等, 山本健一, 木下理恵

     詳細を見る

    出願人:国立大学法人岡山大学

    出願番号:PCT/JP2016/079219  出願日:2016年10月3日

    公開番号:WO2017061354(A1)  公開日:2017年4月13日

    researchmap

  • 好中球活性化に起因する疾患の治療薬、治療方法及び検査方法

    西堀正洋, 森秀治, 和氣秀徳, 橋英夫, 劉克約, 勅使川原匡, 阪口政清

     詳細を見る

    出願人:国立大学法人岡山大学

    出願番号:US2016146835 (A1)  出願日:2016年5月26日

    公開番号:US2015141322 (A1)  公開日:2015年5月21日

    公表番号:EP2859898 (A1)  公表日:2015年4月15日

    特許番号/登録番号:US9504731 (B2)  発行日:2016年11月29日

    researchmap

  • 遺伝子導入リンパ球の移植による細胞療法における治療効果及びGVHDを可視化するPETイメージング技術

    松浦 栄次, 阪口 政清, 公文 裕巳, 黄 鵬, 竹中 文章

     詳細を見る

    出願人:国立大学法人岡山大学

    出願番号:特願2016-66068  出願日:2016年3月29日

    公開番号:特開2017-178818  公開日:2017年10月5日

    特許番号/登録番号:特許6707256  登録日:2020年5月22日 

    出願国:国内  

    researchmap

  • 遺伝子発現用カセット及びその産生物

    阪口 政清, 西堀 正洋, 公文 裕巳, 村田 等, 山本 健一, 木下 理恵

     詳細を見る

    出願人:岡山大学

    出願番号:特願2016-059297  出願日:2016年3月23日

    公開番号:特開2017-169486  公開日:2017年9月28日

    特許番号/登録番号:特許6871679  登録日:2021年4月20日 

    researchmap

  • 遺伝子発現用カセット及びその産生物

    阪口政清, 西堀正洋, 公文裕巳, 村田等, 山本健一, 木下理恵

     詳細を見る

    出願人:国立大学法人岡山大学

    出願番号:特願2015-198160  出願日:2015年10月6日

    公開番号:特開2017-070224  公開日:2017年4月13日

    researchmap

  • NPTNとS100A8の結合の阻害を指標とする細胞増殖抑制剤のスクリーニング方法

    日比野利彦, 山本真実, 阪口政清, 許南浩

     詳細を見る

    出願人:株式会社資生堂

    出願番号:PCT/JP2013/075191  出願日:2013年9月18日

    公開番号:WO2014046143 (A1)  公開日:2014年3月27日

    researchmap

  • 好中球活性化に起因する疾患の治療薬、治療方法及び検査方法

    西堀正洋, 森秀治, 和氣秀徳, 橋英夫, 劉克約, 勅使川原匡, 阪口政清

     詳細を見る

    出願人:国立大学法人岡山大学

    出願番号:PCT/JP2013/064779  出願日:2013年5月28日

    公表番号:WO2013183494 (A1)  公表日:2013年12月12日

    researchmap

  • NPTNとS100A8の結合の阻害を指標とする細胞増殖抑制剤のスクリーニング方法

    日比野利彦, 山本真実, 阪口政清, 許南浩

     詳細を見る

    出願人:株式会社資生堂

    出願番号:特願2012-204279  出願日:2012年9月18日

    公開番号:特開2014-059210  公開日:2014年4月3日

    researchmap

  • PINK1のユビキチンアッセイ及びスクリーニングへの利用

    許南浩, 村田等, 阪口政清

     詳細を見る

    出願人:国立大学法人岡山大学

    出願番号:特願2012-165160  出願日:2012年7月25日

    公開番号:特開2014-025764  公開日:2014年2月6日

    特許番号/登録番号:特許6024953  発行日:2016年10月21日

    国立大学法人 岡山大学

    researchmap

  • 遺伝子発現を上昇させるシステム及び該システムを保持したベクター

    公文 裕巳, 許 南浩, 阪口 政清, 渡部 昌実

     詳細を見る

    出願人:国立大学法人岡山大学 、桃太郎源株式会社

    出願番号:201080061897. 9  出願日:2012年7月19日

    公開番号:RU2012125253 (A)  公開日:2013年12月27日

    特許番号/登録番号:ZL201080061897.9  発行日:2015年3月4日

    researchmap

  • 好中球活性化に起因する疾患の治療薬、治療方法及び検査方法

    西堀正洋, 森秀治, 和氣秀徳, 橋英夫, 劉克約, 勅使川原匡, 阪口政清

     詳細を見る

    出願人:国立大学法人岡山大学

    出願番号:特願2012-129232  出願日:2012年6月6日

    公表番号:特開2016-053022  公表日:2016年4月14日

    特許番号/登録番号:特許6227601  発行日:2017年10月20日

    researchmap

  • REIC発現アデノウイルスベクター

    公文 裕巳, 那須 保友, 柏倉 祐司, 渡部 昌実, 許 南浩, 阪口 政清

     詳細を見る

    出願人:国立大学法人 岡山大学 、桃太郎源株式会社

    出願番号:PCT/JP2012/64250  出願日:2012年5月25日

    特許番号/登録番号:2716756  登録日:2021年12月8日 

    出願国:外国   取得国:外国

    researchmap

  • REIC発現アデノウイルスベクター

    公文裕巳, 許南浩, 阪口政清, 渡部昌実

     詳細を見る

    出願人:公文裕巳 、許南浩 、阪口政清 、那須保友 、アバルズア カベサス フェルナンド ギゲルモ

    出願番号:PCT/JP2012/064250  出願日:2012年5月25日

    公開番号:特開WO2012161352 (A1)  公開日:2012年11月29日

    特許番号/登録番号:特許662534  発行日:2014年12月12日

    researchmap

  • アデノウイルスベクターをがん細胞に対して選択的に導入可能なポリペプチドおよび当該ポリペプチドを備えるアデノウイルスベクター

    阪口 政清, 近藤 英作, 許 南浩, 手塚 克成

     詳細を見る

    出願人:国立大学法人 岡山大学 、愛知県

    出願番号:特願2012-085969  出願日:2012年4月4日

    公開番号:特開2013-215104  公開日:2013年10月24日

    researchmap

  • エンプリンとS100A9の結合の阻害を指標とする慢性炎症抑制剤又は癌転移抑制剤のスクリーニング方法

    日比野利彦, 江浜律子, 本山晃, 宮本章子, 山本真実, 阪口政清, 許南浩

     詳細を見る

    出願人:株式会社資生堂 <SHISEIDO COMPANY,LTD.>

    出願番号:PCT/JP2011/051807  出願日:2011年1月28日

    公開番号:WO2012017700 (A1)  公開日:2012年2月9日

    researchmap

  • エンプリンとS100A9の結合の阻害を指標とする慢性炎症抑制剤又は癌転移抑制剤のスクリーニング方法

    日比野利彦, 江浜律子, 本山晃, 宮本章子, 山本真実, 阪口政清, 許南浩

     詳細を見る

    出願人:株式会社資生堂 <SHISEIDO COMPANY,LTD.>

    出願番号:特願2010-174038  出願日:2010年8月2日

    公開番号:特開2011-047932 (A)  公開日:2011年3月10日

    特許番号/登録番号:特許5729936  発行日:2015年4月17日

    researchmap

  • 遺伝子発現を上昇させるシステム及び該システムを保持したベクター

    公文裕巳, 許南浩, 阪口政清, 渡部 昌実

     詳細を見る

    出願人:国立大学法人岡山大学 、桃太郎源株式会社

    出願番号:PCT/JP2009/063907  出願日:2009年7月30日

    公開番号:WO2011062298 (A1)  公開日:2011年5月26日

    特許番号/登録番号:KR101752941 (B1)  発行日:2017年7月3日

    researchmap

  • 新規悪性中皮腫治療剤及び免疫賦活化剤

    公文裕巳, 那須保友, 柏倉 祐司, 渡部 昌実, 許南浩, 阪口政清

     詳細を見る

    出願人:国立大学法人岡山大学 、桃太郎源株式会社

    出願番号:PCT/JP2009/063907  出願日:2009年7月30日

    公開番号:WO2010013846 (A1)  公開日:2010年2月4日

    researchmap

  • 遺伝子発現を上昇させるシステム及び該システムを保持したベクター

    公文裕巳, 許南浩, 阪口政清, 渡部 昌実

     詳細を見る

    出願人:国立大学法人岡山大学 、桃太郎源株式会社

    出願番号:特願2008-196857  出願日:2008年7月30日

    公開番号:CA2781332 (A1)  公開日:2011年5月26日

    特許番号/登録番号:特許5697042  発行日:2015年2月20日

    researchmap

  • 新規悪性中皮腫治療剤及び免疫賦活化剤

    公文裕巳, 那須保友, 柏倉 祐司, 渡部 昌実, 許南浩, 阪口政清

     詳細を見る

    出願人:国立大学法人岡山大学 、桃太郎源株式会社

    出願番号:特願2008-196857  出願日:2008年7月30日

    公開番号:US2011189237 (A1)  公開日:2011年8月4日

    特許番号/登録番号:特許5551593  発行日:2014年5月30日

    researchmap

  • 炎症および過剰増殖を伴う皮膚疾患モデル

    江浜律子, 日比野利彦, 阪口政清, 許南浩

     詳細を見る

    出願人:株式会社資生堂 <SHISEIDO COMPANY,LTD.>、国立大学法人岡山大学

    出願番号:PCT/JP2008/052185  出願日:2008年2月8日

    公表番号:WO2008096868 (A1)  公表日:2008年8月14日

    researchmap

  • REIC/Dkk-3遺伝子の部分断片及び該断片を含むがん治療薬

    公文裕巳, 許南浩, 阪口政清, 那須保友, アバルズア カベサス, フェルナンド ギゲルモ

     詳細を見る

    出願人:公文裕巳 、許南浩 、阪口政清 、那須保友 、アバルズア カベサス フェルナンド ギゲルモ

    出願番号:PCT/JP2007/071170  出願日:2007年10月24日

    公開番号:WO2008050898 (A1)  公開日:2008年5月2日

    researchmap

  • タンパク質の細胞内導入剤

    山田秀徳, 村田等, 二見淳一郎, 阪口政清, 許南浩, 八木康行, 甲斐敬

     詳細を見る

    出願人:株式会社日本触媒 <NIPPON SHOKUBAI CO.,LTD.>、 、国立大学法人岡山大学

    出願番号:特願2007-046025  出願日:2007年10月13日

    公開番号:特開2008-115150  公開日:2008年5月22日

    特許番号/登録番号:特許5097412  発行日:2012年9月28日

    researchmap

  • タンパク質の細胞内導入剤

    山田秀徳, 村田等, 二見淳一郎, 阪口政清, 許南浩, 八木康行, 甲斐敬

     詳細を見る

    出願人:株式会社日本触媒 <NIPPON SHOKUBAI CO.,LTD.>、 、国立大学法人岡山大学

    出願番号:PCT/JP2007/070392  出願日:2007年10月12日

    公開番号:WO2008044798 (A1)  公開日:2008年4月17日

    researchmap

  • 炎症および過剰増殖を伴う皮膚疾患モデル

    江浜律子, 日比野利彦, 阪口政清, 許南浩

     詳細を見る

    出願人:株式会社資生堂 <SHISEIDO COMPANY,LTD.>、国立大学法人岡山大学

    出願番号:特願2007-030383  出願日:2007年2月9日

    特許番号/登録番号:特許5366077  発行日:2013年9月20日

    researchmap

  • REIC/Dkk-3遺伝子の部分断片及び該断片を含むがん治療薬

    公文裕巳, 許南浩, 阪口政清, 那須保友, アバルズア カベサス, フェルナンド ギゲルモ

     詳細を見る

    出願人:公文裕巳 、許南浩 、阪口政清 、那須保友 、アバルズア カベサス フェルナンド ギゲルモ

    出願番号:特願2006-289040  出願日:2006年10月24日

    公開番号:特開2014-31375 (A)  公開日:2014年2月20日

    特許番号/登録番号:特許5356823  発行日:2013年9月6日

    5662534

    researchmap

  • 前立腺癌細胞のアポトーシス誘発剤

    公文裕巳, 許南浩, 阪口政清, 那須保友

     詳細を見る

    出願人:公文裕巳 、許南浩 、阪口政清 、那須保友

    出願番号:PCT/JP2006/300411  出願日:2006年1月10日

    公開番号:WO2006098074 (A1)  公開日:2006年9月21日

    researchmap

  • 細胞増殖剤及び細胞の増殖方法

    山田 秀徳, 二見 淳一郎, 村田 等, 前田 貴志, 阪口 政清

     詳細を見る

    出願人:株式会社日本触媒

    出願番号:特許2005-356631  出願日:2005年12月9日

    公開番号:特開2007-159429  公開日:2007年6月28日

    researchmap

  • 前立腺癌細胞のアポトーシス誘発剤

    公文裕巳, 許南浩, 阪口政清, 那須保友

     詳細を見る

    出願人:公文裕巳 、許南浩 、阪口政清 、那須保友

    出願番号:特願2005-084495  出願日:2005年3月23日

    特許番号/登録番号:特許4838236  発行日:2011年10月7日

    researchmap

  • 可逆的カチオン化による変性タンパク質の細胞内導入と活性化の方法

    山田秀徳, 二見淳一郎, 村田等, 前田貴志, 阪口政清

     詳細を見る

    出願人:株式会社日本触媒

    出願番号:特願2003-356571  出願日:2003年10月16日

    公表番号:特開2005-120017  公表日:2005年5月12日

    researchmap

  • 細胞増殖を制御する物質のスクリーニング方法、及びSp1分子等をヌクレオリン(nucleolin)分子から解離させる物質のスクリーニング方法

    許 南浩, 阪口 政清, 難波 正義, 宮崎 正博, 牧野 英一

     詳細を見る

    出願人:許 南浩 、阪口 政清 、難波 正義 、宮崎 正博 、牧野 英一

    出願番号:特許2002-311777  出願日:2002年10月25日

    公開番号:特開2004-144680  公開日:2004年5月20日

    researchmap

▼全件表示

受賞

  • 長瀬研究振興賞

    2022年4月   公益財団法人長瀬科学技術振興財団  

     詳細を見る

  • Acta Medica Okayama Best Reviewer Award (2019年)

    2021年3月  

    阪口政清

     詳細を見る

  • Spandios publications excellence in reviewing

    2019年8月   卓越査読

     詳細を見る

  • Spandios publications excellence in reviewing

    2018年2月   卓越査読

     詳細を見る

  • Spandios publications excellence in reviewing

    2018年1月   卓越査読

     詳細を見る

  • Spandios publications excellence in reviewing

    2017年12月   卓越査読

     詳細を見る

  • 岡山医学会賞(結城賞)

    2017年6月  

     詳細を見る

    受賞国:日本国

    researchmap

  • Spandios publications excellence in reviewing

    2017年6月   卓越査読

     詳細を見る

  • Spandios publications excellence in reviewing

    2017年5月   卓越査読

     詳細を見る

  • 平成28年度ウエスコ財団優秀研究者賞

    2017年  

     詳細を見る

    受賞国:日本国

    researchmap

  • 公益財団法人山陽放送学術文化財団第51回学術研究助成医歯薬学分野学術奨励賞

    2014年  

     詳細を見る

    受賞国:日本国

    researchmap

  • 岡山大学若手トップリサーチャー研究奨励賞

    2010年  

     詳細を見る

    受賞国:日本国

    researchmap

  • アメリカがん学会研究奨励賞

    2001年  

     詳細を見る

  • 第100回岡山大学医学賞(結城賞)

    2000年  

     詳細を見る

    受賞国:日本国

    researchmap

  • アメリカ組織培養学会研究奨励賞

    2000年  

     詳細を見る

▼全件表示

共同研究・競争的資金等の研究

  • 原発巣の腫瘍縮小および転移抑制効果を示す膵がん治療薬の開発

    研究課題/領域番号:23K06717  2023年04月 - 2027年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    木下 理恵, 阪口 政清

      詳細を見る

    配分額:4680000円 ( 直接経費:3600000円 、 間接経費:1080000円 )

    researchmap

  • S100A8/A9-向転移とHRG-抗転移の細胞間・分子間クロストークの解明

    研究課題/領域番号:23H02748  2023年04月 - 2026年03月

    日本学術振興会  科学研究費助成事業  基盤研究(B)

    阪口 政清, 山本 健一, 近藤 英作, 豊岡 伸一, 木下 理恵, 西堀 正洋, 山内 明, 友信 奈保子, 村田 等

      詳細を見る

    配分額:18720000円 ( 直接経費:14400000円 、 間接経費:4320000円 )

    researchmap

  • 学会開催(日本組織培養学会第95回大会)

    2022年12月 - 2023年11月

    財団法人岡山医学振興会  地域社会との連携事業の助成 

      詳細を見る

    配分額:150000円

    researchmap

  • ヒト炎症性疾患治療を目指したS100A8/A9抗体の研究開発

    2022年08月 - 2025年03月

    ノーベルファーマ株式会社  共同研究

      詳細を見る

    担当区分:研究代表者 

    配分額:17203000円 ( 直接経費:13233000円 、 間接経費:3970000円 )

    researchmap

  • がん免疫サイクルの観点からみたAd-REICと分泌REICタンパク質の分子機構の解明と新規創薬

    2022年06月 - 2023年02月

    岡山県  特別電源所在県科学技術振興事業  受託研究

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • がん免疫サイクルを活性化する高機能化REICタンパク質製剤の実用化

    2022年06月 - 2023年02月

    岡山県  特別電源所在県科学技術振興事業  受託研究

      詳細を見る

    担当区分:研究代表者 

    配分額:84000000円 ( 直接経費:7636364円 、 間接経費:7636364円 )

    researchmap

  • マトリセルラータンパク質阻害によるがん微小環境の破壊と抗腫瘍効果の検討

    研究課題/領域番号:22H03162  2022年04月 - 2026年03月

    日本学術振興会  科学研究費助成事業 基盤研究(B)  基盤研究(B)

    豊岡 伸一, 冨田 秀太, 枝園 和彦, 山本 寛斉, 岡崎 幹生, 阪口 政清, 冨樫 庸介, 諏澤 憲

      詳細を見る

    配分額:17290000円 ( 直接経費:13300000円 、 間接経費:3990000円 )

    researchmap

  • 乾癬、アトピー性皮膚炎におけるMCAMの意義探求とその制御製剤による病態制御

    研究課題/領域番号:22K08405  2022年04月 - 2025年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    山本 健一, 木下 理恵, 阪口 政清

      詳細を見る

    配分額:4160000円 ( 直接経費:3200000円 、 間接経費:960000円 )

    researchmap

  • 軸索変性誘導分子SARM1の活性・分解制御によるパーキンソン病治療法の開発

    研究課題/領域番号:22K06884  2022年04月 - 2025年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    村田 等, 阪口 政清

      詳細を見る

    配分額:4160000円 ( 直接経費:3200000円 、 間接経費:960000円 )

    researchmap

  • 生物製剤産生のコスト軽減に貢献する第3世代超効率遺伝子発現技術の創出

    2022年04月 - 2023年03月

    公益財団法人長瀬科学技術振興財団  研究助成金  研究助成

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • がん免疫サイクルの観点からみたAb-REICと分泌REICタンパク質の分子機構の解明と新規創薬

    2021年06月 - 2022年02月

    岡山県  特別電源所在県科学技術振興事業 

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • シグナルコンダクターSpred2によるがんの分子・細胞基盤解明と治療への応用

    研究課題/領域番号:21H02988  2021年04月 - 2024年03月

    日本学術振興会  科学研究費助成事業 基盤研究(B)  基盤研究(B)

    松川 昭博, 伊藤 嘉浩, 吉村 禎造, 宮武 秀行, 阪口 政清

      詳細を見る

    配分額:17420000円 ( 直接経費:13400000円 、 間接経費:4020000円 )

    1)がんの増殖・転移・幹細胞性獲得におけるSpred2の役割解明
    肝がん細胞株(HepG2, HepG3, HLE)のSpred2をノックダウンすると細胞増殖能はいずれも増加した。最もSpred2発現の多いHepG2細胞からCRISPR-Cas9法でSpred2を消去した細胞を作製し、がん細胞特性を確認した。その結果、がん細胞増殖能・浸潤能は増加し、細胞形態は紡錘形に変化、上皮間葉移行と幹細胞性は増強した。これらの変化は、Spred2の過剰発現で逆転した。Spred2発現は非がん部に比較してがん部で低く(データベース上、および自験例の検討)、Spred2高発現肝がん患者では低発現患者に比べ有意に予後は高かった(データベース解析)。以上より、Spred2は、ERK経路を抑制し、がん細胞のEMTや幹細胞性を負に制御することを明らかにした(現在、論文投稿中)。
    2)ヒトがん組織におけるSpred2の発現
    275の尿路上皮腫瘍の検討結果から、Spred2 mRNA発現は高異型度非浸潤性乳頭状尿路上皮癌 (HGPUC)で最も高く、上皮内癌 (CIS)と浸潤性尿路上皮癌 (IUC)で低下し、Spred2タンパク発現はHGPUCで高く、CISとIUCではHGPUCに比べて減少していることを見いだした。HGPUCでSpred2膜発現を示すものはSpred2膜陰性のものと比べ、ERK活性化レベルとKi67 indexが有意に低かった。以上より、Spred2は非浸潤性膀胱癌の進展を調節する鍵であるものと考えられた(PLoS One. 2021 Nov 24;16(11):e0254289)。
    3)Spred2のがん治療への応用
    SPR-domainのみのSpred2に加え、さらなる短鎖Spred2プラスミドを6種類作製した。これらを用いて、全長Spred2との活性比較を行っている。

    researchmap

  • 国産高麗人参及びその含有成分によるがん抑制作用の効果検証

    2021年02月 - 2022年02月

    株式会社カイタックトレーディング  共同研究 

      詳細を見る

    担当区分:研究代表者 

    researchmap

  • IPF急性増悪治療を目指したS100A8/A9抗体の研究開発

    研究課題/領域番号:20im0210119h0001  2020年08月 - 2023年03月

    日本医療研究開発機構  産学連携医療イノベーション創出プログラム ACT-M 

      詳細を見る

    担当区分:研究代表者  資金種別:産学連携による資金

    researchmap

  • 突発性肺線維症急性増悪治療を目指したS100A8/A9抗体の研究開発

    2020年08月 - 2022年03月

    ノーベルファーマ株式会社  共同研究  共同研究

      詳細を見る

    担当区分:研究代表者 

    配分額:2600000円 ( 直接経費:2000000円 、 間接経費:600000円 )

    researchmap

  • がん免疫サイクルの観点からみたAb-REICと分泌REICタンパク質の分子機構の解明と新規創薬

    2020年06月 - 2021年02月

    岡山県  特別電源所在県科学技術振興事業 

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • がん転移の予測を可能とする全てのS100タンパク質の同時診断技術の開発

    2020年04月 - 2023年03月

    株式会社ホロンシステム  共同研究 

      詳細を見る

    担当区分:研究代表者 

    researchmap

  • 新規S100A8/A9阻害分子の発見に基づいたがん脳指向転移の機構解明とその制御

    研究課題/領域番号:20H03516  2020年04月 - 2023年03月

    日本学術振興会  科学研究費助成事業 基盤研究(B)  基盤研究(B)

    阪口 政清, 山本 健一, 近藤 英作, 豊岡 伸一, 木下 理恵, 西堀 正洋, 村田 等

      詳細を見る

    配分額:17420000円 ( 直接経費:13400000円 、 間接経費:4020000円 )

    本年度の研究では、(1)HRGとS100A8/A9が遠隔の腫瘍に応答して脳内環境のどの細胞からそれぞれ産生放出されているかを理解すること、(2)HRGの低下と脳転移に関連性があるかを検証すること、さらに、計画終了後の展開を念頭に時間が許せば、(3)HRGによるS100A8/A9阻害作用がなぜ脳選択的に起こるのか、その糸口を見出すことである。成果は以下の通りである。
    <BR>
    (1)S100A8/A9はミクログリア細胞が産生していることが判明したが、HRGは免疫染色用の良い抗体がなく患者由来組織切片において検出することができていない。
    (2)血漿を用いたELISA検討からHRGは脳転移がん患者さんで顕著に低下することが判明した。
    (3)脳転移の起こりやすくしたB16-BL6クローン(HRGへの反応が鈍い細胞)についてRNAseq解析を行った。その結果、親株と比較して数多くの遺伝子発現変動が起こっており、その中でも脳転移の引き金になる、あるいはHRG耐性の理由となる可能性のある遺伝子変動をとらえることができた。

    researchmap

  • S100A8/A9が悪性化する原発巣および転移先がん微小環境を制御する治療法

    研究課題/領域番号:20K07636  2020年04月 - 2023年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    木下 理恵, 阪口 政清

      詳細を見る

    配分額:4420000円 ( 直接経費:3400000円 、 間接経費:1020000円 )

    researchmap

  • ホーミングペプチドを基盤にした新規膵癌バイオマーカー及び膵癌標的化抗体医薬の開発

    研究課題/領域番号:20H03527  2020年04月 - 2023年03月

    日本学術振興会  科学研究費助成事業 基盤研究(B)  基盤研究(B)

    近藤 英作, 飯岡 英和, 阪口 政清, 齋藤 憲

      詳細を見る

    配分額:17810000円 ( 直接経費:13700000円 、 間接経費:4110000円 )

    準備研究により膵がん細胞ホーミングペプチドの細胞内への取り込みに関与するアクセプター分子(受容体)として候補に挙がっているreceptorφについて、その発現と局在を患者浸潤性膵管癌組織30症例に検索を拡大して解析した。結果、receptorφは全例で膵癌細胞膜上に特異的な発現を認め、膵がん細胞ホーミングペプチドに対する特異的受容体であうこと、及び膵癌細胞において膜局在分子として何らかの生物学的役割を果たしていることが推察された。一方、receptorφの細胞外領域を特異的に認識する抗体の初回試作に失敗したため、現在新たな手法で特異抗体作成を実施中である。この経緯から、第2年度に予定していた「新規膵癌細胞膜受容体候補の生物学的な分子機能の洗い出し」のための解析を前倒しし、CRISR/Cas9 systemを用いたreceptorφノックアウトcloneを2種類の膵癌細胞株BxPC3, HPAF IIそれぞれで作成することに成功した。現在、これらノックアウトクローンと野生型を比較サンプルとしたNGS RNA Seq解析を実施中である。この結果から、の重要な膵癌細胞における生物学的機能の洗い出しを進める計画である。

    researchmap

  • 組織障害性HMGB1に着眼した肺虚血再灌流障害に対する新規戦略の確立

    研究課題/領域番号:20K09176  2020年04月 - 2023年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    大谷 真二, 山根 正修, 豊岡 伸一, 杉本 誠一郎, 王 登莉, 西堀 正洋, 岡崎 幹生, 三好 健太郎, 阪口 政清

      詳細を見る

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    ①マウス肺門クランプモデルにおけるHMGB1の動態:HMGB1は通常核内に限局しているタンパクである。マウス左肺門クランプモデルにおいて、再還流後2時間までのHMGB1の血中濃度を測定したところ、HMGB1が時系列に沿って上昇することが確認された。また組織の免疫染色において、虚血再還流障害を加えた群では、HMGB1が核内よりむしろ細胞質で強く染色され、細胞障害性の刺激により核内から細胞質へ移動している様子が確認された。この現象はHMGB1抗体を投与することで抑制されたことから細胞障害によりHMGB1には自己分泌経路が出現し抗体投与によってその経路を停止させることができるのではないか、と考えられた。
    ②抗体投与による虚血再還流障害の抑制:HMGB1抗体を投与する事による虚血再還流障害の抑制効果を調べた。肺機能、組織障害の改善を生理学的、組織学的に確認することができた。
    ③抗体投与による抗炎症効果:HMGB1抗体を投与するとサイトカインの産生が低下することが確認された。HMGB1はRAGEやTLRといったレセプターのリガンドであり、MAPKの経路を介しサイトカイン産生を行っているが、HMGB1抗体によりMAPKの経路が抑制されることが示された。
    ④抗体投与によるアポトーシスの抑制:肺組織の細胞死を定量するため組織でのアポトーシスを検索した。虚血性再還流障害によるアポトーシスが抗体投与により抑制されていることが確認された。

    researchmap

  • 肺虚血再灌流障害におけるS100A8/A9の役割の解明と新しい治療法の開発

    研究課題/領域番号:20K09164  2020年04月 - 2023年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    岡崎 幹生, 大谷 真二, 山根 正修, 坂上 倫久, 豊岡 伸一, 山本 寛斉, 木下 理恵, 杉本 誠一郎, 阪口 政清

      詳細を見る

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    重症肺疾患に対して、肺移植手術が唯一残された治療法となることがあるが、一時的な虚
    血と血液の再灌流により炎症が生じる虚血再灌流障害は依然として肺移植時の大きな問題点である。肺移植後の移植肺の機能不全は虚血再灌流障害によるものがほとんどで、基礎研究による肺虚血再灌流障害の分子メカニズムの解明や革新的治療薬が開発できると、肺移植による治療成績が格段に向上する。最近申請者らは、経時的かつ網羅的遺伝子発現解析から、肺虚血再灌流後に最も早期に過剰発現する遺伝子としてS100A8/A9を見出した。S100A8/A9は、多様な炎症反応の引き金となるためIRIの治療のターゲットとして極めて有望である。本研究では、申請者らが開発したS100A8/A9を標的とした中和抗体を用いて、肺虚血再灌流障害の抑制効果を検証し、臨床応用に向けたProof of Conceptを確立することを目的とする。
    マウス肺虚血再灌流障害モデルでS100A8/A9中和抗体の効果を検証した。抗体を投与した30分後に左肺を60分クランプし(虚血)、再灌流後120分に評価し、Control群と比較・検討した。虚血再灌流障害群(IgG Control群)はSham群と比較して、有意にPaO2が低下していた。それに対して、S100A8/A9中和抗体投与群ではControl群と比較して、優位にPaO2が改善していた。病理組織学的にもS100A8/A9中和抗体群では、Control群と比較して、虚血再灌流障害に伴う炎症細胞浸潤が有意に抑制されていた。S100A8/A9中和抗体による肺虚血再灌流障害抑制効果がみられることがわかった。

    researchmap

  • 免疫チェックポイント阻害剤の効果を高める新たな併用療法の探索

    研究課題/領域番号:20nk010542h0001  2020年04月 - 2022年03月

    日本医療研究開発機構  創薬支援推進事業・創薬総合支援事業(創薬ブースター) 

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • アトピー性皮膚炎を治療する新しい生物製剤

    研究課題/領域番号:20lm0203008j0004  2020年04月 - 2021年03月

    日本医療研究開発機構  橋渡し研究戦略的推進プログラム シーズA 

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • 無菌養蚕冬虫夏草及びその含有成分によるがん免疫誤動作の修復機構の解明

    2020年02月 - 2023年02月

    株式会社カイタックトレーディング  共同研究  共同研究

      詳細を見る

    担当区分:研究代表者 

    配分額:3900000円 ( 直接経費:3000000円 、 間接経費:900000円 )

    researchmap

  • Ad-SGE-REIC製剤の抗腫瘍効果・作用機序の解明

    2019年09月 - 2023年08月

    桃太郎源株式会社  共同研究

      詳細を見る

    担当区分:研究代表者 

    配分額:8000000円 ( 直接経費:6152000円 、 間接経費:1848000円 )

    researchmap

  • がん免疫サイクルの観点からみたAb-REICと分泌REICタンパク質の分子機構の解明と新規創薬

    2019年06月 - 2020年02月

    岡山県  特別電源所在県科学技術振興事業研究委託 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:9000000円

    researchmap

  • 表皮分化および角層成熟制御因子の探索と機能解明

    2019年04月 - 2022年12月

    株式会社資生堂  共同研究 

      詳細を見る

    担当区分:研究代表者 

    researchmap

  • 喫煙によるがん細胞休眠解除と転移能獲得へのS100A8/A9の役割の探求と制御

    2019年04月 - 2022年03月

    公的財団法人喫煙科学研究財団  2019年度研究助成 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:2000000円

    researchmap

  • バイオセンサー分子としてのHMGB1の動態と多機能性解析

    研究課題/領域番号:19H03408  2019年04月 - 2022年03月

    日本学術振興会  科学研究費助成事業 基盤研究(B)  基盤研究(B)

    西堀 正洋, 阪口 政清, 逢坂 大樹, 王 登莉, 和氣 秀徳, 勅使川原 匡

      詳細を見る

    配分額:17550000円 ( 直接経費:13500000円 、 間接経費:4050000円 )

    1.HMGB1トランスロケーションを制御する受容体系ならびにシグナルトランスダクションの同定:研究代表者らは、LPSとTNF-αによるHMGB1トランスロケーションを強力に抑制する物質として、血漿タンパクHistidine-rich glycoprotein (HRG) を見出している。この制御系の実態を明らかにするため、血管内皮細胞のHRG とのインキュベーションによって生じる細胞内シグナルについて解析し、LPS刺激で生じるp38とErk1/2のリン酸化がHRG添加によって著明に抑制されることを明らかにした。さらに活性化型のRhoタンパクを低下させることも見出した。LPS刺激により、内皮細胞におけるHMGB1 mRNA発現は低下したが、HRGはその低下を抑制した。HRG単独ではHMGB1 mRNA発現に有意な効果をもたらさなかった。
    2.ヒスタミンによる血管透過性亢進作用並びにアナフィラキシー性血管反応における細胞外放出HMGB1の関与:これまでに、ボイデンチェンバーを用いて、血管内皮細胞分泌性のHMGB1が血管透過性亢進に関与するかどうかを予備実験で検討した。特異的抗HMGB1抗体の添加は、血管透過性亢進を抑制したことから、細胞外に分泌されたHMGB1が血管透過性亢進にも関与する可能性が強く示唆された 。そこで、まず肥満細胞を活性化し、顆粒(ヒスタミン)分泌を惹起できるCompound48/80のラットへの投与を試みた。Compound48/80を静脈内投与すると、予想された急激な血圧の低下が観察され、その後徐々に血圧低下からの回復が観察された。抗HMGB1抗体をラットに前処理し、その効果を評価した。その結果、抗HMGB1抗体による前処理は、Compound48/80による初期の急激な血圧低下を軽度抑制し、さらに持続する低血圧状態からの回復を促進した。

    researchmap

  • ダメージ関連分子パターンに着眼した肺線維化関連疾患に対する新規治療法の開発

    研究課題/領域番号:19H03746  2019年04月 - 2022年03月

    日本学術振興会  科学研究費助成事業 基盤研究(B)  基盤研究(B)

    豊岡 伸一, 冨田 秀太, 山本 寛斉, 宮原 信明, 阪口 政清, 宗 淳一, 諏澤 憲

      詳細を見る

    配分額:17420000円 ( 直接経費:13400000円 、 間接経費:4020000円 )

    本研究は、特発性肺線維症 (IPF: idiopathic pulmonary fibrosis) を中心とした肺線維化の発症と増悪に導くダメージ関連分子パターン (DAMPs)・RAGE・線維化パスウェイの中心的分子を同定し、肺の異常線維化に関連した疾患・病態に対する新規治療法の開発を目的としている。令和2年度はIPF患者の肺組織におけるS100A8/A9の発現を免疫染色およびウエスタンブロットで評価した。正常肺組織と比較して、IPFの肺組織ではS100A8/A9の発現が上昇していた。またS100A8/A9はIPF患者の血漿中でも上昇が認められた。これらの知見と、令和元年度に得られている知見(ブレオマイシンによる肺線維症モデルマウスの作製プロトコールを確立し、そのモデルを用いた実験で抗S100A8/A9中和抗体により有意な肺線維化抑制効果が得られ、生存率の改善を認めたこと、また線維芽細胞を用いたin vitroでの実験により、S100A8/9蛋白の刺激によって線維芽細胞の増殖能は上昇し、下流の転写因子であるNF-κBの活性の上昇を認め、さらに 抗S100A8/A9中和抗体投与により、活性型線維芽細胞のマーカーであるαSMAの発現低下、コラーゲン産生能の低下、NF-κBの活性の抑制効果を認めたこと)とを併せて、論文にまとめ、Journal of Molecular Medicine誌に投稿し、掲載された。

    researchmap

  • ミトコンドリア呼吸阻害による軸索変性誘導機構の解明とパーキンソン病への展開

    研究課題/領域番号:19K07369  2019年04月 - 2022年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    村田 等, 阪口 政清, 浅沼 幹人

      詳細を見る

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    SARM1の異常活性化を介した軸索変性がパーキンソン病に及ぼす影響を解析するために、ヒトiPS細胞から分化誘導した神経細胞を用いて解析を進めた。前年度において、Parkin遺伝子を欠失している家族性パーキンソン病患者由来の神経細胞は、健常者由来の神経細胞と比較して、神経毒ロテノンに対して脆弱であることを確認した。この応答がParkinの欠失に依存していることを確認するために、ゲノム編集技術を用いて健常者由来の神経細胞からParkinを欠失させた細胞を作製した。Parkinを欠失した神経細胞ではロテノン暴露時のSARM1リン酸化レベルがコントロールの神経細胞よりも増加しており、軸索変性や細胞死の割合も増加していた。Parkinは損傷ミトコンドリアを除去するマイトファジー誘導に関与する分子である。Parkin欠失による機能不全ミトコンドリアの蓄積が、活性酸素種の増加、JNKの活性化を誘導し、SARM1のリン酸化につながったと考えられる。
    SARM1のリン酸化を介した活性化をin vivoで確認するために、ロテノンを用いたパーキンソン病モデルマウスの作製を試みた。ロテノンを注入した浸透圧ポンプを皮下に移植し、0、5、10 mg/kg/dayの濃度で28日間の投与を行った。マウス中脳部分を用いた解析から、ロテノン濃度の増加に伴い、SARM1のリン酸化が上昇することを見出した。また軸索成分NF-Lの分解やドーパミン神経の脱落が生じていることを確認した。今後SARM1の活性化を阻害することで、これらの症状が改善するかどうかを確認していく。

    researchmap

  • 腫瘍幹細胞マーカーDCLK1を標的とした、悪性胸膜中皮腫に対する新規治療戦略

    研究課題/領域番号:19K09286  2019年04月 - 2022年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    三好 新一郎, 豊岡 伸一, 宗 淳一, 山本 寛斉, 諏澤 憲, 阪口 政清, 冨田 秀太

      詳細を見る

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    本研究は腫瘍幹細胞マーカーであるDCLK1の阻害が悪性胸膜中皮腫細胞に抗腫瘍効果を及ぼすことに着目し、悪性胸膜中皮腫において同タンパク質を抑制することによる抗腫瘍効果を検討し、さらに同タンパク質を標的とする薬剤を独自に構築する技術でスクリーニングし、当該疾患に対する新規治療法の確立を目指すものである。悪性胸膜中皮腫細胞株におけるDCLK1アイソフォームの発現パターンは細胞株によって異なっている。一方で正常中皮細胞株ではDCLK1の発現を認めなかった。DCLK1阻害による腫瘍増殖抑制効果は予備実験により明らかとなったが、アイソフォーム選択的に阻害した場合の効果は不明である。令和2年度は、令和元年度に実施したsiRNAによるDCLK1阻害後の細胞増殖抑制効果の機構を解明するため、バイオインフォマティクス解析を行っているが解析途中である。また、DCLK1発現による細胞増殖能の変化や浸潤能の獲得の有無について検討するためにDCLK1発現ベクターを作成し正常中皮細胞株に導入する実験を進めている。さらに、DCLK1を標的とするshRNAを作成・導入して安定的に発現が阻害された悪性胸膜中皮腫細胞株を樹立する実験も進めている。

    researchmap

  • HER2異常肺癌に対する新しい治療法の開発

    研究課題/領域番号:19K09285  2019年04月 - 2022年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    宗 淳一, 冨田 秀太, 豊岡 伸一, 山本 寛斉, 阪口 政清, 光冨 徹哉, 須田 健一, 諏澤 憲

      詳細を見る

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    HER2変異・増幅に代表されるHER2異常の肺癌における頻度は5%程度であり、EGFR標的療法の獲得耐性の一因としてもHER2異常は注目されている。HER2異常肺癌へのHER2標的療法は、先行研究でその有効性が示唆されており、個別化治療として期待されるが、肺癌に対するHER2標的療法は適応外であり、対策が遅れている。ただ、多岐にわたるHER2異常スペクトル別にHER2標的薬の感受性が異なること、他の分子標的薬と同様にHER2標的薬への獲得耐性が生じること、が予想されている。本研究では、多岐にわたるHER2異常スペクトル別にHER2標的薬の効果とその獲得耐性の克服を検討することで、HER2異常肺癌に対するプレシジョン・メディシンの確立を目指した基礎的検討を実施する。具体的には、「#1. HER2 異常タイプ別のHER2 標的薬の効果の検討」「#2. HER2 標的薬耐性細胞株の樹立とオミックス解析による耐性機序の解明」「#3. 獲得耐性例の治療法および耐性例出現の抑制法の開発」を行う。
    これまで複数のHER標的薬について、肺癌・乳癌・胃癌のHER2異常細胞株を用いて、in vitro, in vivoにその効果を検討するとともに、長期暴露による薬剤耐性株を樹立し、耐性化の機序の解明と耐性株の治療法の開発を行い、複数の報告を行っている。今後は、新たなHER異常スペクトルそれぞれについて遺伝子異常を導入した細胞株を樹立し、HER2標的薬の効果と耐性化の機序と克服の検討を続けるとともに、耐性化出現の抑制法の開発に取り組む。また、新たなHER2標的薬の臨床試験結果が発表されたため、標的となり得る新規HER2異常スペクトルの同定も試みている。

    researchmap

  • 癌はなぜ早い時期からリンパ組織へ転移するのか。

    研究課題/領域番号:19K07676  2019年04月 - 2022年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    山内 明, 岡本 秀一郎, 山村 真弘, 片瀬 直樹, 阪口 政清, 栗林 太

      詳細を見る

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    癌転移ではまずリンパ節転移が観られるが、癌細胞がリンパ組織に侵入する機序は不明である。我々はこれまで独自に開発してきた癌細胞解析方法を用いて細胞同士の相互作用や動態制御を解析する中で、炎症関連分子S100タンパク質がリンパ内皮細胞を刺激し、癌細胞の遊走を活性化する現象を見出した。つまり何らかの“リンパ向性転移因子”が存在することが分かった。この因子はケモカインなど既存の遊走因子とは異なる。本研究では、このリンパ向性転移因子を同定し、なぜ早期からリンパ組織への転移が観られるのか、その機序を解明する。
    令和元年(昨年)度の成果では、in vitroでのS100タンパク質刺激の有無によるリンパ内皮細胞の網羅的遺伝子発現解析(DNAマイクロアレイ)を行い、2倍以上の発現上昇92個/減少105個を同定していた。また、低分子物質については活性酸素が癌細胞の遊走を抑える現象を見出していた。
    令和2年(本年)度は、上記の分子群が生体内で働いているかどうかを確かめるために、ヒト膵癌細胞株をヌードマウスに接種して生着させた担癌マウスモデルを用いて癌組織(ヒト癌細胞由来および宿主マウス浸潤細胞由来)の遺伝子について、シングルセルRNA発現解析を行った。その結果、上記in vitro実験と同様に発現上昇・減少した分子を含むい遺伝子群が同定され、リンパ内皮細胞での遺伝子発現がin vivoでも確認された。また、in vitroとin vivoで発現が異なる遺伝子群については現在解析中である。

    researchmap

  • 脂肪酸の質的変化を介した核内受容体によるNASH発症機構の解明

    研究課題/領域番号:19K07474  2019年04月 - 2022年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    井上 裕介, 阪口 政清, 柿崎 暁

      詳細を見る

    配分額:4420000円 ( 直接経費:3400000円 、 間接経費:1020000円 )

    非アルコール性脂肪肝炎(NASH)は良性の脂肪肝から進展し、肝癌に進行する悪性疾患であるが、その発症機構は不明で治療薬もない。申請者は、核内受容体HNF4Aの肝臓特異的欠損マウス(Hnf4aΔHマウス)が脂肪肝を経てNASHを発症し、さらに核内受容体PPARAを欠損させたダブル欠損マウスがNASH改善と寿命延長を示すことを見出した。本研究では、①Hnf4aΔHマウスで発現上昇する脂肪酸不飽和化/伸長酵素が、脂肪酸の質的変化を引き起こし、PPARAを活性化する。②microRNA の発現低下が、PPARAのさらなる活性化と肝線維化を促進する。という2つの仮説を検証することにより、新規NASH発症機序の解明を目指した。Hnf4aΔHマウスで発現上昇する脂肪酸伸長酵素遺伝子のPPARA結合部位を同定し、この脂肪酸伸長酵素遺伝子の発現がこのPPARA結合部位依存的に転写活性化されることを明らかにした。また、miR-194遺伝子の新規標的遺伝子を8個同定することができ、これらの標的遺伝子はHnf4aΔHマウスで発現増加していることも明らかにした。さらにはmiR-192の標的遺伝子候補を32個スクリー二ングした。

    researchmap

  • 無菌養蚕冬虫夏草による抗がん機能の新たな作用点の探求

    2019年01月 - 2020年01月

    株式会社カイタックトレーディング  共同研究  共同研究

      詳細を見る

    担当区分:研究代表者 

    配分額:2000000円 ( 直接経費:1818000円 、 間接経費:182000円 )

    researchmap

  • 新たな治療標的として重要ながん転移を促すS100種の網羅的同定

    2019年01月 - 2019年12月

    公益財団法人テルモ生命科学芸術財団  2018年度 ?. 研究助成金 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:2000000円

    researchmap

  • RAGE-aptamer封入ナノ粒子による肺高血圧症の新規治療法の開発

    研究課題/領域番号:18K08037  2018年04月 - 2021年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    中村 一文, 赤木 達, 阪口 政清, 三好 亨, 深水 圭, 伊藤 浩

      詳細を見る

    配分額:4420000円 ( 直接経費:3400000円 、 間接経費:1020000円 )

    1.肺高血圧モデルラットにおけるRAGE特異的 DNA aptamerの抑制効果: モノクロタリン誘発性肺高血圧症モデルラットにおいてモノクロタリンと同時に終末糖化産物受容体RAGE特異的 DNA aptamerの持続皮下注を行ったところ、肺高血圧症と肺動脈リモデリングの発生抑制効果を認めた。
    2. 肺動脈性肺高血圧症患者の肺動細胞平滑筋細胞におけるRAGE特異的 DNA aptamerの増殖抑制効果: 血小板由来増殖因子刺激による増殖亢進をRAGE特異的DNA aptamerは有意に抑制した。
    上記よりRAGE特異的 DNA aptamerの肺高血圧症発症の抑制作用が認められた。

    researchmap

  • がん細胞の転移を加速するがん微小環境内線維芽細胞の新たな役割

    2018年 - 2019年

    公益財団法人がん研究振興財団  第50 回がん研究助成金 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:1000000円

    researchmap

  • 新規S100 受容体による原発巣転移前がん微小環境構築とがん転移動力獲得の分子機構

    2017年 - 2020年03月

    独立行政法人 日本学術振興会  基盤研究(B) 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:15600000円

    researchmap

  • がん転移の“種と土”を解くS100タンパク質ワールド

    2017年 - 2020年

    公益財団法人武田科学振興財団  2017 年度生命科学研究助成 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:10000000円

    researchmap

  • 希少漢方「冬虫夏草」中に含まれる新規抗がん成分の同定とその薬効解析

    2017年 - 2019年

    公益財団法人小林国際奨学財団  平成29 年度研究助成 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:4500000円

    researchmap

  • 新規S100 受容体による原発巣転移前がん微小環境構築とがん転移動力獲得の分子機構

    2017年 - 2019年

    独立行政法人 日本学術振興会  基盤研究(B) 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:15600000円

    researchmap

  • 分泌REICタンパク質の抗腫瘍の本態解明

    2017年

    岡山医学振興会  第17 回公募助成 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:1000000円

    researchmap

  • 癌遺伝子候補MYNNとp53の統合的解析と肺癌発症メカニズムの解明

    研究課題/領域番号:16K10460  2016年04月 - 2020年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    伊藤 佐智夫, 笹井 香織, 阪口 政清, 片山 博志

      詳細を見る

    配分額:4810000円 ( 直接経費:3700000円 、 間接経費:1110000円 )

    新規癌遺伝子Myoneurin (MYNN)は、BTB/POZ-Zinc Fingerタンパク質ファミリーに属し、肺癌、卵巣癌、食道癌、乳癌等において高頻度に遺伝子増幅がみられる。MYNNがコードされる染色体3q26領域は多くの癌で増幅が確認され、近年、この領域からのCancer driver geneの同定が盛んに試みられている。MYNNが強力な転写抑制能、腫瘍形成能、p53結合能を有することから、MYNNの機能解析は発癌を理解する上で大変重要であると考えた。
    本研究では、MYNNとp53の機能相互作用について新しい知見を示した。

    researchmap

  • 2型糖尿病治療薬メトホルミンと抗PD-1抗体を併用した新しい肺癌免疫療法の開発

    研究課題/領域番号:16K15637  2016年04月 - 2019年03月

    日本学術振興会  科学研究費助成事業 挑戦的萌芽研究  挑戦的萌芽研究

    三好 新一郎, 豊岡 伸一, 山本 寛斉, 阪口 政清, 宗 淳一

      詳細を見る

    配分額:3380000円 ( 直接経費:2600000円 、 間接経費:780000円 )

    肺癌において、メトホルミンによる腫瘍免疫担当細胞の機能増強作用と抗PD-1抗体による免疫寛容状態の解除作用に着目し、肺癌における両者の併用治療の確立を目指す研究を行った。癌患者における末梢血ならびに腫瘍組織中のリンパ球の機能評価を行い末梢血単核球および腫瘍浸潤性T細胞をメトホルミンの存在・非存在下で培養しT細胞に非特異的な刺激を与えたところ、メトホルミン存在下ではサイトカイン産生能が増加したことを確認した。また、初代培養肺癌細胞に対するメトホルミン処理T細胞+抗PD-1抗体の抗腫瘍効果の検討と、メトホルミン処理T細胞+抗PD-1抗体の抗腫瘍効果を予測するバイオマーカーの探索・同定を進めた。

    researchmap

  • HER2新規結合分子サイトケラチン19に着目したHER2活性癌の新規治療法

    研究課題/領域番号:16K10681  2016年04月 - 2019年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    宗 淳一, 三好 新一郎, 冨田 秀太, 佃 和憲, 豊岡 伸一, 山本 寛斉, 阪口 政清, 浅野 博昭

      詳細を見る

    配分額:4550000円 ( 直接経費:3500000円 、 間接経費:1050000円 )

    HER2蛋白は、肺癌・胃癌などで活性化する。既存のHER2分子標的薬は効果や薬剤耐性の問題があり、HER2活性型腫瘍への新しい戦略が必要である。HER2蛋白活性化に関与する新規分子サイトケラチン19を同定した。胃癌細胞株に対するHER2分子標的薬(Afatinib)の治療効果(in vitro&vivo)を報告した。Afatinibの適応がないHER2変異陽性がん患者において、探索的に使用し、その治療効果を報告した。HER2活性型肺癌細胞株における汎HER阻害剤Neratinibの治療効果(in vitro&vivo)を報告した。

    researchmap

  • 遺伝子発現と変異プロファイル解析に基づくEGFR変異肺癌に対する新規治療法の開発

    研究課題/領域番号:16H05431  2016年04月 - 2019年03月

    日本学術振興会  科学研究費助成事業  基盤研究(B)

    豊岡 伸一, 三好 新一郎, 冨田 秀太, 枝園 和彦, 山本 寛斉, 阪口 政清, 宗 淳一

      詳細を見る

    配分額:17550000円 ( 直接経費:13500000円 、 間接経費:4050000円 )

    EGFR変異肺がん治療において、獲得耐性機序を治療前に予測すると同時にその耐性出現を防ぐ初期治療の確立を目指す研究を行った。高感度の検出が可能である分子バーコードを用いたDeepシークエンスにより、肺癌臨床検体で高率に複数のEGFR変異の共存が確認された。オシメルチニブに対する耐性を獲得した細胞株の検討では、EMT化による耐性獲得細胞では、高率にAXLが高発現し、AXL阻害剤であるカボザンチニブの上乗せにより耐性が解除されることを明らかにした。またドラッグリポジショニング解析から抗生物質モネンシンが抗EMT化作用を示し、その耐性獲得を抑制が可能であることを明らかにした。

    researchmap

  • 核内受容体HNF4αとPPARによるNASH発症機序の解明と治療応用への基礎研究

    研究課題/領域番号:16K08728  2016年04月 - 2019年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    井上 裕介, 阪口 政清, 柿崎 暁

      詳細を見る

    配分額:4940000円 ( 直接経費:3800000円 、 間接経費:1140000円 )

    肝臓特異的HNF4α欠損マウス(KOマウス)でのNASH発症におけるPPARαの活性化機構の解明を目的とした。KOマウスでは脂肪酸取り込みに関与するFATP1の発現が顕著に上昇しており、FATP1の転写活性化はPPARα依存的に強く誘導された。また、KOマウスで発現低下するmiRNAを同定し、その標的遺伝子として線維化に関与する遺伝子を同定した。さらに、KOマウス肝臓では数種類の脂肪酸の割合が変動していた。加えて、脂肪酸伸長と不飽和化に関与する複数の遺伝子の発現変動が認められた。以上より、KOマウスでは脂肪酸の質的変化によりPPARαが活性化されてNASHを発症する可能性が示唆された。

    researchmap

  • iPS細胞マーカーTRA-1-60はがん難治性の指標か?

    研究課題/領域番号:16K15245  2016年04月 - 2018年03月

    日本学術振興会  科学研究費助成事業 挑戦的萌芽研究  挑戦的萌芽研究

    近藤 英作, 奥田 修二郎, 阪口 政清

      詳細を見る

    配分額:3640000円 ( 直接経費:2800000円 、 間接経費:840000円 )

    TRA-1-60は糖鎖修飾型PODXL1であることから、ヒト膵がん細胞株においてPODXL1ノックアウトクローンを作成し機能解析した。結果、MiaPaCa-2, AsPC1, Panc-1 PODXL1-KO(PODXL1 -/-)クローンは膵がん肝転移を劇的に抑制した。即ち、PODXL1は膵がんの転移能獲得に直接に機能していることが判明した。PODXL1は複数のサイトカイン受容体と結合能を持ち、がん組織内でこれら受容体の機能活性化に働いていることが判明した膵がん患者病理組織では、上記の遺伝子機能を反映し、腫瘍の浸潤先進部や肝転移巣で高発現していることが判明した。

    researchmap

  • 臓器が発するがん誘引性転移シグナルの遮断を目指して開発した「新規分子標的タンパク質製剤」によるがん細胞転移制御の試み

    2016年 - 2018年

    一般財団法人藤井節郎記念大阪基礎医学研究奨励会  平成28 年度研究助成金 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:2000000円

    researchmap

  • CHO細胞における組み換えタンパク質大量発現に有効な超高効率遺伝子安定発現プラスミドベクター

    2016年 - 2017年

    国立研究開発法人日本医療研究開発機構  革新的医療技術創出拠点プロジェクト(橋渡し研究加速 ネットワークプログラム) 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:2000000円

    researchmap

  • がんの転移をターゲットとした新しい治療法の開発

    2016年 - 2017年

    国立研究開発法人日本医療研究開発機構  次世代がん医療創生研究事業 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:33000000円

    researchmap

  • REIC タンパク質の機能解析による新たな創薬基盤プラットフォームの構築

    2016年 - 2017年

    岡山県  特別電源所在県科学技術振興事業研究委託 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:26000000円

    researchmap

  • RAGE シグナル抑制による肺高血圧症治療法の新規開発

    研究課題/領域番号:15K09158  2015年04月 - 2018年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    中村 一文, 赤木 達, 阪口 政清, 伊藤 浩

      詳細を見る

    配分額:4940000円 ( 直接経費:3800000円 、 間接経費:1140000円 )

    1.乳酸・グリコール酸共重合体(co-poly-lactic/glycolic acid: PLGA)という生体内で加水分解され水と二酸化炭素になる物質をナノ粒子化し、イマチニブならびにベラプロストを封入した薬剤封入ナノ粒子を作成した。肺高血圧症モデルラットに気管内投与すると右室収縮期圧や右室肥大の抑制をみとめ肺高血圧の改善がみられた。
    2.肺動脈性肺高血圧症(PAH)の肺動脈平滑筋細胞の増殖は亢進しており、TIR/BB-loop類似構造体(mimetic), AS-1 にてRAGEシグナルを抑制してみると、過剰な増殖が抑制された。

    researchmap

  • S100A8/A9-Emmprin系を介したメラノーマの増殖転移制御に関する研究

    研究課題/領域番号:15K09788  2015年04月 - 2018年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    坪井 良治, 原田 和俊, 山本 真実, 前 賢一郎, 阪口 政清, 前田 龍郎, 江草 智津, 日比野 利彦

      詳細を見る

    配分額:4810000円 ( 直接経費:3700000円 、 間接経費:1110000円 )

    S100蛋白ファミリーのS100A8/A9に対してEmmprinとneuroplastin bは受容体である。Emmprin高発現メラノーマ細胞をS100A9Tgマウスの尾静脈から注入すると皮膚に転移巣を生じた。本研究ではC57/BL6マウスの皮膚にB16F10細胞を注射し、肺に転移するマウスモデルを確立した。しかし、S100A8/A9-Emmprinの結合を抑制する物質は発見できなかった。

    researchmap

  • がんの転移先臓器親和性を制御する新規生物製剤の開発

    2015年 - 2017年

    独立行政法人 日本学術振興会  挑戦的萌芽研究 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:2900000円

    researchmap

  • ヒトS100A9ホモダイマーおよびヒトS100A8/A9へテロダイマーに対する抗体製剤の開発によるがん転移制御の試み

    2015年 - 2016年

    公益財団法人小林がん学術振興会  第9 回研究助成金 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:1000000円

    researchmap

  • 新開発哺乳細胞超高効率遺伝子安定発現プラスミドベクターのタンパク質製剤大量産生系への有用性の評価

    2015年 - 2016年

    国立研究開発法人日本医療研究開発機構  革新的医療技術創出拠点プロジェクト(橋渡し研究加速 ネットワークプログラム) 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:2500000円

    researchmap

  • 肺癌の新しい癌化機構の解明と治療法確立に向けた基礎的研究

    研究課題/領域番号:26293318  2014年04月 - 2017年03月

    日本学術振興会  科学研究費助成事業  基盤研究(B)

    三好 新一郎, 豊岡 伸一, 宗 淳一, 山本 寛斉, 佃 和憲, 阪口 政清, 片山 博志, 枝園 和彦, 諏澤 憲, 大塚 智昭

      詳細を見る

    配分額:16120000円 ( 直接経費:12400000円 、 間接経費:3720000円 )

    治療抵抗性で予後不良な疾患である肺癌の治療において、発癌に関わる新たな分子機序を解明することが重要と考えられてきた。我々は、ヒト上皮成長因子受容体関連物質2(HER2)遺伝子の新たな変異を発見し、その発癌への寄与について明らかにした。また、HER2と結合してその活性化に関与すると考えられる分子を見出し、新たな治療標的となる可能性を明らかにした。

    researchmap

  • 癌抑制遺伝子REIC/Dkk-3による癌化シグナル制御機構の解明

    研究課題/領域番号:26293352  2014年04月 - 2017年03月

    日本学術振興会  科学研究費助成事業  基盤研究(B)

    公文 裕巳, 高本 篤, 江原 伸, 阪口 政清, 佐々木 克己

      詳細を見る

    配分額:16120000円 ( 直接経費:12400000円 、 間接経費:3720000円 )

    癌治療遺伝子REIC/Dkk-3を用いた固形癌に対するin situ遺伝子治療では、癌細胞の選択的アポトーシスが誘導されることがその主要な機序である。またこれまでに、癌治療遺伝子・タンパク質REIC/Dkk-3による癌細胞増殖抑制作用が報告されており、本申請研究では、当該治療による癌化シグナル制御機構を明らかにする為の研究を実施し、関連する重要な因子群を同定した。

    researchmap

  • 転移先臓器を感知する受容体群の分子制御機構の解明とその応用

    2014年 - 2016年

    独立行政法人 日本学術振興会  基盤研究(B) 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:12500000円

    researchmap

  • 糖尿病網膜症制御法の新構築を目指したRAGE膜直下信号伝達阻害手段の確立

    2014年 - 2015年

    公益財団法人高齢者眼疾患研究財団  平成25 年度研究助成 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:1000000円

    researchmap

  • がん細胞の転移先臓器を感知する新規センサー分子の発見を基盤とした転移機構の解明とその制御

    2014年 - 2015年

    公益財団法人山陽放送学術文化財団  第51 回学術研究助成 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:500000円

    researchmap

  • 独自に開発した超高効率遺伝子発現プラスミドベクターの抗体大量産生系への応用を目指した基礎研究

    2014年 - 2015年

    公益財団法人ウエスコ学術振興財団  平成26 年度学術研究費助成 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:300000円

    researchmap

  • 新規S100A8/A9受容体の発見を切り口とした膿疱性乾癬の分子機構の解明

    2014年 - 2015年

    公益財団法人先進医薬研究振興財団  第33 回一般研究助成金(血液医学分野) 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:1000000円

    researchmap

  • がん転移における「種と土」のクロストークを遮断する分子標的製剤の開発

    2014年

    公益財団法人高松宮妃癌研究基金  平成26 年度研究助成金 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:2000000円

    researchmap

  • 核内受容体による非アルコール性脂肪肝炎発症経路の解明と治療応用への基盤構築

    研究課題/領域番号:25460490  2013年04月 - 2016年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    井上 裕介, 行木 信一, 阪口 政清

      詳細を見る

    配分額:4940000円 ( 直接経費:3800000円 、 間接経費:1140000円 )

    肝臓HNF4α欠損マウス(KOマウス)はNASHを発症するが、PPARαの欠損によりNASHが改善する。KOマウスでFATP1, CD36, CideAの発現増加が認められ、ダブルKOマウスで発現低下することが分かった。また、KOマウスではFATP1のプロモーターにおけるPPARαのDNA結合活性と肝臓での脂肪酸量が増加していることが分かった。このため、内在性脂肪酸がPPARαを活性化し、PGC1αによりPPARα標的遺伝子が転写活性化され、NASHが誘導されると推測された。

    researchmap

  • 転移先臓器を感知する受容体の発見に基づくがん転移機構の解明

    2013年 - 2016年

    公益財団法人武田化学振興財団  2013 年度医学系研究奨励(基礎) 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:2000000円

    researchmap

  • RAGE膜直下信号伝達阻害剤による糖尿病性網膜症治療の試み

    2013年 - 2014年

    公益財団法人薬理研究会  平成25 年度研究助成金 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:1000000円

    researchmap

  • がん幹細胞をも標的とするREIC遺伝子治療の消化器がんへの応用

    研究課題/領域番号:24591943  2012年04月 - 2015年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    片岡 健, 阪口 政清, 村田 等

      詳細を見る

    配分額:5330000円 ( 直接経費:4100000円 、 間接経費:1230000円 )

    マウス組織を用いてREIC/Dkk-3の発現局在の詳細なスクリーニングを行ったところ、皮膚と腸上皮組織において幹細胞のニッチとREIC/Dkk-3の局在が一致していた。また腸管上皮細胞株Caco-2を細胞外マトリクスタンパク質に包埋して3次元培養を行ったスフェロイドにおいてもREIC/Dkk-3の発現を認めた。またREIC/Dkk-3の発現制御因子を探索したところ、TNF-αが表皮ケラチノサイトのREIC/Dkk-3発現を低下させることがわかった。REIC/Dkk-3とTNF-αのバランスが発生過程や炎症における表皮ケラチノサイトと血管内皮細胞による組織構築を調整していることが示唆された。

    researchmap

  • 新開発超高効率遺伝子発現プラスミドベクターによる抗体大量産出技術の確立

    2012年 - 2014年

    公益財団法人加藤記念バイオサイエンス振興財団  平成23年度加藤記念研究助成 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:2000000円

    researchmap

  • 抗体大量産生用超高率遺伝子発現ベクターの開発

    2012年 - 2013年

    財団法人ノバルディス科学振興財団  第25 回ノバルディス研究奨励金 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:1000000円

    researchmap

  • がん特異的 REIC 遺伝子治療の特長を最大限に引き出す超高機能ベクターの開発

    2012年 - 2013年

    財団法人両備てい園記念財団  第34 回研究助成金 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:350000円

    researchmap

  • CD133のリガンド同定によるがん幹細胞特性の解析

    2012年 - 2013年

    公益財団法人アステラス病態代謝研究会  平成24 年度研究助成金 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:1000000円

    researchmap

  • 炎症を感知する新規内因性リガンドセンサーの作動機構解明とがん進展における役割

    2012年 - 2013年

    独立行政法人 日本学術振興会  新学術領域研究 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:7400000円

    researchmap

  • RAGE複合体情報処理ユニットによるがん進展の分子基盤解析

    2012年

    公益財団法人金原一郎記念医学医療振興財団  第27回基礎医学医療研究助成金 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:400000円

    researchmap

  • REIC/Dkk―3遺伝子治療による自己癌ワクチン化療法の基盤解析

    研究課題/領域番号:23390382  2011年04月 - 2014年03月

    日本学術振興会  科学研究費助成事業  基盤研究(B)

    公文 裕巳, 許 南浩, 渡部 昌実, 阪口 政清, 賀来 春紀, 植木 英雄

      詳細を見る

    配分額:18460000円 ( 直接経費:14200000円 、 間接経費:4260000円 )

    癌治療遺伝子REIC/Dkk-3を用いた固形癌に対するin situ遺伝子治療では、「癌細胞の選択的アポトーシス」と「抗癌免疫の活性化」による相乗的効果増強作用(自己癌ワクチン化)が誘導されることが示されている。本申請研究では、当該治療による自己癌ワクチン化機序として、発現したREICタンパク質による骨髄系免疫抑制細胞(MDSC)の分化抑制機構と、その下流の現象としての細胞傷害性T細胞(CTL)の活性化が重要であることを明らかにした。

    researchmap

  • 多機能受容体RAGEによるがん幹細胞活性化と炎症憎悪の負の連鎖

    2011年 - 2013年

    公益財団法人内藤記念科学振興財団  第43回科学奨励金 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:3000000円

    researchmap

  • 炎症性多機能受容体RAGEの活性化動態評価システムの構築

    2011年 - 2012年

    財団法人薬学研究奨励財団  第32回研究助成金(グループA) 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:1000000円

    researchmap

  • RAGE 膜直下信号伝達機構解明を基盤とした糖尿病性血管障害の治療戦略

    2011年 - 2012年

    公益財団法人先進医薬研究振興財  第30回一般研究助成金 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:1000000円

    researchmap

  • がん幹細胞特異的殺傷抗体作成技術の創出

    2011年 - 2012年

    独立行政法人 日本学術振興会  挑戦的萌芽研究 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:2800000円

    researchmap

  • 新世代REICアデノウィルスによる純国産がん遺伝子治療の統合新戦略

    研究課題/領域番号:23650625  2011年 - 2012年

    日本学術振興会  科学研究費助成事業  挑戦的萌芽研究

    許 南浩, 阪口 政清, 片岡 健, 村田 等

      詳細を見る

    配分額:3640000円 ( 直接経費:2800000円 、 間接経費:840000円 )

    抗がんウイルス製剤 REIC アデノウイルスに、独自に開発した「がん特異的新規プロモーターシステム」と「新規アデノウイルスアダプター」を適用することで、REIC アデノウィルスを高機能化させることに成功した。これは、従来に比較して遥かに強力ながん選択的なアデノウイルス感染とREIC 遺伝子発現を可能にし、抗腫瘍効果を大幅に上昇させた。

    researchmap

  • 腹膜播種性転移がんの特性を利用した統合的新規遺伝子治療プロトコールの開発

    研究課題/領域番号:21591699  2009年 - 2011年

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    片岡 健, 阪口 政清

      詳細を見る

    配分額:4160000円 ( 直接経費:3200000円 、 間接経費:960000円 )

    スキルス胃がん腹膜播種マウスモデルにREIC/Dkk-3発現アデノウイルスを投与したところ、抗腫瘍効果が認められた。腫瘍部分にはナチュラルキラー細胞が動員されており、REIC/Dkk-3遺伝子治療はスキルス胃がんに対する統合的なアプローチの選択肢になりうると考えられた。さらにミトコンドリアの品質管理に重要な分子PINK1が、REIC/dkk-3遺伝子治療の耐性克服の新しい標的となることが新たに示された。またREIC/Dkk-3の正常組織における発現制御因子のスクリーニングの結果、TNF-αが同定された。

    researchmap

  • 多機能受容体RAGEの動的イメージングを基盤とした動作原理の解明,

    2009年 - 2010年

    公益財団法人武田科学振興財団  2009年度医学系研究奨励(基礎) 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:3000000円

    researchmap

  • 炎症および神経変性疾患の発症? 進展を制御する受容体RAGEの多機能性の解明

    2009年 - 2010年

    独立行政法人 日本学術振興会  若手研究(A) 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:16500000円

    researchmap

  • がん特異的超高効率発現アデノウィルスベクターの開発とがん遺伝子治療への応用

    2009年

    公益財団法人持田記念医学薬学振興財団  第27回医学薬学振興財団研究助 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:2000000円

    researchmap

  • 不死化関連遺伝子群によるOncogenic Ras制御と前立腺癌化抑制機構の解明

    研究課題/領域番号:20390426  2008年 - 2010年

    日本学術振興会  科学研究費助成事業  基盤研究(B)

    公文 裕巳, 許 南浩, 阪口 政清, 那須 保友, 筒井 研

      詳細を見る

    配分額:17550000円 ( 直接経費:13500000円 、 間接経費:4050000円 )

    岡山大学で同定した新規の不死化関連遺伝子群について、前立腺正常上皮細胞および前立腺癌細胞における発現動態が、細胞内でのRasシグナリングの抑制および細胞増殖抑制にどのような分子機構により関わるのかを系統的に解析した。特に、不死化関連遺伝子の一つであるREIC/Dkk-3の発現が、活性化Rasタンパク質を抑制することによりAktタンパク質の非活性化に関与することを明らかにした。また、REIC発現による細胞死の分子シグナル伝達を、分子シャペロンタンパク質であるBiP/GRP78タンパク質が負に制御することを明らかにした。

    researchmap

  • 誤標的された正常細胞をも抗がんに動員する統合的遺伝子治療の新戦略

    研究課題/領域番号:20015031  2008年 - 2009年

    日本学術振興会  科学研究費助成事業  特定領域研究

    許 南浩, 阪口 政清, 片岡 健

      詳細を見る

    配分額:10700000円 ( 直接経費:10700000円 )

    REIC/Dkk-3発現アデノウイルスベクター(Ad-REIC)のスキルス胃癌への適用
    スキルス胃癌は進行が早く腹膜やリンパ節に転移しやすい難治性のがんの一つである。現在、本がん種を標的とした有効な治療法がない。本年度では、Ad-REICのスキルス胃癌への有効性を検討する目的で、胃がん腹膜播種動物モデルを新規に開発した。Ad-REICを服腔内に投与したところ、胃がん細胞株の腹膜播種の有為な抑制が観察された。これは、Ad-REICの直接効果(がん細胞特異的細胞死誘導)とAd-REICにより誤標的された正常細胞を介した間接効果(正常細胞がIL-7を産生してNK細胞の活性化を誘導)によることが明らかとなった(論文準備中)。
    Ad-REICの改良
    Ad-REICによるアポトーシス誘導作用を高めるために、強力な遺伝子発現システムを独自に開発した。結果、従来のプロモーター(CAGやCMV)を用いた遺伝子発現システムに比較して顕著な遺伝子発現増強効果(各種遺伝子で、100倍から1000倍)が達成された。このシステムをAd-REICに組み込むことにより、現存のAd-REICを上回る治療効果が期待できる(論文準備中)。
    分泌REIC/Dkk-3タンパク質の機能の解明
    分泌型REIC/Dkk-3も免疫系を介した間接的抗腫瘍効果を示す。REIC/Dkk-3の発現組織と分泌されたREIC/Dkk-3を積極的に取り込む細胞の同定を行ったところ、分泌されたREIC/Dkk-3は末梢血単球の樹上細胞様細胞への分化・増殖を制御している可能性が示唆された。
    REIC/Dkk-3ノックアウトマウスの作製
    癌抑制遺伝子REIC/Dkk-3の主要ドメインであるEXON 5、6を全身性にノックアウトしたマウスの作成を行っていたが、2009年10月に、ホモノックアウトマウスの作成に成功した。

    researchmap

  • 尿路性器癌の抗癌剤耐性獲得における新規分子機構解明と治療法開発のための基盤研究

    研究課題/領域番号:18390437  2006年 - 2008年

    日本学術振興会  科学研究費助成事業  基盤研究(B)

    那須 保友, 阪口 政清, 雑賀 隆史, 江原 伸

      詳細を見る

    配分額:14120000円 ( 直接経費:11600000円 、 間接経費:2520000円 )

    抗がん剤による治療を行った場合に、徐々にその効果が低下することは臨床上しばしば認めることであり、そのメカニズムを解明しその結果に基づき新たな治療法を開発することは極めて重要なことである.がん細胞に対してアポトーシス(細胞死)誘導するREIC/Dkk-3が耐性獲得抑制、耐性克服もしくは感受性増強のための標的となることを明らかにした.特に、REIC/Dkk-3により抗がん剤耐性獲得におけるkey moleculeであるP-glycoproteinの発現が低下することを突き止めた.

    researchmap

  • 骨髄由来MAPC類似幹細胞移植による肝不全治療と肝線維症予防の基盤研究

    研究課題/領域番号:18590269  2006年 - 2007年

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    宮崎 正博, 許 南浩, 阪口 政清, 娜依拉 馬合木提

      詳細を見る

    配分額:3860000円 ( 直接経費:3500000円 、 間接経費:360000円 )

    我々は、ラット骨髄からMAPC類似の間葉系幹細胞(CD29^+/CD44^+/CD49b^+/CD90^+/CD45^-、ビメンチン及びフィプロネクチン陽性)を単離、クローン化した。本細胞株は約24時間の倍加時間で対数増殖し、300PDLを越えても正二倍体性を維持した。本細胞をHGFおよびFGF-4を添加してマトリゲル上で1週間培養すると、アルブミン、AFP、G6Pase、TO、TAT、CYP1A1、CYP1A2、HNF1α、HNF4α、CK-8、CK-18を発現する肝細胞類似の細胞(類肝細胞)へほぼ100%の効率で分化する。この類肝細胞を90%肝切除による急性肝不全ラットモデルの脾臓に移植したところ、血中アンモニア濃度の増加が有意に抑制され、15匹中5匹が生還した。一方、対照ラットは術後48時間以内に全例死亡した。本類肝細胞はケモカインSDF-1のレセプターCXCR-4、肝再生因子(HGF、TGF-α)とそのレセプター(c-Met、EGFR)を発現することから、これらの分子が移植細胞の肝臓内へのケモタクシス・リクルートおよびオートクリン、パラクリン増殖促進に関与した可能性が考えられる。
    四塩化炭素誘導ラット肝線維症モデルに対し、未分化幹細胞クローンを脾臓内に移植した結果、Picrosirius Red染色およびα-Smooth Muscle Actin免疫染色により示されるように、肝臓の線維化が顕著に抑制された。未分化幹細胞クローンにMMP-9の活性が認められることから、本細胞移植による線維化抑制効果の一部はMMP-9の作用による可能性が考えられる。
    以上のとおり、本幹細胞クローン由来の類肝細胞は肝不全を救命するポテンシャルを有し、また元未分化幹細胞クローンは肝線維症の治療に有効であることがわかった。今後は、これらの細胞の組み合わせ移植による効果を検討したいと考えている。

    researchmap

  • 正常皮膚および腫瘍に対するWnt調節因子REIC/DKK3の作用に関する研究

    研究課題/領域番号:18591249  2006年 - 2007年

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    片岡 健, 李 代偉, 阪口 政清, 片岡 健

      詳細を見る

    配分額:3500000円 ( 直接経費:3200000円 、 間接経費:300000円 )

    1.培養ヒト正常表皮角化細胞にREIC/Dkk-3を発現するアデノウイルスベクター(Ad-REIC)を感染させ発現が変化する遺伝子をスクリーニングしたところ、免疫機能の調節に重要な役割を果たすサイトカインの発現が誘導されることが分かった。このサイトカイン誘導により個体の免疫機能の亢進することが認められ、REIC/Dkk-3が生体での防護機構に関与する可能性が示唆された。
    2.REIC/Dkk-3を強制発現すると腫瘍特異的にアポトーシスが誘導される。この機構を探るため、Ad-REICに高感受性のがん細胞株をスクリーニングし、マウス腎がん細胞株RENCAを同定した。この細胞株と正常線維芽細胞であるNIH3T3を比較することにより、Ad-REICによる腫瘍特異的アポトーシス誘導にHsp70/72が防護的に働き、それが腫瘍特異的アポトーシス誘導の一因であることを明らかにした。
    3.Ad-REICに感受性がある前立腺がん細胞株PC3に低濃度でAd-REICを感染させながら長期間培養し、耐性細胞を得た。この細胞を用いてPC3親株と比較するためマイクロアレイによる発現解析を行ったが、結果は現在解析中である。また耐性の鍵となるシグナル伝達経路を同定し、詳細な解析を行った。
    4.前年度に開発した方法によりヒト正常線維芽細胞からREIC/Dkk-3タンパク質を培養実験に使用できる純度で精製した。
    5.REIC/Dkk-3のノックアウトマウスを作成中である。当該遺伝子をノックアウトしたマウスES細胞を既に得て、現在個体を作成中である。

    researchmap

  • 上皮細胞増殖制御の機能的ハプタンパク質S100Cの機能解明とがん治療への応用

    研究課題/領域番号:18013035  2006年 - 2007年

    日本学術振興会  科学研究費助成事業  特定領域研究

    許 南浩, 阪口 政清, 宮崎 正博

      詳細を見る

    配分額:12100000円 ( 直接経費:12100000円 )

    本研究計画は1)がんのTGFβ抵抗性とS100A11機能との関連を明らかにする、2)S100A11のAnnexinA1との結合、ヒトがんでの発現充進の意味を明らかにする、3)この知見を治療に応用する、ことを目的とする。平成18年度は1)について報告した。平成19年度は主に2)に取り組み、以下の結果を得た。
    1.正常ヒト表皮角化細胞(NHK)において、S100A11はAnnexin A1と複合体を形成しPhospholipase A2と結合してその活性を抑制した。その結果アラキドン酸カスケードが抑制されて細胞増殖が低下した。EGFという増殖刺激が入るとphospholipase A2活性抑制の解除が起こって細胞増殖が維持される。即ち、TGFβとEGFというシグナル系がS100A11を接点として関連する。(J Biol Chem 282:35679-86,2007)
    3.NHKはS100A11を分泌し、分泌型SIOOA11はNHKの増殖を促進した。この増殖促進は主にEGFファミリーの産生誘導によった。S100A11はRAGE、NFkBとAkt、CREBを介してEGF遺伝子を活性化した。即ち、S100A11は、細胞内では増殖抑制、分泌されると増殖促進という二面性の役割を担う。(Mol Biol Cell 19:78-85,2008)
    4.S100A8とS100A9がNHKから分泌され、NHKに作用して炎症性サイトカインの産生・分泌を誘導する、それが逆にS100A8,S100A9の産生・分泌を促進する、S100A8/A9自体がNHKに対する増殖促進作用を持つ、ことを見出した(J Cell Biochem印刷中)。
    以上の成果によって、S100C/A11の機能的ハブとしての本態の解明に大きな展開が得られた。今後は、SIOOタンパク質群の受容体RAGEの作動機構の本態の解析を通じて治療戦略の構築を目指す。

    researchmap

  • S100C タンパク質を介した新規細胞増殖制御機構の解明

    2005年 - 2006年

    独立行政法人 日本学術振興会  若手研究(B) 

    阪口 政清

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:3300000円

    researchmap

  • S100C/A11を介する新しいTGFβ増殖抑制信号伝達系の発がんにおける意義

    研究課題/領域番号:17014065  2005年

    日本学術振興会  科学研究費助成事業  特定領域研究

    許 南浩, 宮崎 正博, 阪口 政清

      詳細を見る

    配分額:6800000円 ( 直接経費:6800000円 )

    S100C/A11を介する新しい信号伝達系が、ヒト正常表皮角化細胞の増殖抑制と発がんにどのような意義を持っているかを検討し、以下の結果を得た。
    1.TGFβは受容体の活性化からSmadを介する経路とS100C/A11を介する経路に分岐するが、増殖抑制には両経路の活性化が必須であり、一方でもブロックすると抑制が解除されることが明らかになった。このことは、高Caの場合でも、Smad経路がNFAT1経路に代わるだけで成り立つことが分かった。
    2.核内における両経路の集約機構を検討した結果、増殖中の細胞のp21プロモーターにはSp/KLF family memberのKLF16が結合して不活化しており、このKLF16を駆逐してp21プロモーターを活性化するには、両経路によってそれぞれ活性化されたSp1とSmad3を含む複合体が必要であることを明らかにした。以上を纏めて、論文に発表した(ProNAS USA 102:13921,2005)。
    3.ヒト正常上皮細胞の多くはTGFβによって増殖が抑制され、それに対する抵抗性の獲得が発がんや悪性度の進展に関わると考えられている。TGFβに対する抵抗性獲得の機序としてS100C/A11経路の異常が関与しているかどうかを検討した。解析対象としたヒト扁平上皮がん細胞株は、全例がTGFβに対して抵抗性であった。TGFβによるS100C/A11、Smad3、Smad4の核移行は増殖抑制に必須であるが、これらのがん細胞株では様々組み合わせで異常が見られた。従って、がん細胞の示すTGFβ抵抗性の少なくとも一部はS100C/A11経路の異常によることが示唆された(投稿中)。
    4.本研究で明らかになったS100C/A11の機能を治療に応用することを目指して、信号伝達機能を担うドメインとHIV由来の細胞内移行シグナルを融合したペプチドの大量合成と精製条件を確立した。このペプチドを培地中に添加すると多様な細胞でアポトーシスが誘導された。現在、その詳細な細胞内機構を解析中である。

    researchmap

  • 皮膚組織構築に関わる遺伝子のヒト疾患における意義とその再生医学的治療法の開発

    研究課題/領域番号:14370260  2002年 - 2004年

    日本学術振興会  科学研究費助成事業  基盤研究(B)

    許 南浩, 宮崎 正博, 高石 樹朗, 片岡 健, 阪口 政清, 諸橋 正昭

      詳細を見る

    配分額:14600000円 ( 直接経費:14600000円 )

    本研究は、皮膚の組織構築に関わる遺伝子の同定とその作用機序を解明し、その知見を活用して皮膚疾患の再生医学的治療法を開発するための基盤研究を行うものである。研究期間中の主な成果は以下のとおりである。
    1.ヒト表皮角化細胞の増殖抑制:S100C/A11を介する新しい機構の解明
    高CaとTGFβはヒト表皮ケラチノサイトの代表的な増殖抑制因子であるが、その詳細な機構は明らかではなかった。我々は、S100C/A11が両者の増殖抑制シグナル伝達に関与することを明らかにした。高CaかTGFβにヒト表皮ケラチノサイトが曝露されるとPKCαが活性化しS100C/A11をリン酸化する。このS100C/A11がNucleolinと結合して核に移行し、Sp1を介してp21を誘導することにより、細胞増殖抑制をもたらすのである。高CaとTGFβによる増殖抑制には、それぞれNFAT1とSmadsを介する固有経路の活性化も同時に必要であった。
    2.表皮角化細胞の角化:Hornerin遺伝子の解析
    Hornerinはprofilaggrinに類似したタンパク質をコードする新しい遺伝子である。マウスでは皮膚、舌、食道、前胃の重層扁平上皮発現しており、profilaggrinと同一のケラトヒアリン顆粒に見出された。ヒトのHornerin遺伝子を単離してその構造を明らかにした。成人の正常駆幹表皮には発現が見られなかったので様々な表皮を検索し、乾癬病変部および創傷治癒過程にある表皮でHornerinの発現が誘導されることを見出した。
    3.マウス骨髄細胞の皮膚細胞への分化
    マウス骨髄細胞を、ヌードマウス皮膚欠損部での皮膚再構成系に混入すると、3週間で表皮、毛のう、皮脂腺を含む各種皮膚構成細胞に分化することを明らかにした。
    4.マウス皮膚細胞由来幹細胞の単離
    マウス胎児皮膚から、特殊なゲルを用いて簡便に幹細胞を単離する方法を開発した。

    researchmap

  • ヒト細胞の老化、不死化、癌化

    研究課題/領域番号:01J04310  2001年 - 2003年

    日本学術振興会  科学研究費助成事業  特別研究員奨励費

    阪口 政清

      詳細を見る

    配分額:3600000円 ( 直接経費:3600000円 )

    我々は先に、高Caによるヒト表皮角化細胞の増殖抑制が、S100C/A11のリン酸化、核移行、Sp1の活性化によるp21(WAF1/CIP1)の誘導という新しい信号伝達経路を介することを報告した(JCB,163:825-835,2003)。本研究では、ヒト表皮角化細胞に対するもう一つの代表的な増殖制御因子であるTGFβの作用機序を検討した。ヒト正常表皮角化細胞(NHK)をTGFβで処理すると、高Caに曝露した際と同様に、S100C/A11は10Thrがリン酸化され、nucleolinに結合して核に移行し、核内でSp1を介してp21(WAF1/CIP1)を誘導した。S100C/A11をリン酸化する酵素を探るため、皮膚で発現しているprotein kinase C(PKC)のα,δ,ε,η,ζ分子種を強制発現させたところ、PKCαのみがS100C/A11の10Thrをリン酸化した。TGFβ処理により、PKCαは活性化された。また、PKCαのドミナントネガティブ体を導入すると、TGFβによるS100C/A11のリン酸化が阻害され、増殖抑制も解除された。以上の結果は、細胞内でS100C/A11の10Thrをリン酸化するのはPKCαであることを示している。TGFβの信号伝達にSmad s系が働いていることはよく知られている。siRNAを用いてSmad3をdown-regulateすると、TGFβに依る増殖抑制が解除された。抗S100C/A11抗体を用いて、S100C/A11の機能をブロックしても同様であった。即ち、TGFβによる増殖制御はS100C/A11系とSmad s系の両方が機能して初めて起こることが確認された。なお、この条件下でSp1はSmad3と結合し、p21(WAF1/CIP1)プロモーターに作用する。以上、我々はS100C/A11がNHKの増殖抑制に中心的な役割を果たすことを明らかにした。

    researchmap

▼全件表示

 

担当授業科目

  • からだの仕組み (2023年度) 第1学期  - 火1~2

  • がん微小環境学 基礎 (2023年度) 特別  - その他

  • アンチエイジング特論 (2023年度) 特別  - その他

  • アンチエイジング特論(医学) (2023年度) 特別  - その他

  • グローバル医学教育実習 (2023年度) 特別  - その他

  • 再生医療学演習 (2023年度) 特別  - その他

  • 医学セミナー(テュートリアル) (2023年度) 第1学期  - 火2~3

  • 医学セミナー(チュートリアル) (2023年度) 第1学期  - 火2~3

  • 医学教育実習 (2023年度) 特別  - その他

  • 医学生物学 (2023年度) 特別  - その他

  • 医歯科学概論 (2023年度) 集中  - その他

  • 生化学 (2023年度) 集中  - その他

  • 生命の不思議1 (2023年度) 第3学期  - 木1~2

  • 生命の不思議2 (2023年度) 第3学期  - 火1~2

  • 細胞生物学実習 (2023年度) 特別  - その他

  • 細胞生物学演習 (2023年度) 特別  - その他

  • 細胞生物学I(演習・実習) (2023年度) 特別  - その他

  • 細胞生物学I(講義・演習) (2023年度) 特別  - その他

  • 細胞生物学II(演習・実習) (2023年度) 特別  - その他

  • 細胞生物学II(講義・演習) (2023年度) 特別  - その他

  • からだの仕組み (2022年度) 第1学期  - 火1~2

  • アンチエイジング特論(医学) (2022年度) 特別  - その他

  • 再生医療学演習 (2022年度) 特別  - その他

  • 医学セミナー(テュートリアル) (2022年度) 第1学期  - 火2~3

  • 医学セミナー(チュートリアル) (2022年度) 第1学期  - 火2~3

  • 医学入門(医学といのち) (2022年度) 第3学期  - 木5~6

  • 医学教育実習 (2022年度) 特別  - その他

  • 医学生物学 (2022年度) 特別  - その他

  • 医歯科学概論 (2022年度) 集中  - その他

  • 基礎病態演習 (2022年度) 特別  - その他

  • 生化学 (2022年度) 集中  - その他

  • 生命の不思議1 (2022年度) 第3学期  - 木1~2

  • 生命の不思議2 (2022年度) 第3学期  - 火1~2

  • 細胞生物学I(演習・実習) (2022年度) 特別  - その他

  • 細胞生物学I(講義・演習) (2022年度) 特別  - その他

  • 細胞生物学II(演習・実習) (2022年度) 特別  - その他

  • 細胞生物学II(講義・演習) (2022年度) 特別  - その他

  • からだの仕組み (2021年度) 第1学期  - 火1~2

  • 再生医療学演習 (2021年度) 特別  - その他

  • 医学セミナー(テュートリアル) (2021年度) 第1学期  - 火2~3

  • 医学セミナー(チュートリアル) (2021年度) 第1学期  - 火2~3

  • 医学教育実習 (2021年度) 特別  - その他

  • 医学生物学 (2021年度) 特別  - その他

  • 医歯科学概論 (2021年度) 集中  - その他

  • 基礎病態演習 (2021年度) 特別  - その他

  • 生化学 (2021年度) 集中  - その他

  • 生命の不思議1 (2021年度) 第3学期  - 木1~2

  • 生命の不思議2 (2021年度) 第3学期  - 火1~2

  • 細胞生物学I(演習・実習) (2021年度) 特別  - その他

  • 細胞生物学I(講義・演習) (2021年度) 特別  - その他

  • 細胞生物学II(演習・実習) (2021年度) 特別  - その他

  • 細胞生物学II(講義・演習) (2021年度) 特別  - その他

  • 再生医療学演習 (2020年度) 通年  - その他

  • 再生医療学総論 (2020年度) 通年  - その他

  • 医学セミナー(テュートリアル) (2020年度) 第1学期  - 火2,火3

  • 医学セミナー(チュートリアル) (2020年度) 第1学期  - 火2,火3

  • 医学生物学 (2020年度) 特別  - その他

  • 基礎病態演習 (2020年度) 特別  - その他

  • 生化学 (2020年度) 集中  - その他

  • 生命の不思議1 (2020年度) 第3学期  - 木1,木2

  • 生命の不思議2 (2020年度) 第3学期  - 火1,火2

  • 細胞生物学I(演習・実習) (2020年度) 特別  - その他

  • 細胞生物学I(講義・演習) (2020年度) 特別  - その他

  • 細胞生物学II(演習・実習) (2020年度) 特別  - その他

  • 細胞生物学II(講義・演習) (2020年度) 特別  - その他

▼全件表示

 

社会貢献活動

  • 情報サイト学問・大学「みらいぶっく」記事

    役割:寄稿

    経済産業省  2021年3月12日 - 現在

     詳細を見る

    対象: 中学生, 高校生, 大学生

    種別:インターネット

    researchmap

  • 中国赴日本国留学正予備学校 日本語指導教員(オンライン講義)

    役割:講師

    文部科学省  2020年7月23日 - 2020年8月13日

     詳細を見る

    対象: 大学生

    種別:セミナー・ワークショップ

    文部科学省中国赴日本国留学生予備教育事業の一環として、中国赴日本国留学生予備学校に派遣され、専門日本語教育を行う。今回、COVID-19の問題からオンライン教育で行うこととなった

    researchmap